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The prognosis of localised prostate cancer is generally promising, as many tumours 
remain dormant and therefore do not require immediate intervention. In contrast, once 
metastasised, the prognosis for aggressive prostate cancer is often poor, highlighting 
the need for novel, effective treatment approaches. The expression of the six 
transmembrane epithelial antigen of the prostate2 (STEAP2) cell surface protein is 
increased in aggressive prostate cancer compared to normal prostate tissue. In vitro 
studies have shown STEAP2 to aid in prostate cancer progression, and as such this 
molecule shows promise as a potential novel therapeutic target in the treatment of 
advanced disease. The aim of this thesis was to develop a comprehensive 
understanding of the mechanistic role of STEAP2 in promoting aggressive prostate 
cancer traits and evaluate if its knock-out has the capacity to reduce the invasive 
potential of prostate cancer cells in vitro. As prostate cancer is a largely androgen 
dependent disease, this thesis also aimed to evaluate the effects of STEAP2 inhibition 
on the expression of the androgen receptor and androgen-regulated genes. 
This study developed and optimised a protocol for generating a set of 3D prostate 
cancer spheroids to provide more representative models of the in vivo prostate cancer 
environment. In this thesis, one commercial anti-STEAP2 polyclonal antibody and a 
panel of anti-STEAP2 monoclonal antibodies were selected for proof-of-concept 
studies where their effects on reducing prostate cancer cell viability were assessed. 
Receptor internalisation of STEAP2 was evaluated upon anti-STEAP2 monoclonal 
antibody binding to determine its suitability for use with antibody-drug conjugate 
technology. STEAP2 expression was knocked out using CRISPR/Cas9 genome 
engineering technology in two prostate cancer cell lines to evaluate its impact on cell 
proliferation, migration and invasion. Furthermore, gene expression profiling was 
conducted to explore interactions between STEAP2, the androgen receptor and a 
panel of androgen-regulated genes (PSA, FKBP5, GPRC6A and TMPRSS2) 
following: 1) anti-STEAP2 antibody treatment, 2) STEAP2-knockout and 3) the growth 
of prostate cancer cells in androgen-depleted conditions.  
The data presented in this thesis demonstrate that inhibition of STEAP2 by both the 
polyclonal anti-STEAP2 antibody and lead anti-STEAP2 monoclonal antibody 
significantly reduced prostate cancer cell viability. STEAP2 receptor internalisation 
was triggered following treatment of prostate cancer cells with the anti-STEAP2 
monoclonal antibody, demonstrating its potential utility with antibody-drug conjugate 
technology in the future. STEAP2 knockout prostate cancer cells exhibited decreased 
cell proliferation, migration and invasion in comparison to wild-type cells. These 
promising findings highlight the therapeutic value of STEAP2-knockout in inhibiting 
invasive tumour cell traits. Gene expression data from both STEAP2-knockout cells 
and androgen-depleted cells suggest that STEAP2 may be involved in crosstalk 
between the androgen receptor and androgen-regulated genes. STEAP2 could 
therefore provide a novel target in conjunction with current conventional androgen 
deprivation therapy. In conclusion, the in vitro findings presented herein suggest 
STEAP2 as a viable target for the development of more tailored and personalised 
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Chapter 1  
General introduction 
1.1 The biology of cancer  
Cancer is the general term given to the abnormal growth of cells, which 
typically occur in epithelial tissues, which are sheets of cells that line the walls 
of cavities and channels or cover the outside of the body as layers of cells 
forming skin. The epithelia play an important role in oncogenesis – the onset 
of cancerous tumours – as they give rise to the most common of human 
cancers: carcinomas. Carcinomas arise from cells originating in the 
endodermal (inner) or ectodermal (outer) germ layer which form during 
embryogenesis and cause 80% of cancer related deaths in the Western World 
(Weinberg, 2014). The World Health Organisation (WHO) deems cancer as 
the leading cause of mortality globally (Stewart & Wild, 2014). Figures suggest 
that over 1,000 people are diagnosed with cancer each day in the UK, with 
statistics showing 1 in 2 people will be diagnosed with cancer at some point 
throughout their lifetime (Cancer Research UK (CRUK), 2019).  
1.1.2 The Hallmarks of Cancer  
Hanahan and Weinberg first suggested six hallmarks of cancer, which are 
acquired properties of almost all cancer cells that influence the onset and 
progression of the disease (Hanahan & Weinberg, 2000). These include 
excessive proliferation, the ability of cancer cells to evade growth suppressors, 
immortality, invasion and metastasis, angiogenesis and the prevention of 
apoptosis (Hanahan & Weinberg).  
 
1.1.2.1 Uncontrolled proliferation 
The ability of cancer cells to sustain chronic proliferation and grow 
uncontrollably is fundamental to disease progression (Hanahan & Weinberg, 
2011). Normal cell growth is carefully maintained by multiple growth factors 
that control cell cycle progression (Hanahan & Weinberg, 2011). Cancer cells 
utilise a variety of mechanisms to overcome these inhibitory signals, and as 
such are able to grow in an uncontrolled and abnormal manner (Hanahan & 
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Weinberg, 2011). Many cancer types upregulate the expression of growth 
factor receptors, and as such are able to overcome the rate limiting step posed 
by the rapid depletion of growth factors produced by neighbouring cells 
(Witsch et al., 2010). This ability leads to independent cell growth and 
increased proliferative capacity of cancer cells (Witsch et al., 2010). Another 
mechanism by which cancer cells overcome the rate limiting step is by 
triggering neighbouring cells to overproduce growth factors (Witsch et al., 
2010). In many cancers, excessive proliferation can be the result of activation 
of downstream pathways such as phosphoinositide 3-kinase (PI3K), which 
induces mutations allowing for the proliferation of cells (Jiang & Liu, 2009). 
These various mechanisms by which cancer cells are able to rapidly proliferate 
in an uncontrolled manner result in an increase in cell numbers and 
subsequent tumour formation.  
 
1.1.2.2 Evading growth suppressors 
To overcome negative regulators of cell proliferation, cancer cells largely 
depend on the actions of tumour suppressor genes (Hanahan & Weinberg, 
2011). Tumour suppressor genes act as either control points to regulate cell 
proliferation, or activate cell senescence and apoptotic mechanisms (Hanahan 
& Weinberg, 2011). The most widely studied of these is tumour suppressor 53 
(p53), a 53-kDa tumour suppressor protein located on chromosome 17 and is 
the most frequently mutated gene in cancers (Yue et al., 2017). p53 acts 
mainly as a transcriptional regulator and can activate genes involved in 
apoptosis, cellular senescence, repair of deoxyribose nucleic acid (DNA) and 
cell cycle arrest (Yue et al., 2017).  
 
1.1.2.3 Activating invasion and metastasis 
When confined to the primary site, tumours are deemed localised, yet still have 
the potential to mobilise and spread to other parts of the body. Metastasis is 
the term given to this migration of cancerous cells from their original primary 
tumours. Metastasis can give rise to new colonies known as metastases, 
which are usually traceable back to the site of the primary tumour (Fares et 
al., 2020; Lambert et al., 2017).  The most common sites for metastases to 
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occur are the liver, lungs, brain and bones (Fares et al., 2020; Lambert et al., 
2017). Cancer cells leaving primary tumours are carried by blood and 
lymphatic vessels until they relocate and form new colonies. The occurrence 
of metastases is the principal cause of death in patients with cancer (Fares et 
al., 2020; Lambert et al., 2017; Weinberg, 2014).  
 
The invasion-metastasis cascade is the term given to the events cancer cells 
undergo in order to achieve metastasis (Hanahan & Weinberg, 2011; Welch & 
Hurst, 2019). Once a tumour has become established at a primary site, the 
cells begin to invade the local tissues, leading to locally advanced disease 
(Hanahan & Weinberg, 2011; Welch & Hurst, 2019). A series of molecular 
events within the invasion-metastasis cascade trigger distinct cellular changes 
that allow cancer cells to become mobile and enter the blood stream, enabling 
them to spread to distant sites via the circulatory system (Hanahan & 
Weinberg, 2011; Lambert et al., 2017; Welch & Hurst, 2019). A process known 
as epithelial to mesenchymal transition (EMT) is required for cells to gain 
mobility and relies upon a switch in cadherin (Lamouille et al., 2014; Pal et al., 
2018). E-cadherin, expressed in epithelial cells, interacts with β-catenin to 
anchor cells in place, yet when cells undergo EMT, E-cadherin is switched for 
N-cadherin, expressed in mesenchymal cells (Lamouille et al., 2014; Pal et al., 
2018). In order to become mobile, cancer cells must also be able to degrade 
the extracellular membrane (ECM), consisting of the basement membrane and 
connective tissue (Hanahan & Weinberg, 2011). Mobilised cancer cells often 
aggregate with platelets in order to survive in circulation before attaching to 
secondary tissues to form micro-metastases, which subsequently proliferate 
and expand to form metastatic tumours (McGowan et al., 2009; Yan & Jurasz, 
2016). The “seed and soil” idea first hypothesised in 1989 states that cancer 
cells use molecular signalling to seek out distant organs with similar 
characteristics to their primary sites in order to survive (Paget, 1989; Welch & 
Hurst, 2019). Activation of the invasion-metastasis cascade triggers a multi-
step process which allows cancer cells to migrate from their primary sites and 




Figure 1.1. The invasion-metastasis cascade. Following the initiation of a 
tumour at a primary site, cancer cells exit their primary sites (local invasion, 
intravasation). Cancer cells are then able to enter circulation and translocate 
systemically (extravasation). If the cells are able to survive the circulation, they 
arrest at distant sites and adapt to survive in secondary tissue (micro-
metastasis formation, metastatic colonisation). Cells then continue to divide 
and become clinically detectable metastatic disease. Adapted from (Valastyan 
& Weinberg, 2011). Created using BioRender. 
 
 
1.1.2.4 Inducing angiogenesis 
Angiogenesis is the process of forming new blood vessels from existing 
vasculature, which in cancers generates tumour-associated neovasculature 
and is required for cancer cells to obtain the required volumes of nutrients to 
allow for exponential growth (Hanahan & Weinberg, 2011). This tumour-
associated neovasculature often contains an unstable mix of pro-angiogenic 
signals which lead to disproportionate vessel branching, abnormal blood flow, 
micro-haemorrhaging and abnormal levels of endothelial cell proliferation and 
apoptosis (Ebrahem et al., 2010; Nagy et al., 2012). One of the main pro-
angiogenic growth factors is the vascular endothelial growth factor (VEGF), 
which acts upon tyrosine kinase receptors (TKRs) (Aslam et al., 2013; Wu et 
al., 2018). Interactions between VEGF and TKRs trigger increased vascular 
permeability and endothelial sprouting, subsequently allowing new vessels to 
form and aid in tumour growth and progression (Aslam et al., 2013; Hanahan 
& Weinberg, 2011; Wu et al., 2018).  
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1.1.2.5 Enabling replicative immortality  
The ability of cancer cells to divide and replicate indefinitely plays a key role 
in the development of macroscopic tumours (Hanahan & Weinberg, 2011). 
Under normal conditions, once a cell has reached its replicative capacity it 
enters an exit phase known as senescence, during which cells are no longer 
proliferative but remain viable (Hanahan & Weinberg, 2011). The length of a 
cell’s life is dependent on multiple factors, with the presence of telomeres 
being the most important (Lulkiewicz et al., 2020). Telomeres protect cells 
from DNA damage and gradually shorten with age as a section of the telomere 
is lost during each cell replication cycle, resulting in a definite life span for cells 
(Artandi & DePinho, 2010; Lulkiewicz et al., 2020). In cancer cells the 
expression of telomerase, an enzyme able to synthesis telomeric DNA 
sequences, is often upregulated and provides cancer cells with replicative 
immortality (Artandi & DePinho, 2010; Lulkiewicz et al., 2020).  
 
1.1.2.6 Evading cell death  
Programmed cell death, known as apoptosis, acts as a natural defence 
mechanism to cancer development (D’Arcy, 2019; Hanahan & Weinberg, 
2011). The ability to evade this signalling pathway is key to tumourigenesis 
(D’Arcy, 2019; Hanahan & Weinberg, 2011). Apoptosis is activated either by 
an extrinsic or intrinsic pathway, both of which result in caspase activation and 
cell degradation (D’Arcy, 2019). Regulation of apoptosis is essential for 
maintaining cellular homeostasis and is mediated by a variety of pro- and anti-
apoptotic mechanisms (D’Arcy, 2019). Pro-apoptotic factors including Bak and 
Bax become activated by cell stress and trigger cytochrome c production in 
the mitochondria (Singh et al., 2019). An apoptosome is then generated which 
results in the downstream activation of caspases and eventual cell death by 
degradation (D’Arcy, 2019; Dorstyn et al., 2018; Singh et al., 2019). A 
mechanism used by cancer cells to overcome cell death by apoptosis is 
through increased expression of the B-cell lymphoma 2 (Bcl-2) anti-apoptotic 
pathway (Singh et al., 2019). Bcl-2 prevents Bak and Bax activation and 
subsequent cytochrome c release, suggesting a mechanism for cancer cells 
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to evade cell death signals and continue to grow uncontrollably (Singh et al., 
2019).  
 
Another mechanism by which cancer cells evade death is through autophagy. 
The main purpose of autophagy is to recycle cellular components in response 
to nutrient starvation, allowing for cells to survive for extended periods of time 
(Glick et al., 2010). With regards to cancer progression, autophagy plays a 
dual role as it can act either as a quality control mechanism or in promoting 
tumour survival under harsh growth conditions (Yun & Lee, 2018). In terms of 
the hallmarks of cancer, autophagy influences mechanisms involved in 
resisting cell death and activation of invasion and metastasis (Hanahan & 
Weinberg, 2011). This dual-role theory also involves p53 which modulates 
autophagy both positively and negatively (Ryan, 2011; Wawrzynow et al., 
2018). Despite the dual role autophagy plays in cancer, it has been suggested 
that this role is not equally divided, yet favours tumour cell survival by 
increasing stress tolerance levels (Degenhardt et al., 2006; Wawrzynow et al., 
2018; Yun & Lee, 2018). Tumour cell survival is notably promoted by 
autophagy-proficient cells when used to combat high cytotoxic and metabolic 
stresses, such as hypoxia, nutrient deprivation, and an increase in proliferation 
(Towers et al., 2020; Yun & Lee, 2018). Due to increased cellular proliferation, 
tumour cells have increased metabolic needs to maintain the survival of the 
tumour cells. To do so, autophagy becomes activated to stimulate the 
recycling of adenosine triphosphate (ATP), which if maintained can lead to 
continuous growth and proliferation (Towers et al., 2020; Yun & Lee, 2018).  
 
1.1.2.7 Emerging Hallmark: Evading immune destruction 
Emerging hallmarks have also since been identified as the ability of cancer 
cells to evade the immune system, and alterations to energy metabolism 
(Hanahan & Weinberg, 2011). Cancer cells are able to avoid immune 
surveillance, the process by which the immune system monitors, recognizes 
and eliminates the vast majority of foreign cells and tissues (Hanahan & 
Weinberg, 2011). In immunocompromised patients, the absence of a fully 
functioning immune system does promote an increase in the onset of some 
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cancers, which has also been noted in patients following organ transplantation 
who later develop donor-derived cancers (Vajdic & van Leeuwen, 2009). 
However, as the majority of cancers arise in immune-competent patients, the 
mechanism by which cancer cells evade the immune system remains unclear. 
The “elimination, equilibrium, escape” theory has been suggested as a 
mechanism of immune system avoidance (Mittal et al., 2014). In the first 
phase, elimination, cells are detected and destroyed by the immune system, 
however, sporadic tumour cells enter an equilibrium phase where editing and 
mutations occur (Mittal et al., 2014). Finally, during the escape phase, 
immunologically sculpted tumour cells are able to grow exponentially, and 
establish an immunosuppressive tumour microenvironment (Mittal et al., 
2014).  
 
1.1.2.8 Emerging Hallmark: Reprogramming energy metabolism 
Alterations to energy metabolism are required to fuel cell growth and division, 
and ultimately enable the uncontrolled proliferation of cancer cells (Hanahan 
& Weinberg, 2011; Pavlova & Thompson; 2016). Cancer cells undergo a 
metabolic switch, enabling them to reprogram their glucose metabolism and 
energy production to a state known as aerobic glycolysis (Hanahan & 
Weinberg, 2011; Pavlova & Thompson; 2016). Glucose transporters, 
predominantly glucose transporter 1 (GLUT1), are upregulated by cancer cells 
to substantially increase the import of glucose into the cytoplasm (de Castro, 
2019; Pavlova & Thompson; 2016). This increase in glycolysis has been 
reported to correlate with alterations in oncogene and tumour suppressor 
expression, which drive other hallmarks of cancer including cell proliferation 
and avoidance of apoptosis (de Castro, 2019; Hanahan & Weinberg, 2011; 
Pavlova & Thompson; 2016).  
1.1.3 Enabling Characteristics 
Since the first proposal of the original six hallmarks of cancer and addition of 
the two new emerging hallmarks, two enabling characteristics were added: 
inflammation and genomic instability (Hanahan & Weinberg, 2011). These 
characteristics are known to influence the occurrence of the known hallmarks 
of cancer and lead to disease progression (Hanahan & Weinberg, 2011).  
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1.1.3.1 Tumour-promoting inflammation 
The recruitment of inflammatory cells to the site of tumours was initially thought 
of as a process by which to destroy tumour cells, yet has since been suggested 
to benefit tumour survival and neoplastic formation (deNardo et al., 2010; 
Hanahan & Weinberg, 2011). Tumour growth and survival may benefit from 
inflammatory cell recruitment due to an increased supply of growth factors, 
pro-angiogenic factors and signalling to facilitate invasion and metastasis 
(deNardo et al., 2010; Grivennikov et al., 2010). A more aggressive phenotype 
may also be generated as a result of inflammatory cells producing and 
releasing reactive oxygen species (ROS) into the tumour microenvironment 
(Grivennikov et al., 2010).  
 
1.1.3.2 Genome instability and mutation 
Alterations in the genomes of cancer cells allows them to acquire the 
properties identified as the hallmarks of cancer to aid in disease progression 
(Fares et al., 2020; Hanahan & Weinberg, 2011; Macheret et al., 2015; Negrini 
et al., 2010). Mutant genotypes confer advantageous characteristics to enable 
cell growth, proliferation and metastasis (Hanahan & Weinberg, 2011; 
Macheret et al., 2015). Some of these mutations may be the result of 
epigenetic changes such as DNA methylation and histone modifications, or 
heritable phenotypes including inactivation of tumour suppressor genes 
(Flavahan et al., 2017; Negrini et al., 2010). Mutations in genes involved in 
DNA damage repair mechanisms result in a loss of function and subsequent 
increase in cancer development and progression (Negrini et al., 2010; 
Turgeon et al., 2018). 
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1.2 The prostate  
The prostate is an accessory gland around the size of a walnut found only in 
the reproductive system of males (Figure 1.2; Flint et al., 2015). The prostate 
is located in the pelvis and sits behind the urinary bladder, with the urethra 
running through it (Figure 1.2; Fine et al., 2012; Flint et al., 2015). The part of 
the urethra passing through the prostate is known as the prostatic urethra, 
which joins the two ejaculatory ducts (Figure 1.3; Fine et al., 2012; Flint et al., 
2015). The prostate is surrounded by a fibromuscular capsule known as the 
prostatic capsule and contains both glandular and connective tissues (Figure 
1.3; Fine et al., 2012). The primary function of the prostate is related to 
reproduction, as the gland secretes substances including prostatic fluid, which 
is required to nourish sperm, which subsequently alters the viscosity of semen 
(Flint et al., 2015). 
 
 
Figure 1.2. Diagram of the human male reproductive system showing the 
location of the prostate.  The prostate is found only in the reproductive 
system of males and sits below the bladder. The main organs of the male 
reproductive system are the testes, penis, urethra and prostate gland. Adapted 
from (CRUK, 2019). Created using BioRender.  
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The internal structure of the prostate is described in gross anatomy as 
consisting of four lobes: lateral, anterior, median and posterior (Packer & 
Maitland, 2010). In microanatomy the prostate is divided into three zones 
known as the transitional, central and peripheral zones (Figure 1.3; Fine et 
al., 2012; Packer & Maitland, 2010). The peripheral zone lies beneath the 
capsule and is found at the posterior of the gland, making up 70% of the 
prostate and surrounding the distal urethra (Fine et al., 2012; Packer & 
Maitland, 2010). The ejaculatory ducts are surrounded by the central zone 
which contains the ductal tube from the seminal vesicle to the descending 
urethra and makes up 20% of the prostate and also has a separate 
embryological origin (Fine et al., 2012; Packer & Maitland, 2010). The 
transitional zone is found directly below the bladder and surrounds the 
transitional urethra and makes up 5% of the prostate (Fine et al., 2012; Packer 
& Maitland, 2010). Finally, the anterior fibromuscular stroma is usually absent 
of glandular components and, as the name suggests, is composed only of 
muscle and fibrous tissue (Fine et al., 2012; Packer & Maitland, 2010).  
 
 
Figure 1.3. Diagram showing the anatomy of the human prostate. The 
prostate is located beneath the bladder and is composed of 3 distinct zones: 
the central zone (green), the peripheral zone (purple), and the transitional 
zone (blue). The urethra runs through the prostate to the bladder and seminal 
vesicles.  Adapted from (Packer & Maitland, 2010). Created using BioRender.  
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1.3 Prostate cancer  
1.3.1 Epidemiology 
Prostate cancer is the most common non-cutaneous cancers in men, 
accounting for 15% of all male cancer diagnoses globally (Ferlay et al., 2015). 
In the UK, 130 new cases of prostate cancer are diagnosed each day, totalling 
47,700 per year, leading to 11,300 deaths annually (CRUK, 2019). The lifetime 
risk of a man being diagnosed with prostate cancer is 1 in 8, with statistics 
showing that one man in the UK dies from prostate cancer every 45 minutes 
(Nelson & Shah, 2019; Prostate Cancer UK, 2020). Prostate cancer is largely 
a disease of the elderly, with over half (54%) of new cases being diagnosed in 
those aged over 70 and is rarely detected in men under the age of 40 (Center 
et al., 2012; CRUK, 2019). As such, given the ageing population, prostate 
cancer incidence has increased over recent years (Center et al., 2012).  
 
Ethnicity can largely affect the incidence of prostate cancer, which varies 
widely between countries leading to a difference of up to 90-fold between 
populations (Odedina et al., 2009). The risk of a black man being diagnosed 
with prostate cancer is much higher than that of a white man (1 in 4 compared 
to 1 in 8 respectively), yet the reason behind this is unclear (Prostate Cancer 
UK, 2020). A difference in genetics, particularly the androgen receptor (AR) 
gene, is thought to play a role in this increase in incidence amongst black men 
(Platz, 2000; Spratt et al., 2018). Incidence of prostate cancer is lowest in 
Asian countries, notably China (1.9 per 100,000 per year), and highest in North 
America, with African American men more commonly diagnosed (137 per 
100,000 per year) (Kitagawa et al., 2013; Odedina et al., 2009; Pernar et al., 
2018). Studies exploring international variation in prostate cancer 
aggressiveness found that more men of African descent were diagnosed with 
higher grade disease than those from the Caribbean or UK, which also 




1.3.2 Risk factors 
Whilst defined risk factors are yet to be established, other than age, a man’s 
risk of developing prostate cancer may be increased by lifestyle factors 
including smoking, poor diet and obesity, however these risk factors apply to 
cancer development in general and have not been specifically linked to 
prostate cancer (CRUK, 2019). To date, prostate cancer is not thought to be 
clearly linked to any specific preventable risk factors (CRUK, 2019).  
 
Excluding age and race, the only determined risk factor for prostate cancer is 
a family history of the disease (Leitzmann & Rohrmann, 2012; Kicinski et al., 
2011). Compared to men in the general population, the risk for first-degree 
relatives of men with the disease is initially doubled and increases to up to four 
times higher when the first-degree relative is diagnosed at younger than 60 
years of age (Johns & Houlston, 2003; Pernar et al., 2018). When more than 
two-first degree relatives are affected, this risk increases four- to five-fold 
(Kicinski et al., 2011). In terms of first-degree relatives, men who have a 
brother diagnosed with prostate cancer are more likely to develop the disease 
themselves compared to those with their father diagnosed, indicating that 
prostate cancer may be recessive or linked to the X-chromosome (Barber et 
al., 2018; Johns & Houlston, 2003; Monroe et al., 1995). Overall, 10-15% of 
men diagnosed with prostate cancer have at least one relative who has also 
been diagnosed with the disease (Barber et al., 2018; Schaid, 2004). Another 
factor that may influence the risk of prostate cancer is a family history of other 
cancers such as breast, ovarian, bladder and kidney (Barber et al., 2018; Negri 
et al., 2005). This is thought to be the result of germline mutations in BRCA1 
and BRCA2 genes, which can increase the risk of prostate cancer three-fold 
compared to the general population (Negri et al., 2005). 
 
Hormonal factors have also been linked to the onset of prostate cancer, with 
the peak age of prostate cancer development coinciding with the age at which 
serum testosterone levels decline, whilst serum oestrogen levels remain 
constant (Leitzmann & Rohrmann, 2012). A change in the serum testosterone 
to oestrogen ratio has been found to be a determinant of prostate cancer risk, 
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which also correlates with the risks exposed by ethnicity (Leitzmann & 
Rohrmann, 2012; Nelson et al., 2014). In men of Afro-Caribbean origin, serum 
oestrogen levels are highest when compared to Caucasian and Asian men, 
resulting in a more profound difference in the testosterone to oestrogen ratio 
(Leitzmann & Rohrmann, 2012; Nelson et al., 2014).  
1.3.3 Disorders of the prostate 
As men age, the prostate becomes increasingly susceptible to undergo 
changes, such as the onset of benign prostatic hyperplasia (BPH), which 
occurs primarily in the transitional zone, and prostate intraepithelial neoplasia 
(PIN), which often develops in the peripheral zone (see Section 1.2; Packer 
& Maitland, 2010). BPH is the most common non-malignant condition of the 
prostate and can be categorized as either microscopic or macroscopic, with a 
vast majority of men developing microscopic BPH as they age (Roehrborn et 
al., 2002). PIN is also another common disorder of the prostate and is found 
during approximately 5% of initial prostate biopsies (Pullar & Shah, 2016). PIN 
displays similar morphological changes to prostate cancer yet does not 
correlate with an increase in prostate specific antigen (PSA), and in men with 
high-grade PIN additional biopsies are often required as subsequent 
development of prostate cancer occurs in approximately 40% of cases (Pullar 
& Shah, 2016). PIN is categorised as low- or high-grade depending on the 
prominence of nucleoli, with high-grade PIN progressing to cross the epithelial 
basement membrane and becoming invasive adenocarcinoma (Pullar & Shah, 
2016).  
 
Adenocarcinomas account for the vast majority of prostate cancers (>95%), 
which develop from glandular structures in epithelial tissues (Goldstein et al., 
2010). During cancer development, the basal cell layer is lost, and malignant 
cells enter the basement membrane, leading to local invasion (Goldstein et al., 
2010). The remaining minority of prostate cancers include transitional cell 
carcinoma, intra-ductal carcinomas which arise from prostatic ducts, 
sarcomas, small cell carcinomas and metastases forming in the prostate from 
other sites, all of which are very rare and often aggressive forms of the disease 
which have a poor prognosis for the patient (Pullar & Shah, 2016).  
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With regards to Figure 1.3, the prostate is often referred to according to its 
distinct anatomical zones, known as McNeil’s zones (Packer & Maitland, 
2016). The majority (70-80%) of prostate cancers develop in the peripheral 
zone, and 10-20% manifest in the transitional zone (Packer & Maitland, 2010). 
The transitional zone is usually anterior in the gland and is difficult to target 
using traditional transrectal ultrasound (TRUS) biopsy techniques (Pullar & 
Shah, 2016). The central zone gives rise to approximately 2.5% of prostate 
cancers, which tend to be more aggressive and are more likely to invade the 
seminal vesicles (Cohen et al., 2008; Packer & Maitland, 2010; Pullar & Shah, 
2016). 
 
When confined to the gland, prostate cancer is not usually life threatening, as 
localised tumours often remain dormant and can be removed surgically 
through radical prostatectomies, or effectively managed through routine 
observations (Moschini et al., 2017; Wilt et al., 2012). The two main systems 
used to determine the progression of prostate cancer are the tumour, node, 
metastasis (TNM) staging system which is applied to all cancers, and the 
Gleason scoring system which is reserved specifically for prostate cancer 
staging (CRUK, 2019; Chen & Zhou, 2016). The TNM staging system is widely 
used in cancer research, and, in terms of prostate cancer, Stage 3 refers to a 
tumour that has broken through the prostate capsule, whereas Stage 4 
indicates metastases to lymph nodes or other organs (Figure 1.3; CRUK, 
2019). Once prostate cancer has metastasised, the prognosis for the patient 
decreases significantly, with only 30% of men with Stage 4 disease surviving 
for more than 5 years, compared to up to 95% of men with Stage 3 disease 





Figure 1.4. Five-year survival of men with prostate cancer based on stage 
at diagnosis. Graph showing the percentage of men aged 15-99 diagnosed 
with prostate cancer surviving 5-years after diagnosis dependent on stage at 
diagnosis and net overall survival. Adapted from (CRUK, 2019; NCCN, 2018).  
 
1.3.4 Prostate cancer diagnosis 
A combination of tools are employed to confirm a diagnosis of prostate cancer. 
To date, the current gold standards are a blood test to detect circulating PSA 
levels, the digital rectal examination (DRE), and TRUS-guided biopsies 
(Nelson & Shah, 2019). Over the last 30 years, the incidence of prostate 
cancer in the UK has increased dramatically by almost 150%, partly due to 
increased detection from PSA testing, or incidental detection from resected 
tissue following lower urinary tract symptoms (LUTS)-related surgery (Nelson 
& Shah, 2019). Once a suspicion of prostate cancer is apparent, the patient is 
referred to a urologist to repeat the prostate examination and check for a family 
history of the disease (Moschini et al., 2017). Symptoms of advanced disease 
which would prompt an urgent referral include, but are not limited to, back pain, 
leg swelling, or peripheral neurological symptoms (Pullar & Shah, 2016). Once 
a diagnosis is confirmed, the disease requires grading by TNM staging, 
Gleason score, and more recently the International Society of Urological 
Pathology (ISUP) scoring system (National Institute for Health and Care 






















Screening is currently not universally available in the UK and is only 
recommended as an opportunistic screening approach in the form of PSA 
blood testing in men over the age of 55 presenting with prostate cancer 
symptoms (Basch et al., 2012; Lee et al., 2017; Nelson & Shah, 2019). 
However, there is controversy over the age at which to begin screening by 
PSA blood tests, with the European Association of Urology recommending a 
baseline PSA test at 40-45 years, yet the American Urological Association 
suggests reserving this to over 55 years (Cabarkapa et al., 2016; Carter et al., 
2013). Randomised trials of PSA screening have proven inconclusive, with 
one reporting that no improvement in prostate cancer mortality was observed 
following the screening of 420,000 men (Martin et al., 2018). As such, a PSA 
screening programme is not currently recommended by NICE or supported by 
the WHO (Nelson & Shah, 2019).  
 
1.3.4.1 Prostate specific antigen test 
To date, the most widely used diagnostic tool in prostate cancer is the 
detection of PSA (Crawford et al., 2013; Schröder et al., 2009). PSA is a 
glycoprotein serine protease enzyme, part of the kallikrein (KLK) family (Pullar 
& Shah, 2016). PSA is made solely by the epithelial cells of the prostate gland, 
hence its use as a biomarker for prostate cancer in the diagnosis, monitoring 
and risk prediction of the disease (Pullar & Shah, 2016). Circulating PSA levels 
can be indicative of prostate health, as when leaked into the blood stream and 
causing an increase in PSA levels detected by a blood test, an enlarged 
prostate is often present (Nelson & Shah, 2019). Thus, increases in PSA levels 
are often deemed prostate specific yet not prostate cancer specific, warranting 
the need for more specific biomarkers of prostate cancer detection and 
progression (Pullar & Shah, 2016). As shown in Table 1.1, PSA levels also 
increase naturally with age, yet there is no determined PSA level at which 
prostate cancer can be completely excluded. PSA also provides a useful tool 
in the active surveillance of men with prostate cancer following radical 
treatment, as biochemical recurrence may indicate a need for further treatment 
(Nelson & Shah, 2019). PSA detection comes with a risk of over-diagnosis, 
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which has been linked with up to 50% of diagnoses (Crawford et al., 2013; 
Schröder et al., 2009).  
 
Table 1.1. Normal physiological PSA values dependent on age. Adapted 
from (Nelson & Shah, 2019). 
Age (years) PSA value (ng/ml) 






1.3.4.2 Digital rectal examination 
DREs are often performed to confirm a diagnosis following an elevated PSA 
result, as PSA can also increase as a result of BPH, but not PIN (Packer & 
Maitland, 2010). A DRE may also be beneficial, particularly in more elderly 
patients, as they avoid the risks associated with TRUS biopsies (Nelson & 
Shah, 2019). During the DRE, the size and softness of the prostate is 
evaluated by the physician assessing the gland by placing their fingers into 
the rectum of the patient (Kim et al., 2014). The DRE often follows the 
detection of elevated PSA levels and may be of particular use in patients 
presenting with urinary problems which could influence the results of the PSA 
test (Cornford et al., 2020). Abnormalities found in a DRE alongside elevated 
PSA levels warrant further investigations in the form of biopsies of prostate 
tissue being collected, as DRE alone has a sensitivity and specificity below 
60%, and therefore cannot be used to either diagnose or exclude the presence 
of prostate cancer (Naji et al., 2018; Nelson & Shah, 2019). 
 
1.3.4.3 Biopsies 
TRUS-guided biopsies are traditionally used in the diagnosis of prostate 
cancer, during which 12 cores are taken from the prostate via the rectum using 
an ultrasound-guided probe (Nelson & Shah, 2019). Ultrasound waves are 
used to visualise the prostate and the seminal vesicles, with a low echo of the 
ultrasound indicative of prostate cancer, whereas strong echoes usually 
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signify the bone (Lam et al., 2019). TRUS biopsies have the advantage of 
simultaneously imaging and taking biopsies at desired locations of the prostate 
(Nelson & Shah, 2019). TRUS biopsies come with a number of risks, both 
short-term for the patient in the form of pain or infection, and clinically as a 
negative biopsy does not necessarily rule out prostate cancer as 
approximately 30% give false-negative results (Lam et al., 2019; Nelson & 
Shah, 2019; Pullar & Shah, 2016). When a TRUS biopsy returns a negative 
result yet a suspicion of prostate cancer remains, further investigations are 
considered such as MRI scanning or repeated biopsies (Nelson & Shah, 
2019). Biopsied tissue is assessed microscopically by a pathologist and 
determined as either positive, where cancer is present, or negative when a 
cancer diagnosis can be excluded (Lam et al., 2019). Positive biopsies are 
then categorised according to various scoring systems to aid in giving a 
prognosis for the patient (Lam et al., 2019).  
 
1.3.4.4 Gleason Grading System 
Since its development in the 1960s by Dr Donald F Gleason, prostate cancers 
have been graded according to the Gleason grading system, which gives the 
disease a grade between one and five dependent on the degree of gland 
differentiation and glandular architecture, as evaluated under microscopy 
(Chen & Zhou, 2016). A higher grade correlates with a more aggressive 
cancer, with two grades given to represent the two most dominant patterns 
observed, or, if only one pattern is found, the single grade is doubled, giving 
an overall score between 2 and 10 (Humphrey, 2004). For instance, if by 
prostate biopsy or radical prostatectomy a specimen is found to have a 
Gleason 4 as its most dominant pattern, yet some Gleason 3 characteristics 
are present, the patient will be reported as having a Gleason 7 (4 + 3). When 
a man is first diagnosed with prostate cancer, the Gleason score is vital when 
determining the patient’s clinical management and is the most important 
prognostic indicator (Pullar & Shah, 2016). However, not all Gleason 7 scores 
are classified as the same phenotype, as there is a clear distinction between 
a Gleason 7 (3 + 4) and a Gleason 7 (4 + 3) when considering the prognosis 
for the patient (Nelson & Shah, 2019). Prostate cancers with a Gleason 7 score 
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are the most difficult category to manage clinically as a Gleason 6 prostate 
cancer is usually indolent, whereas a Gleason 8 – 10 represents aggressive 
tumours (Nelson & Shah, 2019). Gleason 7 therefore sits in between these 
stages of disease and are much more difficult to predict in terms of prognosis 
for the patient (Nelson & Shah, 2019). In clinical practice, Gleason scores of 1 
and 2 are no longer regarded as cancerous, and as such the lowest possible 
Gleason score indicative of prostate cancer is Gleason 6 (3+3), and the 
highest is Gleason 10 (5+5) (Nelson & Shah, 2019). 
 
With the purpose of simplifying the Gleason scoring system for patients, a new 
5-point grading system was developed in 2016 by ISUP (Table 1.2; Nelson & 
Shah, 2019). The aim of this system was to overcome any confusion regarding 
the Gleason 7 score, and to give patients a more easily recognisable 1 to 5 
score, with 1 being the least aggressive, compared to 6 in the Gleason grading 
system (Table 1.2; Nelson & Shah, 2019; Pullar & Shar, 2016).  
 
Table 1.2. ISUP Grading system for prostate cancer for risk stratification. 
The Gleason sum scores translate to ISUP grades. Adapted from (Nelson & 
Shah, 2019).  
ISUP Grade Gleason 
Score 
Gleason Score breakdown 
1 6 3 + 3 
2 7 3 + 4 
3 7 4 + 3 
4 8 4 + 4 / 5 + 3 or 3 + 5 
5 9 / 10 4 + 5 or 5 + 4 / 5 + 5 
 
1.3.4.4 Tumour Node Metastasis staging 
Following a confirmed diagnosis of prostate cancer, staging the disease must 
be carefully considered as this is the most important process during diagnosis 
as it aids in the choice of treatment, and is often determined following a CT or 
MRI scan, or biopsy to assess whether the lesion is confined to the prostate 
or has metastasised (Pullar & Shah, 2016). Each individual case will then be 
discussed by a multidisciplinary team involving urologists, oncologists, 
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radiologists and pathologists, to review the patient’s imaging and histology 
results in order to produce a treatment plan. A universally used TNM staging 
system is commonly used to classify prostate cancer cases (Sobin et al., 
2009). This system is used in conjunction with the Stage I – Stage IV system, 
which indicates the degree of metastasis present, with Stage I indicating a 
locally contained tumour and Stage IV indicating metastasis involving the 
lymph nodes (CRUK, 2019). 10-year prostate cancer mortality is significantly 
higher in patients diagnosed with metastatic (M1) disease when compared to 
metastatic Stage IV prostate cancer (Shukla et al., 2015). It has also been 
found that the majority of men who die of prostate cancer were diagnosed with 
node-positive (N+), or metastatic (M1) disease, and often had detectable 
distant metastases at diagnosis (Helgstrand et al., 2017; Patrikidou et al., 
2014). Prostate cancers are categorised into three broad categories: localised 
disease (T1/2, N-, M-), locally advanced (T1/2, N+, M- or T3/4, N-/+, M-) and 
metastatic (Any T/N, M+) (Nelson & Shah, 2019). When a high-risk or 
advanced disease is diagnosed, often a bone scan will be requested to 
exclude the possibility of bone metastatic disease, as 80% of prostate cancer 
metastases develop in the bone (CRUK, 2019; Pullar & Shah, 2016).  
 
A newly diagnosed patient must also be categorised into either low-, 
intermediate- or high-risk for risk stratification. A system developed by 
D’Amico, aids in this process and also assists clinicians in determining the 
most appropriate treatment for the patient and determines whether any further 











Table 1.3. D’Amico risk categories for prostate cancer. Adapted from 





Clinical Stage (DRE) 
Low <10 ≤ 6 
 
Tumour confined to prostate  
(T1-T2a) 
Intermediate 10-20 7 Tumour involves more than 
one half of one lobe – both 
lobes 
(T2b) 
High >20 8-10 Tumour extends through 
prostate capsule and may 
have spread to distant organs 
(≥ T2c) 
 
Upon diagnosis, 39-56% of patients in the main age demographic (60-80+ 
years) present with Stage III or Stage IV metastatic prostate cancer due to the 
lack of specific symptoms in the earlier stages of the disease (CRUK, 2019). 
At the later stages of disease, these patients present a clinical problem as due 
to the patient’s age and progress of disease, little chemotherapeutic 
intervention is available, resulting in a poor prognosis for these patients as the 
risk of disease recurrence also increases with stage upon diagnosis (CRUK, 
2019).  
1.3.5 Prostate cancer metastasis 
When metastasis occurs, locally advanced prostate cancer often invades 
surrounding structures such as the penis, seminal vesicles, bladder and distal 
ureter, or, more rarely, the rectum (Pullar & Shah, 2016). Metastasis to the 
regional nodes most commonly affects the obturator and iliac nodes, located 
in the pelvis and detected by lymph node dissection when performed 
alongside radical prostatectomy (Heidenreich et al., 2002). Less frequent sites 
of metastases are the liver, lung and brain (Pullar & Shah, 2016).  
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The most common site for metastases to manifest is the bones, termed 
osteotropism, which occurs in up to 80% of metastatic cases, with the axial 
skeleton, especially the spine, most frequently effected (Bubendorf et al., 
2000; Shiozawa et al, 2011). Contrary to other cancers which also metastasise 
to the bone and form osteolytic lesions, the bone metastases of prostate 
cancer lead to dysregulation of bone formation and are characterised by an 
osteoblastic appearance (Hensel et al., 2016; Ibrahim, 2010; Wang et al., 
2005). Additional cytogenetic abnormalities and an increased metastatic 
potential of prostate cancer cells has been observed following interaction with 
bone stromal cells (Chung, 2003; Hensel et al., 2016). These alterations in 
tumour microenvironment have been suggested to be controlled by matrix 
metalloproteinases (MMPs) which can degrade various cell adhesion 
molecules and alter cell-cell and cell-ECM interactions (Gialeli et al., 2011). 
MMPs can either promote cancer metastasis through the release of 
interleukins and growth factors when released by fibroblasts, or inhibit disease 
progression (Gialeli et al., 2011).  Cells involved in bone function include 
osteoprogenitor cells, osteoblasts, osteoclasts and osteocytes (Vela et al., 
2007). The formation and degradation of bone is controlled by two specialized 
cell types; osteoblasts, which produce bone matrix and assist in its 
mineralisation, and osteoclasts, which dissolve bone mineral (Karsenty et al., 
2009).  
 
In order for bone metastases to successfully develop, the bone 
microenvironment must be suitable and sustainable, which is contributed to 
through the regulation of both osteoblastic and osteoclastic activities (Ibrahim 
et al., 2010). Metastases of the bone are characterized as osteolytic (bone 
destructive), or osteoblastic (bone forming), yet a combination of the two is 
often displayed (Ibrahim et al., 2010). Osteoblastic behaviour is a more 
common occurrence in prostate cancer metastases and develops as a result 
of growth factors produced by tumours, such as bone morphogenetic protein 
(BMP), tumour growth factor β (TGF-β), insulin-like growth factor (IGF), and 
Wnt (Logothetis & Lin, 2005). Parathyroid hormone (PTH) related protein 
(PTHrP) is highly expressed by osteoblastic prostate cancer, and although this 
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is normally characteristic of osteolytic behaviour, it induces osteoblastic 
metastatic lesions (Liao et al., 2008).  
 
One of the most common nutrients associated with bone formation and 
metabolism is calcium (Ca2+), which is taken up by osteoblasts from the blood 
in order to produce bone (Xing & Boyce, 2005). When metastasis of prostate 
cancer to the bone occurs, so does disruption of the natural equilibrium of 
bone homeostasis and calcium levels (Farhat et al., 2017). One of the main 
reasons for this is the production of large amounts of Wnt by prostate cancer 
cells, in comparison with usual levels of Wnt in the body (Dai et al., 2008). Wnt 
proteins are mainly used for developmental control of body axis symmetry in 
utero, however in mature tissues, Wnt are involved in the self-renewal of stem 
cells and upkeep of normal tissues, whilst sometimes contributing to 
oncogenesis (Dai et al., 2008; Hall et al., 2006). Levels of osteoblasts and their 
precursors increase as a result of Wnt overexpression, which leads to rapid 
bone formation whilst simultaneously triggering the production of osteoclasts, 
initiating rapid bone resorption (Xing & Boyce, 2005; Dai et al., 2008). The 
resulting large bone turnover subsequently releases latent TGF-β (LTGF-β), 
which when activated, assists in the proliferation of late-stage disease (Dallas 
et al., 2002). Wnt concentration is then increased, which in turn creates a two-
way crosstalk during which the growing tumour sustains its additional growth 
through bone remodelling, known as the “vicious cycle” of prostate cancer 
metastasis (Cook et al., 2014).  
1.3.6 Clinical management of prostate cancer 
Prostate cancer treatment is broadly divided into the management of localised, 
locally advance and metastatic disease, with high-risk localised disease and 
locally advanced disease often considered in the same category (Nelson & 
Shah, 2019). Given that prostate cancer is predominantly a disease which 
effects older men, radical treatment is often reserved for patients with a life 
expectancy of more than 10 years post-treatment (Bill-Axelson et al., 2014).  
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1.3.6.1 Active surveillance 
Active surveillance, sometimes known as the “watch and wait” strategy, is 
reserved for men with localised disease, as treatment is avoided until 
necessary for symptom relief (Nelson & Shah, 2019). Watch and wait is also 
employed for elderly men or those with co-morbidities, for whom radical 
treatment is deemed inappropriate (Graham et al., 2014; Nelson & Shah 
2019). In these patients, PSA progression is carefully monitored along with 
any symptomatic developments, and as such this approach is palliative as 
opposed to curative (Graham et al., 2014). In younger men, or those with an 
increased life expectancy due to age at diagnosis, active surveillance is used 
to defer radical treatment until it is absolutely necessary, as a way of avoiding 
surgery for low-risk tumours that may not progress or cause harm to the patient 
if left in situ (Graham et al., 2014). A number of factors are considered to switch 
from active surveillance to radical treatment, including patient choice, PSA 
progression, or disease progression determined by repeat biopsies or imaging 
(Nelson & Shah, 2019). One of the main risks posed by active surveillance is 
that once there is evidence of disease progression to warrant radical 
treatment, the disease may no longer be curable, however 10-year survival 
rates following active surveillance remain extremely promising (Bill-Axelson et 
al., 2014; Hamdy et al., 2016).  
 
1.3.6.2 Surgical treatment  
A radical prostatectomy involves the surgical removal of the entire prostate 
and seminal vesicles, requiring the urethra to be reconnected to the neck of 
the bladder (NICE, 2019). This treatment approach is often utilised in men with 
localised disease, where the entire cancer is contained within the prostate 
capsule (NICE, 2019). The most common side effects of radical 
prostatectomies are urinary incontinence and erectile dysfunction, both of 
which can be managed clinically through further surgery and hormone therapy 
respectively (Haglind et al., 2015). Over recent years, the development and 
implementation of robot-assisted radical prostatectomy has become 
increasingly popular and has the added benefits of reducing intraoperative 
blood loss, along with increased continence and erectile function post-surgery 
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(Ficarra et al., 2012; Haglind et al., 2015; Huynh et al., 2018). Following 
surgery, PSA levels are expected to fall to an undetectable level and are 
monitored for 5-years to detect any biochemical recurrence, which may 
indicate a need for further treatment (Nelson & Shah, 2019). 
 
1.3.6.3 Radiotherapy 
Radical radiotherapy is used to treat men with localised or locally advanced 
disease (Cornford et al., 2020). Radiation is delivered either internally 
(brachytherapy) or by external beam radiotherapy (EBRT) (Bolla et al., 2019; 
Nelson & Shah, 2019; Potters et al., 2004). Traditional radiotherapy is 
generated by a linear accelerator which delivers x-rays containing high-energy 
proton beams directly to the prostate, initiating DNA damage, double-strand 
breaks and ultimately cell death (Bolla et al., 2019; Mavragani et al., 2019; 
Reuvers et al., 2020). A daily dose of 2 Gy per treatment is given 5 days a 
week for a period of 7-8 weeks, with a minimum total dose of 78 Gy delivered 
over the treatment period (Dearnaley et al., 2014; Kuban et al., 2008; Pollack 
et al., 2002). Technological developments in the delivery of radiotherapy have 
allowed for more precision, therefore limiting toxicity to neighbouring organs 
such as the rectum (Bolla et al., 2019; Soni et al., 2017).   
 
Brachytherapy uses radioactive seeds containing low doses of radioactive 
iodine (125Iodine) or palladium (103Palladium), which are implanted directly into 
the prostate under the guidance of ultrasound (Peschel et al., 2004; Stish et 
al., 2017). The most commonly used, 125Iodine, has a half-life of 60 days and 
delivers a dose of 145 Gy (Nelson & Shah, 2019). This treatment method is 
best suited to patients with low-risk localised disease, however, can be used 
alongside external beam radiotherapy to treat higher-risk patients (Stish et al., 
2017). Side effects of both external radiotherapy and brachytherapy are similar 
and include worsening LUTS, erectile dysfunction, seed migration 
(brachytherapy) and radiation cystitis (external radiotherapy) (Nelson & Shah, 
2019; Onishi et al., 2019).  
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1.3.6.4 Hormone therapy 
Androgen deprivation therapy (ADT) is commonly used to treat advanced and 
metastatic prostate cancer, or relapsed disease following radical treatment 
(Nelson & Shah, 2019). Prostate cancer cells are reliant on circulating levels 
of testosterone, and therefore the aim of ADT is to reduce these levels 
(Massard & Fizazi, 2011). ADT is delivered in a number of different formats, 
including luteinising hormone releasing hormone (LHRH) agonists (e.g., 
Goserelin), LHRH antagonists (e.g., Degarelix), anti-androgens (e.g., 
Bicalutamide) and surgical castration (Cornford et al., 2020; Nelson & Shah, 
2019). LHRH agonist have become the gold standard form of ADT, replacing 
surgical castration as they offer reversibility whilst avoiding the physical and 
psychological discomfort of surgery (Cornford et al., 2020). Surgical castration, 
or bilateral subcapsular orchiectomy, involves the removal of both androgen-
producing testicles, and is considered successful when the patients’ serum 
testosterone falls below 20 – 50 ng/ml, with these levels carefully monitored 
post-surgery to determine response (Nelson & Shah, 2019). ADT drugs work 
by interfering with the hypothalamus-pituitary-gonadal axis and the LHRH 
receptor, and therefore LHRH agonists downregulate the production of 
androgens through a negative feedback mechanism (Tolkach et al., 2013). 
One of the side effects of ADT is osteoporosis, and as such patients with bone 
metastases must be carefully considered and require a bone density scan 
before commencing treatment (NICE, 2019).  
 
1.3.6.5 Chemotherapy 
Docetaxel, a taxane chemotherapeutic, is the standard first-line treatment for 
men with metastatic, late-stage disease (Tannock et al., 2004; Quinn et al., 
2017). Cell death is achieved through the inhibitory effects of docetaxel on 
microtubule dynamics, triggering mitotic arrest (Herbst et al., 2003). However, 
some metastatic prostate cancers develop resistance to docetaxel, and as 
such a second-generation taxane, cabazitaxel was approved for the treatment 
of patients who had previously received docetaxel-based regimens (D’Amico, 
2014; de Bono et al., 2010). Chemotherapeutic drugs are delivered 
systemically through intravenous drips in cycles and are often accompanied 
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with severe side effects such as nausea, hair loss and extreme fatigue (CRUK, 
2019; Tannock et al., 2004).  A recent study – the STAMPEDE trial – found 
that docetaxel has potential to be used in combination with hormone therapy 
to illicit a significant clinical response when compared to hormone therapy 
alone (James et al., 2016). In this study, median survival was increased by 10 
months and this treatment regimen is now considered the standard of care for 
newly diagnosed locally advanced or metastatic prostate cancer (James et al., 
2016; Sathianathen et al., 2018). Docetaxel has also been used in 
combination with radiotherapy, which achieved a biochemical recurrence-free 
survival of 94% after two years (Chen et al., 2012). Whilst chemotherapy is 
non-selective, it may provide potential to sensitise cells to radiation and 
therefore increase the efficacy of radiotherapies.  
 
1.3.6.6 Immunotherapy 
Recent advances in immunotherapy have allowed for developments in the 
treatment of many types of cancer to be made, including prostate cancer. In 
the treatment of prostate cancer, the potential of vaccines, checkpoint 
inhibitors and immune cytokines are being explored (Gao et al., 2017; Redman 
et al., 2017). The regulation of immune homeostasis relies upon immune 
checkpoint receptors and co-inhibitory molecules, which mediate the functions 
of effector and regulatory cells by altering their expressions on T-cells 
(Marshall & Djamgoz, 2018). V-domain Ig suppressor of T-cell activation 
(VISTA) negatively regulates T-cell responses and is overexpressed on 
tumour infiltrating myeloid and regulatory cells (Lines et al., 2014). In prostate 
cancers, VISTA expression has been identified as a compensatory inhibitory 
pathway as cytotoxic T-lymphocyte-associated (CTLA) protein 4 (CTLA-4) 
blockade triggered an increase in VISTA expression in response to 
ipilimumab, a CTLA-4 inhibitor (Alaia et al., 2018; Gao et al., 2017). A Phase 
III clinical trial of ipilimumab triggered a promising PSA response rate 
compared to a placebo group, and increased progression-free survival (Beer 
et al., 2017). Ipilimumab has also shown promise in reducing PSA levels when 
delivered in combination with ADT or radiotherapy (Hossain et al., 2018). 
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However, ipilimumab treatment was accompanied with adverse effects in 10% 
of patients, including a rash, nausea, vomiting and fatigue (Beer et al., 2017). 
 
A dendritic cell vaccine, Sipuleucel-T, was approved for the treatment of 
metastatic prostate cancer in 2010 (Anassi & Ndefo, 2011; Kantoff et al., 2017; 
Patel et al., 2008; Redman et al., 2017). Sipuleucel-T uses active cellular 
products harvested from a patient’s own peripheral blood (Anassi & Ndefo, 
2011; Redman et al., 2017). The vaccine consists of autologous peripheral 
blood mononuclear cells (PBMC), including antigen-presenting cells, which 
have been activated ex vivo with a recombinant fusion protein (PA2024) 
(Anassi & Ndefo, 2011; Redman et al., 2017). PA2024 consists of prostatic 
acid phosphatase, an antigen highly expressed in the majority of prostate 
cancers, fused to granulocyte-macrophage colony-stimulating factor (GM-
CSF), an important activator of immune response (Anassi & Ndefo, 2011; 
Kantoff et al., 2017; Redman et al., 2017).  
1.3.7 Castrate resistant prostate cancer 
Castrate resistant prostate cancer (CRPC) develops in 10-20% of men 
following ADT treatment due to loss of normal AR activity and is a much more 
aggressive form of the disease (Scher et al., 2004; Kirby et al., 2011). The 
prognosis for men diagnosed with CRPC is generally poor, with a median 
survival of 18 months (Scher et al., 2004). CRPC is defined as castrate serum 
testosterone <50 ng/dL or 1.7 nmol/L plus either biochemical resurgence of 
PSA, or radiological progression detected by the appearance of new lesions 
despite castrate levels of serum testosterone (Scher et al., 2004; Cornford et 
al., 2020). In men who have yet to receive chemotherapy, docetaxel is offered 
as the first-line treatment for CRPC, yet for those who have already received 
docetaxel or have developed resistance, anti-androgens abiraterone and 
enzalutamide are given which can improve median survival by up to 3 months 
(Arsov et al., 2012; Cornford et al., 2020; Nelson & Shah, 2019; Tannock et 
al., 2004). Abiraterone functions by inhibiting the androgen producing enzyme 
in the adrenal gland, whilst enzalutamide blocks AR from entering the cell 
nucleus to trigger DNA activation (Arsov et al., 2012). The STAMPEDE trial 
also found that abiraterone improves overall survival in non-CRPC compared 
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to standard ADT alone (James et al., 2016). Serum testosterone levels have 
proven a useful biomarker in the selection of treatment methods for CRPC, 
with patients presenting with very low levels having a better outcome when 
treated with abiraterone compared to enzalutamide (Hashimoto et al., 2019). 
Recent studies have also shown that dual targeting a co-activator of AR-
mediated gene expression, enhancer of zeste homolog 2 (EZH2), alongside 
enzalutamide treatment results in a synergistic anti-tumour effect (Shankar et 
al., 2020).  
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1.4 Current challenges 
One of the main challenges in the treatment of all cancers is the resistance to 
established therapeutic approaches (Zugazagoitia et al., 2016). Through 
recent advances in the modelling of the human genome, a more targeted and 
personalised approach has become available (Nevedomskaya et al., 2018). 
Through this research, the development of more viably therapeutic antibodies 
has been made possible, the clinical application of which has increased 
rapidly. Another challenge in the treatment of cancers, particularly with regards 
to prostate cancer, is the toxic side-effects associated with current treatment 
regimes, which can have a significant negative impact upon a patient’s quality 
of life (Herbst et al., 2003; Onishi et al., 2019). To overcome this, ongoing 
research into the potential of immunotherapies, such as ipilimumab and 
Sipuleucel-T, have allowed for more patient-specific treatments (Gao et al., 
2017). However, given the relatively new field of immune-oncology, more 
efficient drugs are still needed for the treatment of advanced or metastatic 
prostate cancer, whilst limiting any side effects for patients. The onset of 
CRPC also presents clinical challenges, with many cases developing 
resistance to first-line docetaxel treatment (Arsov et al., 2012). The 
identification of novel drug targets for clinical application is therefore still 














1.5 The STEAP family 
Through the identification of novel biomarkers for cancer progression, a further 
insight into the mechanisms behind metastasis can be developed, which may 
subsequently aid in the management of the disease (see Section 1.1.2.3). Of 
particular interest is the six transmembrane epithelial antigen of the prostate 
(STEAP) family, which warrants further evaluation into its role in prostate 
cancer progression (Grunewald et al., 2012; Sikkeland et al., 2016; Whiteland 
et al., 2014). The STEAP family has four members, STEAP1 – 4, all of which 
comprise of six transmembrane helices (Porkka et al., 2002; Grunewald et al., 
2012; Sikkeland et al., 2016).  
 
All four members of the STEAP family have a COOH-terminal domain, which 
shares significant homology with the yeast FRE family of b-type cytochrome 
metalloreductases (Gomes et al., 2012). They also all have an N-terminal with 
homology to the archaeal and bacterial F420H2:NADP+ oxidoreductase (FNO)-
binding proteins (Ohgami et al., 2006). Two conserved histidine residues are 
present which allow for the uptake of iron and copper by STEAP proteins by 
binding to an intramembranous heme group (Ohgami et al., 2005). STEAP 
proteins contain a heme-binding domain known as the apoptosis, cancer and 
redox associated transmembrane domain (ACRATA) (Sanchez-Polido et al., 
2004). This ACRATA domain is also present in a structurally related family 
which includes STEAP family members, the bacterial NADPH oxidase (Nox) 
family, and the oxidoreductase family YedZ (Ohgami et al., 2005 & 2006; 
Sanchez-Polido et al., 2004). Electron transfer may be supported through this 
heme-binding function, which has been found to affect cell growth and 
metabolism in Nox proteins, and electron transport across membranes in both 
Nox and STEAP proteins (Oosterheert et al., 2020; Yamada et al., 2004).  
 
Another shared property of the STEAP family members is the Rossman fold 
(GXGXXG/A motif), which is a common feature of proteins with 
oxidoreductase and dehydrogenase functions (Ohgami et al., 2005). The first 
identified role of the STEAP family of proteins, with the exception of STEAP1 
due to the absence of the FNO-like domain in the Rossman fold, was their 
 33 
function in metal homeostasis and metabolism through reducing iron and 
copper, allowing for their uptake (Gomes et al., 2012; Ohgami et al., 2006). 
1.5.1 STEAP1  
The first member of the STEAP family to be identified was STEAP1 (Hubert et 
al., 1999). STEAP1 is located on chromosome 7q21.13 and comprises of 5 
exons and 4 introns (Gomes et al., 2012). When transcribed, the STEAP1 
gene gives rise to two different messenger ribonucleic acid (mRNA) transcripts 
of 1.4 kb and 4.0 kb, yet only the 1.4 kb transcript is processed into the mature 
protein, consisting of 339 amino acids (aa) with an estimated molecular weight 
of 36 kilodaltons (kDa) (Korkmaz et al., 2002). In the prostate, STEAP1 mRNA 
and protein expression is significantly elevated, with protein expression 
particularly high in lymph and bone metastases of prostate cancer (Whiteland 
et al., 2014). STEAP1 overexpression has also been found in cancers of the 
breast, bladder, lung and colon and Ewing’s sarcoma, yet research is 
predominantly focussed on its involvement in prostate cancer progression 
(Gomes et al., 2014; Grunewald et al., 2012; Lee et al., 2016; Xie et al., 2019). 
In vitro, STEAP1 is highly overexpressed in the AR-sensitive prostate cancer 
cell line LNCaP and overexpressed to a lesser extent in the AR-independent 
prostate cancer cell lines PC3 and DU145 (Gomes et al., 2014).  
 
STEAP1, a membrane-bound channel protein, is implicated in tumour 
intercellular communication through regulating the transfer of small molecules 
between neighbouring cells (Ohgami et al., 2016). The expression level of 
STEAP1 has also been found to be proportionate to Gleason score in prostate 
cancers, implying STEAP1 overexpression correlates with a more advanced, 
aggressive disease (Gomes et al., 2014). This hypothesis is supported by 
studies which have shown STEAP1-knockdown to reduce tumour proliferation, 
growth and metastasis in Ewing’s sarcomas and lung cancers in vivo 
(Grunewald et al., 2012; Zhuang et al., 2015). It has been suggested that 
STEAP1 promotes tumourigenesis through elevated activity levels of ROS in 
Ewing’s sarcomas and in thyroid epithelial cells (Grunewald et al., 2012; Pan 
et al., 2008). STEAP1 is a homologue of NAPDH oxidases, which are 
frequently overexpressed in cancers and are involved in the production of 
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cellular ROS (Lambeth et al., 2004; Sanchez-Pulido et al., 2004; von Rozycki 
et al., 2004). STEAP1 has also been linked to EMT-related genes, which 
promote cancer metastasis and invasion (Xie et al., 2019). This is thought to 
occur through the regulation of calcium ion concentration by STEAP1, which 
affects the balance of E-cadherin and N-cadherin, and in turn increase tumour 
motility and invasiveness (Hazan et al., 2004; Xie et al., 2019).  
 
The expression of STEAP1 may also be influenced by a separate but related 
gene, STEAP1b (Gomes et al., 2014). STEAP1b is located on the same 
chromosome as STEAP1, shares 88% of its amino acid profile with STEAP1 
and encodes for two transcripts; STEAP1b1 and STEAP1b2 (Gomes et al., 
2014). Studies have found that in prostate cancer cells, both STEAP1 and 
STEAP1b2 are overexpressed, whereas STEAP1b1 has no differential 
expression when comparing prostate cancer cells and normal prostate 
epithelial cells (Gomes et al., 2014).  
1.5.2 STEAP2  
STEAP2, also known as six transmembrane protein of prostate 1 (STAMP1), 
is located on chromosome 7q21.13, contains 6 exons and 5 introns, and 
encodes for a 490 aa long protein with an estimated molecular weight of 56.1 
kDa (Gomes et al., 2012; Korkmaz et al., 2002; Porkka et al., 2002). The 
upregulation of STEAP2 has recently been suggested to be the result of 42 
deleterious non-synonymous single nucleotide polymorphisms (nsSNPs) 
altering the protein sequence (Naveed et al., 2016). STEAP2 is predominantly 
located to the plasma membrane, and green-fluorescent protein (GFP) 
labelling revealed STEAP2 as a cell-surface protein (Porkka et al., 2002). 
STEAP2 has been suggested to play a role in protein sorting and secretory 
pathways, as it shuttles to the Golgi organelle and trans-Golgi network (Figure 
1.5; Gomes et al., 2012; Grunewald et al., 2012; Korkmaz et al., 2002). 
STEAP2 is significantly overexpressed in prostate cancer when compared to 
normal healthy tissue (Burnell et al., 2018; Whiteland et al., 2014). 
Transfection with STEAP2 in the normal prostate cancer cell line PNT2 
resulted in a more aggressive phenotype, with cells gaining an increased 
migratory potential (Whiteland et al., 2014). When STEAP2 expression was 
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knocked down using small interfering RNA (siRNA), cancer cell migration and 
invasion was significantly inhibited, further suggesting a role for STEAP2 in 
driving aggressive prostate cancer traits (Burnell et al., 2018).  
 
In prostate cancer, overexpression of MMPs -2, -7, -9, -13 and -14 have been 
found to promote disease progression and proliferation (Kue et al., 2002). 
STEAP2, a molecule whose downstream effectors are MMPs has been found 
to increase extracellular signal regulated kinase (ERK) signalling and is 
involved in the endocytotic and secretory pathways (Korkmaz et al., 2002; 
Wang et al., 2010). Using these pathways, STEAP2 moves in both directions 
between the Golgi complex and the plasma membrane, suggesting it may act 
as a receptor for both endogenous and exogenous ligands, for example lipids 
and proteins, or play a role in protein regulation (Figure 1.5; Gomes et al., 
2012; Grunewald et al., 2012; Korkmaz et al., 2002). When down-regulated, 
STEAP2 has been found to up-regulate cell cycle inhibitors such as cyclin-
dependent kinase inhibitors (CDKIs) and p21, both in vivo and in vitro, which 
exerts an effect of tumour growth (Wang et al., 2010). This down-regulation 
also has an effect on proliferation, as apoptosis levels are increased. 
Knowledge of the exact function of STEAP2 in human prostate cancer tumours 
is still limited, in particular its effects on migration and invasion. Previous 
studies did however find that STEAP2 was in fact up-regulated up to 2.5-fold 
in prostate tumours when compared to normal glands, indicating that the 
molecule may play a role in oncogenesis (Korkmaz et al., 2002). This 
overexpression was also confirmed through immunohistochemical analysis of 
benign and cancerous tissues, which correlated with mRNA expression data 
(Wang et al., 2010). This study did not, however, find a correlation between 
Gleason score and expression of STEAP2, suggesting the protein acts 
independently of cancer stage. STEAP2 is also involved in the uptake of iron 
and copper, acting as a ferrireductase and cupric reductase by reducing Fe3+ 
to Fe2+, and Cu2+ to Cu+ (Figure 1.5; Knutson et al., 2007; Ohgami et al., 
2006). Iron and copper availability in the choroid plexus (where cerebrospinal 
fluid is synthesised and ions between the blood and cerebrospinal fluid is 
controlled) and in the gastrointestinal tract, may be regulated by STEAP2 in 
the enterocytes of the proximal duodenum (Knutson et al., 2007). 
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The overexpression of STEAP2 in prostate tissue combined with the fact that 
prostate cancer progression is androgen dependent warrants investigations 
into the involvement of androgens in the regulation of STEAP2 expression. In 
vitro, the highest STEAP2 expression levels have been found in the androgen-
sensitive lymph node metastatic prostate cancer cell line LNCaP when 
compared to the normal prostate epithelial cell line PNT2 (Burnell et al., 2018; 
Whiteland et al., 2014). Androgen-dependent CWR22 tumours significantly 
regressed following castration when grown in mice, regardless of altering the 
mRNA expression of STEAP2 (Korkmaz et al., 2002). Subsequently, when 
LNCaP cells were cultured with a synthetic androgen, STEAP2 expression 
was not significantly different to untreated cells (Korkmaz et al., 2002; Porkka 
et al., 2002). However, a decrease in STEAP2 expression may be due to 
another deregulatory mechanism occurring during disease progression as 
these studies did not find any major genomic changes or mutations (Korkmaz 
et al., 2002; Porkka et al., 2002). A partial cell cycle arrest was found at the 
G0-G1 phase, suggesting that STEAP2 may regulate genes involved in this 
stage of the cell cycle, as prostate cancer cell proliferation has been seen to 
increase by STEAP2 both in vitro and in vivo (Wang et al., 2010). When 
knocked down, STEAP2 has been found to increase apoptosis in prostate 
cancer cells, yet further studies are required to explore the mechanisms 




Figure 1.5. Structural overview of STEAP2. STEAP2, like all four members 
of the STEAP family, comprises of six transmembranes resulting in three 
extracellular loops. At the N-terminus of STEAP2, a NAD(P)H/FAD domain is 
present. STEAP2 comprises of 490 aa. Two heme metal binding sites are also 
present where ferriductase activity takes place. Image adapted from (Gomes 
et al., 2012; Grunewald et al., 2012). Created using BioRender. 
 
1.5.3 STEAP3  
STEAP3 – also known as tumour-suppressor activated pathway-6 (TSAP6) – 
is located on chromosome 2q14.2, consists of 6 exons and 5 introns, is 
composed of 488 aa and has a molecular weight of 50-55 kDa (Ohgami et al., 
2005; Passer et al., 2003). Like other STEAP family members, STEAP3 is 
localised to the plasma membrane, close to the nucleus and vesicular tubular 
structures (Amzallag et al., 2004). STEAP3 is highly expressed in 
haematopoietic tissues and supports physiological functions involved in iron 
metabolism, and as such has been linked to several types of anaemia, 
including iron deficiency anaemia and hypochromic microcytic anaemia 
(Lambe et al., 2009; Ohgami et al., 2005). In hypochromic microcytic anaemia, 
an autosomal recessive disorder resulting from a deletion in both STEAP3 
alleles, insufficient iron is supplied to erythrocytes leading to impaired 
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haemoglobin synthesis, which has been found to be completely reversed once 
STEAP3 expression is restored (Ohgami et al., 2005).  
 
Overexpression of STEAP3 mRNA has also been linked to cancers of the 
lungs, prostate, liver, colon and brain along with myeloid leukaemia (Han et 
al., 2018; Lespagnol et al., 2008; Na et al., 2020; Passer et al., 2003). STEAP3 
has been linked with apoptosis and inhibition of the cell cycle during G2 – M 
phase through interactions with Myt1 kinase, a regulator of cyclin-dependent 
kinase activity and Nix, a mitochondrial proapoptotic protein (Passer et al., 
2003; Schweers et al., 2007). Apoptosis and cell cycle inhibition is also 
triggered through functional p53-binding sites present in the promotor region 
of the STEAP3 gene, which interact with My1 and Nix proteins (Amzallag et 
al., 2004; Lespagnol et al., 2008; Ohgami et al., 2005; Passer et al., 2003; 
Schweers et al., 2007). In vivo, p53 activation following induced DNA damage 
triggered the production of exosomes in a STEAP3-dependent manner, 
suggesting that STEAP3 modulates protein secretion in exosomes that are no 
longer required for cell survival (Lespagnol et al., 2008). In vitro, STEAP3 
became upregulated in response to p53 activation in myeloid leukaemia and 
breast cancer cell lines, increasing cell death (Lespagnol et al., 2008; Passer 
et al., 2003). Cell cycle arrest at the G0-G1 phase has also been triggered in 
colon cancer cells in response to STEAP3-knockdown, alongside inhibition of 
cancer cell proliferation and migration (Na et al., 2020).  
1.5.4 STEAP4 
STEAP4, also known as six transmembrane protein of prostate 2 (STAMP2), 
is located on chromosome 7q21, contains 5 exons and 4 introns, consists of 
495 aa and has an estimated molecular weight of 52 kDa (Korkmaz et al., 
2005). STEAP4 cellular localisation is similar to that of STEAP2, as it is located 
in the plasma membrane close to the nuclear region where it co-localises to 
the Golgi complex and trans-Golgi network (Korkmaz et al., 2005). Whilst 
STEAP4 is overexpressed in prostate cancer, the main focus of research into 
STEAP4 has focussed on its involvement in lipid metabolism due to its 
overexpression in adipose tissue (Korkmaz et al., 2005; Ohgami et al., 2006; 
Zhang et al., 2008). As such, STEAP4 has been implicated in obesity and 
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obesity-dependent insulin resistance, as its expression becomes 
downregulated in patients who are obese (Arner et al., 2008; Chen et al., 2014; 
Ozmen et al., 2016; Qi et al., 2015; Qin et al., 2010). The involvement of 
STEAP4 in obesity has been found to be the result of low-grade inflammation, 
with STEAP4 suggested to play a role in other inflammatory disorders (Ozmen 
et al., 2016; Sharma et al., 2015). The expression of a STEAP4 mouse 
homologue, tumour necrosis factor alpha (TNF-a)-induced adipose-related 
protein (TIARP) was found to be significantly increased by TNF-a, IL-6 and IL-
1B (Arner et al., 2008; Inoue et al., 2009; Qin et al., 2010; Yoo et al., 2014). In 
human adipose tissue, treatment with TNF-a increased the expression of 
STEAP4 in a dose-dependent manner, further suggesting its role in 
inflammatory processes (Qin et al., 2010). TNF-a along with STEAP4 has also 
been found to correlate with rheumatoid arthritis in obese patients, with 
STEAP4 and CD68+ co-localising in the joints, and STEAP4 overexpression 
found in synovial fluid (Inoue et al., 2009; Matsumoto et al., 2008).  
 
In prostate cancer progression, STEAP4 plays a vital role in cell viability, 
proliferation and apoptosis, the latter of which is mediated by caspase-3 and 
caspase-8 (Qin et al., 2010). The role of androgens in the involvement of 
STEAP4 upregulation has also been explored and it was found that synthetic 
androgen induction increased the expression of STEAP4 mRNA in both a 
time- and dose-dependent manner (Korkmaz et al., 2005). Androgen-
insensitive prostate cancer cell lines were also found not to express STEAP4, 
further suggesting STEAP4 expression is dependent on an active AR being 
present (Korkmaz et al., 2005).  STEAP4 overexpression has also been found 
to increase prostate cancer cell proliferation, which is thought to be due to 
interactions between STEAP4 and focal adhesion kinase (FAK) (Tamura et 
al., 2009). Insufficient activation of FAK when STEAP4 is inhibited reduced 
cell growth of prostate cancer cells in vitro, suggesting that FAK 
phosphorylation by STEAP4 induces a proliferative effect in prostate cancer 




1.5.5 The STEAP family as therapeutic targets  
The STEAP protein family present an attractive target for novel therapeutic 
agents to treat prostate cancer. Given its specific localization to the cell 
membrane, STEAP1 has been suggested as a tumour-associated antigen, 
with studies reporting STEAP1 to be an effective antigen for T-cell based 
immunotherapy (Alves et al., 2006; Moreaux et al., 2012; Rodeberg et al., 
2005). STEAP1 has also been the target of specific monoclonal antibodies, 
which exerted a significant effect on reducing the cell growth of prostate and 
bladder tumours in vivo (Challita-Eid et al., 2007). Prostate cancer progression 
has been inhibited in vivo through the immunisation of mice with recombinant 
DNA and modified vaccinia virus Ankara (MVA) vectors encoding STEAP1 
(Krupa et al., 2011). These vaccinations significantly reduced tumour burden 
and proliferation, whilst increasing T-cell infiltration to the prostate tissues 
(Krupa et al., 2011). Furthermore, it has been hypothesised that the survival 
mechanism of high membranous STEAP1 expression as a result of elevated 
ROS levels may sensitise cells to radiotherapy (Grunewald et al., 2012; Sun 
et al., 2010).  
 
STEAP2 has previously been suggested as a potential drug target for the 
treatment of advanced prostate cancer due to its overexpression in correlation 
with high Gleason Score (Burnell et al., 2018). Targeting the ECL2 of STEAP2 
with anti-STEAP2 monoclonal antibodies found that antibody internalisation 
was dependent on cholesterol activity, yet the exact mechanisms remain 
unclear (Hasegawa et al., 2018).  
 
Increased STEAP3 expression increases the transcriptional levels of the major 
histocompatibility complex (MHC) -1 and -2 in exosomes derived from 
dendritic cells, giving rise to STEAP3 as a potential immunotherapeutic target 
(Amzallag et al., 2004; Machlenkin et al., 2005). In vivo, an anti-tumour effect 
was observed when activated autologous cytotoxic T-lymphocyte (CTL) cells 
were administered subcutaneously to previously induced prostate tumours in 
mice (Machlenkin et al., 2005). STEAP3 has also been suggested as an 
indicator of disease progression in glioma patients, as its overexpression 
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activates STAT3-FoxM1 axis signalling and induces mesenchymal transition 
and promotes transferrin receptor (TfR) expression, which correlates with an 
invasive phenotype (Han et al., 2018).  
 
Targeting STEAP4 with an anti-STEAP4 antibody in preadipocyte cells 
reduced proliferation and inhibited the cell cycle at G1-S phase, suggesting 
that STEAP4 may be a potential target in the clinical management of obesity 
(Qin et al., 2010). In prostate cancer cells in vitro, treatment with an anti-
STEAP4 monoclonal antibody inhibited cell proliferation (Tamura et al., 2009). 
Collectively, the STEAP family of proteins present an attractive target for 
therapeutic agents in the treatment of various cancers and other 
haematological disorders. The FNO-like domain, which is present in STEAP2, 
STEAP3, and STEAP4 could also be a potential target given its specificity to 




1.6 Antibodies and their use as therapeutics 
1.6.1 Antibody structure  
Antibodies have become the most rapidly expanding and evolving class of 
pharmaceuticals since their identification over one hundred years ago and 
have been used to treat a variety of human disease, including cancers (Chen 
et al., 2020; Strebhardt & Ullrich, 2008). Antibodies are immunoglobulins, the 
majority of which used in the clinical management of patients are of the 
immunoglobulin G (IgG) format and are composed of antigen-binding sites 
within the variable domain in the heavy chain (VH) and light chain (VL) and 
constant regions (CH & CL) (Chen et al., 2020). Traditional full-length 
antibodies also consist of Fab fragments which are involved in antigen binding, 
and Fc fragments which can activate a variety of immunological pathways to 
trigger cell death (Figure 1.6; Chen et al., 2020). To reduce the production of 
human anti-mouse antibodies, antibody genetic engineering technology is 
used to humanise antibodies which are predominantly generated in 
mammalian, often murine, cells (Chen et al., 2020; Reichert et al., 2005).  
 
Cell death is triggered by antibodies through immune-mediated processes 
including antibody-dependent cellular cytotoxicity (ADCC), antibody-
dependent cell phagocytosis (ADCP), complement-dependent cytotoxicity 
(CDC) and regulation of T-cell activation (Chen et al., 2020). Signalling 
pathway blockade is often the principal mechanism for antibody-based cell 
killing, which is mediated by the Fc fragments on antibodies through 
interactions with receptors (FcγRs) expressed on effector cells (Chen et al., 




Figure 1.6. Immunoglobulin G (IgG) antibody structure. Fab: antigen 
fragment binding regions; Fc: constant fragment region; H and L: heavy chain 
and light chain peptides; VH and VL: variable heavy and light chain domains; 
CH1, CH2, CH3 and CL constant heavy chain and light chain domains. 
Antigen binding site (black) where the paratope of the antibody binds to the 
epitope (red) of an immunogen. Adapted from (Chen et al., 2020). Created in 
BioRender.  
 
1.6.2 Polyclonal antibodies  
Polyclonal antibodies (pAbs) target multiple epitopes, offering broad strain 
protection and, unlike monoclonal antibodies (mAbs), are less likely to induce 
selective resistance (Stiehm et al., 2008). pAbs are used to treat a number of 
diseases, including those caused by viruses, venoms and toxins along with 
cancers (Stiehm et al., 2008; Wang et al., 2013). Often higher doses of pAbs 
are needed to observe a clinical effect as a smaller fraction of antibodies bind 
the target of interest, with only a low percentage of these triggering the desired 
result (Wang et al., 2013). To overcome this lack of specificity, the 
development of cocktails of antibodies have been of particular interest which 
bind multiple non-overlapping epitopes and allow the broad-spectrum activity 
of a pAb to be combined with the benefits of an engineered mAb (Wang et al., 
2013). These oligoclonal antibody cocktails have proven effective in the 
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treatment of some cancers, particularly those with mutated epidermal growth 
factor (EGF) receptor (EGFR) (Ben-Kasus et al., 2009; Demarest et al., 2011). 
Combining two anti-EGFR mAbs (Cetuximab and Panitumumab) was proven 
effective at inhibiting tumour growth by triggering EGFR internalisation and 
degradation in pancreatic cancer cells in vitro (Ben-Kasus et al., 2009). PSA 
expression has previously been reduced in a clinical trial which studied the 
effects of treatment with the polyclonal recombinant antibody Bevacizumab 
delivered in combination with immunotherapy, yet negative effects on dendritic 
cells were observed suggesting a more selectively targeted approach is 
required (Rini et al., 2006).  
1.6.3 Monoclonal antibodies  
mAbs are those that originate from the same parent clone and have become 
increasingly popular in the treatment of various diseases such as cancer, 
autoimmune disorders and chronic inflammatory disorders due to their high 
specificity and affinity for targeted antigens (Tsumoto et al., 2019; Weiner, 
2015). Since the development of the first FDA approved mAb drug OKT3 in 
1985, therapeutic mAbs have entered a rapid development phase (Tsumoto 
et al., 2019). Advances in genetic engineering and conjugation technology 
have allowed for the development of more complex mAbs that include the full-
length IgG (Wang et al., 2018). These include derivates such as single-chain 
variable fragments (scFvs), nanoparticle-based antibodies and 
immunoconjugates (Wang et al., 2018). Improvements have also been made 
to the binding activity, immunogenicity, stability and selectivity of therapeutic 
mAbs, allowing for increased safety and efficacy in clinical applications (Wang 
et al., 2018). In prostate cancer, a recent study targeting secreted extracellular 
nicotinamide phosphoribosyltransferase (eNAMPT) with a humanised 
eNAMPT-neutralising mAb significantly reduced tumour invasiveness both in 
vitro and in vivo (Sun et al., 2020).  
1.6.4 Antibody-Drug Conjugates  
Recent advances in antibody-drug conjugates (ADCs) which compose of a 
humanised antibody and small molecular drug via a chemical linker, have 
progressed the clinical management of certain cancers (Beck et al., 2017; 
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Zhao et al., 2020). The largest class of cytotoxic ADCs in clinical development 
are auristatin derivatives, including monomethyl analogues monomethyl 
auristatin E/F (MMAE and MMAF, respectively) (Beck et al., 2017). ADCs build 
upon the specific binding properties of mAbs and selectively bind to receptors 
on tumour cells, triggering internalisation, usually through the endocytosis 
pathway (Sievers & Senter, 2013). The chemical linker is then rapidly cleaved, 
allowing for the release of the cytotoxic drug and subsequent mechanisms of 
action to be triggered (Diamantis & Banerji, 2016; Sievers & Senter, 2013; 
Zhao et al., 2020). Internalisation is a key element to the cytotoxic effects of 
an ADC drug, as non-internalised ADCs can exert a bystander effect, inducing 
cell death by penetrating the membranes of neighbouring cells (Kovtun et al., 
2006). A clinical trial utilising humanised mAb targeting PSA combined with 
ADC technology has shown promise in the treatment of prostate cancer, yet 
neurotoxicity was increased, highlighting the need for further investigations in 
















1.7 CRISPR/Cas9 technology  
Clustered regularly interspaced short palindromic repeat (CRISPR) –
associated protein 9 (Cas9) is a novel ribonucleic acid (RNA)-guided 
endonuclease-based genome editing technique (Yi & Li, 2016). The Cas9 
endonuclease is precisely guided to target sites by a single-guide RNA 
(sgRNA) in order to induce double strand breaks (DSBs), which trigger DNA 
repair processes to produce site-specific genomic modification (Yi & Li, 2016).  
  
The most commonly used CRISPR/Cas9 system consists of three main 
components; the Cas9 endonuclease, CRISPR RNA (crRNA) and trans-
activating crRNA (tracrRNA), and is known as the type II CRISPR/Cas9 
system (Jinek et al., 2012). To make smaller edits to the genome, the most 
simple and successful method is the use of single stranded DNA 
oligonucleotides (ssODNs) as active repair templates in nuclease-mediated 
genome editing (Bialk et al., 2015). To render high-efficiency cleavage of any 
target sequence, combining the expression of sgRNA and Cas9 has been 
proven most effective (Jinek et al., 2012). 
 
One of the main advantages this RNA guided CRISPR/Cas9 system has over 
conventional genome editing processes is its ease of use and cost-effective 
synthesis, as only a short complementary sgRNA is required for DNA targeting 
(Wei et al., 2013). In studies requiring a more high-throughput approach to 
genome editing, CRISPR/Cas9 can edit multiple different sites simultaneously 
simply through the use of multiple sgRNAs for various target sequences (Cong 
et al., 2013; Wang et al., 2013). One further advantage of CRISPR/Cas9 
systems over RNA interference (RNAi) techniques is that fewer off-target 
effects are encountered as it functions at a DNA level, knocking down or 
permanently inactivating the gene (Sanchez-Rivera et al., 2015).  
1.7.1 CRISPR/Cas9 in cancer research  
Given the many advantages of CRISPR/Cas9 technology, these systems have 
proven successful tools in genome editing of cancers, as many involve 
numerous mutations and therefore require the ability to edit several genes 
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simultaneously (Chen et al., 2015; Hsu et al., 2014). In cancer therapeutics, 
the CRISPR/Cas9 system allows for the direct targeting of cancer cell 
genomes and is also applicable in the precise engineering of immune cells in 
cancer immunotherapy (Hsu et al., 2014; Shi et al., 2017). Cancer progression 
may be inhibited using CRISPR/Cas9 systems, as genetic alterations may be 
corrected through the induction of precise loss of function (LOF) and gain of 
function (GOF) modifications both in vitro and in vivo, which has the potential 
to be applied to numerous different cancers (Hsu et al., 2014; Yi & Li, 2016). 
One of the main challenges faced in the development of chemotherapeutic 
agents is the ability of cancer cells to overcome resistance, which accounts for 
the main cause of chemotherapy failure. However, CRISPR/Cas9 systems 
provide the potential to inactivate such genes causing chemotherapeutic 
resistance, which may subsequently increase the efficacy of chemotherapy (Yi 
& Li, 2016). This theory has been proven successful in an osteosarcoma cell 
line, when MDR1, known to confer drug resistance, was efficiently knocked 
out by targeting of exon 5 by CRISPR/Cas9 (Liu et al., 2016). Tang & Shrager, 
2019, also overcame drug resistance in EGFR-mutant lung cancers by using 
CRISPR/Cas9 to target a mutation at position 790, exon 20 which causes a 
substitution of threonine with methionine (T790M) and is related to resistance 
to tyrosine kinase inhibitors (TKIs). 
1.7.2 CRISPR/Cas9 limitations 
The application of CRISPR/Cas9 genome editing systems as a potential future 
therapeutic option in cancer treatment warrants further investigations to 
enhance the efficacy of their application, and to develop such systems for 
clinical use once off-target effects and delivery methods have been addressed. 
The off-target effect of Cas9-induced DNA cleavage is one of the main 
hindrances in the universal application of the CRISPR/Cas9 system, and has 
been studied through a variety of techniques including computational, 
crystallography and single-cell analysis (Klein et al., 2018; Nishimasu et al., 
2014; Singh et al., 2016). The ability of Cas9 to cleave targets with a minor 
number of mismatches is the result of the genetic sequence of the virus 
mutating to evade Cas9 nuclease attack (Herai, 2019; Li et al., 2019). There 
have been several suggested approaches to overcome off-target effects by 
 48 
stabilising on-target binding. One method is to chemically modify the gRNA 
backbone to incorporate 2′-O-methyl-3′-phosphonoacetate at specific sites of 
gRNA, or partly replace RNA nucleotides with DNA nucleotides (Ryan et al., 
2018; Yin et al., 2018). Another possible limitation of the CRISPR/Cas9 
system is the ability of surviving colonies to contain wild-type (WT) sequences 
as a result of incomplete CRISPR-based editing (Vento et al., 2019). These 
colonies, referred to as “escaper colonies” are the result of mutations in either 
the gRNA or Cas9 related genes, or both, leading to the deactivation of the 
delivered CRISPR system (Vento et al., 2019). To prevent the formation of 
escaper colonies, optimisation of Cas9 endonuclease and gRNA expression 
is needed, which can be achieved through the use of high-copy number 
plasmids or stronger gRNA promotors (Guo et al., 2019; Wu et al., 2019). 
Despite its limitations and challenges, CRISPR/Cas9 offers a promising 
genome editing tool which could be implemented in the treatment of a wide 










1.8 The role of androgens in prostate cancer  
The androgen family of hormones have long been implicated in prostate 
development, normal prostate homeostasis, and the development and 
progression of prostate cancer (Davey & Grossman, 2016). Androgens, of 
which testosterone (T) is the prototype, are produced primarily by the testes in 
males with a small amount produced by the adrenal glands (Davey & 
Grossman, 2016; Lonergan & Tindall, 2011). Androgen regulation is mediated 
through AR, a ligand-dependent nuclear transcription factor (Davey & 
Grossman, 2016; Heinlein & Chang, 2004).  
1.8.1 Androgen receptor 
The human AR gene is located on the X chromosome (q11-12) and consists 
of 8 exons, coding for a protein of 919 aa with a mass of 110 kDa (Davey & 
Grossman, 2016; Lonergan & Tindall, 2011). AR consists of four structurally 
and functionally distinct domains: a poorly conserved N-terminal domain 
(NTD), a highly conserved DNA-binding domain (DBD), a moderately 
conserved ligand-binding domain (LBD) and a short amino acid sequence 
known as the hinge region, separating the DBD from the LBD (Davey & 
Grossman, 2016; Heinlein & Chang, 2004 Lonergan & Tindall, 2011).  
 
The cytochrome P450 enzyme, 5α-reductase, converts testosterone to 
dihydrotestosterone (DHT), and is highly expressed within the prostate 
(Figure 1.7; Lonergan & Tindall, 2011; Schmidt & Tindall, 2011). Both 
testosterone and DHT can bind to and activate AR, with the latter having a 
greater affinity and therefore activates target genes at lower concentrations 
than testosterone (Figure 1.7; Lonergan & Tindall, 2011; Schmidt & Tindall, 
2011). AR is located primarily in the cytoplasm prior to ligand binding, and 
associates with heat shock proteins (HSP)-56, -70 and -90 (Smith & Toft, 
2008). These HSPs are attached to cytoskeletal proteins such as Filament A 
(FlnA), which modulates the nuclear translocation and transcriptional activity 
of AR through interactions with the hinge region (Loy et al., 2003). Once inside 
the nucleus, AR binds to specific recognition sequences known as androgen 
response elements (AREs) located in the promotor and enhancer regions of 
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target genes (Dehm & Tindall, 2006). Gene expression is then modulated by 
the completion of the AR transcriptional complex once co-regulators are 
recruited by AR in the nucleus (Figure 1.7; Dehm & Tindall, 2006).  
 
 
Figure 1.7. Summary of androgen receptor activation in the prostate. 
Testosterone (T) is converted to dihydrotestosterone (DHT) by 5α-reductase. 
Androgen receptor (AR) interacts with heat shock proteins (HSP) in the 
cytoplasm and translocates to the nucleus upon binding to DHT where it 
recruits co-regulators required for completion of the AR transcriptional 
complex. Adapted from (Lonergan & Tindall, 2011). Created using BioRender. 
 
 
Under normal conditions, stromal AR signalling promotes cell growth, which is 
balanced by epithelial AR signalling which suppresses basal cell proliferation 
and maintains differentiated luminal cell survival (Wu et al., 2007; Yu et al., 
2012). However, during the onset of prostate cancer and subsequent disease 
progression, epithelial AR undergoes a malignant switch and begins to 
stimulate proliferation rather than maintaining differentiation (Dehm & Tindall, 
2006; Zhou et al., 2015). AR activity also acts as a survival mechanism by 
increasing the ability of prostate cancer cells to evade apoptosis (Dehm & 
Tindall, 2006). Increased AR expression is observed in almost all primary and 
metastatic prostate cancers regardless of stage or grade, hence its suitability 
as a target of various prostate cancer therapies through androgen deprivation 
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(Massard & Fizazi, 2011; Zaffuto et al., 2017). AR has not been implemented 
as a clinical prognostic biomarker for prostate cancer due to a lack of 
reproducible detection methods or defined thresholds (McAllister et al., 2019).  
 
Although the exact mechanisms driving this malignant switch remain unclear, 
several possibilities have been hypothesised including AR overexpression, AR 
mutation, and a shift from paracrine to cell autonomous AR signalling (Han et 
al., 2005; Lonergan & Tindall, 2011). AR and downstream signalling pathways 
are subject to modifications by various factors including post-translational 
alterations, methylation and phosphorylation, and are also involved in 
crosstalk with other signalling pathways such as the PI3K / protein kinase B 
(Akt) and ERK1/2 pathways (Figure 1.8; Górowska-Wójtowicz et al., 2017; 
van der Steen et al., 2013).  
 
Figure 1.8. Summary of the major androgen signalling pathways in 
prostate cancer. Androgen receptor (AR) signalling can arise from several 
non-mutually-exclusive mechanisms including extracellular peptides, 
epidermal growth factor (EGF) and interleukin-6 (IL-6). Adapted from 





1.8.2 Androgen-regulated genes 
AR has been linked to the regulation of many genes involved in the onset and 
progression of prostate cancer. The translation of androgen-responsive genes 
is regulated through the binding of AR to AREs (Heinlein & Chang, 2004; 
Davey & Grossman, 2016). The most widely studied of these genes is PSA, 
which is used to determine the restoration of AR activity post-treatment 
(Cornford et al., 2020; Lipianskaya et al., 2014; Scher et al., 2004). AR is 
recruited to the enhancer region of PSA, increasing its expression through 
transcriptional activation in the N-terminal domain of AR in the nucleus (Dehm 
& Tindall, 2007). In the enhancer region of PSA, AREs recruit other co-
activators and transcription factors including histone acetyltransferases, p160 
family, mediator and RNA polymerase II (PolII) (Takayama et al., 2007; Wang 
et al., 2005). Once activated, PSA triggers disease progression by initiating 
epithelial-mesenchymal transition and cell migration, which is mediated by 
PSA protease activity (Whitbread et al., 2006).  
 
Recent studies have found that up to 90% of all prostate cancer overexpress 
an erythroblast transformation-specific (ETS) oncogene, such as ETS-related 
gene (ERG), ETS translocation variant (ETV)-1, ETV5 and ETV6 (Tomlins et 
al., 2007). Of these, the most common mechanism of overexpression is fusion 
of the ETS gene, usually ERG, with the 5’-untranslated region of the highly 
AR-regulated transmembrane protease serine 2 (TMPRSS2) (Tomlins et al., 
2005 & 2007). PSA and TMPRSS2 overexpression have also been linked to 
CRPC onset following a gain in function mutation in DHT synthesis allowing 
for the restoration of circulating androgens in the serum (Chang et al., 2013).  
 
Other genes regulated by AR activity include FK506 binding protein 5 (FKBP5) 
and G-protein coupled receptor family C group 6 member A (GPRC6A) (Febbo 
et al., 2005; Pi & Quarles, 2012). Both genes are implemented in the 
progression of prostate cancer from localised or locally advanced disease to 
metastatic disease, playing a vital role in intracellular communication and 
increased cell proliferation (Dhondt et al., 2020 & 2016; Pi & Quarles, 2012). 
FKBP5 modulates AR function and signalling through the formation of 
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complexes with HSP90 and HSP70 (Li et al., 2011; Ni et al., 2010). Like AR, 
GPRC6A is also activated through the PI3K/Akt signalling pathway and has 
therefore been linked to disease progression to CRPC (Pi et al., 2015; Zarif & 
Miranti, 2016). Targeting these genes alongside AR may provide novel 






























1.9 Thesis aims 
At present, the treatment of advanced prostate cancer is often challenging as 
current therapies present serious adverse effects which impact upon patients’ 
quality of life. To overcome these challenges, the identification of novel 
biomarkers capable of detecting the progression from early to advanced 
disease in order to offer more personalised treatment approaches are urgently 
needed. One biomarker of interest is STEAP2, which has been previously 
identified within the wider research group at Swansea as being highly 
expressed in advanced prostate cancer when compared to normal prostate 
tissue (Burnell et al., 2018; Whiteland et al., 2014). Research within the group 
found that in vitro, elevated STEAP2 protein expression correlates with an 
invasive phenotype, and increased levels of cell migration and invasion 
(Burnell et al., 2018). The role of STEAP2 in the metastatic spread of prostate 
cancer to the bone remains unclear. These aggressive traits in response to 
elevated STEAP2 expression has been linked with increasing Gleason scores 
and prostate cancer progression (Whiteland et al., 2014). STEAP2 therefore 
presents an attractive molecular drug target for antibody-based drugs in the 
treatment of advanced prostate cancer.  
The aim of this thesis was to determine whether STEAP2 holds potential as a 
viable drug target, specifically focusing on targeted STEAP2-knockout by 
CRISPR/Cas9 engineering. This thesis also aimed to assess the link between 
STEAP2 and AR in relation to prostate cancer progression. To address these 
aims, the thesis objectives were to: 
1. Develop and optimise a robust method to generate and characterise 3D 
prostate cancer spheroid models; 
2. Develop and optimise CRISPR/Cas9 engineering for STEAP2-
knockout to: 
a. Evaluate the impact of STEAP2-knockout on aggressive 
prostate cancer traits (e.g., cell proliferation, migration and 
invasion) and; 
b. Assess AR gene expression in response to STEAP2-knockout; 
3. Select one monoclonal anti-STEAP2 antibody lead candidate to provide 
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proof-of-concept of STEAP2 as a drug target by:  
a. Studying the effect of the anti-STEAP2 monoclonal antibody 
lead candidate on cell viability in 2D and 3D prostate cancer cell 
models and; 
b. Evaluating STEAP2 receptor internalisation to assess the 
suitability of the anti-STEAP2 monoclonal antibody lead 
candidate for use in ADC technology.  
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Chapter 2 
Materials and methods 
2.1 Materials and Reagents 
2.1.1 Reagents 
The reagents used throughout this thesis are detailed in Table 2.1 
 
Table 2.1. Reagents used throughout this thesis. DMEM: Dulbecco’s 
Modified Eagle Medium; MTT: 3-(4,5-Dimethyl- 2thiazoyl)-2,5-diphenyl-2H-
tetrazolium bromide; HCL: hydrochloride; RIPA: Radioimmunoprecipitation 
assay; RPMI-1640: Roswell Memorial Park Medium-1640; TEMED: N, N, N’, 
N’ Tetramethylenethylenediamine; SDS: Sodium-Dodecyl Sulfate; TRIS: 
Tris(hydroxymethyl)aminomethane. 
Reagent Supplier and catalogue number 
Acrylamide/Bis solution 19:1 (30%) BioRad, USA, #161015 
Agarose Sigma Aldrich, UK, #A6013 
Ammonium persulfate (APS) Sigma Aldrich, USA # 215589 
alamarBlue BioRad, UK, #BUF012A 
Bovine serum albumin Sigma Aldrich, UK, #A2153 
Chemiluminescence reagent (ECL) BioRad, USA, #170-5060 
DEPC-treated (RNAse-free) water Thermo Fisher, USA, #AM9916 
DMEM, phenol red-free Life Technologies, UK, #21063029 
Foetal bovine serum Life Technologies, UK, #10271  
Foetal bovine serum (charcoal-
stripped) 
Sigma Aldrich, USA, #F6765 
Formaldehyde, ultra-pure (16%) Polysciences, USA, #18814-20 
Glutamine  Life Technologies, UK, #25030-024  
Glycine Sigma Aldrich, USA, # G8898 
Hoechst  Thermo Fisher, UK, #62249  
MTT  Sigma Aldrich, UK, #T9281  
Miller’s LB Broth powder Sigma Aldrich, USA, #L3152 
RIPA buffer  Sigma Aldrich, USA, #R0278 
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Phosphate-buffered saline Life Technologies, UK, #10010023  
Phosphate-buffered saline 10x MerckMillipore, USA, #6505 
Propidium Iodide  Thermo Fisher, UK, #P1340MP  
RPMI-1640  Life Technologies, UK, #31870025  
SDS 10% BioRad, USA, # 1610416 
TEMED  Sigma Aldrich, USA, #T9281  
Tris-base BioRad, USA, #1610716 
Tris-Glycine (TG) 10x Sigma Aldrich, USA #T4904 
Tris-Glycine-SDS (TGS) 10x Sigma Aldrich, USA, #T7777 
Triton-X 100  Thermo Fisher, UK, #T8787  
Trypsin-EDTA  Life Technologies, UK, #25300-062  
























The material used throughout this thesis are detailed in Table 2.2  
 
Table 2.2. Material used throughout this thesis. 
Material Supplier and catalogue number 
Filter paper BioRad, USA, #1703956 
Flask, T175 VWR, USA, #82050-870 
Flask, T25 VWR, USA, #82051-070 
Flask, T75 VWR, USA, #82050-854 
Foam pads BioRad, USA, #1703933 
Migration culture inserts (2-well)  Ibidi, Germany, #80209  
Mini-Protean glass plates, short  BioRad, USA, #165331 
Mini-Protean outer glass plates BioRad, USA, #1651824 
Nitrocellulose membrane BioRad, USA, # 1620115 
Petri dish, 100 mm VWR, USA, #25384-342 
Transwell inserts, 8.0 µm pore size Sigma Aldrich, USA, #CLS3422 
6-well plate  VWR, USA, # 734-2323 
12-well plate  VWR, USA, #82050-928  
24-well plate  VWR, USA, # 734-2325  
96-well plate  VWR, USA, #10861-666  














The equipment used throughout this thesis are detailed in Table 2.3 
 
Table 2.3. Equipment used throughout this thesis.  
Equipment Supplier and model number 
Bacterial incubator Amerex, USA, GIROMAX 737R 
Benchtop centrifuge VWR, USA, Himac CT6E 
Cell culture imaging system Invitrogen, USA, EVOS XL Core 
Cell culture inverted microscope  ZEISS, Germany, AxioCamERC55  
Cell culture incubator  MarshallScientific, USA, NU-5510  
Centrifuge  ThermoTec, UK, Centra CL3R  
Confocal microscope  ZEISS, Germany, LSM710  
Electrophoresis cell  BioRad, USA, Mini-PROTEAN Tetra Cell 
Heat block Thermo Fisher, USA, Dry Block Heater 
Liquid nitrogen container  Thermo Fisher, UK, Locator JR Plus  
Nanodrop spectrophotometer Thermo Fisher Scientific, UK, ND-1000 
Membrane transfer cell BioRad, USA, Mini Trans-Blot® Cell 
Olympus microscope  Olympus, UK, BX51TF  
Plate centrifuge  Beckman Coulter, USA, Allegra-X14 
Plate reader  BMG Labtech, UK, POLARstar  
PowerPacTM  BioRad, USA, PowerPac HC  
qRT-PCR profiler Thermo Fisher, USA, QuantStudio™ 12K  
Thermal cycler BioRad, USA, T100 Thermal Cycler 
Water bath  Grant, UK, SUB Aqua 18  








2.1.4 Buffers and solutions 
Buffers and solutions used throughout this thesis are detailed in Table 2.4 
 
Table 2.4. Buffers and solutions. APS: Ammonium persulphate; BSA: 
Bovine Serum Albumin; MTT: 3-(4,5-Dimethyl-2thiazoyl)-2,5-diphenyl-2H-
tetrazolium bromide, NaCl: Sodium chloride; SDS: Sodium-Dodecyl Sulfate; 
PBS: Phosphate- buffered Saline; PFA: Paraformaldehyde, TRIS-base: 
tris(hydroxymethyl)aminomethane.  
Blocking buffer (3%) Transfer buffer 
3.0 g BSA 100 ml of TRIS / Glycine 10x 
100 ml of PBS-T 200 ml of methanol 
0.22 µm filtered 700 ml of ddH2O 
Stored at 4oC Stored at room temperature  
Triton-X 100 (0.1%) Running buffer 
0.1 µl of Triton-X 100 100 ml TRIS / Glycine / SDS 10x 
PBS to 100 ml 900 ml ddH2O 
Stored in aliquots at -20oC Stored at room temperature 
PBS-T APS (10%) 
100 ml of PBS (10x) 1.0 g APS 
900 ml of ddH2O 1 ml ddH2O 
1 ml of Tween 20 Stored in aliquots at -20oC 
PFA (4%) MTT (5 mg/ml) 
10 ml of 16% PFA 1 mg of MTT in 200 ml PBS 
40 ml of PBS 0.22 µm filtered  
Stored in aliquots at -20oC Stored in aliquots at -20oC 
10% SDS Miller’s LB Broth 
25.0 g SDS 20 g Miller’s LB Broth powder 
250 ml ddH2O 800 ml ddH2O 
1.0 M Tris, pH 6.8 1.5 M Tris, pH 8.8 
30.4 g TRIS-base 45.4 g Tris-base 
250 ml ddH2O, pH 6.8 250 ml ddH2O, pH 8.8 
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2.1.5 Computer programs 
The computer programs used for analysis throughout this thesis are detailed 
in Table 2.5. 
 
Table 2.5. Computer programs used for analysis. 
Program Supplier and version 
BioRender BioRender, USA, Institution Version 
EVOS XL Core software Invitrogen, USA, Version 1.0.131 
ImageJ ImageJ, USA, Version FIJI 2.0.0. 
ImageLab software BioRad, USA, Version 6.0.1 






2.2 Cell lines 
Cell lines were purchased from American Type Culture Collection ((ATCC), 
LGC Standard). Human prostate cancer cell lines of different origins (C4-2B, 
DU145, LNCaP, PC3), human bone stromal cell line (HS5) and human 
prostate epithelial cell line (PNT2) were utilised throughout this thesis. A 
representative image of each cell line can be seen in Figure 2.1. Details of the 
origins, and diseased state of each cell line used throughout this thesis can be 
found in Table 2.5. 
 
Figure 2.1. Representative images of the cell lines used throughout this 
thesis. A) Normal, non-cancerous prostate epithelial cells PNT2 were used as 
a negative control given the low STEAP2 protein expression in-vitro. B) 
LNCaP-derived prostate cancer cell line C4-2B; C) Brain metastatic prostate 
cancer cell line DU145; D) Lymph node metastatic prostate cancer cell line 
LNCaP; E) Bone metastatic cancer cell line PC3; F) Human, normal bone 
stromal cell line HS5 was used in co-culture with prostate cancer cells. Images 
were acquired with a standard light microscope (AxioCam ERC55, Zeiss, 










Table 2.6. Summary of cell lines used throughout this thesis. 
Cell line Species Origin Diseased state 
LNCaP Human Lymph node Prostate cancer 
C4-2B Human C4-2 derivative Prostate cancer 
DU145 Human Brain Prostate cancer 
PC3 Human Bone marrow Prostate cancer 
PNT2 Human Prostate epithelia Normal 
HS5 Human Bone marrow Normal 
 
2.2.1 LNCaP cell line  
Human, prostate cancer cells derived from a lymph node metastases of a 50-
year-old male patient (ATCC, USA, #CRL-1470). Cells were sub-cultured at a 
ratio of 1:3 or 1:6 according to the supplier’s recommendations in RPMI-1640 
supplemented with 10% FBS, 1% penicillin / streptomycin (P/S) and 1% L-
glutamine, all of which were purchased from Gibco, Life Technologies, UK. 
2.2.2 C4-2B cell line 
Human prostate cancer cells derived from a derivative subline of LNCaP-
derived C4-2 cells. (ATCC, USA, #CRL-3315). The LNCaP cell line described 
in Section 2.2.1 was co-inoculated into an athymic male nude mouse along 
with human fibroblasts derived from an osteosarcoma by Thalmann et al., in 
1994. Following 8 weeks incubation, the mouse was castrated, and after an 
additional 4 weeks a tumour specimen was removed. The C4 cell line 
comprises of the in vitro cultured cells grown from the tumour removed from 
the host mouse. To achieve the C4-2 subline, C4 cells were then co-inoculated 
with osteosarcoma fibroblasts in an already castrated athymic nude male 
mouse for a further 12 weeks, as previously described, and the C4-2 subline 
generated from the prostatic epithelial cells cultured from the host’s resultant 
tumour (Thalmann et al., 1994 & 2000). Cells were sub-cultured at a ratio of 
1:8 or 1:10 according to the supplier’s recommendations in DMEM 
supplemented with 10% FBS and 1% P/S and 1% L-glutamine, all of which 
were purchased from Gibco, Life Technologies, UK. 
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2.2.3 DU145 cell line 
Human, prostate cancer cells derived from a brain metastases of a 69-year-
old male patient (ATCC, USA, #HTB-81). Cells were sub-cultured at a ratio of 
1:4 or 1:6 according to the supplier’s recommendations in RPMI-1640 
supplemented with 10% FBS, 1% P/S and 1% L-glutamine, all of which were 
purchased from Gibco, Life Technologies, UK. 
2.2.4 PC3 cell line 
Human, prostate cancer cells derived from a bone metastases of a 62-year-
old male patient with grade IV prostate cancer (ATCC, USA, #CRL-1435). 
Cells were sub-cultured at a ratio of 1:3 or 1:6 according to the supplier’s 
recommendations in RPMI-1640 supplemented with 10% FBS, 1% P/S and 
1% L-glutamine, all of which were purchased from Gibco, Life Technologies, 
UK. 
2.2.5 PNT2 cell line 
Human, normal prostate epithelial (immortalised). Primary cells were obtained 
from a 33-year-old male post-mortem. Cells were sub-cultured at a ratio of 1:5 
or 1:10 according to the supplier’s recommendations in RPMI-1640 
supplemented with 10% FBS, 1% P/S and 1% L-glutamine, all of which were 
purchased from Gibco, Life Technologies, UK. 
2.2.6 HS5 cell line  
Human, stromal fibroblast cells derived from the bone marrow / stroma of a 
30-year-old healthy male patient (ATCC, USA, #CRL-11882). Cells were sub-
cultured at a ratio of 1:3 or 1:9 according to the supplier’s recommendations in 
RPMI-1640 supplemented with 10% FBS, 1% P/S and 1% L-glutamine, all of 








2.2.7 Cell culture  
 
2.2.7.1 Monolayer cells (2D) 
All cell culture was undertaken with the intention to maintain a safe and sterile 
environment, with cell culture conducted in a biological safety hood with 
laminar-airflow circulation (Scanlaf Mrs, VWR International Ltd, UK). Prior to 
use, all materials (culture flasks, plates and pipettes, cell culture media, PBS 
and trypsin) were disinfected with 70% ethanol. Cells were grown in standard 
cell culture conditions of 37oC / 5% CO2 in an incubator (NuairTM DHD 
AUTOFLOW CO2 Air-Jacketed Incubator). Cell culture media was obtained 
from Gibco, Life Technologies, UK. 
 
DU145, HS5, LNCaP, PC3 and PNT2 cells were maintained in Roswell Park 
Memorial Institute media (RPMI-1640 media, Life Technologies, UK, Cat. 
31870025) supplemented with 10% foetal bovine serum (FBS), 1% glutamine, 
and 1% penicillin/ streptomycin. C4-2B cells were maintained in Dulbecco’s 
Modified Eagle Medium media (DMEM media, Life Technologies UK, Cat. 
21063029) supplemented with 10% FBS, 1% glutamine, and 1% P/S. Phenol-
red free DMEM media (Life Technologies, UK, Cat. 21063029) supplemented 
with 10% FBS, 1% glutamine, and 1% P/S was used for microscopical 
endpoint analysis.   
 
Prior to use, cell culture media, PBS (Gibco, Life Technologies, UK, Cat. 
10010023) and trypsin-EDTA were pre-warmed in an incubator (SUB Aqua 
18, Grant, UK) set at 37oC. To detach cells from tissue culture flasks, all media 
was removed, and they were first washed with 5 ml of PBS and 3 ml of trypsin 
(0.05%; Life Technologies, UK, Cat. 25300-062) was added and cells were 
incubated in standard cell culture conditions (37oC, 5% CO2) for 5-10 minutes, 
incubation times were cell line dependent. 6 ml of fresh media was added to 
neutralise the trypsin, and the cell suspension was transferred to a 15 ml 
centrifuge tube, which was centrifuged at 270 g for 5 minutes using a bench-
top centrifuge (VWR, Himac CT6E, UK). The old media was discarded, and 
the cell pellet resuspended in 10 ml of fresh media, and cells split according 
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to the supplier’s recommended ratio. All cells were propagated in standard cell 
culture conditions (37oC, 5% CO2) in cell cultured treated T75 flasks (VWR, 
USA, Cat. 82051-070). Media was replenished every 3 days when required. 
Once cells had reached 70-80% confluency, cells were sub-cultured according 
to the supplier’s guidelines for each cell line. After 10-15 passages, cells were 
discarded. 
 
2.2.7.2 Determination of cell numbers 
A haemocytometer was used to calculate the number of cells/ml present in the 
cell solutions. 50 µl of cell suspension (Section 2.2.7.1) was pipetted into 
separate 200 µl Eppendorf tubes; 50 µl of 0.4% trypan blue stain was added 
to each Eppendorf tube and thoroughly mixed to create a 1:1 dilution. Each 
chamber of the haemocytometer was loaded with 10 µl of the trypan blue/cell 
suspension, covered with a glass slide and transferred to an inverted light 
microscope (AxioCam ERC55, Zeiss, Germany) using a 10X magnification to 
determine the number of cells present, both total and viable. Cells were 
counted in the four outer corners of the counting grid of the haemocytometer, 
and non-viable cells were distinguished as being stained with trypan blue, as 
opposed to viable cells which remained unstained, as demonstrated in Figure 
2.2. Each sample was counted once.  Only cells touching the top and right 
lines per corner square were counted. An average was calculated by dividing 
the total number of cells by four, and this number used to calculate the cell 
concentration using the following calculations: 
Cell densityf (x 105 cell/ml) x volumef (ml) / cell densityi (x 105 cell/ml) = cell 
suspension (ml) + [volumef (ml) – cell suspension (ml)]  
Where: Cell densityf = final cell density (x 105 cell/ml); Cell densityi = initial cell 
density (x 105 cell/ml); Volumef = final volume (ml)  
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Figure 2.2. Haemocytometer chamber used for cell counting. Schematic 
diagram of one chamber on a haemocytometer loaded with 10 µl of cell 
suspension. The cell number located in four corner squares (primary squares) 
was counted. Inset shows an enlargement of one corner square. Only viable 
cells (white cells), touching the top and right borders (red) were scored and 
those that were non-viable (blue cells) were excluded. 
 
 
2.2.7.3 Growth of 3D spheroids 
For miniaturised 3D cultures, 1.5% agarose gel was prepared by adding 0.15 
g agarose powder (Sigma Aldrich, UK, Cat. A6013) to 10 ml phenol red free 
(PRF) DMEM (Life Technologies, UK, Cat.21063029) in the absence of 
additional supplements and autoclaved at 121oC for 60 minutes and stored at 
room temperature. As the agarose medium is solid at room temperature, it was 
briefly microwaved at half power (450 W) for 45 seconds to liquify prior to use. 
50 µl of 1.5% agarose / culture medium was added to 96-well plates and left 
to solidify at room temperature for 15 minutes. Cells were counted as 
described in Section 2.2.7.2 and seeded at the required density on top of the 
solidified agarose in 100 µl PRF media per well, as depicted in Figure 2.3. 
Spheroids were maintained in standard tissue culture conditions. Media was 
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carefully removed and replenished every 3 days. 3D cultures were maintained 
for up to 7 days.  
 
 
Figure 2.3. Side profile of an individual well of a 96-well plate seeded with 
PCa cells to form spheroids. 96-well tissue culture plates were coated with 
50 µl 1.5% agarose which was left to solidify before a cell suspension of 
prostate cancer cells in 100 µl PRF DMEM was added and incubated in 
standard tissue culture conditions to form spheroids.  
 
2.2.7.4 Cryopreservation 
A 1:9 solution of 1 ml 10% dimethyl sulfoxide (DMSO) and 9 ml FBS was 
prepared for the routine cryopreservation of cells. Once cells reached 80% 
confluency, they were detached from tissue culture flasks by the addition of 10 
ml trypsin, which was then neutralised by the addition of 6 ml cell culture 
media. Cells were suspended and transferred to a 15 ml centrifuge tube and 
centrifuged at 270 g for 5 minutes. The old cell culture media was discarded, 
and the cell pellet resuspended in DMSO/FBS (1:9) solution. 1 ml of this 
solution was added per cryo-preservative vial. Vials were transferred into cryo-
vessels and stored at -80oC for 24 h and then moved to a -140oC liquid 
nitrogen container for long-term storage (Locator JR Plus, Thermo Fisher, UK).  
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2.3 Gene expression 
2.3.1 RNA extraction 
Cells were grown to 80% confluency, trypsinised and neutralised with RPMI-
1640 as described in Section 2.2.7.1. Samples were centrifuged, old media 
discarded, and cell pellets resuspended in 1 ml of TRIzol reagent (Thermo 
Fisher, USA, Cat. 15596026) in 1.5 ml Eppendorf tubes. 200 µl of chloroform 
was then added to each sample in a fume hood, samples were shaken and 
incubated at room temperature for 3 minutes before centrifugation at 270 g for 
15 minutes at 4oC. The upper, clear layer (approximately 500 µl) was 
transferred to a fresh 1.5 ml Eppendorf tube, to which 500 µl isopropanol 
(100% v/v) was added. Tubes were again shaken and incubated at room 
temperature for 10 minutes, prior to centrifugation at 270 g for 10 minutes at 
4oC. The supernatant was then discarded, 1 ml of ethanol (70% v/v) was 
added to each tube which was then vortexed and subsequently centrifuged at 
6010 g for 5 minutes at 4oC. The supernatant was again discarded, and the 
pellet left to air dry for 10 minutes. Pellets were then resuspended in 50 µl 
RNA-free water (Thermo Fisher, USA, Cat. AM9916), and the RNA 
concentration and quality (A260/280) measured using a Nanodrop machine 
(Thermo Fisher, ND-1000, USA). RNA with a A260/280 value between 1.8-2.1 
was considered acceptable. RNA samples were standardised to 200 ng/µl in 
RNAse-free water (Thermo Fisher, USA, Cat. AM9916) and kept on ice for 
immediate cDNA synthesis or transferred to -80oC for long-term storage until 
needed.  
2.3.2 cDNA synthesis 
First strand total cDNA was synthesised using a Promega M-MLV Reverse 
Transcriptase kit (Promega, USA). 20 µl of total RNA (200 ng/µl) obtained from 
Section 2.3.1 was pipetted into 200 µl Eppendorf tube. 1 µl of OligodT15 
(Promega, USA, Cat. C1101) and 1 µl of random hexamer primers (Promega, 
USA, Cat. C1181) were added to each sample. The tubes were then heated 
on a heating block (Thermo Fisher, USA, Cat. 88870001) set at 70oC for 5 
minutes and cooled immediately on ice. A master mix was prepared from the 
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reagents detailed in Table 2.7, 28.5 µl of which was added to each sample in 
the 200 µl Eppendorf tubes. Samples were then heated to 37oC using a 
thermocycler machine (BioRad, T100 Thermal Cycler, USA) and incubated for 
60 minutes. The tubes were then heated on a heating block set at 90oC for 10 
minutes and cooled immediately on ice for immediate use or transferred to  
-20oC for storage up to a maximum of 2-weeks.  
 
Table 2.7. Master mix reagents for cDNA synthesis, per sample.   
Reagent Volume (µL) 
M-MLV 5X Reaction Buffer (Promega, USA, Cat. M5313) 10 
10mM dNTPs (Promega, USA, Cat. U1515) 2.5 
DNAse free H2O (Thermo Fisher, USA, Cat. AM9916) 7 
M-MLV RT (Promega, USA, Cat. M1701) 1 
 
2.3.3 Quantitative reverse transcriptase polymerase chain 
reaction 
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was 
carried out to determine the profiles of genes of interest. A BLAST search was 
performed prior to carrying out each experiment to design unique primer 
sequences specific to each gene of interest. Pre-validated primers for two 
housekeeping genes, b-actin (NM_001101) and GAPDH (NM_002046) were 
used throughout this thesis, the sequences of which are detailed in Table 2.8. 
All primers were reconstituted and diluted in RNAse free water (Thermo 









Table 2.8. Sequences of primers utilised in qRT-PCR experiments 
throughout this thesis. Sequences of primers for the detection of STEAP1-
4, AR, PSA, FKBP5, TMPRSS2 and GPRC6A, including housekeeping genes 
b-actin and GAPDH. 





















































PowerUpTM SYBRTM Green Master Mix (Thermo Fisher, USA, Cat. A25742) 
was used for detection of genes of interest by qRT-PCR. 4 µl PowerUpTM 
SYBRTM Green Master Mix, 1 µl forward primer, 1 µl reverse primer and 2 µl 
cDNA were pipetted into each well of a 384-well PCR plate (VWR, USA, Cat. 
732-3237) in triplicate. Plates were sealed with an adhesive sealing film 
(BioRad, USA, Cat. MSB1001) and centrifuged using a bench-top plate 
centrifuge at 8,000 g for 2 minutes (Beckman Coulter, Allegra-X14, USA). 
Gene profiling was then carried out using an Applied Biosystems™ 
QuantStudio™ 12K Flex Real-Time PCR System, 384-well block (Thermo 
Fisher, USA, Cat. 4471134), the conditions for which are detailed in Table 2.9. 
 
Table 2.9. Cycling conditions for qRT-PCR.  




Heat activation 5 minutes 95 1 
Denaturation 10 seconds 95 40 
Annealing 30-40 seconds 55 40 
Extension 30 seconds 72 40 
 
2.3.4 qRT-PCR gene expression analysis 
Cycle threshold (CT) values obtained from gene profiling (Section 2.3.3) were 
used to calculate the fold expression changes of each gene of interest, 
normalised to control cells. An average was taken of the raw CT values of each 
experimental sample and each control sample for both genes of interest and 
the housekeeping genes.  
 
Expression fold change = 2-DDCT 
 
Delta (D) CT values were calculated as follows: 
GE - HE = DCGE 




GE = Average CT value of genes of interest in experimental cells 
HE = Average CT value of housekeeping gene in experimental cells  
GC = Average CT value of genes of interest in control cells 
HC = Average CT value of housekeeping gene in control cells  
 
DCGE - DCGC = DDCT 
 
2.4 Cell viability quantification 
2.4.1 MTT assay 
Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma Aldrich, UK, Cat. M5655) reduction 
assay. The MTT assay, introduced in 1983, is one of the most widely used 
colourimetric, quantitative biochemical tests for assessing cell viability and 
proliferation (Mossman, 1983). MTT, a tetrazolium salt, can only be cleaved 
by active mitochondria present in metabolically active cells, and is therefore a 
relevant survival assay for distinguishing living cells from dead ones (van 
Meerloo et al., 2011). Upon cleavage by the dehydrogenases in the 
mitochondria of a live cell, the yellow tetrazolium salt is converted into a blue 
formazan crystal, with the principle of this assay being that the amount of 
formazan produced is directly proportional to the number of live, viable cells 
(Figure 2.4; Borra et al., 2009; Van Meerloo et al., 2011).  
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Figure 2.4. Schematic representation of the MTT cell viability assay. Cells 
are seeded in a 96 well plate, to which the yellow MTT tetrazolium salt is 
added. Cells are then incubated for 2-4h, during which the yellow MTT salt is 
reduced to purple formazan crystals by dehydrogenases in the mitochondria 
of viable cells. Absorbance is then read on a plate reader at 570 nm 
wavelength. Adapted from (Präbst et al., 2017). Created using BioRender. 
 
Cells were seeded in clear, flat bottomed 96-well plates at a known, cell line 
dependent density in a volume of 100 µl media per well. Cells were then 
incubated in standard cell culture conditions until the MTT assay was 
performed as an end-point analysis of cell viability. MTT solution was prepared 
by dissolving 5 mg MTT powder in 10 ml PBS, which was then sterile 0.22 µm 
filtered and stored at 4oC while protected from light. 10 µl MTT stock solution 
(5 mg/ml) was then added to each well prior to incubating for a further 2 h for 
2D cell culture models and 4 h for 3D culture models, in the absence of light. 
MTT containing medium was then removed, cells were washed in PBS and 
formazan crystals were solubilised by the addition of 100 µl DMSO per well. 
Plates were placed on a rocker at room temperature for 15 minutes. 
Absorbance was read at A = 570 nm using a POLARstar plate reader 
(POLARstar, BMG Labtech, UK). Cell viability was calculated as a percentage 
of the control cells. Cell viability experiments were conducted in triplicate 
unless otherwise stated. 
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2.4.2 alamarBlue assay for cell viability 
The alamarBlue assay was also utilised for cell viability assessments. 
alamarBlue (blue) is a commercial, resazurin (7-hydroxy-3H-phenoxazin-3-
one 10-oxide)-based, fluorogenic redox indicator which is reduced to resorufin 
(pink), which can be quantified by fluorescence (Borra et al., 2009; Nakayama, 
1997). This reduction occurs enzymatically when resazurin is taken up by the 
mitochondria of cells, by nicotinamide adenine dinucleotide phosphate 
(NADPH) dehydrogenase, which is responsible for the transference of 
electrons from NADPH and H+ to resazurin, which is subsequently reduced to 
resorufin (Figure 2.5; O’Brien et al., 2000; Rampersad et al., 2012).  
 
 
Figure 2.5. Schematic representation of the alamarBlue cell viability and 
proliferation assay. Cells are seeded in a 96 well plate, to which the blue 
alamarBlue reagent is added. Cells are then incubated for 4-6h, during which 
the blue alamarBlue reagent is reduced to pink resorufin by dehydrogenases 
in the mitochondria of viable cells. Absorbance is then read on a plate reader 
at wavelengths of 570 and 600 nm. Adapted from (O’Brien et al., 2000). 
Created using BioRender. 
 
Assays were performed in 96-well plates using the commercial resazurin-
based dye alamarBlue (BioRad, UK, Cat. BUF012A). Cells were cultured in 
96-well plates in 100 µl media per well and left to adhere in standard cell 
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culture conditions for up to 5 days, until the alamarBlue assay was performed 
as an end-point analysis of cell viability. Readings were obtained through the 
application of 10 µl alamarBlue per well, achieving a final concentration of 10% 
(v/v). After the addition of alamarBlue, cells were further incubated for 4 h for 
2D cell culture models and 6 h for 3D models, in standard cell culture 
conditions in the absence of light. Plates were read using a POLARstar plate 
reader (POLARstar, BMG Labtech, UK) at A = 570 nm and A = 600 nm. 
Percentage viability was calculated according to the manufacturer’s 
instructions, using the calculation detailed below and the Molar extinction 
coefficients (E) for alamarBlue at different wavelengths detailed in Table 2.10. 
 
Percentage viability (%) = (O2 x A1) - (O1 x A2) / (O2 x P1) - (O1 x P2) x100 
 
Where:  
O1 = molar extinction coefficient (E) of oxidised alamarBlue (Blue) at 570nm 
O2= E of oxidised alamarBlue at 600nm 
P1 = E of reduced alamarBlue (Red) at 570nm 
P2= E of reduced alamarBlue at 600nm 
A1 = absorbance of test wells at 570nm 
A2 = absorbance of test wells at 600nm 
N1 = absorbance of negative control well (media plus alamarBlue but no cells) 
at 570nm N2 = absorbance of negative control well (media plus alamarBlue 
but no cells) at 600nm 
 
Table 2.10. Molar extinction coefficients (E) for alamarBlue at different 
wavelengths. 
Wavelength (nm) Reduced (E)  Oxidised (E) 
570 155677 80586 
600 14652 117216 
 
 77 
2.5 Cell proliferation 
2.5.1 alamarBlue assay for cell proliferation 
To assess cell proliferation in mono and co-cultured 2D and 3D cells, the 
alamarBlue assay was conducted in the same manner as when assessing cell 
viability, as detailed in Section 2.4.2. Percentage proliferation was calculated 
according to the manufacturer’s instructions, using the calculation detailed 
below and the Molar extinction coefficients for alamarBlue at different 
wavelengths detailed in Section 2.4.2, Table 2.10. Proliferation assays were 
conducted in triplicate unless otherwise stated. 
 
Percentage proliferation (%) = (O2 x A1) - (O1 x A2) / (R1 x N2) - (R2 x N1) 
x10 
2.6 Fluorescence microscopy 
2.6.1 Sample preparation and staining 
2D monolayer and 3D spheroid cultures of prostate cancer cells either as 
monocultures or as co-cultures with HS5 stromal cells were grown in 96-well 
tissue culture plates as described in Section 2.2.7.3. Once incubated for the 
desired length of time, cell cultures were carefully washed 3x with PBS and 
fixed with 4% paraformaldehyde (PFA) for 15 minutes at room temperature. 
For immunofluorescence labelling, cells were again washed 3 times with PBS 
then permeabilised with 0.1% Triton-X 100 for 10 minutes at room 
temperature. Cells were then incubated with primary antibodies, the 
concentration of which was antibody dependent, in blocking buffer (3% 
BSA/PBS) overnight at 4oC. Cells were subsequently washed 3x with PBS and 
incubated with species-specific polyclonal Alexa Fluor-488 secondary 
antibody (Abcam, UK) and incubated for 2-4 hours in standard cell culture 
conditions, protected from light. Cells were then washed 3x with PBS, 3x with 
ddH2O, and counterstained with the nuclear stain Hoechst prior to imaging 
(Thermo Fisher, UK).  
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2.6.2 Confocal microscopy  
A confocal laser scanning microscope (LSM710, ZEISS, Germany) was used.  
To excite green emission fluorochromes (Alexa Fluor-488), the argon-ion was 
used, to excite blue emission fluorochromes (Hoechst) the diode was used, 
and to excite red emission fluorochromes the helium-neon light was used 
(propidium iodide (PI)) (Table 2.11). Zen Black software Version 10 was used 
to process images, and scale bars were based on the known microscope pixel 
sizes for each objective (µm). The red-blue-green (RBG) setting was used to 
display coloured images. 
 
Table 2.11. Excitation and emission wavelengths (nm) of each channel 
used for confocal microscopy and their emission colour. Ex.: excitation 
wavelength (nm), Em.: emission wavelength (nm); PI; propidium iodide. 
Channel Ex. (nm) Em. (nm) Em. colour Light source 
Alexa Fluor-
488 
488 520 Green Argon 
Hoechst 350 461 Blue Diode 
PI 493 636 Red Helium neon 
 
2.7 CRISPR/Cas9 genome engineering in vitro 
2.7.1 Plasmid design  
Oligos were designed using BLAST analysis to encode either the whole 
protein of interest or a variant sequence. Plasmids were then generated from 
chosen sequences using Sanger QuickPick Knockout gRNA (Sigma Aldrich, 
USA). Viral blue fluorescent protein (BFP) guide RNA (gRNA; vector: U6-
gRNA/PGK-Puro-2A-BFP; Cat. HSANGERV) plasmids were purchased from 
Sigma Aldrich, USA. PsPAX-2 (Cat. 12260) lentiviral packaging protein and 
pCMV-vsvg (Cat. 8454) envelope protein were purchased from Addgene, 
USA.  
2.7.2 Plasmid amplification  
Knockout, gRNA (Sigma Aldrich, USA, Cat. HSANGERV), PsPAX-2 
(Addgene, USA, Cat. 12260) and pCMV-vsvg (Addgene, USA, Cat. 8454) 
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plasmids were separately streaked onto agar plates and incubated at 37oC, 
5% CO2 in order to form single colonies. Miller’s LB broth was prepared in 1 L 
conical flasks by dissolving 20 g Miller’s LB Broth powder (Sigma Aldrich, USA, 
Cat. L3152) in 800 ml dH2O, which was then autoclaved at 121oC for 95 
minutes and stored at room temperature. After autoclaving, 200 µl ampicillin 
(Sigma Aldrich, USA, Cat. A0166) was added to each flask of LB broth. Once 
single colonies had formed (approx. 24 h), colonies were extracted and 
amplified in each separate flask of Miller’s LB Broth and incubated at 37oC 
with constant agitation for 4 h to amplify. Once the LB broth had turned from 
transparent to cloudy, each flask was split into 50 ml centrifuge tubes and 
centrifuged at 10,000 g for 15 minutes. The supernatant was then discarded, 
and the pellet kept at 4oC for future purification. gRNA (Sigma Aldrich, USA, 
Cat. HSANGERV) and knockout plasmids were also separately streaked onto 
agar plates, and incubated at 37oC, 5% CO2 in order to form single colonies. 
Single colonies were then selected and added to 3.5 ml of Miller’s LB Broth in 
bacteria tubes and incubated at 37oC with constant agitation overnight 
(minimum 16 h) to amplify. The following day, amplified plasmids in 3.5 ml LB 
Broth were added to 10 ml LB Broth in 50 ml centrifuge tubes, and again 
amplified further at 37oC with constant agitation for 1-2 h. Once amplified, 
tubes were centrifuged at 10,000 g for 15 minutes. The supernatant was then 
discarded, and the bacterial cell pellet was kept at 4oC for future purification. 
2.7.3 Plasmid DNA purification  
DNA from amplified and harvested bacterial plasmids was purified using the 
NucleoBond Xtra Midi kit and protocol (Macherey-Nagel, USA, Cat. 
740410.50). Cell pellets were first thawed at room temperature for 15 minutes 
prior to being resuspended in resuspension (RES) buffer and RNAse A (kept 
at 4oC). Resuspended plasmids were combined in one 50 ml centrifuge tube 
to a total volume 8 ml. 8 ml of lysis (LYS) buffer was then added, and tubes 
were incubated at room temperature for 5 minutes. Filters were equilibrated 
by pipetting 12 ml of equilibrating (EQU) buffer to the rim of the column filters, 
which were placed in 15 ml centrifuge tubes in a rack ready for the collection 
of lysates. 8ml of blue neutralisation (NEU) buffer was then added to the 50 
ml tubes, and the solution was mixed thoroughly by inversion until colourless. 
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50 ml tubes were then centrifuged at 4,000 g for 15 minutes and the lysate 
loaded onto the NucleoBond Xtra Column Filters.  Once the lysate had filtered 
through, the rims of the filters were washed with 5 ml EQU buffer. The filter 
was then removed, and the column washed with 8 ml wash (WASH) buffer. 
The plasmid was then eluted by adding 5 ml elution (ELU) buffer. 3.5 ml of 
room temperature isopropanol was then added to precipitate the eluted 
plasmid DNA and vortexed thoroughly. Tubes were then centrifuged at 4,000 
g for 30 minutes at 4oC, after which the supernatant was carefully discarded. 
2 ml of room temperature 70% ethanol was added to the pellet, which was 
again centrifuged at 4,000 g for 5 minutes at room temperature (18-25oC). 
Ethanol was carefully removed with a pipette tip, and the pellet left to dry at 
room temperature. The pellet was then reconstituted in 50 µl of Tris-EDTA 
(TE) buffer (Sigma Aldrich, USA, Cat. 93283) and DNA yield measured using 
a Nanodrop machine (Thermo Fisher, ND-1000, USA). DNA concentrations of 
>200.0 ng/µl were considered acceptable. Plasmids were diluted to 200.0 
ng/µl in aliquots of 100 µl of TE buffer and stored at -20oC for future use.  
2.7.4 Cas9 transfection of HEK293T cells 
Cas9 was transfected into HEK293Tcells using polybrene. HEK293T cells 
were purchased from ATCC (ATCC, USA, #CRL-11268). HEK293T cells are 
derived from human embryonic kidney cells taken from a foetus. They are a 
highly transfectable variation of the human embryonic kidney HEK293 cell line 
and contain the SV-40 T-antigen (ATCC, USA, #CRL-3216). HEK293T cells 
were seeded at a density of 2x105 cells per well in a 6-well tissue culture plate 
under standard tissue culture conditions for 24 h prior to transfection. Healthy 
cells at a confluency of 40-80% are required for successful transfection. After 
24 h, a mixture of complete medium with polybrene (Santa Cruz 
Biotechnology, USA, Cat. sc-134220) was prepared to a final concentration of 
5 µg/ml. Original media was removed and this polybrene mix was added at a 
volume of 1.5 ml per well. Cas9 plasmids were then thawed at room 
temperature and mixed gently prior to being added to the culture medium. The 
plate was gently swirled to mix and incubated overnight. The medium 
containing polybrene was removed and 1.5 ml of complete medium added per 
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well, without polybrene. Cells were again incubated and routinely sub-cultured 
until needed.  
2.7.5 Preparation of lentiviral particles  
3 ml of Opti-MEM media (Thermo Fisher, USA, Cat. 31985070) was added to 
two separate 15 ml centrifuge tubes. Ps-PAX2 and p-CMV-vsvg vector 
plasmids were thawed at room temperature and mixed gently before both 
being added at a ratio of 1p-CMV-vsvg:2Ps-PAX2 to one of the 3 ml aliquots 
of Opti-MEM, which was then mixed by pipetting and separated into three 
separate 15 ml centrifuge tubes (1 ml of mix per tube). gRNA and knockout 
plasmids were all thawed at room temperature, before each being added 
separately to one of the newly aliquoted 1 ml Opti-MEM/vector mixes, to 
achieve a ratio of 1p-CMV-vsvg:2Ps-PAX2:3plasmid. 100 µl of lipofectamine 
3000 (Thermo Fisher, USA, Cat. L3000015) was added to the second 3 ml 
aliquot of Opti-MEM, gently pipetted to mix, and incubated for 5 minutes at 
room temperature. 1 ml of this mix was then added to each of the 1 ml aliquots 
of Opti-MEM/plasmid, gently pipetted to mix, and incubated for 20 minutes at 
room temperature.  
2.7.6 Lentiviral transfection of knockout plasmids into Cas9-
positive HEK293T cells 
Cas9-positive HEK293T cells at 50-75% confluency were transfected with 
knockout plasmids. First, the medium of the HEK293T cells cultured in a 100 
mm dish was removed and replaced with 6 ml of DMEM containing 5% FBS 
only and no other supplements. Dishes were incubated at room temperature 
for 20 minutes before each of the 2 ml of Opti-MEM/lipofectamine/vector mixes 
were added to separate dishes, which were then incubated overnight. Medium 
was replaced with complete DMEM and dishes were again incubated 
overnight. Medium was collected into a 50 ml tube and 0.45 µm filtered. 
Complete DMEM was again added to cells, which were incubated and sub-
cultured as needed.  
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2.7.7 Concentrating retroviral knockout stock 
The Retro-X Concentrator kit (Clontech, USA, Cat. 631455) was used to 
concentrate retroviral stocks of STEAP2. The viral supernatant collected from 
the virus-producing HEK293T cells as described in Section 2.7.6 was 
centrifuged at 270 g for 10 minutes to further remove cells and debris following 
filtration. The clarified supernatant was then transferred to a sterile 15 ml 
centrifuge tube and made up to achieve 1 volume of Retro-X concentrator with 
3 volumes of clarified supernatant, mixed by gentle inversion and incubated 
overnight at 4oC. The sample was centrifuged at 1,500 g for 45 minutes at 4oC. 
The supernatant was discarded, and the pellet gently resuspended in 10 ml of 
complete DMEM, and aliquoted into 1 ml single-use samples which were then 
stored at -80oC until needed. 
2.7.8 Transfection of Cas9 plasmids into wild-type cells 
Cas9 (Addgene, USA, Cat. 129727) was transfected into wild-type cells using 
polybrene. Once at ~50% confluency, wild-type cells were seeded at a density 
of 2x105 cells per well in a 6-well tissue culture plate under standard tissue 
culture conditions for 48 and 24 h respectively prior to transfection. A mixture 
of complete medium with polybrene was prepared to a final concentration of 1 
µg/ml. Original media was removed and this polybrene mix was added at a 
volume of 1 ml per well. Cas9 plasmids were thawed at room temperature and 
mixed gently prior to being added at a volume of 500 µl per well to the culture 
medium containing polybrene. The plate was gently swirled to mix and 
incubated overnight. An additional 1 ml of medium containing polybrene was 
then added per well, and cells were again incubated until ~50% confluency 
was reached.  
2.7.9 Optimisation of selection antibiotic doses in wild-type 
cells 
A selective antibiotic titration was carried out for each wild-type cell line. Wild-
type cells were seeded at a density of 3x105 per well in 6-well plates for 48 h, 
or until ~70% confluent. Cells were then exposed to a serial dilution of the 
selection antibiotics blasticidin (Sigma Aldrich, USA, Cat. SBR00022) and 
puromycin (Sigma Aldrich, USA, Cat. P9620) at 0.625, 1.25, 2.5, 5.0 and 10.0 
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µg/ml for 120 h. Cells were viewed under the microscope at 48 h and 120 h 
and any morphological changes were noted to determine toxicity. Based on 
these results, cell line specific doses of blasticidin and puromycin were chosen 
for the selection of Cas9-positive cells, and the selection of knockout-positive 
cells respectively. Medium was replaced with fresh selective antibiotic-
containing medium every 3-4 days as needed.  
2.7.10 Blasticidin selection of Cas9-activated cells 
Cas-9 activated cells were selected via blasticidin selection, with the aim of 
using a sufficient dose to kill non-transfected cells. Medium containing 
polybrene was removed from the Cas9-transfected cells obtained in Section 
2.7.9 and replaced with complete medium containing the chosen dose of 
blasticidin for each cell line, as determined in Section 2.7.9. Once ~70% 
confluency was reached, cells were transferred from the 6-well plates to 100 
mm petri dishes and sub-cultured until confluent.  
2.7.11 Transfection of knockout plasmids into Cas9-activated 
cells 
gRNA and knockout plasmids were transfected into wild-type cells using 
polybrene. Once at ~50% confluency, Cas9-activated wild-type cells were 
seeded at a density of 2x105 cells per well in a 6-well tissue culture plate under 
standard tissue culture conditions for 24 h prior to transfection. A mixture of 
complete medium with polybrene was prepared to a final concentration of 1 
µg/ml. Original media was removed and this polybrene mix was added at a 
volume of 1 ml per well. gRNA and knockout plasmids were then thawed at 
room temperature and mixed gently prior to being added at a volume of 500 
µl per well to the culture medium containing polybrene. The plate was gently 
swirled to mix and incubated overnight. An additional 1 ml of medium 
containing polybrene was added per well, and cells were again incubated until 
~70% confluency was reached. Medium containing polybrene was removed 
and replaced with complete medium containing the chosen dose of puromycin 
for each cell line, as determined in Section 2.7.9. Once ~70% confluency was 
reached, cells were transferred from the 6-well plates to 100 mm petri dishes 
and sub-cultured until confluent.  
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2.7.12 Isolation and amplification of single knockout clones 
To isolate single colonies of positive knockout cells, cells were seeded at a 
density of 300 cells per plate in 96-well tissue culture plates, in 100 µl media 
supplemented with the appropriate dose of puromycin. Plates were then 
incubated for 10-14 days and routinely checked for single colony formations. 
Once formed, 6 single colonies per cell line, per knockout plasmid were 
transferred to 24-well tissue culture plates in 0.5 ml of complete medium 
supplemented with the appropriate dose of puromycin and incubated for a 
further 7 days. Microscopy was then used to assess morphology of knockout 
cells in comparison to their wild-type counterparts, and 3 colonies per cell line, 
per knockout plasmid that most closely resembled wild-type cells were 
transferred to 6-well tissue culture plates and incubated until ~70% confluent. 
Western blotting was performed to confirm successful target gene knockout, 
and stable clones were further expanded and routinely sub-cultured in 100 mm 
dishes in the same manner as their wild-type counterparts, with the addition of 
an appropriate dose of puromycin. 
 
2.8 Protein expression 
2.8.1 Protein extraction  
Once cells had reached ~80% confluency, they were trypsinised, neutralised 
and centrifuged as described in Section 2.2.7.1. Old media was discarded, 
cells were washed twice in ice-cold PBS, centrifuged again at 270 g for 5 
minutes, PBS discarded, and the cell pellet was resuspended in 1 ml of ice-
cold radioimmunoprecipitation assay buffer (RIPA; Sigma Aldrich, USA, Cat. 
R0278). RIPA buffer was supplemented with the addition of one tablet of 
protease-inhibitor cocktail (Sigma Aldrich, USA, Cat. S8830) which was fully 
dissolved in 10 ml of buffer. Samples were transferred to pre-cooled 1.5 ml 
Eppendorf tubes and incubated on ice for 10 minutes. Cells were lysed by 
pipetting followed by a 10 s vortex and kept on ice for immediate use or 
transferred to -20oC for long-term storage.  
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2.8.2 Protein quantification  
For protein quantification, a Bradford assay was carried out in a 96-well clear-
bottomed plate using the Coomassie based BioRad Protein Assay Kit 
(BioRad, USA, Cat. 5000002) according to manufacturer’s instructions. 10 µl 
of protein per sample was loaded in duplicate alongside an albumin (BSA) 
standard series (0 – 2,000 µg/ml), as displayed in Figure 2.4. 
 
 
Figure 2.6. The Bradford assay for protein quantification. A 96-well plate 
containing the protein standard (albumin) with a known concentration range (0 
– 2,000 µg/ml) is illustrated in blue. Each standard concentration was loaded 
in triplicate horizontally from the lowest (0 µg/ml at A1 – A3) to the highest 
concentration (2,000 µg/ml at H1 – H3). Samples were loaded vertically in 
triplicate, as illustrated in green, orange and yellow.  
 
The albumin standard (BSA) was prepared according to the supplier’s 
instructions. Absorbance was read at A = 595nm to determine protein 
concentration using a fluorescence plate reader (POLARstar, BMG Labtech, 
USA). To calculate the sample loading concentration, a protein standard curve 
of known concentration plotted against the measured absorbance with the 
mathematical equation (y = mx + c) was generated. Using the protein 
standard, a line of best fit was displayed with a minimum r2 value of 0.95 
(Figure 2.5). The protein concentration of each sample was calculated using 
the equation of the line of best fit and adjusted by dilution with RIPA buffer to 
match the concentration of the sample with the lowest protein concentration.   
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Figure 2.7. Standard curve generated from a Bradford assay for protein 
quantification showing proteins of a known concentration (µg/ml) 
against absorbance (nm). Following the Bradford assay for protein 
quantification a protein standard curve of known concentration 0 – 2,000 µg/ml 
was plotted against the measured absorbance at A = 595 nm for which the 
equation y = mx + c is displayed. r2 ≥ 0.95.  
 
2.8.3 Sodium-Dodecyl-Sulphate polyacrylamide gel 
preparation  
As STEAP2 has a molecular weight of 56 kDa, a 12% resolving gel was 
prepared as detailed in Table 2.12. Glass plates and plastic well-combs were 
wiped with 70% ethanol and dried before being assembled into the casting 
stand. First, the 12% resolving gel was prepared (Table 2.12) and pipetted 
between the glass plates, leaving 2 cm at the top for the stacking gel, and left 
to solidify at room temperature for 1 h. A small amount of ethanol was pipetted 
between the glass plates to aid in polymerisation and ensure no bubbles 
formed at the top of the gel. Once solidified, the ethanol was carefully removed 
using filter paper and flushed with water. A 4% stacking gel (Table 2.13) was 
prepared and pipetted on top of the resolving gel, before an appropriately 
sized comb was carefully inserted to prevent bubble formation and the gel was 
left to solidify at room temperature for an additional 30 minutes. Once 




















y = mx + c
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small plastic pouches and stored at 4oC until needed. Gels were used within 
7 days of preparation. 
 
Table 2.12. Resolving gel preparation for SDS-PAGE. A 12% resolving gel 
was prepared using the reagents detailed below. A total volume of 10 ml was 
prepared for each gel.   
Reagent Volume (ml) 
ddH2O 0.8 
30% Acrylamide 4.0 
1.5M Tris-HCL, pH 8.8 5.0 
SDS 10% 0.15 
10% APS 0.1 
TEMED 0.01 
 
Table 2.13. Stacking gel preparation for SDS-PAGE. A 4% stacking gel was 
prepared using the reagents detailed below. A total volume of 5 ml was 
prepared for each gel.   
Reagent Volume (ml) 
ddH2O 2.1 
30% Acrylamide 0.8 
1M Tris-HCL, pH 6.8 3.0 
SDS 10% 0.15 
10% APS 0.06 
TEMED 0.006 
 
2.8.4 Sodium-Dodecyl-Sulphate polyacrylamide gel 
electrophoresis  
Proteins were thawed on ice and denatured for 5 minutes using a heating block 
set at 90oC (Thermo Fisher, USA, Cat. 88870001) and kept on ice until use. 
One casted gel and one buffer dam (BioRad, USA, Cat. 1653130) for balance 
were cleaned with 70% ethanol, they were assembled either side of the 
electrophoresis cassette and clamped into place. The cassette was placed into 
the buffer chamber and running buffer was first slowly poured in between the 
gel and buffer dam to remove and bubbles, followed by the rest of the 
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chamber. The plastic well combs were then carefully removed from the casted 
gel. A Precision Plus Protein™ Dual Color Standards pre-stained molecular 
weight ladder (BioRad, USA, Cat. 1610374) was added into well number 1 of 
the gel, at a volume of 15 µl. Prior to loading onto the gel, 15 µl of each protein 
sample was mixed with 3 µl of GeneRuler 100 bp DNA Ladder (6X) loading 
dye (Thermo Fisher, USA, Cat. SM0244) on ice. 15 µl of each of this sample 
mix was loaded into separate wells of the gel, from well number 2 onwards. 
To ensure an equal running of the gel, any empty wells were filled with 10 µl 
of SDS 10% buffer (BioRad, USA, Cat. 1610416). The SDS-PAGE was run at 
120 V until the protein samples had all stacked into a horizontal line (approx. 
20 minutes). Once the protein samples had entered the resolving gel, the 
voltage was increased to 150 V for 45 minutes.   
2.8.5 Membrane transfer 
A Mini Trans-Blot® Cell cassette (BioRad, USA, Cat. 1703931) was prepared 
as demonstrated in Figure 2.6. The central core was placed in the transfer 
tank and filled with ice whilst the cassette was prepared. First, a sheet of trans-
blot filter paper (BioRad, USA, Cat. 1703956) was cut into six pieces approx. 
10 cm wide using a guillotine. A plastic transfer tray was filled with transfer 
buffer and two foam pads (BioRad, USA, Cat. 1703933) and the six pieces of 
filter paper were soaked in the transfer buffer. A transfer cassette was opened 
in the tray containing transfer buffer, with the black (negative; -ve) side at the 
bottom of the tray. One piece of soaked foam padding was placed on top of 
the back of the cassette, followed by three pieces of filter paper. After the SDS-
PAGE, the cassette was carefully opened with a glass-plate opener and the 
stacking gel removed. The gel was then carefully placed on top of the three 
pieces of filter paper in transfer buffer to keep moist. A nitrocellulose 
membrane for protein blotting (BioRad, USA, Cat. 1620115) was manually cut 
to the desired size to match that of the SDS gel. A small plastic tray was filled 
with 5 ml of 100% methanol and the nitrocellulose membrane was added for 
30 s to activate. Tweezers were used to remove the nitrocellulose membrane 
and place it on top of the gel, followed by the remaining three pieces of filter 
paper and then the second piece of foam padding. A roller was used to remove 
any bubbles before the cassette was clamped together. The transfer tank was 
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emptied of ice and the cassette was loaded into place. The middle of the 
cassette was first filled with transfer buffer, followed by the rest of the tank up 
to the 2 plates mark. Membrane transfer was carried out at 60 V for 150 
minutes at room temperature, or overnight at 4oC.  
 
 
Figure 2.8. Diagram showing the assembly of a transfer cassette 
assembly utilised for the transfer of proteins from polyacrylamide gel 
onto a nitrocellulose membrane. From bottom (black; cathode, -ve) to top 
(red; anode, +ve): One sponge pad is placed at the bottom of the blotting 
sandwich, followed by three pieces of filter paper, polyacrylamide gel, 
nitrocellulose membrane, another three pieces of filter paper and another 
sponge pad on top.  
 
2.8.6 Blocking and antibody incubations 
Once the membrane transfer was complete to limit any non-specific binding of 
the primary antibody, the membrane was placed into a small plastic tray 
containing 5% blocking buffer (5.0 g milk powder in 10 ml PBS-T) and placed 
on a plate rocker for 30 minutes at room temperature. The membrane was 
then washed 3x 5 minutes with PBS-T and cut horizontally dependent on the 
molecular weight of the protein of interest (Figure 2.7). The top right-hand 
corner of the membrane sections was cut to be able to determine their 
orientation. Membrane sections were incubated with their respective 
antibodies for detection of STEAP2 and the house-keeping loading control 
GAPDH (1:1,000 / 3% BSA) on a plate rocker overnight at 4oC. Membranes 
were again washed for 3x 5 minutes with PBS-T on a plate rocker to remove 
any residual primary antibody and incubated with secondary anti-rabbit HRP 
 90 
antibody (1:5,000 / 5% blocking buffer) for 2 h on a plate rocker at room 
temperature, or overnight at 4oC.  
 
 
Figure 2.9. Diagram showing the cuts made to the nitrocellulose 
membrane following membrane transfer prior to antibody incubation. 
Vertical, short lines = gel wells; numbers = number of gel wells; well 1 + 10 = 
dual colour precision MWL (kDa) with red and blue short, vertical lines which 
represent the relevant molecular weight bands for this study. Horizontal line at 
approx. 45kDa indicates the cut separating STEAP2 (56 kDa) from 
housekeeping loading control GAPDH (37 kDa). Diagonal line in top-right 
corner indicates the cuts to determine orientation. 
 
2.8.7 Protein detection and analysis 
A 1:1 mix of Clarity ECL Western Substrate reagent (BioRad, USA, Cat. 
1705060) was prepared in a 1.5 ml brown Eppendorf tube to keep the solution 
protected from light, as per the manufacturer’s recommendations. After 
incubation, membranes were washed for 3x 5 minutes with PBS-T on a plate 
rocker to remove any residual secondary antibody. The membranes were 
placed onto a Chemisorbs tray and covered with 500 µl of ECL developing 
solution for 30 s. The ChemiDocXRS+ (BioRad, USA) was used for image 
acquisition, and ImageLab software, Version 6.0.1 was used for analysis. 




2.9 Cell migration assay 
Once cells had reached 80% confluency, media was replaced for 24 h with 
serum-free cell line specific media. Cells were then trypsinised, resuspended 
and adjusted to a desired cell concentration. One cell culture insert (IBIDI, 
Germany, Cat. 80209) was placed in the centre of each well of a 12-well plate, 
70 µl of cell suspension was added to each chamber and cells were left to 
adhere in standard tissue culture conditions for 24 h. Media and inserts were 
removed following a period of incubation and cells were washed with PBS to 
remove cell debris, before fresh complete media was applied. The time taken 
to close the gap created was monitored using an inverted light microscope 
(Invitrogen, EVOS XL Core, USA) every 24 h until the wound created by the 
silicone insert had closed. Media was replaced every 3 days. The experiment 
was conducted in triplicate unless otherwise stated.  
2.10 Invasion assay 
To investigate the role of various stimuli in mediating invasive cell behaviour, 
Transwell plate inserts (polycarbonate, 8.0 µm pore size; Sigma Aldrich, USA, 
Cat. CLS3422) were used. Prior to each invasion assay, cells were 
trypsinised, resuspended and seeded in 6-well tissue culture plates at a 
desired density and left to adhere in standard cell culture conditions for 48 h. 
Cells were then serum starved in serum-free media (SFM) for 24 hours. Prior 
to seeding cells, 20 µl of GFR Matrigel (1:5 dilution/SFM; Sigma Aldrich, USA, 
Cat. E1270) was applied to the Transwell insert, one of which was placed in 
each well of a 12-well tissue culture plate and left to polymerise for 1 hour in 
standard cell culture conditions. Cells were trypsinised from the 6-well plates, 
resuspended and adjusted to a desired seeding density and pipetted onto the 
Matrigel-coated Transwell insert in 250 µl of SFM. Subsequent to the addition 
of cells, 600 µl of complete media was added to the lower chamber, as 
depicted in Figure 2.8, and the inserts were incubated for 48h in standard cell 
culture conditions to allow cell invasion to occur. Cell invasion was then 
quantified by staining with crystal violet (Sigma Aldrich, USA, Cat. V5265). The 
Transwell inserts were removed, and invaded cells were fixed with 100% 
methanol for 15 minutes at room temperature and allowed to air dry. They 
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were then stained with a crystal violet staining solution (0.5% crystal violet in 
100% methanol) for 30 minutes to allow for the visualisation of cells. The non-
invaded cells on the upper surface of the Transwell inserts were removed with 
a cotton swab moistened with PBS. The inserts were then washed in purified 
water and left to air dry for 1 hour. Invaded cells were visualised using an 
inverted light microscope (Invitrogen, EVOS XL Core, USA) at 10x 
magnification. Images were taken of different planes of each insert and the 
experiment was conducted in triplicate unless otherwise stated.  
 
 
Figure 2.10. Schematic representation of the side profile of a Transwell 
insert situated in one well of a 12-well tissue culture plate for invasion 
assays. Transwell plate inserts were coated with Matrigel and left to 
polymerise in individual wells of a 12-well tissue culture plate. Cells were 
suspended in serum-free media and added to the top chamber. Complete 
media was added to the bottom chamber.  
 
2.11 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 8 for iOS. 
Data was considered statistically significant when a p-value of < 0.05 (*), p-
value < 0.01 (**) or a p-value of < 0.001 (***) or p-value < 0.0001 (****) was 
obtained, which were annotated within the respective figures. 
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Chapter 3  
 
Development and characterisation of 3D in vitro 
prostate cancer-stromal cell co-culture models 
 
3.1 Introduction 
STEAP family members are known to be over-expressed in multiple cancer 
types, with STEAP2 particularly over-expressed in prostate cancer (see 
Chapter 1, Section 1.5.2; Gomes et al., 2012). Previous studies into the 
expression of STEAP2 have shown that high protein levels are present in 
metastatic prostate cancer cell lines (bone metastatic PC3 cells and lymph 
node metastatic LNCaP calls) in comparison to lower expression levels seen 
in normal epithelial prostate cells lines such as PNT2 (Burnell et al., 2018; 
Whiteland et al., 2014). However, such studies have not assessed the gene 
expression levels of all four STEAP family member across multiple metastatic 
prostate cancer cell lines of different origins. 
Two-dimensional, flat, monolayer cell culturing has long been the standard 
culture method in cancer research since its development in 1907 (Breslin & 
O’Driscoll, 2013; Harrison et al., 1907). The main advantages of 2D cell culture 
techniques include convenience, low costs and ability to maintain cell viability 
(Breslin & O’Driscoll, 2016; Duval et al., 2017). Cells grown in 2D are able to 
proliferate at a continuous rate, provided they have the space to do so, and as 
such provide an easily reproducible platform for in vitro drug testing (Breslin & 
O’Driscoll, 2013 & 2016; Edmonson et al., 2014; Lin & Chang 2008). 
Monolayers of cells also show little variance in cell morphology over time and 
are able to receive a constant supply of nutrients in the growth medium (Breslin 
& O’Driscoll, 2013; Duval et al., 2017). Furthermore, 2D cell culturing is 
advantageous when performing high-throughput assays, due to ease of cell 
harvesting and sub-culturing (Breslin & O’Driscoll, 2013; Duval et al., 2017). 
However, differences between the properties of cells grown in 2D cultures in 
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vitro compared to equivalent cells in vivo have been noted (Breslin & 
O’Driscoll, 2013). A major limitation of 2D monolayer cultures grown on a flat 
solid surface is their lack of stroma, which is of vital importance when 
modelling human cancers, particularly prostate cancer, in which the stroma 
plays a critical role in cancer dissemination and metastatic potential (Chung, 
2003; Langley et al., 2011; Lovitt et al., 2014). Cells grown in 2D cultures also 
lack the complex architecture present in complex 3D tissues, such as the cell-
cell or cell-ECM interactions which are only present in 3D structures (Donglai 
et al., 2017; Gialeli et al., 2011; Lovitt et al., 2014). Recent advances in cell 
culturing techniques have highlighted the importance of the tumour 
microenvironment in cancer development and progression (Nath & Devi, 
2016). The tumour microenvironment (TME) is composed of multiple cell types 
including transformed epithelial cells, cancer-associated fibroblasts (CAFs), 
tumour infiltrating lymphocytes (TILs), mesenchymal stem cells (MSCs) and 
endothelial cells (Nath & Devi, 2016; Quail & Joyce, 2013). These various cell 
types interact with cancer cells and exert an effect on multiple biological 
characteristics such as proliferation, migration, invasion and resistance to 
therapeutic agents (Nath & Devi, 2016; Quail & Joyce, 2013; Smith & Kang, 
2013). As 2D models therefore fail to fully represent the complex 
pathophysiology of tumour cells, and in order to overcome the limitations 
surrounding 2D cell culturing, the concept of tumour spheroids was developed 
to bridge the gap between in vitro and in vivo research (Donglai et al., 2017; 
Hirschhaeuser et al., 2010; Lovitt et al., 2014). Various methods for 3D culture 
exist, including the use of scaffold-based systems such as Matrigel or Jellagen 
products, or growth on agarose supports, to provide a platform for cells to grow 
in a semi-solid matrix. These matrices allow for the influence of external 
physical factors to be observed on cell growth and signalling (Fong et al., 2016; 
Greiner et al., 2012; Muir et al., 2006; Thoma et al., 2014). Other 3D culture 
methods include liquid-based approaches such as the hanging drop method 
or rotation-based culture methods which prevent cell adhesion to a substrate 
and instead encourage 3D cell cluster formation (Fong et al., 2016; Greiner et 
al., 2012; Muir et al., 2006; Thoma et al., 2014).  
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Previous studies have successfully generated and maintained 3D cancer cell 
spheroid structures to create a more physiologically relevant model of 
assessing cancer traits (Fong et al., 2016; Muir et al., 2006; O’Connor et al., 
2007; Sung et al., 2008; Zhang et al., 2011). Spheroids are spherical cell 
colonies which self-form spontaneously in environments where cell-cell 
interaction is superior to the cell-substrate interactions of 2D monolayer 
cultures (Friedrich et al., 2009; Ingram et al., 1997; Kunz-Schughart et al., 
2004). Spheroids provide more relevant physiological tumour models than 2D 
cell culturing techniques as they naturally mimic avascular tumours and 
micrometastases, generating more meaningful results (Hirschhaeuser et al., 
2010; Nath & Devi, 2016). These structures have inherent metabolic and 
proliferative gradients and share many physiological characteristics with in 
vivo models such as cell-cell and cell-matrix interactions, altered gene 
expression and signalling pathway profiles, heterogeneity and structural 
complexity (Friedrich et al., 2009; Hirschhaeuser et al., 2010; Kunz-Schughart 
et al., 2004; Nath & Devi, 2016). Mechanistic investigations can also be 
performed to observe molecular and cellular events, allowing for the validation 
of molecular targets in drug development through the discovery of novel intra- 
and intercellular signalling networks (Thoma et al., 2014). As prostate cancer 
predominantly metastasises to the bone which is a leading cause for morbidity, 
a co-culture system of cancerous and bone marrow-derived stromal cells 
would provide a relevant model for studying aggressive prostate cancer traits 
(Taichman et al., 2007; Sun et al., 2007).  
PC3 prostate cancer cells and HS5 bone derived stromal cells have been 
proven to be a successful combination to grow as 3D co-cultures for observing 
cellular interactions (Windus et al., 2013; Zhang et al., 2011). Previously, the 
two cell lines have been co-cultured in 3D models generated on a laminin-rich 
extracellular matrix (lrECM), which promotes the growth of cancer cells in 3D 
structures (Lovitt et al., 2013 & 2014; Muranen et al., 2012; Windus et al., 
2013). This matrix allowed for investigation of cell-to-cell interactions and 
crosstalk between the two different cell types, demonstrating the altered 
expression of certain cellular components by integrins such as E-cadherin. 
(Windus et al., 2013). From this study, it was evident that culturing prostate 
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cancer and stromal cells in 3D can alter gene and protein expression profiles, 
yet it remains unknown as to whether such differences between 2D and 3D 
cultures can aid in the identification of novel drug targets, or sensitivity to 
chemotherapeutic agents (Lovitt et al., 2014; Windus et al., 2013). This study 
solely focussed on androgen-independent prostate cancer cell lines PC3 and 
DU145, and as such was not representative of an androgen-sensitive prostate 
cancer model (Windus et al., 2013). Therefore, applying 3D cell culture to 
androgen responsive prostate cancer cell lines in co-culture with bone stromal 
cells would provide a more representative model of the disease.  
 
Although the advantages of 3D tumour spheroid models have been widely 
studied, their production does come with its own challenges, mainly 
surrounding the formation and maintenance of stable, viable models. Some of 
the main concerns regarding spheroid development are efficiency of 
consistent and reproducible spheroid formation, control of spheroid size, 
longevity of spheroid culture, and, where co-culture systems are involved, 
uniform distribution of different cell types throughout the model (Edmondson 
et al., 2014; Mehta et al., 2012; Ryu et al., 2019). These challenges are 
therefore the main hurdles when developing and applying such alternative 
models in cancer-based research programmes, and highlights the need for 
developing a robust model for generating viable 3D prostate cancer-bone 
stromal co-culture spheroids. Work within the wider Swansea research group 
applied 3D spheroid culture techniques to PC3 prostate cancer cells, providing 
a proof-of-concept study which will be utilised in this thesis and applied to 
multiple prostate cancer cell lines and co-culture models (Wang, 2019).  
 
The aim of this chapter was therefore to develop and optimise 3D models of 
prostate cancer cells, as mono- and co-culture systems with bone stromal 
cells. This chapter also aimed to determine a platform for analysis of the 
STEAP signalling molecules through evaluating the expression of STEAP 
family members across a panel of multiple prostate cancer cell lines not 
previously assessed. The objectives were to: 
1. Determine the expression of STEAP family members in a panel of 
prostate cancer cell lines;  
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2. Develop and optimise the growth of 3D prostate cancer models by 
assessing the effects of varying seeding density on viability over time; 
3. Determine cell death in 3D models through fluorescent microscopy; 
4. Identify the most appropriate ratio of prostate cancer-stromal cells in 






3.2 Materials and methods 
3.2.1 Cell culture 
 
3.2.1.1 2D monolayer cells 
The four prostate cancer cell lines C4-2B, DU145, LNCaP and PC3, the 
normal epithelial cell line PNT2 and the stromal cell line HS5 were routinely 
cultured as described in Chapter 2, Section 2.2.7.1. For absorbance-
dependent endpoint analyses, cells were grown in phenol-red free DMEM 
supplemented with 10% FBS, 1% L-glutamine and 1% P/S (Thermo Fisher, 
UK).  
 
3.2.1.2 3D cell spheroids 
Cells were counted as described in Chapter 2, Section 2.2.7.2 and seeded at 
a desired density onto agarose coated 96-well tissue culture plates, as 
described in Chapter 2, Section 2.2.7.3.  
3.2.2 Detection of STEAP family members 
 
3.2.2.1 qRT-PCR 
Four prostate cancer cells C4-2B, DU145, LNCaP and PC3 and the normal 
prostate epithelial cell line PNT2 were cultured to ~70% confluency. RNA was 
extracted, cDNA synthesised, and qRT-PCR carried out as described in 
Chapter 2, Section 2.3. Cells were probed for all four STEAP family members 
with GAPDH as the housekeeping control using the primers detailed in 
Chapter 2, Section 2.3.3, Table 2.8. The results were subsequently analysed 








3.2.3 3D Prostate cancer cell spheroid stability and viability 
over time 
 
3.2.3.1 Measurement of size over time (monoculture 3D spheroids) 
Cell suspensions of 2,500, 5,000, 7,500 and 10,000 prostate cancer cells per 
100 µl culture media were prepared as described in Chapter 2, Section 
2.2.7.2 and seeded into an agarose-coated 96-well tissue culture plate, as 
described in Chapter 2, Section 2.2.7.3. Every 24 h for 5 days spheroids were 
imaged using an inverted light microscope (AxioCam ERC55, Zeiss, 
Germany), and their diameter (µm) measured. Media was replenished every 
2-3 days as required. The average size of the spheroids was reported as mean 
diameter ± standard deviation. Measurements were taken in triplicate. 
 
3.2.3.2 Cell viability (monoculture 3D spheroids) 
Cell suspensions of 2,500, 5,000, 7,500 and 10,000 prostate cancer cells per 
100 µl culture media were prepared as described in Chapter 2, Section 
2.2.7.2 and seeded into an agarose-coated 96-well tissue culture plate, as 
described in Chapter 2, Section 2.2.7.3. Every 24 h for 5 days, cell viability 
was assessed by MTT assay as described in Chapter, 2, Section 2.4. 
Absorbance was read at A = 570 nm using a POLARstar plate reader 
(POLARstar, BMG Labtech, UK). The cell viability assay was performed in 
triplicate unless otherwise stated.  
 
3.2.3.3 Measurement of size over time (co-culture 3D spheroids) 
Prostate cancer cells and HS5 cells were counted as described in Chapter 2, 
Section 2.2.7.2 and normalised to ensure the same number of each cell line 
were present in each cell suspension. Based on the results of microscopy and 
size over time obtained in Section 3.2.3, the most viable initial seeding density 
was determined for each prostate cancer cell line. Varying ratios of prostate 
cancer (PCa)-stromal cells – 1PCa:1HS5, 1PCa:2HS5 and 2PCa:1HS5 – 
were created by mixing the appropriate volume of cells by pipetting. This co-
culture mix was seeded onto an agarose-coated 96-well tissue culture plate, 
as described in Chapter 2, Section 2.2.7.3, to the total number of cells per 
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well determined to be the most viable seeding density for each cell line. Every 
24 h for 5 days spheroids were imaged using an inverted light microscope 
(AxioCam ERC55, Zeiss, Germany), and their diameter (µm) measured. 
Media was replenished every 2-3 days as required. The average size of the 
spheroids was reported as mean diameter ± standard deviation. 
Measurements were taken in triplicate. 
 
3.2.3.2 Cell viability (co-culture 3D spheroids) 
Co-culture 3D spheroids of prostate cancer and stromal cells were prepared 
in various ratios as described in Section 3.2.3.3 and seeded into an agarose-
coated 96-well tissue culture plate, as described in Chapter 2, Section 
2.2.7.3. The MTT assay has successfully been used to assess the viability of 
3D cell spheroid models across a variety of cancer types, including but not 
limited to; breast, liver and prostate (Abuela et al., 2015; Fotakis & Timbrell, 
2006; Rhee et al., 2001; Risbud et al., 2012; Takagi et al., 2007). Every 24 h 
for 5 days, cell viability was assessed by MTT assay as described in Chapter, 
2, Section 2.4. Absorbance was read at A = 570 nm using a POLARstar plate 
reader (POLARstar, BMG Labtech, UK). The cell viability assay was 
performed in triplicate unless otherwise stated. 
 
3.2.3.5 Cell proliferation (co-culture 3D spheroids) 
Co-culture 3D spheroids of prostate cancer and stromal cells were prepared 
in various ratios as described in Section 3.2.3.3. Every 24 h for 5 days, cell 
proliferation was assessed by alamarBlue assay as described in Chapter, 2, 
Section 2.5.1. Absorbance was read at A = 570 nm and A = 600 nm using a 
POLARstar plate reader (POLARstar, BMG Labtech, UK). The cell 
proliferation assay was conducted in triplicate unless otherwise stated. 
3.2.4 Fluorescent Microscopy 
 
3.2.4.1 Sample preparation and staining for live/dead imaging 
Optimal ratios of prostate cancer-stromal cell co-culture models were 
determined from spheroid size over time measurements and cell viability 
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assay results and used for subsequent fluorescent microscopy. The following 
samples were prepared in the absence of light. Co-culture 3D spheroids of 
prostate cancer and stromal cells were prepared in 96-well tissue culture 
plates as described in Section 3.2.3.3. and incubated to form spheroids. The 
following antibodies were applied for live/dead cell imaging: nuclear stain 
Hoechst (1:100, Thermo Fisher, UK) and chromosomal stain propidium iodide 
(PI; 1:500, BioLegend) Cells were incubated for 15 minutes on a plate rocker 
at room temperature, protected from light. Staining was carried out 1, 3 and 5 
days after seeding. 
 
3.2.4.2 HS5 cell preparation for imaging of stromal cell integration  
Approximately 5 x 105 HS5 cells were seeded per well of a 6-well tissue culture 
plate in phenol-red free, serum-free DMEM (Thermo Fisher, UK) for 24 h. 
Media was replaced with phenol-red free, supplemented DMEM, to which 
stromal-specific antibody 1 (STRO-1) (1:200, R&D, UK) was added and cells 
were incubated for 24 h protected from light. Subsequently, cells were washed 
free of the primary STRO-1 antibody (3 x PBS), and secondary antibody 
human antibody Alexa Fluor-488 (1:1,000, Abcam, UK) was added in phenol-
red free, supplemented DMEM and cells were incubated at room temperature 
on a plate rocker for 2 h protected from light.   
 
3.2.4.3 Co-culture sample preparation and staining for imaging of 
stromal cell integration 
Co-culture 3D spheroids of prostate cancer and pre-stained stromal cells 
prepared in Section 3.2.4.1 were prepared in 96-well tissue culture plates as 
described in Section 3.2.3.3. and incubated to form spheroids. Spheroids 
were carefully washed (3 x PBS) and fixed with 4% paraformaldehyde (PFA) 
for 15 minutes at room temperature. For immunofluorescence labelling, cells 
were again washed (3 x PBS) and permeabilised with 0.1% Triton-X 100 for 
10 minutes at room temperature. Hoechst (1:100, Thermo Fisher, UK) was 
added as a nuclei counterstain. Cells were incubated for 15 minutes on a plate 
rocker at room temperature, protected from light. Staining was carried out 1, 3 
and 5 days after seeding. 
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3.2.4.4 Fluorescent imaging analysis and image processing  
For fluorescent microscopical analysis, a confocal laser scanning microscope 
(LSM710, ZEISS, Germany) was used (Chapter 2, Section 2.6). The 
analysed channels and emission wavelengths (nm) were blue (405 nm) for the 
nuclei and red (543 nm) for dead cells. Zen Black software Version 10 was 
used to process images, and scale bars were based on the known microscope 
pixel sizes for each objective (µm). The red-blue-green (RBG) setting was 
used to display coloured images. 
3.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 8 for iOS, 
using the one-way ANOVA post-hoc Dunnett test. Data was considered 
statistically significant when a p-value of < 0.05 (*), p-value < 0.01 (**) or a p-
value of < 0.001 (***) or p-value < 0.0001 (****) was obtained, as annotated 
within the respective figures.  
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3.3 Results 
The aim of this chapter was to determine the optimal conditions for generating 
the most viable prostate cancer-stromal cell spheroids in order to develop a 
platform for subsequent analysis, with relevance to STEAP2 expression. The 
aim was addressed by determining the expression levels of STEAP family 
members in four human prostate cancer cell lines in comparison to the normal 
prostate epithelial cell line PNT2. The properties of four prostate cancer cell 
lines when cultured as 3D spheroids over time was then evaluated by 
assessing spheroid size, viability and proliferation, in both mono- and co-
culture models.  
 
3.3.1 STEAP2 is highly expressed in androgen-sensitive 
prostate cancer cell lines 
To determine the expression of the four STEAP family members, a panel of 
human prostate cancer cell lines were screened by qRT-PCR. The normal 
prostate epithelial cell line PNT2 was used for comparison.  
 
Upon analysis of gene expression of the four STEAP family members, 
STEAP2 was found to have the highest increase in expression in 3 of the 4 
cell lines screened (>2-fold increase). Moreover, the highest levels of STEAP2 
were observed in androgen-sensitive cell lines; LNCaP and C4-2B, which 
exhibited 264.7-fold and 53.5-fold increases in expression respectively 
(Figure 3.1). STEAP1, STEAP3 and STEAP4 all showed a decrease in 
expression in all prostate cancer cell lines when compared to the normal PNT2 
cell line, with the exception of STEAP1 in LNCaP cells (31.7-fold increase); 
however, this change in expression did not reach significance. qRT-PCR 
analysis of STEAP family expression therefore demonstrated that STEAP2 is 
highly expressed in androgen-sensitive prostate cancer cell lines and thus, 




Figure 3.1. Fold changes in STEAP1-4 gene expression in four human prostate cancer cell lines.  qRT-PCR of STEAP1-4 to establish 
gene expression levels in four human prostate cancer cell lines. Gene expression fold changes are normalised to the normal prostate 
epithelial cell line PNT2, which was defined as having an expression value of 1.0. GAPDH was used as the housekeeping gene. An ANOVA 
post-hoc Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**). (N = 3).
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3.3.2 Development of a 3D in vitro monoculture prostate 
cancer model 
 
3.3.2.1 Size of 3D monoculture prostate cancer spheroids reduces over 
time  
To monitor the effects of culturing prostate cancer cells in 3D on the size of 
the resultant spheroids over time, the diameter of the spheroids associated 
with different initial seeding densities were measured over 5 days. To 
determine the difference in spheroid size over time, spheroids were 
normalised to spheroids formed on day 1 for each seeding density.  
 
In PC3 cell spheroids, no significant changes in spheroid size were observed 
at any seeding density until 4 days after seeding, when a significant decrease 
in the size of spheroids seeded with 7,500 cells per well was seen on days 4 
and 5 (-100 µm and -150 µm diameters respectively; p £ 0.05; Figure 3.2A). 
In DU145 cell spheroids, significant decreases in spheroid size were observed 
across all initial seeding densities from days 2 to 5, with the most significant 
decreases observed in all spheroids seeded with ³ 5,000 cells per well on days 
4 and 5. The largest decrease in size observed in spheroids seeded with 7,500 
cells on day 4, which remained unchanged on day 5 (-300 µm; p = 0.0001; 
Figure 3.2B). LNCaP cell spheroids followed a similar growth curve to DU145 
cell spheroids, with significant decreases in spheroid size observed across all 
initial seeding densities from days 3 to 5, with the most significant decreases 
observed in all spheroids seeded with 7,500 and 10,000 cells per well on day 
5 (-300 µm & -150 µm respectively; p = 0.0001; Figure 3.2C). A significant 
decrease in spheroid size was observed when comparing C4-2B spheroids 
seeded with 10,000 cells on day 5 to spheroids on day 1 (-200 µm; p = 0.0001; 
Figure 3.2D). These data implied that the optimal initial seeding density to 
generate stable sized spheroids was cell line dependent (Figure 3.2). The 
optimal seeding density for each cell line was determined as follows; PC3: 
10,000 cells per well, DU145: 5,000 cells per well, LNCaP: 10,000 cells per 




Figure 3.2. Growth curves showing the effects of different initial seeding densities on the size of 3D monoculture prostate cancer 
cell spheroids over time. A) PC3, B) DU145, C) LNCaP and D) C4-2B prostate cancer cell lines were cultured at various initial seeding 
densities on agarose coated 96-well flat-bottomed plates to generate cultures of reproducibly sized, single spheroids in each well. The 
diameter of each spheroid was measured (µm) every day for 5 days. Measurements were taken from images acquired from 3 separate 
spheroids per cell line, per seeding density using a standard light microscope (AxioCam ERC55, Zeiss, Germany) using a 5x objective. An 
ANOVA post-hoc Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-
value < 0.001 (***), p-value < 0.0001 (****) (N = 3).  
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3.3.2.2 Viability of monoculture prostate cancer 2D monolayers and 3D 
spheroids over time is dependent on initial seeding density 
To determine the optimal initial seeding density for generating viable 3D 
spheroids over 5 days, light microscopy images were taken, and the MTT cell 
viability assay was used. To determine the difference in spheroid viability over 
time, spheroids were normalised to spheroids formed on day 1 for each 
seeding density. 
 
In PC3 cell spheroids, no significant change in the percentage of viable cells 
was observed over 5 days when cells were seeded at an initial density of 
10,000 cells per spheroid. However, a significant decrease in the percentage 
of viable cells was observed at all lower initial seeding densities, with the most 
significant decrease observed at 7,500 cells per spheroid on day 2 (50.8%, p 
= 0.001; Figure 3.3A). In DU145 cell spheroids no significant decreases in the 
percentage of viable cells were observed at any initial seeding density at any 
day across 5 days, yet a significant increase was found at an initial seeding 
density of 5,000 cells per spheroid (223.7%, p = 0.05; Figure 3.3B), with the 
least changes in the percentage of viable cells observed at an initial seeding 
density of 7,500 cells per spheroid (Figure 3.3B). In LNCaP cell spheroids, no 
significant change in the percentage of viable cells was observed over 5 days 
when cells were seeded at an initial density of 5,000 cells per spheroid. LNCaP 
cell spheroids showed a significant decrease in the percentage of viable cells 
on day 4 when seeded at an initial density of 7,500 (11.1%, p = 0.05) and 
10,000 cells (11.4%, p = 0.01) per spheroid (Figure 3.3C). In C4-2B cell 
spheroids significant decreases were observed in the percentage of viable 
cells when cells were seeded at initial seeding densities of 7,500 after 2, 3 and 
4 days (18.9%, 20.8% and 7.3% respectively, p £ 0.05; Figure 3.3D) and 
10,000 cells per spheroid, also after 2, 3, 4 and 5 days (9.4%, 14.3%, 10.2% 
and 10.2% respectively, p = £ 0.01 respectively; Figure 3.3D). These data, 
together with the data on spheroid size (Section 3.2.2.1), suggest that the 
optimal initial seeding densities for each cell line for generating viable 
spheroids over 5 days are as follows; PC3 – 10,000, DU145 – 7,500, LNCaP 




Figure 3.3. Effects of different initial seeding densities on the viability of 3D prostate cancer cell spheroids over time. A) PC3, B) 
DU145, C) LNCaP and D) C4-2B prostate cancer cells were cultured as 3D spheroids with a range of initial seeding densities. An MTT 
viability assay was carried out each day for 5 days, with viability calculated as a percentage of day 1 per seeding density, per cell line. An 
ANOVA post-hoc Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-
value < 0.001 (***), p-value < 0.0001 (****) (N = 3). 
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Standard light microscopy was used to visualise spheroid formation and 
monitor size over time. PC3 and C4-2B cells formed uniform spheroids at all 
initial seeding densities (Figure 3.4 A & D). A necrotic core was indicated by 
a darkening of the centre of each spheroid when visualised under light 
microscopy, as seen in DU145 cell spheroids seeded with 5,000 and 7,500 
cells per well on day 3 (Figure 3.4B) and LNCaP cell spheroids seeded with 
7,500 cells per well on day 3 (Figure 3.4C). A wider range of seeding densities 
and time points can be found in Appendix 1, Figure A1. 2. When combined 
with the MTT cell viability assay results from Figure 3.3, the optimal seeding 
densities for each cell line were determined as follows; PC3 – 10,000, DU145 




Figure 3.4. Representative light microscopy images of spheroids over time (A) PC3, (B) DU145, (C) LNCaP and (D) C4-2B prostate 
cancer cells were cultured as 3D spheroids with a range of initial seeding densities. Images were taken 1 and 3 days after seeding and 
were acquired using a standard light microscope (AxioCam ERC55, Zeiss, Germany) using a 5x objective. Scale bar = 100 µm. 
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3.3.3 Development of a 3D in vitro co-culture prostate cancer-
stromal model 
 
3.3.3.1 Size of 3D co-culture spheroids reduces over time  
To monitor the effects of culturing prostate cancer cells in co-culture with 
stromal HS5 cells on spheroid size, the diameter of spheroids of different co-
culture ratios – 1PCa:1HS5 (1:1), 2PCa:1HS5 (2:1) and 1PCa:2HS5 (1:2) – 
was measured over 5 days. To determine the difference in spheroid size over 
time, spheroids were normalised to spheroids formed on day 1 for each 
seeding density. 
 
In PC3-HS5 cell spheroids, no significant changes in spheroid were observed 
at any ratio at any day across 5 days, yet the least changes in size were 
observed at a 1:1 prostate cancer-stromal cell ratio (Figure 3.5A). In DU145-
HS5 cell spheroids significant decreases in spheroid size were observed at all 
ratios on days 3, 4 and 5 (p £ 0.05; Figure 3.5B). The only significant 
increases in spheroid size across all four cell lines were observed in LNCaP 
cells when spheroids were seeded at a ratio of 2LNCaP:1HS5 cells spheroid 
after 2 days (+100 µm p = 0.05; Figure 3.5C). However, in the same cell line, 
significant decreases in spheroid size were observed when cells were seeded 
at a ratio of 1LNCaP:2HS5 cells after 3, 4 and 5 days (-150 µm, -183.3 µm & 
-200 µm respectively, p £ 0.05; Figure 3.5C). In C4-2B co-culture spheroids, 
no significant differences in size were observed over time in spheroids cultured 
at a 1C4-2B:1HS5 ratio, yet significant decreases in spheroid size were found 
in spheroids cultured at ratios of both 1C4-2B:2H5 cells at days 3, 4 and 5 (-
300 µm, -383.3 µm & -416.7 µm respectively, p = 0.01; Figure 3.5D) and 2C4-
2B:1HS5 cells, also at days 3, 4 and 5 (-233.3 µm, -283.3 µm and -350 µm 
respectively, p = 0.01; Figure 3.5D). These data implied that a 1PCa:1HS5 
ratio of prostate cancer-stromal cell co-culture spheroids was optimal for all 
cell lines as this ratio resulted in the most consistently sized spheroids across 





Figure 3.5. Growth curves showing the effects of different ratios of stromal and prostate cancer cells on the size of 3D co-culture 
spheroids over time. A) PC3, B) DU145, C) LNCaP and D) C4-2B prostate cancer cell lines were cultured with various ratios of HS5 
stromal cells on agarose coated 96-well flat-bottomed plates to generate cultures of reproducibly sized, single spheroids in each well. The 
diameter of each spheroid was measured (µm) every day for 5 days. Ratios of prostate cancer (PCa) to stromal cells were as follows: 
1PCa:1HS5 (1:1), 2PCa:1HS5 (2:1) and 1PCa:2HS5 (1:2). Measurements were taken from images acquired from 3 separate spheroids 
per cell line, per seeding density using a standard light microscope (AxioCam ERC55, Zeiss, Germany) using a 5x objective. An ANOVA 
post-hoc Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 
0.001 (***), p-value < 0.0001 (****) (N = 3).
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3.3.3.2 The ratio of stromal-prostate cancer cells grown as 3D spheroids 
has little effect on viability over time 
To further evaluate the optimal ratio for generating viable prostate cancer-
stromal cell spheroids over 5 days, the MTT cell viability assay was used. To 
determine the difference in spheroid viability over time, spheroids were 
normalised to spheroids formed on day 1 for each seeding density. 
 
In PC3-HS5 (Figure 3.6A), DU145-HS5 (Figure 3.6B) and C4-2B-HS5 
(Figure 3.6D) co-culture spheroids, no significant changes in the percentage 
of viable cells were observed across all 5 days. In LNCaP-HS5 spheroids, a 
significant decrease in the percentage of viable cells was found on days 2, 3, 
4 and 5 in co-culture spheroids cultured at a 1LNCaP:1HS5 ratio (15.4% 
14.3%, 17.8% and 18.0% respectively, p = 0.0001; Figure 3.6C). The 
percentage of viable HS5 cells was seen to decrease after day 3, yet no 
significant changes in the percentage of viable HS5 cells were observed 
across all 5 days (Figure 3.6). These data suggest that the optimal ratios of 
prostate cancer-stromal cells for generating viable co-culture spheroids over 
5 days are as follows: 2PC3:1HS5, 1DU145:1HS5, 2LNCaP:1HS5 and 2C4-
















Figure 3.6. Effects of different stromal-prostate cancer cell ratios on the viability of 3D co-culture spheroids over time. A) PC3, B) 
DU145, C) LNCaP and D) C4-2B prostate cancer cells were cultured with different ratios of HS5 stromal cells as 3D spheroids. An MTT 
viability assay was carried out each day for 5 days, with viability calculated as a percentage of day 1 per ratio, per cell line. Ratios of 
prostate cancer (PCa) to stromal cells were as follows: 1PCa:1HS5 (1:1), 2PCa:1HS5 (2:1) and 1PCa:2HS5 (1:2). An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.001 (***), p-value < 0.0001 
(****) (N = 3). 
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3.3.3.3 Proliferation assays revealed PC3-stromal spheroids show the 
most variation over time  
To evaluate the impact of prostate cancer-stromal cell ratio on the proliferation 
of spheroids over 5 days, the alamarBlue cell proliferation assay was used. To 
determine the difference in spheroid proliferation over time, spheroids were 
normalised to spheroids formed on day 1 for each seeding density. 
 
The alamarBlue assay demonstrated a highly significant increase in the 
percentage of proliferating PC3 cells on day 3 both as mono- and co-culture 
across all ratios (p £ 0.001; Figure 3.7A). Significant increases were also 
observed on days 4 and 5 at ratios of 1PC3:1HS5 (233.7% and 163.2% 
respectively, p = 0.05; Figure 3.7A), and 1PC3:2HS5 on days 2, 4 and 5 
(109.4%, 199.5% and 148.2% respectively, p = 0.01; Figure 3.7A). As 
monoculture spheroids, DU145 cells showed a significant increase in the 
percentage of proliferating on day 3 (117.3%, p = 0.01; Figure 3.7B), and in 
co-culture with HS5 at ratios of 1DU145:1HS5 and 2DU145:1HS5 on day 4 
(156.3% and 145.2% respectively, p = 0.01; Figure 3.7B). LNCaP 
monoculture spheroids showed a decrease in the percentage of proliferating 
cells on days 2 and 4 (78.9% and 76.2% respectively, p £ 0.05; Figure 3.7C) 
yet no significant changes in the percentage of proliferating cells were 
observed in co-culture spheroids. No significant changes in the percentage of 
proliferating cells of mono- or co-culture C4-2B-HS5 cell spheroids were 
observed across the 5 days (Figure 3.7D), nor were any significant changes 
in the percentage of proliferating cells of monoculture HS5 cell spheroids 
observed across the 5 days (Figure 3.7). These data suggest that the optimal 
ratios of prostate cancer-stromal cells for generating proliferating co-culture 
spheroids over 5 days are as follows: 1PC3:2HS5, 1DU145:1HS5, 
2LNCaP:1HS5 and 1C4-2B:1HS5 based on the consistency of cell 




Figure 3.7. Effects of different stromal-prostate cancer cell ratios on the proliferation of 3D co-culture spheroids over time. A) 
PC3, B) DU145, C) LNCaP and D) C4-2B prostate cancer cells were cultured with different ratios of HS5 stromal cells as 3D spheroids. 
An alamarBlue proliferation assay was carried out each day for 5 days, with proliferation calculated as a percentage of day 1 per ratio, per 
cell line. An ANOVA post-hoc Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 
0.001 (***), p-value < 0.0001 (****) (N = 3). 
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3.3.3.4 Fluorescent imaging indicated high levels of cell death in the 
cores of spheroids  
To evaluate the levels of cell death occurring within cells co-cultured as 3D 
spheroids, PI stain was used to identify dead cells. PI is a vital stain which can 
be used to identify dead cells, as the membranes of dead and damaged cells 
are permeable to PI, whilst those that are intact are impermeable (Kole et al., 
2016). Staining with PI alongside another stain such as the nucleic dye 
Hoechst 33342 allows for cells that are considered viable and dead to be 
visualised simultaneously (Dasiram et al., 2017; Liu et al., 2012; Oosterhoff et 
al., 2003). 
 
Confocal microscopy demonstrated PI as a strong, red fluorescent signal of 
varying strength dependent on the cell line (Figures 3.8 – 11, illustrate 
representative images; a z-stack showing PI distribution throughout each 
spheroid can be found in Appendix 1, Figures A1. 9 – 12. In PC3 cells, PI 
staining was evenly distributed throughout both mono- and co-culture 
spheroids, which increased in strength over time. PI staining was consistently 
stronger in co-culture cells, with highest expression observed on day 5 (Figure 
3.8). DU145 cell spheroids also showed relatively low levels of PI staining 
which was evenly distributed throughout the spheroid in mono- and co-cultures 
alike, with the exception of monoculture spheroids imaged on day 5 which 
showed highly concentrated PI staining in the core of the spheroid (Figure 
3.9). LNCaP cell spheroids exhibited the highest levels of PI staining across 5 
days, in both mono- and co-culture models. PI was evenly distributed 
throughout all LNCaP cell spheroids, with the highest signal observed on day 
5 in both mono- and co-culture spheroids (Figure 3.10). C4-2B cell spheroids 
also showed an even distribution of PI staining throughout all spheroids, with 
no discrimination between mono- and co-culture models (Figure 3.11). 
Collectively, these images imply that cell death within spheroids is mainly 
occurring within the core and they also confirmed that cell death increases 
over time in both mono- and co-culture prostate cancer-stromal cell models. 
As monocultures, PC3 cells generated the most viable 3D spheroid models 
over time to be utilised in future experiments, which was also the case when 
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cultured as co-culture models with HS5 stromal cells. DU145 cells also 
produced a viable co-culture model for use going forward. Viability was 
significantly compromised in LNCaP and C4-2B cells both as mono- and co-
culture 3D spheroid models, suggesting their use going forward should be 
restricted to 2D monolayer systems.  
 
 
Figure 3.8. PI staining of 3D PC3 co-culture spheroids by fluorescence 
microscopy shows a decrease in viability over time. PI / Hoechst co-
staining of 3D mono- and co-culture spheroids at 10x magnification show an 
increase in PI uptake in co-culture spheroids, indicative of cell death over time. 
Scale bar = 100 µm Blue: nuclei; red: dead cells. Images were taken on days 
1, 3 and 5 after seeding and were acquired with the Confocal LSM 710 (ZEISS, 
Germany) (N = 3).
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Figure 3.9. PI staining of 3D DU145 co-culture spheroids by fluorescence 
microscopy shows a decrease in viability over time. PI / Hoechst co-
staining of 3D mono- and co-culture spheroids at 10x magnification showing 
an increase in PI uptake in mono-culture spheroids, indicative of cell death by 
day 5. Scale bar = 100 µm. Blue: nuclei; red: cell death. Images were taken 
on days 1, 3 and 5 after seeding and were acquired with the Confocal LSM 







Figure 3.10. PI staining of 3D LNCaP co-culture spheroids by 
fluorescence microscopy shows a decrease in viability over time. PI / 
Hoechst co-staining of 3D mono- and co-culture spheroids at 10x 
magnification showing an increase in PI uptake in both mono- and co-culture 
spheroids, indicative of cell death. Scale bar = 100 µm. Blue: nuclei; red: cell 
death. Images were taken on days 1, 3 and 5 after seeding and were acquired 







Figure 3.11. PI staining of 3D C4-2B co-culture spheroids by 
fluorescence microscopy shows a decrease in viability over time. PI / 
Hoechst co-staining of 3D mono- and co-culture spheroids at 10x 
magnification showing an increase in PI uptake in both mono- and co-culture 
spheroids, indicative of cell death. Scale bar = 100 µm. Blue: nuclei; red: cell 
death. Images were taken on days 1, 3 and 5 after seeding and were acquired 
















3.3.3.5 Fluorescent imaging indicated stromal cells integrate well with 
androgen-sensitive prostate cancer cells in 3D models  
To evaluate the distribution of HS5 stromal cells within 3D co-culture prostate 
cancer-stromal cell spheroids, the expression of STRO-1 was evaluated. 
STRO-1 is a monoclonal IgM antibody specific for an undefined cell surface 
antigen expressed by a small population of adult human bone marrow cells 
(Gronthos et al., 2003; Simmons & Torok-Storb, 1991). Therefore, staining of 
STRO-1 allowed for differentiation and observation of stromal cells within a 3D 
structure, using confocal microscopy (Brusnahan et al., 2010; McArthur et al., 
2006; Windus et al., 2013). The nucleic counterstain Hoechst 33342 was used 
to differentiate cells positive for both the nucleic stain and STRO-1 as stromal 
cells in these models (Windus et al., 2013; Xu et al., 2009). 
 
Confocal microscopy demonstrated STRO-1 as a strong, green fluorescent 
signal. Images show that stromal cells were evenly distributed within LNCaP 
and C4-2B spheroids (Figure 3.12C & D, respectively), as opposed to PC3 
and DU145 spheroids where STRO-1 staining is predominantly observed at 
the spheroid periphery and surrounding media (Figure 3.12A & B, 
respectively). These images suggest that the androgen-sensitive prostate 
cancer cell lines LNCaP and C4-2B form more evenly distributed co-culture 
spheroids with HS5 cells than the androgen-independent PC3 and DU145 cell 
lines (Figure 3.14 where representative images are illustrated; Z-stacks for 




Figure 3.12. Integration of bone stromal (HS5) cells when co-cultured as 
3D spheroids with prostate cancer cells. A) PC3, B) DU145, C) LNCaP and 
D) C4-2B prostate cancer cells were cultured with HS5 stromal cells as 3D 
spheroids. Confocal microscopy revealed HS5 cells were better integrated into 
androgen-sensitive prostate cancer cell spheroids (C & D). Scale bar = 100 
µm. Blue: nuclei; green: STRO-1 stromal-specific antibody expression. 
Images were taken 3 days after seeding and were acquired with the Confocal 











3.4.1 STEAP family gene expression in human prostate cancer 
cell lines 
This chapter aimed to determine the gene expression levels of all four 
members of the STEAP family in a panel of prostate cancer cell lines of 
different metastatic origins, in order to determine the most appropriate platform 
to carry forward for subsequent analysis throughout this thesis. Previous 
studies have predominantly focussed on STEAP2 expression (Burnell et al., 
2018; Whiteland et al., 2014), however to date, all four STEAP family members 
had not been assessed across all the prostate cancer cell lines studied in this 
chapter.  
 
STEAP1, the first of the STEAP family of genes, is known to play a role in 
prostate cancer progression through the control of intracellular communication 
between prostate cancer cells and cancer-associated stromal cells 
(Yamamoto et al., 2013). In this study, STEAP1 expression was found to be 
overexpressed in LNCaP cells, consistent with previous studies (Figure 3.1; 
Challita-Eid et al., 2007; Romanuik et al., 2010; Whiteland et al., 2014), yet 
down regulated in DU145, PC3 and C4-2B cells when compared to the normal 
prostate epithelial cell line PNT2. These findings are consistent with previous 
studies which also found that STEAP1 gene expression is relatively low in PC3 
and DU145 cells, despite previous reports of an overexpression in the 
STEAP1 protein (Hubert et al., 1999; Wang et al., 2010).  
 
STEAP2 has been found to be expressed in low levels in normal human 
prostate tissues, with little to no expression in other normal human tissues 
(Shyamsundar et al., 2005). This expression has then been found to increase 
when the prostate is in a diseased state (Korkmaz et al., 2002; Porkka et al., 
2002; Wang et al., 2010). Previous studies have found STEAP2 to be most 
highly expressed in LNCaP cells, with lower but still increased levels recorded 
in PC3 cells, which correlate with the results of this study (Figure 3.1; Gonen-
Korkmaz et al., 2014; Porkka et al., 2002; Whiteland et al., 2014). Of the four 
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prostate cancer cell lines assessed here, DU145 cells were the only cell line 
to exhibit lower levels of STEAP2 than the normal cell line PNT2, consistent 
with previous studies (Figure 3.1; Korkmaz et al., 2002; Porkka et al., 2002). 
In previous studies, STEAP2 overexpression has been induced either 
ectopically or by transfection in DU145 cells to monitor its effects in androgen-
independent cells, further suggesting its expression in this cell line is relatively 
low (Gonen-Korkmaz et al., 2014; Wang et al., 2010).  The highest significant 
increases in STEAP2 expression were found in androgen-sensitive prostate 
cancer cell lines; LNCaP and C4-2B, suggesting that AR signalling may play 
a role in its expression, hence the inclusion of the androgen-sensitive, LNCaP-
derived C4-2B cell line in this study. Whilst the expression of STEAP2 in this 
cell line has not previously been investigated, the significant increase in 
STEAP2 expression found in this study further suggests that STEAP2 
expression correlates with androgen sensitivity. It is of particular interest that 
previous studies have also noted that STEAP2 is highly expressed in AR-
sensitive cells, warranting further investigations into this link (Gonen-Korkmaz 
et al., 2014; Porkka et al., 2002; Wang et al., 2010). 
 
STEAP3 gene expression is highly upregulated in haematopoietic tissues and 
has been known to play a role in iron homeostasis in iron deficiency anaemia 
(Ohgami et al., 2005; Zhang et al., 2012). STEAP3 expression was decreased 
in all four prostate cancer cell lines (Figure 3.1). These results are in line with 
previous studies, as STEAP3 has been found to be highly expressed in cell 
lines originating from other cancer types such as lung and melanomas, when 
compared to prostate cancer (Grunewald et al., 2012). However, an increase 
in STEAP3 expression has previously been observed in LNCaP cells by 
Machlenkin et al., who found that LNCaP cells demonstrated specific CTL 
responses when targeted with CTL epitopes of STEAP3. This was not found 
to be the case in PC3 and DU145 cells, suggesting that STEAP3 is naturally 
processed and presented by LNCaP cells (Machlenkin et al., 2005). 
 
STEAP4 expression is primarily known to be associated with metabolic 
disease as opposed to prostate cancer, and therefore the lower levels of 
STEAP4 expression observed across the panel of prostate cancer cell lines in 
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this study is not surprising (Freyhaus et al., 2012; Wellen et al., 2007). 
Similarly, low expression levels of STEAP4 have previously been observed in 
DU145 and PC3 prostate cancer cells (Figure 3.1; Korkmaz et al., 2005). 
STEAP4 expression has been found to increase in LNCaP cells in a time-
dependent manner, which may account for the low levels observed in this 
study as cells were assessed 48 h after seeding (Korkmaz et al., 2005). The 
same study by Korkmaz et al., also reported that STEAP4 in LNCaP cells was 
expressed in a cell line dependent manner following treatment with a synthetic 
androgen, suggesting STEAP4 expression could be androgen-mediated.  
 
Based on the findings of this study and those carried out previously, of the four 
family members STEAP2 was selected for further analysis in this thesis due 
to its markedly high expression in three of the four prostate cancer cell lines 
studied (Burnell et al., 2018; Whiteland et al., 2014). Thus, it was of particular 
interest to develop a platform for modelling prostate cancer cells known to 
express high levels of STEAP2 as viable 3D spheroids. 
3.4.2 Size vs viability of prostate cancer cells when cultured in 
a 3D format 
3D tissue models provide a more physiologically relevant in vitro system that 
are more representative of in vivo tumours than the same cells cultured as 2D 
monolayers. Spheroids can be cultured with single cell types (monocultures) 
to represent localised or locally advanced disease, or with cell types of multiple 
origins (co-cultures), which are more representative of metastatic, advanced 
disease. Whilst in vitro 3D spheroid models have become more popular in 
recent years, they still come with limitations such as limited efficiency and 
reproducibility of spheroid formation, spheroid maintenance, and cell 
heterogeneity, particularly in 3D co-culture models. Hence the need for a 
robust method for the reproducible generation of viable spheroid models. A 
co-culture model of prostate cancer and bone stromal cells is of particular 
interest given that the predominant site for prostate cancer metastases is the 
bone. This chapter aimed to determine the most suitable and reproducible 
method for growing prostate cancer cells as viable 3D spheroid models, as 
both monocultures and in co-cultures with HS5 stromal cells. The development 
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of such methods would allow spheroids to be readily established without the 
need of specialised equipment, with conditions optimised to each individual 
cell line. Previous work within the group had established a method for culturing 
prostate cancer cells as 3D spheroid cell models grown on agarose gel; 
however, this previous work had only focussed on the PC3 prostate cancer 
cell line (Wang et al., 2019). Therefore, this method was applied to other 
prostate cancer cell lines within this chapter, with the addition of HS5 stromal 
cells to develop and optimise a prostate cancer-stromal cell co-culture model.   
 
A variety of seeding densities and viability assessments were employed to 
monitor the growth of a panel of human prostate cancer cell lines in 3D format, 
as it has previously been found that altering the seeding density can 
subsequently produce spheroids with a wide range of characteristics (Hurrell 
et al., 2018). Previous work within the group when monitoring the growth 
characteristics of PC3 cells over a 14-day period found that viability peaked 
within the first 72 h after seeding and subsequently decreased, hence a 
decision was made to monitor cells over a 5-day period within this chapter 
(Wang et al., 2019). In this chapter, optimal seeding densities were 
established such that the viability of tumour spheroids for each cell line tested 
(regardless of their proliferative potential and cell cycle time) did not fall below 
50% by day 5, which was considered appropriate for initiating experimental 
studies. 
 
Previous studies using experimental measurements and mathematic 
modelling have found that spheroid size can influence viability, with spheroids 
larger than 200 µm known to have steep oxygen gradients (Charoen et al., 
2014; Hirschhaeuser et al., 2010; Khaitan & Dwarakanath, 2006). In these 
spheroids, the centre of the spheroid is starved of oxygen and nutrients, 
leading to the formation of a necrotic core (Charoen et al., 2014; 
Hirschhaeuser et al., 2010; Khaitan & Dwarakanath, 2006). Concurrently, the 
periphery of the spheroid has been found to be a viable, proliferating zone as 
it continues to interact with nutrient-rich media (Grimes et al., 2014; 
Hirschhaeuser et al., 2010; Riffle et al., 2017). Using standard light 
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microscopy, a necrotic core appears as a darker centre of the spheroid in 
relation to its periphery (Gong et al., 2015; Vinci et al., 2012; Zanoni et al., 
2016). Cell viability increased significantly in spheroids of all cell lines seeded 
at an initial density of 2,500 cells per well, and the smallest sized spheroids 
were produced (Figure 3.3, Appendix 1.1). However, when visualised with 
light microscopy, DU145 and LNCaP spheroids with a seeding density of 
2,500 cells did exhibit a necrotic core by days 3 and 5 (see Appendix 1, 
Figures A2.1B & C), which correlated with a reduction in viability at this 
density (Figure 3.4B & C). This suggests that as these spheroids still 
measured > 350 µm, an oxygen gradient may still present (Charoen et al., 
2014; Hirschhaeuser et al., 2010; Khaitan & Dwarakanath, 2006). Previous 
studies have also noted that the necrotic core increases in size proportionate 
to the overall size of the spheroid, suggesting that it is relatively small in these 
models (Riffle et al., 2017).  
 
When visualised using light microscopy, PC3 cells cultured as a monoculture 
were the only cell line to not display a necrotic core under standard light 
microscopy at any seeding density across 5 days (Appendix 1, Figure 
A1.2A), suggesting that metabolic limitation did not play a role in these 
models, despite PC3 spheroids measuring > 600 µm (Figure 3.2A; 
Hirschhaeuser et al., 2010; Mosaad et al., 2018). 10,000 cells per well was 
chosen as the optimum seeding density for PC3 spheroids as the diameter 
stayed the most consistent over time, which also correlates with the results 
from the MTT viability assay, where no significant changes in the viability of 
these spheroids were observed across 5 days (Figures 3.3A and 3.4A). 
Previous studies measuring the size of cancer cell spheroids over time have 
found a decrease in spheroid size, which correlates with a decrease in viability, 
as demonstrated by DU145, LNCaP and C4-2B monoculture spheroids, the 
size of which continually reduced 3-5 days after seeding (Figures 3.2B & C; 
(Dvir-Ginzberg et al., 2003). 7,500 cells per well was chosen as the optimum 
seeding density for DU145 cells as although they decreased in size more 
rapidly that spheroids seeded with 10,000 cells per well, when assessed by 
the MTT assay, their viability remained higher than 50% on all 5 days. In 
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contrast, the viability of spheroids seeded with 10,000 cells per well dropped 
below 50% by day 3 (Figures 3.2B & 3.3B). 5,000 cells per well was chosen 
as the optimum seeding density for both LNCaP and C4-2B cells, as this 
seeding density did not result in any significant decreases in spheroid viability 
in either cell line across the 5-day culture period (Figures 3.3C & D). Initially, 
the size of the LNCaP spheroids slightly increased 2 days after seeding, which 
may be due to their longer doubling time of 60 hours (Cunningham & You, 
2015). This was also found to be the case with C4-2B cells seeded at 7,500 
and 10,000 cells per well (Figures 3.2D and 3.3D), yet these spheroids 
displayed a significant (p < 0.001) decrease in both viability and size on days 
4 and 5, which when observed under standard light microscopy correlated with 
a darker core (Figure 3.4D; Appendix 1, Figure A1.2D). In higher density 
spheroids, cellular functions such as the secretion of urea and albumin in 
hepatocytes, have been found to remain high across up to 7 days of culture in 
3D, highlighting the importance of spheroid density on cell viability (Dvir-
Ginzberg et al., 2003). In prostate cancer cell spheroids this could be assessed 
through monitoring secretions of PSA, which has been known to increase in 
the culture supernatant of healthy LNCaP spheroids (Takagi et al., 2007).  
 
Morphologically, the cell lines used in this chapter have been known to form 
spheroids of two distinct phenotypic categories; round (PC3 and DU245) or 
mass (LNCaP and C4-2B) (Harma et al., 2010; Kenny et al., 2007). As time 
progresses, such cell spheroids have been known to undergo metamorphosis 
to an invasive or stellate phenotype, during which cells dissociate around the 
periphery of the spheroid (Harma et al., 2010). Seeding densities of > 5,000 
cells per well resulted in the dissociation of cells from the tightly packed 
spheroid by day 5 in all cell lines (Figure 3.4 & Appendix 1; Figure A1.2) 
This could explain the discrepancy between an increase in viability shown in 
DU145 cells on Day 5 (Figure 3.3B) and the presence of a necrotic core 
(Figure 3.4B & Appendix 1; Figure A1.2B), as MTT would not have been 
able to penetrate this core. However, an increase in MTT cleavage by the 
mitochondria of these readily available and metabolically active dissociated 
cells may have occurred, in turn increasing the metabolic production of 
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formazan crystals and therefore influencing the peak in spheroid viability 
(Borra et al., 2009; Van Meerloo et al., 2011). 
 
In monoculture, no significant changes were observed in either the size or 
viability of HS5 cells, with viability remaining high until day 3, suggesting that 
any impact on spheroid viability is exerted by prostate cancer cells in co-
culture models (Appendix 1, Figures A1.1 & A1.3; Windus et al., 2013). 
When co-cultured with stromal HS5 cells, the size of spheroids generally 
decreased over the 5-day period, in a trend matching the monocultured 
prostate cancer cell line as opposed to the stromal cell line, with LNCaP co-
cultures still showing an increase in size on day 2 (Figure 3.5C). This 
downward trend in spheroid size resulted in the formation of denser, and 
therefore more tightly packed, spheroids over time. Collectively, the viability of 
monoculture spheroids was higher than that of co-culture spheroids, 
potentially due to the formation of more compact structures as size decreases, 
which may not have allowed for MTT to fully penetrate the spheroids when 
assessing viability (Figure 3.6; Lazzari et al., 2018). 
 
In co-culture spheroids, the viability of PC3-HS5 models remained high 
(Figure 3.6A). PC3 cells have been known to undergo an EMT in vitro, which 
may be due to a loss of phosphatase and tensin homolg (PTEN) (Dubrovska 
et al., 2009; Harma et al., 2010; Windus et al., 2013). This loss of PTEN has 
been found to occur simultaneously with activation of the Akt and PI3K 
pathway, which has been found to be integral in the maintenance of spheroid 
viability (Dubrovska et al., 2009). PTEN loss has also been found to correlate 
with an increased sphere-forming ability in PC3 and DU145 cells, along with 
an increase in tumorigenicity (Dubrovska et al., 2009).  
 
The viability of LNCaP cells in co-culture models at a ratio of 2:1 LNCaP:HS5 
compared to a 1:1 or 1:2 ratio was higher when assessed by the MTT viability 
assay and when visualised under standard light microscopy (Figure 3.6C; 
Appendix 1, Figure A1.4C). This could be due to an overexpression of the 
Bcl-2 antigen which has been found to be expressed on the peripheral layer 
of LNCaP spheroids (Takagi et al., 2007). As these spheroids contain higher 
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numbers of LNCaP cells compared to the other ratios studied due to the higher 
seeding ratio of 2 LNCaP: 1 HS5 cells, Bcl-2 expression may also be higher. 
This could be associated with protecting LNCaP cells from cell death through 
inhibiting caspases 3 and 7 during apoptosis (Cohen et al., 2012; Erdogan et 
al., 2018; Takagi et al., 2007). Another possible explanation for these 
spheroids displaying higher viability than those containing lower numbers of 
LNCaP cells is an enhanced level of VEGF production (Takagi et al., 2007). 
VEGF production has been found to correlate with the levels of hypoxia 
present in LNCaP cell spheroids, as it is regulated by hypoxia-inducible 
transcriptional mediator HIF-1 (Muir et al., 2006; Riffle et al., 2007). In the 
spheroids studied here, VEGF could play a role in enabling the survival of the 
spheroids. For future studies, to assess the degree of hypoxia occurring within 
a spheroid, the levels of the hypoxic marker micro-RNA (miRNA)-210 could be 
measured, which have found to be elevated in both prostate cancer cell lines 
LNCaP, PC3 and DU145 when cultured under hypoxic conditions, and in the 
serum of prostate cancer patients (Ivan & Huang, 2014; Quero et al., 2011). 
mi-RNA expression has been found to be regulated by HIF-1 in a variety of 
tumour types through a hypoxia responsive element, including prostate 
cancers (Huang et al., 2009; Porkka et al., 2007). Future work should therefore 
focus on the characterisation of these genes in the 3D prostate cancer cell 
systems to confirm their hypothesised effect and determine their role in 
spheroid viability over time.  
 
Many previous studies have employed fluorescent markers to visualise 
spheroid viability, proliferation and the regionalisation of cells. For example, 
Ki-67 staining is used to distinguish areas of proliferation, whilst double 
fluorescent staining using Hoechst 33342 to stains the condensed chromatin 
in both apoptotic and viable cells, and PI to stain only dead cells (Gomes et 
al., 2016; Laurent et al., 2013; Liu et al., 2013; Mosaad et al., 2018; Vinci et 
al., 2012). Previous studies within the research group had also employed this 
method in PC3 prostate cancer cells, and found that spheroid viability 
decreases after 72 h, as visualised by PI staining (Wang et al., 2019). This co-
staining method differs from the MTT assay used to assess viability as MTT 
provides a quantitative measurement of metabolic activity and is only cleaved 
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by the mitochondria of metabolically active cells. PI staining, however, allows 
for visualisation of cell death by specifically identifying dead cells as it is 
excluded from intact, viable cells (van Meerloo et al., 2011).  
 
The most viable ratios of prostate cancer and HS5 stromal cells were selected 
for fluorescence imaging based on the results of the MTT viability assay and 
alamarBlue proliferation assay and were chosen specific to each prostate 
cancer cell line. As shown in Figures 3.8 – 3.11, minimal dead cells were 
detected by staining with PI on day 1 across all spheroids in mono- and co-
cultures, suggesting these spheroids are healthy and viable. As time 
progressed, an increase in positive PI staining of dead cells was observed on 
day 3 in LNCaP and C4-2B co-culture models (Figures 3.10 & 3.11) yet was 
not present in PC3 mono- or co-culture models at any point (Figure 3.8) and 
were only observed in DU145 monocultures on day 5 (Figure 3.9). On day 5, 
DU145 monoculture spheroids show the highest levels of PI staining (Figure 
3.9), consistent with the MTT (Figure 3.6B) and alamarBlue (Figure 3.7B) 
assays, which, on day 5, showed the lowest viability and proliferation rates 
respectively. PC3 cells have previously been found to be viable in 3D co-
cultures with osteoblast and endothelial cells across 7 days when visualised 
with DsRed, which co-localised with viable cells stained with Calcein-AM 
(Hsiao et al., 2009). PI staining was found to be more concentrated at the 
centre of each spheroid in the present study, further suggesting the 
development of a central necrotic core and outer proliferating zone (Grimes et 
al., 2014; Hirschhaeuser et al., 2010; Riffle et al., 2017). Similar patterns of 
cell death have also been observed when co-staining with Hoechst 33342 and 
cleaved caspase 3, a marker of apoptosis (Riffle et al., 2017; Slee et al., 2001). 
To provide a more quantitative assay, future work may utilise the CellTiterGlo 
test (Promega), which correlates the absorbance with the cell viability using a 
simple add and read format. This assay is not dissimilar to the alamarBlue 
assay and has been successfully implemented in the assessment of 3D 
spheroid viability (Mosaad et al., 2018; Zanoni et al., 2015).  
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3.4.3 Changes in proliferation rate of prostate cancer-stromal 
cells grown as mono- and co-culture models 
The proliferation rates of cells cultured in 2D and 3D are usually different and 
are often matrix and cell line dependent (Edmondson et al., 2014). Compared 
to cells cultured in 2D, many cell lines display lower proliferation rates when 
cultured in 3D (Luca et al., 2013). Tumour cells which continue to display 
proliferative capacity under the hypoxic conditions associated with 3D models 
has been associated with tumour aggression and lower disease-free survival 
rates (Hoogsteen et al., 2005). As the 3D cell spheroids grow, chemical and 
oxygen diffusion gradients develop across the radius of each individual 
spheroid, which can influence cellular proliferation and viability (Gomes et al., 
2016; Mosaad et al., 2018; Zanoni et al., 2015). alamarBlue was used in this 
study to assess proliferation rates, as it has successfully been implemented 
as a tool for tracking proliferation rates in similar 3D models, particularly those 
using prostate cancer cells (Florczyk et al., 2012; Windus et al., 2013).  
 
Proliferation rates in 3D models as opposed to their 2D counterparts remain 
consistently low, as self-assembled spheroids do not experience the same cell 
tensions found in cells cultured on 2D surfaces, which stimulate proliferation 
(Khaitan et al., 2006). This was found to be the case in this study, with the 
proliferation rate of 3D spheroids remaining consistently low, with the 
exception of PC3 cells (Figure 3.7A; Mosaad et al., 2018). PC3 cells cultured 
with medium from HS5 cells have previously shown increased invasion and 
proliferation rates, suggesting secretions of certain growth factors such as 
granulocyte from stromal cells-colony stimulating factor (G-CSF), GM-CSF, 
and macrophage-colony stimulating factor (M-CSF) could influence prostate 
cancer cell metastases (Wang et al., 2020). Proliferation rates in PC3-HS5 co-
culture spheroids were highest in the 1:1 PC3:HS5 co-culture on day 3, which 
correlates with the viability data shown previously (Figure 3.6A) that indicates 
the lowest decline in viability also occurred on day 3. These results are 
consistent with those of Windus et al., who found that by day 3, PC3 cells in 
co-culture spheroids proliferated at significantly higher rates in comparison to 
HS5 cells and followed a similar pattern to PC3 cells in monocultures. It has 
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also been demonstrated that PC3 cells are able to survive and proliferate 
within osteoblast and endothelial cell co-cultures, independently of the other 
cell types present (Hsaio et al., 2009). A 2:1 PC3:HS5 ratio was chosen for 
PC3 cells in co-culture as this ratio exhibited the most stable viability across 
the 5-day culture period, and the proliferation rates of all ratios studied followed 
the same trend, despite variances in viability and therefore a 2:1 PC3:HS5 
ratio was deemed the most consistent (Figures 3.6A and 3.7A). As the 
proliferation rates of all co-culture spheroids (regardless of PC3:HS5 ratio) 
follow the same trend as PC3 monocultures after day 3, it could be suggested 
that PC3 cells are influencing the proliferative behaviour of HS5 cells 
(Appendix 1, Figure A1.5; Windus et al., 2013). Recently, PC3 cells have 
been found to influence an increase in the proliferative capacity of bone-
derived MSCs, thought to be the result of the secretion of pro-inflammatory 
cytokines from prostate cancer cells (Ridge et al., 2017).  
 
For DU145 cells in co-culture, a ratio of 1:1 DU145:HS5 ratio was chosen as, 
whilst a ratio of 1:1 DU145:HS5 and 2:1 DU145:HS5 both followed similar 
patterns in spheroid size and proliferation rates (Figures 3.5B and 3.7B), the 
viability profile of spheroids cultured at a 1:1 DU145:HS5 ratio more closely 
mirrored that of the DU145 cells in monoculture (Figure 3.6B). The growth of 
prostate cancer cells that do not metastasise to the bone, i.e., DU145 cells, 
are inhibited by BMP-4 (Cooper et al., 2003; Lamm et al., 2001; Nishimori et 
al., 2012). In co-culture with LNCaP cells, osteoblastic differentiation of bone 
stromal cells has been noted to be induced by BMP-4 through the production 
of Sonic hedgehog (Shh) (Nishimori et al., 2012; Zunich et al., 2009). It has 
been suggested that the hedgehog signalling pathways in bone development 
may also play a role in the formation of bone metastases where osteoblast 
differentiation is induced when Shh-expressing prostate cancer cells activate 
the signalling pathway in osteoblast progenitor cells (Zunich et al., 2009). In 
these models, proliferation may also be increased through the production of 
growth factors stimulated by BMP-4, which has been noted in bone stromal 
cells producing fibroblast growth factor (FGF)-2 and EGF when co-cultured 
with LNCaP cells (Nishimori et al., 2012).  
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The considerably lower rates of proliferation observed in the non-invasive 
LNCaP cell line (Figure 3.7C) in comparison with the invasive metastatic PC3 
cell line (Figure 3.7A) suggest that cells in 3D cultures exhibit proliferation 
rates that mimic those of prostate cancers found in vivo (Windus et al., 2012). 
Whilst tumour cells have been known to influence the proliferative potential of 
stromal cells, proliferation is also known to increase in the bone 
microenvironment through osteomimicry, the acquisition of bone cell-like 
properties by tumour cells (Knerr et al., 2004; Windus et al., 2013). This could 
explain the increase in proliferation observed when the number of HS5 cells 
in co-cultures is twice that of LNCaP cells, suggesting that HS5 cells are 
proliferating at a faster rate than LNCaP cells (Figure 3.7C). The viability of 
LNCaP cells in a 1:1 LNCaP:HS5 co-culture was significantly lower than 
spheroids seeded with either 2:1 LNCaP:HS5 cells or 1:2 LNCaP:HS5 cells, 
which may explain the low rates of proliferation observed at this ratio as only 
viable, proliferating cells would be able to metabolise alamarBlue (Rampersad 
et al., 2012). For LNCaP cells in co-culture, a ratio of 1:2 LNCaP:HS5 cells 
was chosen as the viability of these spheroids was the most consistent over 
time, whilst the proliferation profiles of all ratios studied remained similar 
(Figures 3.6C & 3.7C). It has previously been noted that the proliferation rate 
of C4-2B cell spheroids gradually increases from days 0 – 5, as observed in 
this study (Figure 3.9D; Florczyk et al., 2012; Mosaad et al., 2018). For C4-
2B cells in co-culture, a ratio of 1:1 C4-2B:HS5 was chosen as these spheroids 
displayed the most consistent size and proliferation rates over time (Figures 
3.5D & 3.7D) whilst also maintaining a viability of > 60% across all 5 days 
(Figure 3.6D). 
 
As the surface of a spheroid is curved, it has been reported that the surface 
cells experience higher levels of tension as they can spread over this curved 
surface, and therefore proliferate at a higher rate than those at the core of the 
spheroid (Kenny et al., 2007; Mosaad et al., 2018; Zanoni et al., 2015). To 
assess this theory, other studies have used fluorescent markers such as Ki-
67 to determine zones of proliferation within spheroids, and model a gradient 
of proliferation (Friedrich et al., 2007; Kenny et al., 2007; Mosaad et al., 2018; 
Vinci et al., 2012). Ki-67 is a protein present in all phases of the cell cycle, with 
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the exception of G0, and is therefore used as a marker for the growth fraction 
of a cell population (Riffle et al., 2017). In smaller spheroids of < 400 µm, Ki-
67 staining has been observed throughout the spheroid, yet once spheroid 
size exceeds 500 µm, Ki-67 positive cells only become present around the 
spheroid surface (Riffle et al., 2017). This phenotype relates back to the 
presence of a necrotic core, as larger spheroids (> 500 µm) have previously 
been characterised by an external proliferating zone surrounding a necrotic 
core, which resembles the cellular heterogeneity of solid in vivo tumours 
(Charoen et al., 2014; Hirschhaeuser et al., 2010; Khaitan & Dwarakanath, 
2006; Takagi et al., 2007). It has also been noted that the thickness of the 
proliferating zone remains consistent over time, despite the size of the necrotic 
core increasing in proportion to the size of the spheroid, which may account 
for the consistent levels of proliferation observed in some spheroids in this 
study (Riffle et al., 2017). Mosaad et al., noted a gradual increase in the DNA 
content of C4-2B spheroids over the first 5 days of culture, suggestive of an 
increase in proliferation over the first 5 days of culture, which subsequently 
decreased by day 7, consistent with a reduction in cellular proliferation when 
visualised by confocal microscopy using Ki67 staining. Further studies should 
therefore focus on the use of proliferative markers such as Ki67 to visually 
determine how representative the models generated in this Chapter are of the 
in vivo environment in terms of the formation of proliferative peripheral zones. 
 
Spheroid shape has been known to contribute to proliferation rates, with more 
spherical, rounded spheroids similar to those generated in this chapter 
showing slower rates of proliferation due to a reduced distance between each 
cell and the culture medium (Kenny et al., 2007; Mosaad et al., 2018; Zanoni 
et al., 2015). It has been found that non-spherical spheroids, which have an 
irregular morphology and larger surface area for interaction with culture 
medium, have a wider zone of active cell proliferation (Kenny et al., 2007; 
Mosaad et al., 2018; Zanoni et al., 2015). In co-culture with HS5 cells, 
spherical DU145 and PC3 cells spheroids have been found to have 
proliferative zones around the periphery of each spheroid, visualised when 
stained with EdU (Windus et al., 2013). Staining with EdU, which marks cells 
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in the S-phase – has also been found to be more restricted to the periphery of 
spheroids than Ki-67 staining, indicating a failure to progress through S-phase 
(Riffle et al., 2017). 
3.4.4 Use of fluorescent markers to distinguish between cell 
types in 3D prostate cancer-stromal models 
In order to distinguish between prostate cancer and stromal cells and to 
evaluate stromal cell integration within the prostate cancer spheroid models, 
the human STRO-1 antibody was used as a fluorescent marker specific to 
stromal cells (Fong et al., 2016; Nishimori et al., 2012; Ono et al., 2007). It was 
of importance to generate a uniformly distributed co-culture model to assess 
the impact of prostate cancer-stromal cell interactions on spheroid formation, 
viability and proliferation. To date, there are no known specific markers for any 
of the prostate cancer cell lines used in this study, and therefore to visualise 
all cells a general nucleic stain, Hoechst 33342, was used (Dasiram et al., 
2017; Liu et al., 2012; Oosterhoff et al., 2003). This co-staining allowed the 
identification of cells negative for STRO-1 yet positive for Hoechst 33342 as 
prostate cancer cells, whilst those both STRO-1 and Hoechst 33342 positive 
were HS5 stromal cells (Fitter et al., 2017; Windus et al., 2013). 
 
STRO-1 has previously been used to co-stain PC3-HS5 and DU145-HS5 
prostate cancer and stromal cell 3D co-culture models (Windus et al., 2013). 
Here, when co-cultured with PC3 cells, minimal STRO-1 staining was 
observed, and therefore it could be suggested that PC3 cells are altering the 
proliferative behaviour of HS5 cells when compared to their monoculture 
counterparts (Figure 3.12A; Windus et al., 2013). In this study, HS5 cells were 
located primarily around the outer regions of the spheroid when co-cultured 
with DU145 cells (Figure 3.12B), with a distinct absence of cells in the inner 
region when visualised by Z-stacks (see Appendix A1.10B). A similar pattern 
was noted by Windus et al., who reported that HS5 cells seeded in co-culture 
3D models with DU145 cells retained their characteristic phenotype and rarely 
formed cell-cell interactions. Immunostaining of these models found that in co-
cultures, E-cadherin was upregulated when compared to monocultures of both 
prostate cancer and stromal cell spheroids, further suggesting the induction of 
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an EMT (Windus et al., 2013). Evidence of a switch to EMT has been found to 
initiate the release of cancer cells from their organ of origin, which also 
correlates with an increase in proliferation in co-culture models as opposed to 
monocultures, as observed in PC3 and DU145 co-cultures in this study 
(Figure 3.7A & B; Gravdal et al., 2007; Putzke et al., 2011; Trimboli et al., 
2008; Windus et al., 2013). In co-culture models with LNCaP and C4-2B cells, 
STRO-1 staining of HS5 cells was more pronounced (Figure 3.12C & D), with 
stromal cells integrated with the prostate cancer cells throughout the spheroids 
(see Appendix A1.10C & D). As C4-2B cells were derived from a bone 
metastasis of the LNCaP parental line, they exhibit a higher affinity for cell-cell 
interactions with stromal cells (Sobel et al., 2005; Windus et al., 2013). Positive 
STRO-1 staining of HS5 cells was observed towards the centre of the spheroid 
in co-culture with C4-2B cells (Figure 3.12D), suggesting HS5 cells have a 
higher affinity to interact with bone-derived metastatic prostate cancer cells 
(Windus et al., 2013). This effect has recently been reported in bone-derived 
MSCs which showed a significantly increased chemoattraction towards bone 
metastasis-derived PC3 cells in comparison to non-metastatic 22Rv1 cells or 
brain metastasis-derived DU145 cells (Ridge et al., 2017). 
 
To establish communications between metastasising cancer cells and 
surrounding bone stromal cells, it is important to determine how cancer cells 
exit the vasculature once in the bone marrow. Two chemokines of particular 
interest in the trafficking of prostate cancer cells to the bone, which are 
involved in the C-X-C (CXC) motif, are CXC receptor 4 (CXCR4) and CXC 
ligand 12 (CXCL12) (Sun et al., 2010; Taichman et al., 2002; Windus et al., 
2012). CXCL12, also known as stromal cell-derived factor-1 (SDF1), is 
expressed by stromal cells in target organs of prostate cancer metastasis such 
as the bone, brain and lymph (Taichman et al., 2002). CXCR4, the receptor of 
CXCL12, has been found to be highly expressed by all four prostate cancer 
cell lines used in this chapter, both in 2D and 3D models, consistent with a 
metastatic phenotype (Taichman et al., 2002; Windus et al., 2012). 
Colonisation of tumour cells to the bone is thought to be the result of co-
operative signalling between CXCR4 and CXCL12, establishing interactions 
between tumour and stromal cells (Schneider et al., 2011; Taichman et al., 
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2002). CXCL12 has also been demonstrated as a chemoattractant of both 
PC3 and C4-2B cells to stromal cells (Cooper et al., 2003). To determine the 
use of the CXCL12/CXCR4 pathway in the models used in this chapter, 
immunostaining for each chemokine could be employed. It has previously 
been demonstrated that CXCR7, another CXCL12 receptor, is highly 
expressed in 3D PC3 models co-cultured with HS5 cells in areas where STRO-
1 expression was also increased (Windus et al., 2013). In the bone 
microenvironment, integrin signalling through alpha-v-beta-3 (αvβ3) on tumour 
cells has been known to promote tumour metastasis and proliferation 
(Schneider et al., 2011). In metastatic prostate cancer cells, CXCR4 ligation 
has been reported to increase αvβ3 expression and subsequently increase 
aggressiveness (Sun et al., 2007). αvβ3 is an essential integrin for the 
adherence and migration of prostate cancer cells to the bone matrix in the 
early stages of bone metastasis, assisting cells with interactions with bone 
stromal cells, osteoblasts, osteoclasts and the bone matrix itself (Nakamura et 
al., 2007). To further evaluate the effect co-culturing prostate cancer cells with 
bone stromal cells has on tumour aggressiveness, it would be of interest to 
characterise changes in the expression of genes known to be involved in cell-
cell communication and disease progression, such as CXCR4 and CXCL12. 
This information would assist in determining the mechanisms driving prostate 






3D co-culture spheroid models can be used to mimic the tumour 
microenvironment, exhibiting populations of cells that are viable and 
proliferating in niches similar to those seen in solid tumours. The data 
generated in this chapter provides strong evidence for the successful 
generation of viable 3D monoculture prostate cancer cell spheroids, which will 
be used as a platform for subsequent experiments in this thesis. This chapter 
provides a comprehensive, simple method for yielding reproducible 3D 
prostate cancer spheroid models that recapitulate in vitro some of the key 
characteristics of in vivo tumours, whilst also providing a platform for imaging 
and quantitative analysis. Data here also suggests that this method is capable 
of producing viable 3D co-culture prostate-cancer stromal cell spheroids 
models. The androgen-sensitive prostate cancer cell lines LNCaP and C4-2B 
provide the most relevant model for assessing the effects of altering and 
monitoring STEAP2 expression, whilst also proving capable of forming evenly 




Impact of exposure to anti-STEAP2 mono- and poly-
clonal antibodies on prostate cancer cell properties 
and androgen-regulated responses 
 
4.1 Introduction 
STEAP2 has been identified as a potential drug target in the treatment of 
prostate cancer (see Chapter 1; Section 1.5.2; Burnell et al., 2018; Whiteland 
et al., 2014). Studies to date have highlighted the potential for viable 
therapeutic antibodies against STEAP2 in the treatment of advanced prostate 
cancer (Burnell et al., 2018; Nguyen-Chi, 2020; Whiteland et al., 2014). The 
use of antibodies in the treatment of various diseases, including cancer, has 
rapidly expanded over recent years (see Chapter 1, Section 1.6; Chen et al., 
2020; Strebhardt & Ullrich, 2008). Antibodies target a specific sequence on 
antigens and induce cell death through an immune-mediated signalling 
cascade (see Chapter 1, Section 1.6; Chen et al., 2020; Shields et al., 2001). 
pAbs target multiple epitopes and are associated with more off-target adverse 
effects, whereas mAbs specifically target single epitopes. This allows for mAbs 
to be delivered at lower doses than pAbs whilst inducing less off-target side 
effects (Wang et al., 2013).  
 
STEAP2 holds potential as a therapeutic target for antibody-based treatments 
due to its transmembrane location and correlation with prostate cancer 
progression (see Chapter 1, Section 1.5.5; Burnell et al., 2018). Specific 
targeting of STEAP2 may allow for promoting prostate cancer cell death, whilst 
preserving healthy cells from the toxic off-target side-effects posed by many 
current therapies (Sikkeland et al., 2016). Given that STEAP2 has six 
transmembrane helices and three extracellular loops (ECLs), work within the 
research group has previously identified these loops as accessible targets for 
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mAbs (Grunewald et al., 2012; Nguyen-Chi, 2020). A commercially available 
pAb was also identified by previous members of the group as a lead candidate 
that is highly specific to membranous STEAP2, targeting the third extracellular 
loop (ECL3) (Nguyen-Chi, 2020).  
 
Whilst anti-STEAP2 pAbs and mAbs have been found to be effective at 
decreasing cell viability in 2D monolayers of prostate cancer cells, it currently 
remains unknown whether such agents have the potential to induce cell death 
in 3D prostate cancer cell models (Hasegawa et al., 2018; Nguyen-Chi, 2020). 
This is an important consideration because, while 2D cells have the advantage 
of low costs and simplicity of use during the early stages of drug development, 
they lack the complex physiology and heterogeneity presented in tumour 
tissues (Hirschhaeuser et al., 2010). 3D culture models allow for cell-cell 
interactions to occur in a manner that is more representative of the in vivo 
system, allowing for evaluation of interaction between the drug and tissue in a 
more realistic test system (Hirschhaeuser et al., 2010; Kunz-Schughart et al., 
2004; Thoma et al., 2014). To date, anti-STEAP2 antibodies have not been 
applied to 3D prostate cancer models, and hence the 3D models generated in 
Chapter 3 provide a platform for interrogation with anti-STEAP2 pAbs and 
mAbs in this Chapter.  
 
A potential approach to reducing off-target toxicity would be to enhance the 
specificity of drugs through the use of ADCs (see Chapter 1, Section 1.6.4; 
Tarcsa et al., 2020). ADCs allow for drugs to be transported into cells by 
utilising the ability of mAbs to specifically target tumour-specific cell surface 
biomarkers (Tarcsa et al., 2020). To enable drug delivery to cells, receptor 
internalisation must be triggered, which for STEAP2 to be considered for use 
in ADC technology would occur upon the highly specific binding of the mAb to 
STEAP2 (Hasegawa et al., 2018; Tarcsa et al., 2020). Cell death is then 
achieved by lysosomal enzymes degrading the ADC-receptor complex and 
subsequently releasing the cytotoxic payload (Kamath & Iyer, 2015; Tarcsa et 
al., 2020). As it is currently unclear whether STEAP2 becomes internalised 
upon the application of mAbs, the suitability of anti-STEAP2 mAbs with ADC 
technology also remains unknown (Hasegawa et al., 2018).  
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Previous work within the wider Swansea research group has focussed on 
assessing the viability of PC3 prostate cancer cells in response to a 
commercially available anti-STEAP2 pAb, and the generation of anti-STEAP2 
mAbs (Nguyen-Chi, 2020). However, such antibodies have not been applied 
to a wide range of prostate cancer cell lines to compare the responses of 
androgen-sensitive and androgen-independent cell lines, nor have they been 
applied to 3D spheroid models. To date, the effects of targeting STEAP2 with 
pAbs and mAbs on downstream genes associated with prostate cancer 
progression has not been studied, and therefore the effect of targeting 
STEAP2 on AR expression is also currently unknown. This is of interest when 
developing a potential therapeutic agent to treat prostate cancer, as the 
disease is largely androgen-regulated and therefore any changes in AR 
expression may affect disease progression (see Chapter 1, Section 1.8; 
Gonen-Korkmaz et al., 2014; Myung et al., 2013; Tanner et al., 2011). 
Overexpression of STEAP2 has been linked with increased cell proliferation 
via the ERK/MAPK signalling pathways, resulting in a more aggressive 
phenotype leading to enhanced cell migration and invasion (Gomes et al., 
2012). The MAPK signalling pathway is also linked with resistance to 
androgen therapy, and it is therefore of interest to determine links between 
STEAP2 and AR expression with regards to identifying novel therapeutic 
targets in the treatment of prostate cancer (Jia et al., 2013; Li et al., 2019).  
 
The aim of this Chapter was to assess the suitability of STEAP2 as a 
therapeutic target. This aim was addressed through the following objectives: 
1. To identify a lead anti-STEAP2 mAb candidate capable of significantly 
reducing cell viability in a panel of prostate cancer cell lines from a panel 
of  anti-STEAP2 mAbs previously generated within the wider Swansea 
research group; 
2. To evaluate the impact of anti-STEAP2 mono- and polyclonal 
antibodies on the viability of 3D prostate cancer spheroids; 
3. To evaluate the impact of an anti-STEAP2 pAb on the gene expression 
of AR and androgen-regulated genes; 
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4. To assess the ability of an anti-STEAP2 monoclonal antibody to trigger 
STEAP2 receptor internalisation in order to determine the suitability for 
use with ADC technology.  
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4.2 Materials and methods 
4.2.1 Cell culture 
 
4.2.1.1 2D monolayer cells 
The four prostate cancer cell lines C4-2B, DU145, LNCaP and PC3 and the 
normal prostate epithelial cell line PNT2 were routinely cultured as described 
in Chapter 2, Section 2.2.7.1. For absorbance-dependent endpoint analyses, 
cells were grown in phenol-red free DMEM supplemented with 10% FBS, 1% 
L-glutamine and 1% P/S (Thermo Fisher, UK).  
 
4.2.1.2 3D cell spheroids 
Cells were counted as described in Chapter 2, Section 2.2.7.2 and seeded at 
a desired density onto agarose coated 96-well tissue culture plates, as 
described in Chapter 2, Section 2.2.7.3.  
4.2.2 Exposure of 2D monolayers and 3D spheroids to STEAP2 
antibodies 
 
4.2.2.1 Polyclonal STEAP2 antibody treatment 
A commercially available anti-STEAP2 polyclonal antibody (stock 
concentration 1 mg/ml) was used within this Chapter (Aviva Systems Biology, 
OASG06901). Approximately 10,000 cells per well in a 96-well were cultured 
for 24 h before 24 h exposure to the anti-STEAP2 polyclonal antibody 
treatment in triplicate.  
 
4.2.2.2 Monoclonal STEAP2 antibody treatment  
Three anti-STEAP2 monoclonal antibodies were previously developed by 
group members in conjunction with Antibody Production Services, the 
concentrations of which can be found in Table 4.1 (Nguyen-Chi, 2020). 
Approximately 10,000 cells per well in a 96-well were cultured for 24 h before 
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24 h exposure to the anti-STEAP2 monoclonal antibodies treatment in 
triplicate. 
 
Table 4.1. Stock concentrations of anti-STEAP2 mAbs. 
mAb # Target Stock concentration (mg/ml) 
1 Linear 2.0 
2 Linear 1.3 
3 Linear 1.8 
 
4.2.2.3 Cell viability quantification 
Monolayers of prostate cancer cells were cultured in 96-well plates as 
described in Section 4.2.1.1, whilst 3D prostate cancer cell spheroids were 
generated in 96-well plates as described in Section 4.2.1.2. Cells were 
exposed to anti-STEAP2 antibodies as described in Sections 4.2.2.1 & 
4.2.2.2. The MTT cell viability assay was used following treatment with either 
poly- or monoclonal anti-STEAP2 antibodies, as described in Chapter 2, 
Section 2.4.1. Absorbance was read at A = 570 nm using a fluorescence plate 
reader (POLARstar, BMG Labtech, UK). The cell viability experiments were 
conducted in triplicate. 
4.2.3 Detection of AR and AR-regulated genes in prostate 
cancer cells following treatment with STEAP2 antibodies 
PC3, DU145, LNCaP and C4-2B cells were treated with anti-STEAP2 
polyclonal antibody as described in Section 4.2.2.1. Treated cells were 
harvested, RNA was extracted, cDNA synthesised, and qRT-PCR performed 
as described in Chapter 2, Section 2.3. Cells were probed for the detection 
of AR and its downstream targets; PSA, FKBP5, TMPRSS2, and GPRC6A, 
with GAPDH as the housekeeping control, using the primers detailed in 
Chapter 2, Section 2.3.3, Table 2.8. The results were subsequently analysed 
as described in Chapter 2, Section 2.3.4. 
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4.2.4 Receptor internalisation  
 
4.2.4.1 Slide preparation 
In an 8-well chamber slide (Ibidi, Germany), cells were seeded in 300 µl 
serum-free media for 48 h at 37°C/ 5% CO2 receptor internalisation was 
carried out. Once cells had reached 80% confluency, old serum-free media 
was discarded, cells were washed with PBS and the treatment was added in 
complete media. Slides were initially incubated on ice for 30 minutes prior to 
incubation at 37°C/ 5% CO2 for the desired time (0, 3, 12 or 24 h) to allow for 
receptor internalisation. Following the desired incubation time, the chamber 
was washed with PBS and fixed with PFA (Polysciences, USA, Cat. 18814-
20) for 20 minutes at room temperature. Chambers were washed with PBS 
and cells were permeabilised with 0.1% Triton-X 100 (Sigma Aldrich, UK, Cat. 
T8787) for 5 minutes at room temperature. Chambers were washed with PBS 
and cells were blocked with 3% BSA (Sigma Aldrich, UK, Cat. A2153) for 1 
hour at room temperature. Chambers were washed with PBS and incubated 
with secondary Alexa-Fluor 488 antibody (1:200, Invitrogen, UK) in 3% BSA 
overnight at 4oC blocked from light. The secondary antibody was removed, 
and cells washed with PBS. Nuclei were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI) (Vectorlabs, UK, Cat. H-1200). Images were acquired 
with the confocal LSM 710 microscope (Zeiss, Germany) at a 63x zoom 
magnification. The experiment was conducted in duplicate unless otherwise 
stated. 
 
4.2.4.2 Fluorescent imaging analysis and image processing  
For fluorescent microscopical analysis, a confocal laser scanning microscope 
(LSM710, ZEISS, Germany) was used (Chapter 2, Section 2.6). The 
analysed channels and emission wavelengths (nm) were blue (405 nm) for the 
nuclei and red (543 nm) for internalised STEAP2-receptor mAb. The 
secondary goat anti-mouse anti-IgG antibody (1:1,000, Invitrogen, UK) was 
used to detect the primary antibodies. Zen Black software Version 10 was 
used to process images, and scale bars were based on the known microscope 
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pixel sizes for each objective (µm). The red-blue-green (RBG) setting was 
used to display coloured images. 
4.2.5 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 8 for iOS, 
using the one-way ANOVA post-hoc Dunnett test. Data was considered 
statistically significant when a p-value of < 0.05 (*), p-value < 0.01 (**) or a p-
value of < 0.001 (***) or p-value < 0.0001 (****) was obtained, which were 
annotated within the respective figures. Confocal microscopy for receptor 
internalisation studies was conducted through acquisition of three images at 












The aim of this Chapter was to evaluate the impact of a commercially available 
anti-STEAP2 polyclonal antibody, along with three anti-STEAP2 monoclonal 
antibodies, on the viability of prostate cancer cells grown as both 2D 
monolayers and 3D spheroids, as determined by the MTT assay. The impact 
of the anti-STEAP2 polyclonal antibody on AR and androgen-regulated gene 
expression was then assessed by qRT-PCR. Finally, this Chapter aimed to 
address the potential of a selected anti-STEAP2 monoclonal antibody for use 
with ADC technology, by assessing receptor internalisation by confocal 
microscopy. 
 
4.3.1 Anti-STEAP2 pAb substantially reduces cell viability in 
four prostate cancer cell lines in 2D 
In order to determine the ability of a commercially available anti-STEAP2 
polyclonal antibody to induce cell death in 2D prostate cancer cells, the MTT 
cell viability assay was utilised. Four prostate cancer cell lines were exposed 
to three different doses of anti-STEAP2 polyclonal antibody ranging from 25, 
50 and 75 µg/ml of pAb for 24 h before the assay was conducted (Figure 4.1). 
All doses induced significant reductions in the percentage of viable cells in 
PC3, DU145 and LNCaP cells (Figures 4.1). However, only > 50% cell death 
was achieved in LNCaP cells treated with 50 and 75 µg/ml anti-STEAP2 pAb, 
as indicated by the calculated IC50 values (Table 4.2; AAT Bioquest Inc., 
2020). The largest reduction in the percentage of viable cells was observed in 
LNCaP cells at the highest pAb dose of 75 µg/ml (-63.4%, p < 0.0001; Figure 
4.1C). In C4-2B cells, only the highest dose of 75 µg/ml induced a significant 
reduction in cell viability (-19.2%, p < 0.05); Figure 4.1D). Interestingly, in PC3 
cells, reduction in the number of viable cells did not occur in a dose-dependent 
manner, with an initial decrease in the percentage of viable cells of -28.5% 
when treated with 25 µg/ml anti-STEAP2 pAb, which plateaued across the 
range of doses (p < 0.01; Figure 4.1A). These data suggest that in the interest 
of conserving the drug, increasing the dose in PC3 cells is not warranted. 
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Overall, these data suggest that 75 µg/ml anti-STEAP2 pAb substantially 
decreases the cell viability of all four prostate cancer cell lines.  
 
 
Figure 4.1. Effect of anti-STEAP2 pAb on prostate cancer cell viability. 
PC3, LNCaP, C4-2B and DU145 prostate cancer cells were treated with 
increasing concentrations of anti-STEAP2 pAb. After 24 h treatment, cell 
viability was assessed by the MTT assay. An ANOVA post-hoc Dunnett test 
was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.01 
(**), p-value < 0.001 (***), p-value < 0.0001 (****) (N = 3).  
 
Table 4.2. IC50 values of the anti-STEAP2 pAb determined by the results 
of the MTT cell viability assays displayed in Figure 4.1. Calculated using 
AAT Bioquest Inc. Quest Graph™ IC50 Calculator (AAT Bioquest Inc., 2020). 
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4.3.2 Anti-STEAP2 pAb does not substantially reduce cell 
viability in two prostate cancer cell lines in 3D 
Following the results of Section 4.3.1, it was of interest to assess the impact 
of the same commercially available anti-STEAP2 polyclonal antibody on 
reducing the percentage of viable cells in 3D prostate cancer spheroids, again 
using the MTT cell viability assay. To represent a low STEAP2 expression 
model, PC3 cells were chosen, whilst LNCaP cells were selected to represent 
a high STEAP2 expression model. 3D spheroids were exposed to the same 
three different doses ranging from 25, 50 and 75 µg/ml of pAb for 24 h before 
the assay was conducted (Figure 4.2). Neither of the doses induced 
significant reductions in the percentage of viable cells in either cell line (Figure 
4.2). Interestingly, the pAb exposure did reduce the percentage of viable cells 
in a dose dependent manner in 3D PC3 cell spheroids, with the greatest 
reduction observed at a dose of 75 µg/ml (-28.0%; Figure 4.2). These data 
suggest that to significantly induce a reduction in 3D spheroid viability, higher 
doses of anti-STEAP2 pAb may be needed than those that are able to reduce 
viability in a 2D cell culture system.  
 
Figure 4.2. Effect of Anti-STEAP2 pAb on 3D prostate cancer spheroid 
viability. PC3 and LNCaP prostate cancer cells were grown as 3D spheroids 
treated with increasing concentrations of anti-STEAP2 pAb. After 24 h 
treatment, cell viability was assessed by the MTT assay. An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. Error bars denote S.E.M. 
p-value < 0.01 (**), p-value < 0.001 (***), p-value < 0.0001 (****) (N = 3).  
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4.3.3 Anti-STEAP2 pAb increases the expression of AR in 
androgen-sensitive prostate cancer lines  
AR plays a vital role in prostate progression and therefore it was of interest to 
explore AR expression following exposure to anti-STEAP pAb. Four prostate 
cancer cell lines were exposed to three different doses of anti-STEAP pAb 
ranging from 25, 50 and 75 µg/ml of pAb for 24 h before RNA was extracted, 
cDNA synthesised, and qRT-PCR conducted. 
 
LNCaP and C4-2B are both androgen-sensitive cell lines, whilst PC3 and 
DU145 are androgen-independent. Whilst the results did not reach statistical 
significance, 75 µg/ml of pAb increased AR expression in PC3 and DU145 
cells (3.8- and 5.6-fold respectively; Figure 4.3). AR was found to be highly 
and significantly overexpressed in C4-2B cells exposed to pAb doses of 25 
and 50 µg/ml (28.6- and 28.9-fold respectively, p < 0.01; Figure 4.3), yet this 
was not found to be significant at the highest dose of 75 µg/ml (13.5-fold; 
Figure 4.3). pAb exposure increased AR expression in a dose dependent 
manner in LNCaP cells, inducing a 332905.6-fold increase at 75 µg/ml pAb (p 
< 0.0001; Figure 4.3). These data suggest that anti-STEAP2 pAb exposure 
significantly increases AR expression in androgen-sensitive but not androgen-
independent cell lines. On the basis of these results, qRT-PCR was further 
utilised to explore the impact of anti-STEAP2 pAb treatment on the expression 
of four genes downstream of AR: PSA, FKBP5, TMPRSS2 and GPRC6A in 





Figure 4.3. Effect of anti-STEAP2 pAb on AR expression in prostate 
cancer cells. Fold changes in AR gene expression in a panel of human 
prostate cancer cell lines treated with anti-STEAP2 pAb as compared to 
untreated cells. An ANOVA post-hoc Dunnett test was performed for statistical 
analysis. GAPDH was used as the housekeeping gene. Error bars denote 



















4.3.4 Anti-STEAP2 pAb increases the expression of androgen-
related genes in androgen-sensitive prostate cancer lines  
Section 4.3.3 demonstrated that AR is significantly overexpressed in the 
androgen-sensitive cell lines LNCaP and C4-2B cells following anti-STEAP2 
pAb treatment.  Following these results, the gene expression of four androgen-
regulated genes – PSA, FKBP5, TMPRSS2 and GPRC6A – were quantified 
in response to anti-STEAP2 pAb treatment by qRT-PCR in LNCaP and C4-2B 
cells. Untreated cells were used for comparison. 
 
Upon gene expression analysis of the four androgen-regulated genes, the 
highest overexpression was found in C4-2B cells treated with the lowest dose 
of pAb of 50 µg/ml, which induced a significant increase in TMPRSS2 
expression (1.9x1010-fold, p < 0.001; Figure 4.4B). PSA was also significantly 
increased at all three doses of pAb exposure, the lowest of which (25 µg/ml) 
induced the highest fold increase in expression (197.7-fold, p < 0.01; Figure 
4.4B). In LNCaP cells, a significant increase in FKBP5 expression was 
induced following exposure to both 50 and 75 µg/ml pAb (1128.0- and 469.0-
fold respectively, p < 0.0001; Figure 4.4A). GPRC6A overexpression was also 
significant following exposure to 75 µg/ml pAb in LNCaP cells (95495.5-fold, p 
< 0.05; Figure 4.4A). qRT-PCR analysis of PSA, FKBP5, TMPRSS2 and 
GPRC6A expression therefore demonstrated that all four genes are 







Figure 4.4. Effect of anti-STEAP2 pAb on AR regulated genes in 
androgen-sensitive prostate cancer cells. Fold change in expression of 
PSA, FKBP5, TMPRSS2 and GPRC6A genes in LNCaP (A) and C4-2B (B) 
prostate cancer cells treated with anti-STEAP2 pAb as compared to untreated 
cells. An ANOVA post-hoc Dunnett test was performed for statistical analysis. 
GAPDH was used as the housekeeping gene. Error bars denote S.E.M. p-









4.3.5 Anti-STEAP2 mAbs substantially reduce cell viability in 
four prostate cancer cell lines in 2D 
Whilst pAbs are effective at inducing cell death, they target multiple epitopes 
of the target antigen and therefore offer reduced specificity compared to mAbs 
which target single epitopes. mAbs also have the potential to be used in ADC 
technology whereas pAbs are therefore less suitable. Hence, it was of interest 
to utilise the MTT cell viability to assess the toxicity of a panel of three anti-
STEAP2 monoclonal antibodies in 2D prostate cancer cells. Four prostate 
cancer cell lines were exposed to doses of anti-STEAP2 monoclonal 
antibodies ranging from 31.25 to 1,000 µg/ml of mAb for 24 h before the assay 
was conducted (Figure 4.5). 
 
In PC3 cells, the lower doses of 31.25, 62.5 and 125 µg/ml mAb2 increased 
the percentage of viable cells by +49.1%, +53.6% and +42.8% respectively (p 
£ 0.05; Figure 4.5A). In PC3 cells only the highest dose of 1,000 µg/ml of all 
three mAbs significantly reduced the percentage of viable cells, with mAb2 
inducing the biggest reduction of -71.8% (p < 0.001; Figure 4.5A). In LNCaP 
cells, mAb3 did not induce a significant reduction in the percentage of viable 
cells at any dose, yet both mAb1 and mAb2 significantly reduced the 
percentage of viable cells at doses between 250 – 1,000 µg/ml (Figure 4.5B). 
The most significant reduction in the percentage of viable LNCaP cells of -
84.7% was observed in cells treated with 1,000µg/ml mAb2 (p < 0.001; Figure 
4.5B). C4-2B cells were the most responsive to treatment with all three mAbs, 
with all doses significantly reducing the percentage of viable cells (Figure 
4.5C). In C4-2B cells, the biggest reduction in the percentage of viable cells of 
-89.9% was induced by mAb2 at a dose of 1,000 µg/ml (p < 0.0001; Figure 
4.5C). Finally, DU145 was the only cell line to exhibit a significant reduction in 
the percentage of viable cells in response to all doses of mAb3 (Figure 4.5D). 
However, as with the previous three cell lines, the greatest reduction in the 
percentage of viable cells was following treatment with 1,000 µg/ml of mAb2 
(-81.8%, p < 0.0001; Figure 4.5D). Based on these data, mAb2 was selected 
to be carried forward for further analyses within this Chapter as this antibody 
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induced cell death at lower doses across all four cell lines (Figure 4.5; Table 
4.3). 
 
Table 4.3. IC50 values of each anti-STEAP2 mAb determined by the 
results of the MTT cell viability assays displayed in Figure 4.5. Calculated 
using AAT Bioquest Inc. Quest Graph™ IC50 Calculator (AAT Bioquest Inc., 
2020). 
 PC3 DU145 LNCaP C4-2B 
mAb1 (µg/ml) 510 289 566 57 
mAb2 (µg/ml) 650 441 248 42 
mAb3 (µg/ml) 770 235 1,028* 189 





Figure 4.5 Effect of three anti-STEAP2 mAbs on 2D prostate cancer cell viability. PC3 (A), LNCaP (B), C4-2B (C) and DU145 (D) 
prostate cancer cells were treated with increasing concentrations of anti-STEAP2 mAbs. After 24 h treatment, cell viability was assessed 
by the MTT assay. An ANOVA post-hoc Dunnett test was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.01 (**), 
p-value < 0.001 (***), p-value < 0.0001 (****) (N = 3).  
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4.3.6 Anti-STEAP2 mAbs substantially reduce cell viability in 
two prostate cancer cell lines in 3D 
Based on the results of Section 4.3.5, mAb2 was selected to be carried 
forward for assessing cell viability in 3D prostate cancer cell spheroids. PC3 
and LNCaP cells were chosen to represent one low and one high STEAP2 
expression model respectively (see Chapter 3, section 3.3.1). 3D spheroids 
were left to form for 24 h before being exposed to doses of anti-STEAP2 mAb2 
ranging from 31.25 to 1,000 µg/ml of mAb2 for 24 h before the assay was 
conducted (Figure 4.6).  
 
As in 2D cells (Figure 4.5A), the percentage of viable PC3 spheroids initially 
increased at doses between 31.25 – 125 µg/ml mAb2 (Figure 4.6). Only the 
highest mAb2 dose of 1,000 µg/ml induced a significant reduction in the 
percentage of viable PC3 spheroids (-68.5%, p < 0.001; Figure 4.6). LNCaP 
spheroids were more susceptible to mAb2 treatment, with doses between 62.5 
– 1,000 µg/ml all inducing significant reductions in the percentage of viable 
spheroids (Figure 4.6). Interestingly, a dose of 250 µg/ml reduced the 
percentage of viable LNCaP spheroids the most (-88.2%, p < 0.0001; Figure 
4.6). As such, increasing the dose of mAb2 in LNCaP spheroids did not 
continue to reduce the percentage of viable spheroids, with doses of 500 and 
1,000 µg/ml mAb2 reducing viability by -87.3% and -78.1% respectively (p £ 
0.001; Figure 4.6). Therefore, in the interest of conserving the drug, in LNCaP 
spheroids increasing the dose of mAb2 above 250 µg/ml would not be 
warranted, whilst in PC3 spheroids viability decreased in a dose dependent 
manner. These data, combined with that of Section 4.3.5, suggest that 
prostate cancer spheroids with higher STEAP2 expression are more 
susceptible to mAb2 treatment than those with low STEAP2 expression 
(Figures 4.5 & 4.6). 
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Figure 4.6. Effect of Anti-STEAP2 mAb2 on 3D prostate cancer spheroid 
viability. PC3 and LNCaP prostate cancer cells were grown as 3D spheroids 
treated with increasing concentrations of anti-STEAP2 mAb2. After 24 h 
treatment, cell viability was assessed by the MTT assay. An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. Error bars denote S.E.M. 















4.3.7 Anti-STEAP2 mAb2 triggers STEAP2 receptor 
internalisation in both a time and dose dependent manner 
To visualise cell surface STEAP2 prior to evaluating receptor internalisation, 
the fluorescent signal of STEAP2 was activated through conjugation with 
Alexa-488 (green), whilst cell nuclei were counterstained with DAPI (blue). 
This represented time point 0 h (see Figures 4.7 – 4.9). PC3, LNCaP and C4-
2B cells were exposed to anti-STEAP2 mAb2 for 3, 12 and 24 h to observe 
STEAP2 receptor internalisation (Figures 4.7 – 4.9 respectively, where 
representative images are shown; additional images from the second replicate 
can be found in Appendix 2, Figures A2.1 – A2.3). Anti-STEAP2 mAb2 doses 
that induced a significant reduction in cell viability were selected for future use 
in this Chapter (Figure 4.5).  
 
STEAP2 receptor internalisation became more evident in all three cell lines in 
a time- and dose-dependent manner. In PC3 cells, STEAP2 receptor 
internalisation was observed as early as 3 h post incubation and was fully 
internalised by 24 h (Figure 4.7). At 24 h, prominent STEAP2 staining (green) 
was evenly distributed in PC3 cells exposed to 100 and 200 µg/ml (Figure 
4.7). In PC3 cells, a dose of 500 µg/ml did not trigger as prominent receptor 
internalisation at either time point (Figure 4.7). In LNCaP cells, some STEAP2 
receptor internalisation was visible at 0 h, prior to incubation with anti-STEAP2 
mAb, and increased in a dose-dependent manner (Figure 4.8). A lack of 
STEAP2 receptor internalisation was visible following exposure to 200 µg/ml 
in LNCaP cells at either time point, suggesting this dose was too high and 
therefore saturated cells (Figure 4.8). Both 50 and 100 µg/ml mAb2 triggered 
STEAP2 receptor internalisation from as early as 3 h, with 50 µg/ml triggering 
a more even distribution (Figure 4.8). In C4-2B cells, receptor internalisation 
was also triggered as early as 3 h post incubation with all three anti-STEAP2 
mAb2 doses and was most evenly distributed following 12 h exposure to 50 
µg/ml mAb2 (Figure 4.9). 
 
These data suggest that STEAP2 receptor internalisation is triggered following 
exposure to lower doses of anti-STEAP2 mAb2 in LNCaP and C4-2B cells 
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than in PC3 cells. Anti-STEAP2 mAb2 also triggered STEAP2 receptor 
internalisation in a shorter time frame in LNCaP and C4-2B cells than in PC3 
cells. Together, these data suggest that anti-STEAP2 mAb2 holds potential for 




Figure 4.7. Anti-STEAP2 mAb2 exposure triggers STEAP2 receptor 
internalisation in PC3 cells. PC3 cells were exposed to anti-STEAP2 mAb2 
for 0, 3, 12 and 24h at doses of 0, 100, 200 and 500 µg/ml. 0h: cell surface 
STEAP2 was visualised before receptor internalisation. 3h & 12h: STEAP2 
receptor internalisation was initiated. 24h: fully internalised STEAP2 was 
evident. Blue: nuclei; green: STEAP2. Images were acquired with a Confocal 






Figure 4.8. Anti-STEAP2 mAb2 triggers STEAP2 receptor internalisation 
in LNCaP cells. LNCaP cells were exposed to anti-STEAP2 mAb2 for 0, 3, 
12 and 24h at doses of 0, 50, 100 and 200 µg/ml. 0h: cell surface STEAP2 
was visualised before receptor internalisation. 3h & 12h: STEAP2 receptor 
internalisation was initiated. 24h: fully internalised STEAP2 was evident. Blue: 
nuclei; green: STEAP2. Images were acquired with a Confocal LSM 710 with 





Figure 4.9. Anti-STEAP2 mAb2 triggers STEAP2 receptor internalisation 
in C4-2B cells. C4-2B cells were exposed to anti-STEAP2 mAb2 for 0, 3, 12 
and 24h at doses of 0, 25, 50 and 100 µg/ml. 0h: cell surface STEAP2 was 
visualised before receptor internalisation. 3h & 12h: STEAP2 receptor 
internalisation was initiated. 24h: fully internalised STEAP2 was evident. Blue: 
nuclei; green: STEAP2. Images were acquired with a Confocal LSM 710 with 









This Chapter aimed to determine the ability of a commercially available anti-
STEAP2 pAb, and previously developed anti-STEAP2 mAbs on reducing cell 
viability in a panel of prostate cancer cell lines. To do so, viability assays were 
conducted to evaluate whether treatment with the pAb or mAbs could induce 
significant cell death in a panel of human prostate cancer cell lines. Assays 
were first conducted in 2D monolayers in order to identify which cell lines 
responded to treatment, with chosen cell lines carried forward for culture as 
3D spheroid models to assess viability in response to anti-STEAP2 antibody 
treatment in more physiologically relevant models. The results demonstrated 
that the commercial pAb significantly reduced cell viability in all four cell lines 
(Figure 4.1), yet this was not the case in 3D PC3 and LNCaP spheroid models 
(Figure 4.2). This Chapter also aimed to evaluate the effect of anti-STEAP2 
pAb treatment on the expression of AR and androgen-regulated genes. qRT-
PCR analysis found that AR increased in a dose-dependent manner following 
pAb treatment of AR-sensitive LNCaP and C4-2B cells (Figure 4.3). The 
expression of four androgen-regulated genes – PSA, FKBP5, TMPRSS2 and 
GPRC6A – also increased in LNCaP and C4-2B cells following pAb treatment 
(Figure 4.4). Furthermore, all three mAbs significantly reduced cell viability in 
all four prostate cancer cell lines (Figure 4.5). Viability assays aimed to identify 
a lead mAb candidate to carry forward to evaluate STEAP2 receptor 
internalisation, a key property that underpins its suitability for use in ADC 
technology. mAb2 was selected following its ability to significantly reduce cell 
viability in both PC3 and LNCaP cells (Figure 4.5) as 2D monolayer and 3D 
LNCaP cell spheroid models (Figure 4.6). Receptor internalisation of cell 
surface STEAP2 was triggered upon anti-STEAP2 mAb2 binding (Figures 4.7 
– 4.9). Together these data highlight STEAP2 as a potential therapeutic target 
in the treatment of prostate cancer, including use in ADC technology, yet its 





4.4.1 Cell viability following STEAP2 antibody treatment 
The ability of a drug to induce targeted cell death is an essential property when 
evaluating its suitability as a potential therapeutic agent in the treatment of 
cancer (Kepp et al., 2011; Liu et al., 2011). To determine whether anti-STEAP2 
pAb and mAbs triggered cell death in prostate cancer cells, MTT cell viability 
assays were conducted. Treatment with anti-STEAP2 pAb and mAbs triggered 
significant cell death in all four prostate cancer cell lines as 2D monolayers, 
whilst mAb2 triggered significant cell death in LNCaP cells grown as 3D 
spheroids.  
 
Upon cell death, the apoptotic cascade is triggered, yet it is unclear which of 
the apoptotic pathways STEAP2 is involved in (Wang et al., 2010). As STEAP2 
is localised to the cell membrane, it has been suggested that the extrinsic 
apoptosis pathway may be affected by STEAP2 (Wang et al., 2010). During 
the extrinsic apoptosis pathway, the signalling of cell surface receptors 
initiates a cascade, ultimately resulting in cell death through the formation of 
the death-inducing signalling complex (DISC) (Dickens et al., 2012; Wang et 
al., 2010). STEAP2 may exert its effect on this pathway by decreasing the 
stability of the DISC (Wang et al., 2010). It has also been suggested that 
STEAP2 may play a role in the intrinsic apoptosis pathway, as cells with 
STEAP2-knockdown have been found to undergo apoptosis in the absence of 
induction of the extrinsic apoptosis pathway through transcription factors 
(Sayers, 2011; Wang et al., 2010). STEAP2 is localised to the Golgi, and as 
such may interact with and affect the function of an anti-apoptotic proteins 
such as the Golgi anti-apoptotic protein, which has been found to inhibit 
apoptosis through modulation of intracellular calcium fluxes (De Mattia et al., 
2009). The endocytic trafficking of cell surface receptors that influence 
receptor signalling, essential for cell growth or apoptosis, may also be 
influenced by STEAP2 (Wang et al., 2010).  
 
LNCaP cells were found to have the highest naturally occurring levels of 
STEAP2 expression (see Chapter 3, Section 3.3.1), and in this Chapter, 3D 
LNCaP cell spheroids where susceptible to anti-STEAP2 mAb induced cell 
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death (Figure 4.5B). Previously STEAP2-knockdown has also been found to 
increase the sensitivity of LNCaP cells to tumour necrosis factor–related 
apoptosis-inducing ligand (TRAIL)-induced apoptosis (Wang et al., 2010). 
Other drugs that trigger TRAIL-induced apoptosis in prostate cancer include 
the anthracycline doxorubicin (Kelly et al., 2002; Wu et al., 2002). TRAIL-
induced apoptosis is often the result of caspase-3, -6 and -8 mediated cell 
death (Dickens et al., 2012; Nimmanapalli et al., 2001; Sayers, 2011; Wu et 
al., 2002). Caspase-8 mediated apoptotic cell death has also been linked to 
DISC formation in response to TRAIL signalling receptors triggering the 
extrinsic pathway of apoptosis (Dickens et al., 2012). Furthermore, targeting 
other members of the STEAP family with mAbs has been found to trigger 
caspase-dependent apoptosis (Qin et al., 2010 & 2011; Tanaka et al., 2012).  
 
A study by Fong et al., 2014 showed that 3D prostate cancer cells grown as 
patient derived xenograft (PDX) models do show an increased resistance to 
chemotherapeutic agents compared to standard culture methods. This 
suggests that genetic differences between human and cell culture models may 
alter treatment responses (Fong et al., 2014). As noted previously, cells which 
display higher STEAP2 expression levels such as LNCaP and C4-2B cells 
were more susceptible to anti-STEAP2 antibody treatment than cell lines with 
lower STEAP2 expression levels (see Chapter 3, Section 3.3.1; Figures 4.1, 
4.5B & 4.5C). Due to time limitations in the current study plan, it was not 
possible to quantify STEAP2 expression levels in 3D spheroid models. This 
will be an interesting piece of future work that is required to support a 
comparison of STEAP2 levels in the 3D models versus their 2D counterparts, 
to determine the role of STEAP2 expression on the differences in cell death 
observed between 2D and 3D models.  
 
3D models are more representative of tumours in situ as they display key 
characteristics, such as a hypoxic core and extensive ECM, particularly in 
stromal co-culture models, allowing for a more realistic assessment of drug 
penetration (Thoma et al., 2014). A possible explanation for the observed 
lower cell death levels induced in 3D models treated with anti-STEAP2 pAb in 
comparison to 2D cells is the capability of the drug to fully penetrate the 
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spheroid (Lazzari et al., 2018). It would therefore be warranted to also 
measure cell death by fluorescent microscopy with a viability dye such as PI 
to observe the location of any changes in spheroid viability, as the observed 
cell death may only be occurring around the periphery of the spheroid 
(Hirschhaeuser et al., 2010; Riffle et al., 2017). Future work could also utilise 
fluorescently tagging of the anti-STEAP2 antibodies in order to observe their 
capability at penetrating through the spheroid. In order to inhibit cell growth in 
3D spheroid models, higher doses of antibodies may be required to induce the 
same levels of cell death as those administered in 2D systems. Whilst all 
doses above 62.5 µg/ml triggered significant cell death in LNCaP spheroids, 
only the highest dose of 1,000 µg/ml significantly reduced the viability of PC3 
spheroids. Previous studies have found that higher concentrations of drugs 
are needed to induce cell death in 3D versus 2D models, as cells at the core 
of the spheroid can still survive despite higher drug concentrations (Mehta et 
al., 2012; Sarisozen et al., 2014; Zoetemelk et al., 2019). A similar observation 
has been made with colorectal cancer cell spheroids, where it was reported 
that an 8-times greater dose of drug was required to achieve the same level 
of cell death in 3D models compared to 2D monolayers (Sarisozen et al., 
2014). This not only suggests that the drug may not be able to fully penetrate 
PC3 spheroids in the present study, but also that the MTT dye may only be 
metabolised by cells at the periphery of the spheroid (Borra et al., 2009; Van 
Meerloo et al., 2011). As demonstrated in Chapter 3, Section 3.3.2, PC3 cells 
formed more dense spheroids with a visibly noticeable necrotic core when 
compared to LNCaP spheroids, further warranting the use of fluorescent 
imaging such as PI to visually evaluate cell death in these model (Gong et al., 
2015; Vinci et al., 2012; Zanoni et al., 2016).   
 
Whilst anti-STEAP2 monoclonal antibodies have not yet been widely studied, 
targeting other STEAP family members has induced promising tumour growth 
inhibition both in vitro and in vivo (Barroco-Ferreira et al., 2018; Challita-Eid et 
al., 2007). Two anti-STEAP1 monoclonal antibodies specific to STEAP1 
extracellular loops successfully inhibited STEAP1-mediated intercellular 
communication and transport in vitro, and significantly reduced the growth of 
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prostate cancer xenografts in vivo (Challita-Eid et al., 2007). STEAP1 and 
STEAP2 share similar expression profiles in in vitro cell lines (see Chapter 3, 
Section 3.3.1). STEAP1 and STEAP2 both act as ion transporter channels, 
and as such the effects of STEAP1 on intercellular communication have been 
attributed to the regulation of adhesion or gap junction activity, through 
modulation of calcium influx (Jørgensen et al., 2003). Another STEAP family 
member, STEAP3, has been found to be associated with promoting 
communication between neighbouring cells through exosome secretion (Yu et 
al., 2006). Cell-cell communication plays a vital role in the progression of 
prostate cancer, as it allows for the exchange of small molecules such as 
nutrients and metabolites required to support tumour growth and progression 
(Edlund et al., 2004; Maia et al., 2018). The ability of anti-STEAP2 mAb2 to 
inhibit cell growth warrants further investigations into its effects on intercellular 
communication, which may provide a link between STEAP2 and intercellular 
ion transport.  
 
Like STEAP1, STEAP2 also contains a heme-binding domain known as the 
ACRATA (Sanchez-Polido et al., 2004). This ACRATA domain is also present 
in a structurally related family which includes STEAP family members, the 
bacterial Nox family, and the oxidoreductase family YedZ (Ohgami et al., 2005 
& 2006; Sanchez-Polido et al., 2004). Electron transfer may be supported 
through this heme-binding function, which has been found to affect cell growth 
and metabolism in Nox proteins, and electron transport across membranes in 
both Nox and STEAP proteins (Oosterheert et al., 2020; Yamada et al., 2004). 
It would therefore be of interest in the future to evaluate the role of the 
ACRATA domain when cell death is induced in response to anti-STEAP2 
antibody exposure.  
 
Collectively the data in this Chapter suggest that anti-STEAP2 poly- and 
monoclonal antibodies successfully inhibit cell growth in 2D monolayers, whilst 
only mAb2 impacted upon the viability of 3D LNCaP spheroids.  
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4.4.2 Androgen responses following STEAP2 antibody 
treatment 
Treatment of cells with anti-STEAP2 pAb induced significant increases in 
STEAP2 expression in androgen-sensitive LNCaP and C4-2B cells in a dose-
dependent manner. These two cell lines also display the highest baseline 
levels of STEAP2 expression (see Chapter 3, Section 3.3.1). To date, it 
remains unclear whether STEAP2 and AR expression are linked, yet STEAP2 
expression has been suggested to be androgen regulated as it is more highly 
expressed in androgen-sensitive prostate cancer cell lines including LNCaP 
and CWR22Rv1 (Chen et al., 2010; Gomes et al., 2012; Porkka et al., 2002; 
Xu et al., 2001).  
 
Prostate cancer is a largely androgen-regulated disease, with androgen being 
the primary molecule to stimulate prostate cancer progression through 
promoting proliferation and inhibiting apoptosis upon binding to and activation 
of AR (Buchanan et al., 2002; Heinlein & Chang, 2004). As such any changes 
to androgen expression may be significant for patients and can trigger 
unfavourable changes, affect treatment responses and trigger metabolic 
changes (Mitsuzuka & Arai, 2018). AR signalling in prostate cancer stimulates 
malignant growth through binding of the ligand domain of circulating testicular 
androgens with testosterone and DHT (Askew et al., 2007; Tan et al., 2015). 
ADT with therapeutic agents such as docetaxel and more recently 
enzalutamide remains the gold standard in the treatment of prostate cancer, 
however many tumours develop androgen independence and resistance, 
often through an AR mutation (Guo et al., 2009; Nelson & Shah, 2019). Of 
these mutations, those in androgen receptor splice variant 7 (ARv7) as a result 
of alternate splicing of the AR transcript are most prevalent and have been 
linked to treatment resistance and hormone refractory disease (Dehm et al., 
2008; Nakazawa et al., 2014; Scher et al., 2018; Qu et al., 2015). ARv7 lacks 
the ligand-binding domain of AR yet retains transcriptional activity, allowing for 
ARv7 to act as a constitutively active AR protein independent of binding with 
DHT (Hu et al., 2009; Qu et al., 2015). Drugs which target AR disrupt DHT-
dependent AR signalling, and as such ARv7 signalling would not be inhibited 
 171 
(Chan et al., 2012). Therefore, future work should employ qRT-PCR to 
determine whether the observed increases in AR expression were of the full-
length gene or one of its variants.  
 
The substantially significant increase in AR receptor expression observed in 
response to anti-STEAP2 pAb treatment of androgen-sensitive cells could be 
the result of a switch to androgen-independence. When nsSNPs were 
evaluated in STEAP2, 42 alterations were found (Naveed et al., 2016). Of 
these, a mutation in H316R replaced amino acids histidine with arginine at 
position 316, disturbing the domain and interactions with metal ions, 
subsequently destroying its function (Naveed et al., 2016). In human AR when 
a nsSNP results in the replacement of arginine 773 with histidine, androgen 
insensitivity develops which confers resistance to androgen targeting (Prior et 
al., 1992). More recent studies have found that androgen resistance as a result 
of such mutations is due to disruption of N- and C-terminal interactions in the 
AR ligand binding domain (Jaaskelainen et al., 2006; McPhaul, 2016).  
 
In prostate cancer, MMPs are known to regulate disease progression, in 
particular MMPs -2, -7, -9, -13 and -14 (Brehmer et al., 2003; Daja et al., 2003; 
Morgia et al., 2005). STEAP2 has been found to increase ERK signalling, the 
downstream effectors of which are MMPs (Wang et al., 2010). This 
upregulation of ERK has been hypothesised to promote an invasive phenotype 
through the stimulation of the transcription factor activating protein-1 (AP-1), 
which may then activate MMPs -2, -7, -9, -13 and -14 (Whiteland et al., 2014). 
AR expression has also been found to increase MMP-9 signalling in the 
promotion of prostate cancer metastasis (Hu et al., 2015). Therefore, the 
increase in AR expression in response to anti-STEAP2 pAb treatment is 
potentially worrying for patients as it may induce a more invasive phenotype 
and warrants further investigations into the signalling pathways involved (Hu 
et al., 2015; Whiteland et al., 2014).  
 
The expression of AR target genes is modulated by the binding of AR to AREs 
in the genome, or through interactions with other transcription factors bound 
to specific recognition sites on target genes (Davey & Grossman, 2016; 
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Heinlein & Chang, 2004; Wang et al., 2005). AREs are involved in regulating 
the transcription of androgen-responsive genes (Davey & Grossman, 2016; 
Heinlein & Chang, 2004). In prostate cancer progression, AR promotes the 
expression of specific target genes, of which PSA expression is the most 
widely studied and correlates with increased AR expression and metastatic 
disease (Baek et al., 2012; Lipianskaya et al., 2014). PSA expression is 
triggered through transcriptional activation in the N-terminal domain of AR in 
the nucleus (Dehm & Tindall, 2007). AREs in the promotor and enhancer 
regions of PSA have been found to recruit numerous co-activators and 
transcription factors including histone acetyltransferases, p160 family, 
mediator and RNA polymerase II (PolII) (Takayama et al., 2007; Wang et al., 
2005). STEAP2 has also been found to contain an AR-binding site (ARBS) in 
intron 3 (Takayama et al., 2007). Moderate histone acetylation and PolII 
recruitment was observed in ARBS-4 located in intron 3 of STEAP2 in 
response to the synthetic androgen R1881 (Takayama et al., 2007; Wang et 
al., 2005).  
 
Another member of the STEAP family, STEAP4, has been found to contain an 
androgen-dependent cis-regulator element in the 5’ flanking sequence of the 
gene, thought to be involved in ARE binding (Sak et al., 2007). STEAP2 and 
STEAP4 share structural similarities as the six transmembrane domains of 
STEAP2 and STEAP4 are both flanked by a large N-terminal and a short C-
terminal domain (Korkmaz et al., 2005). The 5’ gene region of the STEAP4 
gene was found to induce androgen-dependent promotor activity in androgen-
sensitive but not androgen-independent cell lines, increasing the expression 
of androgen-regulated genes including PSA (Sak et al., 2007). The expression 
of STEAP4 has also been found to be androgen-mediated through the 
expression of the haematological and neurological expressed 1 (HN1) gene, 
which in prostate cells down-regulates PI3K-dependent Akt activation (Varisli 
et al., 2011 & 2012). The downregulation of STEAP4 and PSA was found to 
correlate with HN1 overexpression which induced AR degradation, suggesting 
HN1 may be involved in the increased AR and PSA expression observed in 
this Chapter (Varisli et al., 2012). It would therefore be of interest going forward 
to assess HN1 expression in anti-STEAP2 pAb treated cells.  
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PSA contributes to disease progression through its protease activity, which 
induces epithelial-mesenchymal transitions and cell migration (Whitbread et 
al., 2006). The response elements of PSA and nuclear factor kappaB (NFκB) 
are located at the AR promotor region, suggesting that AR expression may be 
affected by NFκB (Zhang et al., 2004). The progression of prostate cancer 
from androgen dependence to androgen independence has been linked with 
the activation of Akt and NFκB in LNCaP cells in vitro and mouse models in 
vivo (Kikuchi et al., 2003; Murillo et al., 2001). Together this suggests that 
inhibition of NFκB may hold potential as a targeted pathway in the inhibition of 
prostate cancer progression (Gonen-Korkmaz et al., 2014; Sun et al., 2010). 
STEAP2 expression has been found to correlate with androgen stimulation 
and NFκB signalling in LNCaP cells, suggesting a potential mechanism behind 
the increase in AR and PSA expression observed in anti-STEAP2 pAb treated 
LNCaP cells in this Chapter (Figures 4.3 & 4.4A; Gonen-Korkmaz et al., 
2014).  
 
Other target genes implicated in the progression of prostate cancer which are 
regulated by AR include FKBP5, TMPRSS2 and GPRC6A (Febbo et al., 2005; 
Pi & Quarles, 2012; Tomlins et al., 2005). The expression of all three genes 
increased in response to anti-STEAP2 pAb treatment in both LNCaP and C4-
2B (Figure 4.4). TMPRSS2 expression has also been found to increase 
alongside PSA in CRPC following a gain in function mutation in DHT synthesis 
(Chang et al., 2013). In this Chapter, TMPRSS2 expression was also observed 
alongside an increase in PSA expression in C4-2B cells treated with anti-
STEAP2 pAb (Figure 4.4B). High transcript levels of TMPRSS2 have been 
observed alongside high levels of STEAP2 in CRPC, further suggesting that 
STEAP2 is an androgen-regulated gene (Ylitalo et al., 2017). Interestingly, 
patients with high levels of STEAP2 and TMPRSS2 also presented with higher 
serum PSA levels and were determined as having AR-driven CRPC (Ylitalo et 
al., 2017).  
 
Similar to PSA, FKBP5 and TMPRSS2 have also been found to be increased 
in extracellular vesicle (EV)-rich prostate cancers, and their expression has 
been found to decrease in response to treatment either via a radical 
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prostatectomy or radiation (Dhont et al., 2020). In EV-rich prostate cancers, 
FKBP5 and TMPRSS2 play a vital role in intracellular communication, implying 
that the increase observed in this Chapter may be compromising for patients 
as increased intracellular communication may aid in the formation of 
metastases (Dhondt et al., 2020 & 2016). The overexpression of PSA, FKBP5 
and TMPRSS2 and another STEAP family member STEAP1 has also been 
found to increase following androgen stimulation by R1881 in androgen-
independent PC3 cells, suggesting that anti-STEAP2 pAb may act as an 
androgen stimulant in this Chapter (Marques et al., 2011). PSA, FKBP5 and 
TMPRSS2 have been suggested to hold potential as markers predictive of 
treatment outcome, as their expression has been found to decrease in 
response to successful treatment of prostate cancer (Shaw et al., 2016). Their 
overexpression in response to anti-STEAP2 pAb treatment may therefore be 
indicative of an androgen-mediated response and potential onset of CRPC 
(Chang et al., 2013; Shaw et al., 2016; Ylitalo et al., 2017).  
 
The triggering of GPRC6A overexpression would also be of concern for the 
patient, as GPRC6A activation has been found to increase cell proliferation (Pi 
& Quarles, 2012). The effects of AR are mediated by GPRC6A, and as such 
its overexpression observed in this Chapter could signal a switch to CRPC 
through the activation of PI3K/Akt signalling pathways responsible for AR-
independent disease progression (Pi et al., 2015; Zarif & Miranti, 2016). 
Overexpression of GPRC6A has also been found to promote epithelial-
mesenchymal transitions leading to prostate cancer progression, particularly 
to the bone as GPRC6A is a ligand for osteocalcin and has been identified as 
a marker of prostate cancer metastasis (Liu et al., 2016; Pi & Quarles, 2012; 
Suva et al., 2011). A further concern regarding the overexpression of GPRC6A 
in response to anti-STEAP2 pAb treatment is its involvement in ERK 
signalling, which has been found to increase upon GPRC6A activation (Ye et 
al., 2017). As STEAP2 is also involved in the ERK signalling pathway, it would 
be of interest to further explore the crosstalk between GPRC6A and STEAP2 
(Gomes et al., 2012; Wang et al., 2010; Ye et al., 2017). 
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Future studies are required to extend this work, utilising qRT-PCR to evaluate 
AR levels post treatment with anti-STEAP2 mAb2 in 2D and 3D PC3 and 
LNCaP monolayer and spheroid models to determine whether the reduction 
in viability of 3D models affects AR expression. Androgen-sensitive C4-2B 
cells grown in 3D models as compared to their 2D counterparts have been 
found to express lower levels of AR and PSA, whilst the opposite was 
observed in androgen-independent 22Rv1 cells (Xu et al., 2019). It would also 
be of interest to assess the expression of the four androgen-regulated genes 
in response to anti-STEAP2 pAb treatment in androgen-independent cell lines. 
Together, the data presented here suggests anti-STEAP2 pAb treatment may 
have concerning knock on effects for the patient in terms of increased AR and 
AR-mediated gene expression, warranting further investigations into the 
mechanisms driving this increase.  
4.4.3 Receptor internalisation following anti-STEAP2 mAb2 
treatment 
STEAP2 receptor internalisation was induced upon treatment with anti-
STEAP2 mAb in PC3, LNCaP and C4-2B cells, with lower doses triggering 
internalisation in androgen-sensitive cell lines (Figures 4.7 – 4.9). It was of 
importance to study STEAP2 receptor internalisation following anti-STEAP2 
mAb2 treatment to evaluate the potential of mAb2 to be utilised in conjunction 
with ADC technology. ADCs utilise highly specific mAbs to link potent 
chemotherapeutic agents in order to target tumour-specific antigens on the 
surface of cancer cells (Kamath & Iyer, 2015; Tarcsa et al., 2020). Cell killing 
is achieved through ADC binding with the receptor on the target disease cell, 
which becomes internalised and releases the active drug payload (Tarcsa et 
al., 2020). ADCs are of particular interest as off-target or systemic side effects 
can be limited through their increased specificity and targeted, localised killing 
of diseased cells compared to the administration of standard 
chemotherapeutic agents (Kamath & Iyer, 2015; Tarcsa et al., 2020). For an 
ADC to be viable, factors such as target antigen, antibody, conjugation 
technology and payload must all be considered as they have the potential to 
affect the efficacy and toxicity of the drug (Kamath & Iyer, 2015; Tarcsa et al., 
2020).  
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To date, studies into the precise subcellular localisation and the intracellular 
site of STEAP2 function remain unclear. STEAP2 localises to the plasma 
membrane and numerous cytoplasmic structures of unknown identity in 
DU145 cells; it co-localises with trans-Golgi network markers and early 
endosomes in COS-1 cells, and also co-localises with transferrin and the 
transferrin receptor in the endosomes of HEK293T cells (Korkmaz et al., 2002; 
Ohgami et al., 2006; Porkka et al., 2002). When developing ECL2 mAb 
targeting of STEAP2, Hasegawa et al., characterised the location of STEAP2 
to the juxtanuclear Golgi region and endosome-like puncta. They also reported 
transient cell surface localisation of STEAP2 to be dependent on the local 
membrane cholesterol levels (Hasegawa et al., 2018). The internalisation of 
metal-containing molecules such as heme, iron and copper may be facilitated 
by cell surface STEAP2 (Korkmaz et al., 2005). The metalloreductase activity 
of STEAP2 in STEAP2-transfected HEK293T cells was also suppressed at the 
cell surface, suggesting that whilst STEAP2 is broadly distributed its activity 
could be regulated in a conformation and localisation dependent manner 
(Hasegawa et al., 2018). Previous studies within the wider Swansea research 
group have also identified STEAP2 to be localised to the cell membrane prior 
to internalisation, yet this work was limited to PC3 cells, hence the need for its 
application to a wider range of prostate cancer cells within this Chapter 
(Nguyen-Chi, 2020).  
 
In this Chapter, STEAP2 was found to be specifically localised to the cell 
membrane in PC3 cells (Figure 4.7), however some internal STEAP2 was 
detected in LNCaP and C4-2B cells at the 0 h timepoint prior to incubation with 
anti-STEAP2 mAb2 (Figures 4.8 & Figures 4.9). Cells at all timepoints were 
exposed to anti-STEAP2 mAb2 for 30 minutes on ice to keep the temperature 
of samples at around 4oC prior to incubation at 37oC for either 3, 12 or 24 h, 
or in the case of the 0 h cohort immediately fixed and stained. This 30-minute 
period allows for uniform and evenly distributed mAb binding, as receptor 
internalisation becomes triggered once samples are incubated and the 
temperature is raised to 37oC (Vainshtein et al., 2015). However, the slight 
internalisation observed in LNCaP and C4-2B cells at 0 h suggests that this 
could be sufficient time for anti-STEAP2 mAb internalisation to be triggered.  
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STEAP2 may also be involved in fatty acid metabolism, as it was found to be 
one of nine genes reported to be associated with resistance to lovastatin, a 
statin traditionally used for lowering serum cholesterol levels (Savas et al., 
2011). This resistance is thought to be the result of a SNP in intron 2 of 
STEAP2 which may be used to predict resistance to lovastatin (Savas et al., 
2011). This resistance was found to decrease in response to silencing of 
elongation factor for RNA Polymerase II (ELL)-associated factor 2 (EAF2), an 
androgen-response gene also involved in the inhibition of cell growth and 
induction of apoptosis, further suggesting a role of androgen-mediated 
STEAP2 regulation (Hahn et al., 2007; Savas et al., 2011).  
 
Doses of anti-STEAP2 mAb2 below the calculated IC50 value for each cell line 
were chosen to ensure significant cell death did not occur during the full 24-
hour incubation period (Figure 4.5; Table 4.3; AAT Bioquest Inc., 2020). 
Maintenance of high cell viability before and during the incubation period is 
critical in ensuring receptor internalisation is not affected by the cytotoxic 
effects of the antibody (Hasegawa et al., 2018). In this Chapter, lower doses 
of anti-STEAP2 mAb triggered receptor internalisation in androgen-sensitive 
LNCaP and C4-2B cells, further suggesting androgen plays a role in the effects 
of STEAP2. STEAP2 is more naturally abundant in these cell lines (see 
Chapter 3, Section 3.3.1), which may suggest a reason for the faster 
internalisation observed in LNCaP and C4-2B cells in comparison to PC3 cells. 
Higher concentrations of anti-STEAP2 mAb2 appeared to saturate the cells, 
as depicted by the pooling of strong fluorescent signals after 12 h incubation 
at mAb2 doses greater than 100 µg/ml in LNCaP and C4-2B cells, and 500 
µg/ml in PC3 cells (Figures 4.7 – 4.9). This saturation may reduce the maximal 
uptake capacity of the cells due to complete occupation of binding sites 
(Rhoden et al., 2012). If the STEAP2 binding sites of the cells become fully 
saturated and no longer capable of internalising the monoclonal antibody, a 
binding site barrier may be produced which may lead to a cytotoxic bystander 
effect inducing cell death of antigen-negative cells (Rhoden et al., 2012). This 
may be overcome through the incorporation of ADC technology, which would 
allow for more specific target receptor internalisation, as ADCs are clinically 
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administered at their maximum tolerated dose in order to overcome receptor 
saturation (Li et al., 2016; Khera et al., 2018; Tarcsa et al., 2020; Singh et al., 
2020). For mAb2 to translate clinically, it would also be of interest to determine 
its effects on the metalloreductase function of STEAP2. Previously, an ECL2-
targetting mAb did not trigger uncontrollable metalloreductase activity in 
prostate cancer cells, which was suggested as a desired property of a potential 
therapeutic STEAP2 target, as the function of STEAP2 which is expressed at 
lower levels in other cell types throughout the body would be left unaffected 
(Hasegawa et al., 2018).  
 
To determine the suitability of anti-STEAP2 mAb2 for use in ADC technology, 
more information regarding STEAP2 localisation would be required. It would 
have been beneficial to fluorescently label the Golgi network to determine the 
site of STEAP2 localisation upon receptor internalisation; which should be the 
focus of future work. Such future studies aimed at determining whether 
STEAP2 had internalised to specific acidic cell components, would need to 
use a pH amine dye conjugate to confirm whether internalisation to the 
endosomes and lysosomes had occurred. Here, the presence of proton pumps 
creates an acidic environment (pH 4.5 – 5.5) for the degradation of 
endocytosed macromolecules (Nath et al., 2016).  
 
Together, the data presented in this Chapter suggest anti-STEAP2 mAb2 
triggers receptor internalisation within 3 h in androgen-sensitive LNCaP and 
C4-2B cells, and within 12 h in androgen-independent PC3 cells. Thus, anti-
STEAP2 mAb2 may hold potential for use with ADC technology in clinical 
translation as a therapeutic target for the treatment of prostate cancer.  
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4.5 Conclusion 
The data presented in this Chapter provides strong evidence for the potential 
of both a commercially available anti-STEAP2 pAb and anti-STEAP2 mAb for 
the development of novel therapies to treat prostate cancer. This Chapter also 
identified a lead mAb candidate (mAb2) which shows potential for use in ADC 
technology following the successful triggering of receptor internalisation. Both 
the pAb and mAb2 target ECL3, suggesting targeting the ECL3 reduces 
prostate cancer cell viability, both in 2D monolayers and 3D spheroids. 
However, the anti-STEAP2 pAb significantly increased AR expression, along 
with the expression of androgen-regulated genes associated with the 
progression of prostate cancer. Together, the anti-STEAP2 mAb lead 
candidate (mAb2) holds potential for future clinical translation as an ADC for 
the treatment of prostate cancer, however further investigations into its effect 






Design and development of CRISPR/Cas9 engineering 
for the knockout of STEAP2 in prostate cancer cell 
lines and its effects on aggressive prostate cancer 
traits 
 
5.1 Introduction  
Members of the STEAP family of genes are known to be over expressed in a 
variety of cancer types, with STEAP2 particularly over expressed in prostate 
cancer (see Chapter 1, Section 1.7; Gomes et al., 2012). When compared to 
the normal prostate epithelial cell line PNT2, high protein expression of 
STEAP2 has been found in the metastatic prostate cancer cell lines PC3 and 
LNCaP, which are derived from bone and lymph node metastases, 
respectively (Burnell et al., 2018; Whiteland et al., 2014). Such studies suggest 
that an increase in STEAP2 expression leads to a more aggressive cancer 
phenotype, with cell proliferation, migration and invasion higher in cells with 
elevated STEAP2 levels, suggesting that STEAP2 may promote prostate 
cancer progression (Burnell et al., 2018; Wang et al., 2010; Whiteland et al., 
2014). When assessed as a potential therapeutic target through gene 
knockdown and transfection, previous studies have shown that STEAP2 
provides promise in reducing these aggressive prostate cancer traits (Burnell 
et al., 2018; Korkmaz et al., 2002; Ohgami et al., 2006; Wang et al., 2010; 
Whiteland et al., 2014).  
 
Previous studies have altered STEAP2 expression through gene knockdown 
using siRNA (Burnell et al., 2018). However, the use of siRNA comes with 
limitations, including variability in the degree of knockdown that can be 
achieved, which can often differ across experiments (Boutros & Ahringer, 
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2008). Additionally, siRNA induces a transient knockdown effect, and as such 
may not be sustained over time (Boutros & Ahringer, 2008). Given these 
limitations, in the present Chapter, gene-knockout using CRISPR/Cas9 
engineering technology will be explored to achieve a more efficient, longer 
term knock-out of STEAP2 expression. Clustered randomly interspaced short 
palindromic repeats / caspase-9 (CRISPR/Cas9) genome editing technology 
has gained popularity in recent years as a versatile editing tool which has been 
widely utilised in a variety of cell types and organisms, both in vitro and in vivo, 
resulting in efficient gene disruption and gene modification (see Chapter 1, 
Section 1.7; Chen et al., 2019; Yuen et al., 2017). The CRISPR/Cas9 system 
is comprised of an sgRNA and DNA endonuclease Cas9, with sgRNA directing 
Cas9 to specific, targeted DNA sequences to induce site-specific cuts in 
double stranded DNA (Figure 5.1A; Jiang & Doudna, 2017).  
 
Once the targeted DNA sequence is cleaved by Cas9, DSBs are made in the 
genome sequence of interest and are located at approximately three 
nucleotides before the proto-spacer adjacent motif (PAM) region (Doudna & 
Charpentier, 2014; Li et al., 2020). The repair of these DSBs can be initiated 
by either non-homologous end joining (NHEJ) or homology-directed repair 
(HDR) (Figure 5.1B; Hsu et al., 2014). Of these repair mechanisms, HDR is 
less frequently initiated and uses donor DNA templates to precisely repair the 
DSB for gene modification with low efficiency (Jiang & Doudna, 2017). NHEJ 
often dominates as a repair mechanism for gene disruption and loss-of-
function mutations with high frequency, yet regularly results in frameshift 
mutations due to the generation of insertion or deletion mutations (indels) near 
the Cas9 cleavage site (Sanchez-Rivera et al., 2015; Sander & Joung, 2014). 
By taking advantage of these DSB repair pathways, specific gene disruption, 
deletion, correction and insertion can be achieved (Doudna & Charpentier, 
2014). Novel changes to the CRISPR/Cas9 system can also be made by 
fusing either wild-type or engineered mutant Cas9 with other functional ligands 
or protein domains, allowing for specific gene labelling, activation, silencing, 
enhanced specificity or even single base editing of DNA and RNA (Wang et 
al., 2017). By simply altering the sgRNA sequence and respective expression 
of different sgRNAs, the CRISPR/Cas9 system can retarget new DNA 
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sequences, introducing multiple DSBs, and therefore allows for a more 




Figure 5.1. The mechanisms of CRISPR/Cas9-mediated genome editing. 
(A) The Cas9 nuclease is guided to specific genomic sequences by the 
sgRNA. Double strand breaks (DSBs) are introduced close to the PAM region 
by the Cas9 nuclease. (B) Two DNA repair pathways can be induced to repair 
DSBs; the NHEJ pathway which results in small random insertions or deletions 
for gene knockout, or the HDR pathway which results in the insertion of a 
homologous donor template at the site of the DSBs for gene knock-in. Adapted 





In order for CRISPR/Cas9 system to successfully be used as a genome editing 
tool, sgRNA with the Cas9 protein complexed in the nucleus is required (Glass 
et al., 2018). For this to be achieved, the Cas9 can be introduced by either 
protein, mRNA, or DNA (plasmid or viral genome) formats (Glass et al., 2018). 
Using these approaches, the sgRNA can either be in vitro transcribed (IVT) 
RNA, chemically synthesised, or encoded in viral genomes to be expressed 
directly by the target cell (Glass et al., 2018).  A delivery system is necessary 
as one of the main challenges in the CRISPR/Cas9 system is that neither the 
protein nor the nucleic acid components can bypass the physical and chemical 
barriers of the target cells and tissues without assistance (Glass et al., 2018; 
Li et al., 2020). To allow for the intracellular delivery of CRISPR/Cas9 
components, physical (e.g., micro-injection or electroporation), viral (e.g., 
retrovirus or lentivirus), and non-viral (e.g., lipids or inorganic particles) carrier 
methods have been developed (Hansen-Bruhn et al., 2018; Kim et al., 2014; 
Tang et al., 2017). Of these options, viral carriers are often preferred as they 
support the stable delivery of CRISPR/Cas9 components into cells and are 
advantageous as they pose low immunogenicity, low risk of carcinogenesis 
and serotype-associated target cell specificity (Kotterman & Schaffer, 2014). 
Adeno-associated viruses (AAVs) are the most widely applied and studied 
delivery viral vector. Whilst efficiently infecting cells, the virus provokes little to 
no innate or adaptive immune response or associated toxicity, allowing viral 
vectors to successfully deliver CRISPR/Cas9 particles to target sites (Daya & 
Burns, 2008; Lino et al., 2018).  
Several open access, freely available online tools exist to facilitate the design 
and production of plasmids for gene knockout (Ran et al., 2013). These tools 
take a genomic sequence of interest and identify suitable target sites, with the 
aim of minimizing identical genomic matches or near-matches, to help prevent 
cleavage away from target sites, and therefore reduce any off-target effects 
(Bauer et al., 2015; Ran et al., 2013). When using such tools, it is essential to 
ensure that the guide sequences consist of a 20-mer protospacer sequence 
upstream of the PAM region at the genomic recognition site (Bauer et al., 
2015; Ran et al., 2013). The system also provides a scoring system for the off-
target potential of a similar sequence in the genome, allowing for the selection 
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of optimal sites (Hodgkins et al., 2015; Shen et al., 2014). Lentiviral 
CRISPR/Cas9 can be used to infect a wide variety of mammalian cells through 
the co-expression of a mammalian codon-optimised Cas9 nuclease in 
conjunction with a sgRNA to facilitate genome editing (Sanjana et al., 2014; 
Shalem et al., 2014). 
The therapeutic potential of CRISPR technology lies in the fact that the 
targeted cleavage activity of the Cas9 protein can be guided via synthetic 
sgRNA, allowing a wide variety of genomic sequences to be targeted (Li et al., 
2020). CRISPR/Cas9 is a rapidly evolving field of genetic engineering that has 
been successfully developed for the knockdown of many well studied genes 
involved in cancer progression. For example, CRISPR/Cas9 mediated 
knockout of hypoxia-inducible factor-1α (HIF-1α) has been found to supress 
metastasis in pancreatic cancer cells whilst targeted knockout of EGFR has 
been reported to limit proliferation in glioma cells, showing promise for the 
application of CRISPR/Cas9 genome editing technology as a novel tool in 
cancer therapeutics (Huang et al., 2017; Li et al., 2019).  
 
Several studies have recently successfully utilised CRISPR/Cas9 systems in 
prostate cancer research. A study by Zhen et al., in 2017 designed an 
aptamer-liposome-CRISPR/Cas9 chimera-based system to combine the 
efficient delivery and modified flexibility of the model. This study investigated 
A10, an RNA aptamer which is reported deliver therapeutic CRISPR/Cas9-
gRNA to target polo-like kinase 1, which plays a role in the survival of prostate 
cancer cells and binds specifically to the cell surface receptor of prostate 
specific membrane antigen (PMSA) (Troyer et al., 1997). This study used 
LNCaP cells in vitro and male nude mice for in vivo work and used RT-PCR to 
assess the successful gene knockdown of A10 in mRNA. It was concluded 
that modified A10 in the chimeras mediated cell type-specific binding to human 
prostate specific membrane antigen (PSMA) and suggested that 
CRISPR/Cas9 systems may be applicable to more widespread therapeutic 




A more recent study by Ye et al. in 2017 used CRISPR/Cas9 to edit the 
endogenous GPRC6A gene, which is increased in human prostate cancer cell 
lines (LNCaP and PC3) and human prostate cancer tumours (Pi & Quarles, 
2012). Cell proliferation and chemotaxis had previously been found to increase 
when GPRC6A is activated, and the gene also plays a role in prostate cancer 
progression as it was found to promote epithelial-mesenchymal transitions (Liu 
et al., 2016; Pi & Quarles, 2012). Removal of GPRC6A expression using 
siRNA-mediated knockdown had previously been found to inhibit the migration 
and invasion of prostate cancer cells (Pi & Quarles, 2012). One of the ligands 
of GPRC6A is osteocalcin, which is released into circulation by activated 
osteoblasts and can be used as both a marker and therapeutic target of 
prostate cancer metastasis (Suva et al., 2011). In vitro, it was found that 
editing the endogenous GPRC6A gene inhibited the osteocalcin activation of 
ERK, Akt and mTOR signalling pathways, which subsequently inhibited cell 
proliferation and migration. This recent study also found that CRISPR/Cas9 
deletion or endogenous modification of GPRC6A in prostate cancer xenograft 
models altered the response to osteocalcin and subsequent disease 
progression (Ye et al., 2017). This study therefore suggested that GPRC6A 
and osteocalcin may collectively provide therapeutic targets for the 
suppression of prostate cancer progression (Ye et al., 2017). CRISPR/Cas9 
engineering therefore offers multiple benefits in both providing new knowledge 
on the mechanisms and signalling pathways underlying carcinogenesis, whilst 
also offering the potential for future use as a therapeutic tool in the treatment 
of a variety of cancers.  
Previous work within the wider Swansea research group successfully used 
siRNA knockdown to reduce transient levels of STEAP2, however such a 
reduction is neither stable nor permanent unlike that offered by CRISPR/Cas9 
engineering (Burnell et al., 2018). The aims of this Chapter were to identify if 
CRISPR/Cas9 knockout could successfully knockout STEAP2 expression and 
determine whether such knockout of STEAP2 could reduce aggressive 
prostate cancer traits. To achieve this aim, the Chapter was therefore divided 
into the following objectives: 
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1. To design and develop CRISPR/Cas9 technology for STEAP2 
knockout in LNCaP and C4-2B prostate cancer cells in vitro. 
2. To evaluate the impact of STEAP2 knockout in LNCaP and C4-2B 
prostate cancer cells on aggressive prostate cancer traits, including cell 
proliferation, migration and invasion.  
3. To evaluate the impact of STEAP2 knockout on the gene expression of 




5.2.1 Cell culture 
The human prostate cancer cell lines LNCaP and C4-2B, and the normal 
prostate epithelial cell line PNT2 were utilised in this Chapter, and are 
described in Chapter 2, Section 2.2.1, 2.2.2 & 2.7.4. Wild-type (WT) LNCaP 
cells (LNCaPWT) and wild-type C4-2B cells (C4-2BWT) cells were routinely 
cultured and maintained as described in Chapter 2, Section 2.2.7.1. The 
selection antibiotic puromycin was used to select for STEAP2 knockout (KO) 
positive cells. LNCaP knock-out (LNCaPKO) cells were maintained in complete 
RPMI media supplemented with 0.625 µg/ml puromycin, whilst C4-2B knock-
out (C4-2BKO) cells were maintained in complete RPMI media supplemented 
with 1.25 µg/ml puromycin. These doses were utilised following a serial dilution 
implemented to determine the optimum dose for each cell line (see Chapter 
2, Section 5.2.3.5). HEK293T cells were maintained in DMEM supplemented 
with 10% FBS, 2% L-glutamine and 1% P/S. HEK293T cells were routinely 
sub-cultured at a ratio of 1:3 or 1:8 as per the supplier’s recommendations.  
5.2.2 Detection of STEAP2 in a panel of prostate cancer cell 
lines 
Four human prostate cancer cells C4-2B, DU145, LNCaP and PC3 and the 
normal human prostate epithelial cell line PNT2 were cultured to ~70% 
confluency. RNA was extracted, cDNA synthesised, and qRT-PCR performed 
as described in Chapter 2, Section 2.3. qRT-PCR for STEAP2, with GAPDH 
as the housekeeping control, involved the use of primers detailed in Chapter 
2, Section 2.3.3, Table 2.8. The results were subsequently analysed as 







5.2.3 Design and optimisation of CRISPR/Cas9 engineering for 
STEAP2 knockout 
The Welcome Trust Sanger Institute Genome Editing (WGE) database was 
used for plasmid design, which is based on successfully arrayed lentiviral 
CRISPR knockout libraries and provides a highly interactive tool for the 
visualisation of all possible CRISPR and paired Cas9 sites (Metzakopian et 
al., 2017). CRISPR/Cas9 engineering was developed, optimised and utilised 
for the knockout of STEAP2 from LNCaP and C4-2B prostate cancer cells, 
using the method outlined in Chapter 2, Section 2.7. 
 
5.2.3.1 Plasmid design  
gRNA, PsPAX-2 lentiviral packaging protein and pCMV-vsvg envelope protein 
were purchased as described in Chapter 2, Section 2.7.1. Two STEAP2 
oligonucleotides were designed using BLAST analysis to encode for either the 
complete protein (STEAP2 plasmid #1) or a STEAP2 transcript variant 
(STEAP2 plasmid #2), as shown in Table 5.1. Plasmids were generated from 
chosen sequences using Sanger QuickPick Knockout gRNA (Sigma Aldrich, 
USA).  
 
Table 5.1. Sequences of gRNA and STEAP2 plasmids utilised in 
CRISPR/Cas9 targeted knockout of STEAP2. 
Plasmid Sequence 
gRNA CGCGATAGCGCGAATATATT 
STEAP2 #1 AATATTCAAGCGCGACAAC 
STEAP2 #2 GGAATGAAATTCAACTGGC 
 
5.2.3.2 Plasmid amplification and purification  
Both STEAP2 plasmids, BFP gRNA control, (Sigma, USA), PsPAX-2 (Sigma, 
USA) and pCMV-vsvg (Sigma, USA) plasmids were separately amplified and 
purified following the methods outlined in Chapter 2, Section 2.7.2 & 2.7.3. 
Purified plasmid pellets were reconstituted in 50 µl of TE buffer and DNA yield 
measured. The DNA yields outlined in Table 5.2 were then diluted to 200.0 
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ng/µl in aliquots of 100 µl of TE buffer and stored at -20 oC for future use 
throughout this Chapter.  
 
Table 5.2. Quantification of bacterial plasmid DNA. The amplified and 
purified plasmid DNA generated in Section 5.2.3.2 was quantified for use 
throughout this Chapter. 
Plasmid Concentration (ng/µl) 
PsPAX-2 2189.1 
pMCV-vsvg 2339.7 
BFP gRNA control 457.8 
STEAP2 plasmid #1 398.2 
STEAP2 plasmid #2 470.1 
 
5.2.4 CRISPR/Cas9 knockout of STEAP2 
 
5.2.4.1 Cas9 transfection of HEK293T cells 
Cas9 was transfected into HEK293Tcells using polybrene, as described in 
Chapter 2, Section 2.7.4.  
 
5.2.4.2 Preparation of lentiviral particles  
Lentiviral particles were prepared using Opti-MEM media and lipofectamine, 
as described in Chapter 2, Section 2.7.5.  
 
5.2.4.3 Lentiviral transfection of STEAP2 plasmids into Cas9-positive 
HEK293T cells 
Cas9-positive HEK293T cells were transfected with STEAP2 knockout 
plasmids, as described in Chapter 2, Section 2.7.6. 
 
5.2.4.4 Concentrating lentiviral STEAP2 stock 
The Retro-X Concentrator kit (Clontech, USA, #631455) was used to 
concentrate lentiviral stocks of STEAP2 as described in Chapter 2, Section 
2.7.7 using the viral supernatant collected from the virus-producing HEK293T 
cells as described in Section 5.2.3.2. 
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5.2.4.5 Transfection of Cas9 plasmids into LNCaP and C4-2B wild-type 
cells 
Cas9 was transfected into wild-type LNCaP and C4-2B wild-type cells using 
polybrene, following the method detailed in Chapter 2, Section 2.7.8. Once 
at ~50% confluency, LNCaP and C4-2B wild-type cells were seeded at a 
density of 2x105 cells per well in a 6-well tissue culture plate under standard 
tissue culture conditions for 48 and 24 h respectively prior to transfection. A 
mixture of complete medium with polybrene was prepared to a final 
concentration of 1 µg/ml. Original media was removed and this polybrene mix 
was added at a volume of 1 ml per well. Cas9 plasmids were thawed at room 
temperature and mixed gently prior to being added at a volume of 500 µl per 
well to the culture medium containing polybrene. The plate was gently swirled 
to mix and incubated overnight. An additional 1 ml of medium containing 
Polybrene was added per well, and cells were again incubated until ~50% 
confluency was reached.  
 
5.2.4.6 Optimisation of selection antibiotic doses in wild-type cells 
A selective antibiotic titration (see Chapter 2, Section 2.7.9) was carried out 
for each wild-type cell line. C4-2BWT and LNCaPWT cells were seeded at a 
density of 3x105 per well in 6-well plates for 48 h and 72 h respectively. Cells 
were exposed to a serial dilution of the selection antibiotics blasticidin and 
puromycin (Sigma, USA) at 0.625, 1.25, 2.5, 5.0 and 10.0 µg/ml for 120 h. 
Cells were viewed using standard light microscopy (Invitrogen, EVOS XL 
Core, USA) at 48 h and 120 h and any morphological changes were noted to 
determine toxicity, as described in Tables 5.3 & 5.4. Based on these results 
0.625 µg/ml and 2.5 µg/ml blasticidin was used for the selection of Cas9-
positive LNCaP and C4-2B cells respectively (Tables 5.3 & 5.4). 0.625 µg/ml 
and 1.25 µg/ml puromycin were used to maintain STEAP2-positive LNCaPKO 
and C4-2BKO cells respectively (Tables 5.3 & 5.4). Medium was replaced with 





Table 5.3. Changes in viability of LNCaPWT and C4-2BWT cells following 
exposure to puromycin. 
Dose 
(µg/ml) 
48 h 120 h 
0.625 Some survival of both cell 
lines 
No survival of either cell line 
1.25 Some C4-2BWT survival, no 
LNCaPWT survival 
No survival of either cell line 
2.5 No survival of either cell line No survival of either cell line 
5.0 No survival of either cell line No survival of either cell line 
10.0 No survival of either cell line No survival of either cell line 
 
Table 5.4. Changes in viability of LNCaPWT and C4-2BWT cells following 
exposure to blasticidin. 
Dose 
(µg/ml) 
48 h 120 h 
0.625 Both cell lines healthy Some C4-2BWT survival, no 
LNCaPWT survival 
1.25 Both cell lines healthy Some C4-2BWT survival, no 
LNCaPWT survival 
2.5 Both cell lines healthy No survival of either cell line 
5.0 Some LNCaPWT survival, 
C4-2BWT healthy  
No survival of either cell line 
10.0 LNCaPWT mostly dead, 
C4-2BWT healthy 








5.2.4.7 Transfection of STEAP2 plasmids into Cas9-activated LNCaP and 
C4-2B cells 
STEAP2 knockout and gRNA plasmids were transfected into wild-type LNCaP 
and C4-2B cells using polybrene, as outlined in Chapter 2, Section 2.7.11. 
Once at ~50% confluency, Cas9-activated LNCaP and C4-2B cells were 
seeded at a density of 2x105 cells per well in a 6-well tissue culture plate under 
standard tissue culture conditions for 48 and 24 h respectively prior to 
transfection. A mixture of complete medium with polybrene was prepared to a 
final concentration of 1 µg/ml. Original media was removed and this polybrene 
mix was added at a volume of 1 ml per well. STEAP2 plasmids #1 and #2, and 
gRNA plasmids, were thawed at room temperature and mixed gently prior to 
being added at a volume of 500 µl per well to the culture medium containing 
polybrene. The plate was gently swirled to mix and incubated overnight. An 
additional 1 ml of medium containing polybrene was added per well, and cells 
were again incubated until ~70% confluency was reached. Medium containing 
polybrene was removed and replaced with complete medium containing the 
chosen dose of puromycin for each cell line, as determined in Section 5.2.3.5. 
Once ~70% confluency was reached, cells were transferred from the 6-well 
plates to 100 mm petri dishes and sub-cultured until confluent.  
 
5.2.4.8 Isolation and amplification of single STEAP2 knockout clones 
Single STEAP2 knockout clones were isolated and amplified as outlined in 
Chapter 2, Section 2.7.12. To isolate single colonies of positive STEAP2 
knockout cells, cells were seeded at a density of 300 cells per plate in 96-well 
tissue culture plates, in 100 µl media supplemented with the appropriate dose 
of puromycin. Plates were incubated for 10-14 days and routinely checked for 
single colony formations. Once formed, 6 single colonies per cell line, per 
STEAP2 plasmid were transferred to 24-well tissue culture plates in 0.5 ml of 
complete medium supplemented with the appropriate dose of puromycin and 
incubated for a further 7 days. Microscopy was used to assess morphology of 
knockout cells in comparison to their wild-type counterparts, and 3 colonies 
per cell line, per STEAP2 plasmid that most closely resembled wild-type cells 
were transferred to 6-well tissue culture plates and incubated until ~70% 
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confluent. Western blotting was performed to confirm successful target gene 
knockout, and stable clones were further expanded and routinely sub-cultured 
in 100 mm dishes in the same manner as their wild-type counterparts, with the 
addition of an appropriate dose of puromycin. These expanded colonies are 
annotated herein as depicted in Figure 5.2 to distinguish between STEAP2 
knockout plasmid, colony number and cell line.  
 
Figure 5.2. Annotation of single colonies of knockout cells. Schematic 
representation of the system used to annotate expanded colonies of knockout 
cells dependent on STEAP2 knockout plasmid, colony number and cell line. 
 
5.2.5 Confirmation of STEAP2 knockout by Western blotting 
 
5.2.5.1 Protein extraction and quantification 
Protein was extracted from expanded single knockout colonies as described 
in Chapter 2, Section 2.8.1 and quantified using a Bradford assay for protein 
quantification as described in Chapter 2, Section 2.8.2. 
 
5.2.5.2 Blocking and antibody incubations 
Western blotting was conducted as described in Chapter 2, Section 2.8. 
Membranes were first probed overnight at 4°C with anti-STEAP2 (1:1,000, 
Sigma, US). After washing 3x in PBST, the secondary rabbit anti-IgG-HRP 
antibody was applied at 1:5,000 for 1 h at room temperature to detect STEAP2 
protein expression. The membranes were washed, stripped, washed and 
blocked for 1 h in 5% BSA at room temperature (Chapter 2, Section 2.8.6) 
before cutting (Figure 5.3) prior to specific antibody staining for STEAP2 and 
the loading control GAPDH.   
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Figure 5.3. Diagram showing the cuts made to the nitrocellulose 
membrane following membrane transfer prior to antibody incubation. 
Vertical, short lines = gel wells; numbers = number of gel wells; well 1 + 10 = 
dual colour precision MWL (kDa) with red and blue short, vertical lines which 
represent the relevant molecular weight bands for this study. Membrane was 
cut into two pieces indicated by the horizontal lines. Horizontal line at approx. 
45kDa indicates the cut separating STEAP2 (56 kDa) from housekeeping 
loading control GAPDH (37 kDa). Cell lysates from the WT (high STEAP2 
expression) and KO (no STEAP2 expression) cell lines were utilised. Diagonal 
line in top-right corner indicates the cuts to determine orientation. 
 
5.2.5.4 Protein detection analysis 
Images were acquired and analysed as described in Chapter 2, Section 
2.8.7. Protein quantification of STEAP2 was carried out every 5th passage of 
cells to ensure a stable knockout had been achieved. 
5.2.6 Assays to study the effect of STEAP2 knockout on 
aggressive cancer traits 
 
5.2.6.1 Cell viability quantification 
Cell suspensions of desired cell numbers were prepared as described in 
Chapter 2, Section 2.2.7.2 and seeded in 100 µl culture media in 96-well 
tissue culture plates. To assess cell viability in STEAP2-knockout cells, the 
commercial resazurin-based dye alamarBlue assay (BioRad, UK, Cat. 
BUF012A), was performed as described in Chapter 2, Section 2.4.2. Viability 
was assessed in knockout cells and compared to that of wild-type cells every 
24 h for 5 days. Viability assays were conducted in triplicate unless otherwise 
stated. 
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5.2.6.2 Cell proliferation 
Cell suspensions of desired cell numbers were prepared as described in 
Chapter 2, Section 2.2.7.2 and seeded in 100 µl culture media in 96-well 
tissue culture plates. The alamarBlue assay was used to assess cell 
proliferation in STEAP2-knockout cells, as described in Chapter 2, Section 
2.5.1. The alamarBlue assay offers a more simplistic, one-step in vitro assay 
for cell viability and proliferation and was applied in this Chapter due to the 
more fragile nature of knockout cells compared to their wild-type counterparts 
(Squatrito et al., 1995). Proliferation was assessed in knockout cells and 
compared to that of wild-type cells every 24 h for 5 days. Proliferation assays 
were conducted in triplicate unless otherwise stated. 
 
5.2.6.3 Cell migration assay 
Migration assays were carried out as described in Chapter 2, Section 2.9. 
After C4-2B and LNCaP cells had reached ~80% confluency, medium was 
replaced for 24 h with serum-free DMEM and RPMI-1640 medium 
respectively. Cells were trypsinised, resuspended and adjusted to a desired 
cell concentration, as described in Chapter 2, Section 2.2.7.2. One cell 
culture insert (IBIDI, Germany, Cat. 80209) was placed in the centre of a well 
of a 12-well plate, and 70 µl cell suspension was added per chamber adhered 
for 24 h (C4-2B) or 48 h (LNCaP) in standard tissue culture conditions. 
LNCaPWT and LNCaPKO cells were incubated for 72 h prior to the removal of 
the silicone inserts, whilst C4-2BWT and C4-2BKO cells were incubated for 48 
h.  Media and inserts were removed, and cells were washed with PBS to 
remove cell debris, before fresh media was applied. The time taken to close 
the gap created was monitored using an inverted light microscope (Invitrogen, 
EVOS XL Core, USA). Media was replaced every 3 days. The migration assay 
was conducted in triplicate unless otherwise stated.  
 
5.2.6.4 Invasion assay 
Invasion assays were carried out as described in Chapter 2, Section 2.10. 48 
h prior to each invasion assay, cells were harvested and seeded in 6-well 
plates at a density of 3 x 105 cells/ml and left to adhere in standard cell culture 
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conditions. Cultures were serum starved in SFM for 24 hours. Prior to seeding 
cells, 20 µl of GFR Matrigel (1:5 dilution/SFM; Corning) was applied to the 
Transwell insert and polymerised for 1 hour in standard cell culture conditions. 
Cells were harvested with trypsin and adjusted to a desired seeding density in 
a volume of 250 µl SFM. Prior to the addition of cells, 600 µl of serum 
containing media was added to the lower chamber. LNCaPWT and LNCaPKO 
cells were incubated for 72 h prior to staining, whilst C4-2BWT and C4-2BKO 
cells were incubated for 48 h in standard cell culture conditions to allow for cell 
invasion to occur. Cell invasion was quantified through staining with crystal 
violet. Invaded cells were fixed with 100% methanol for 15 minutes at room 
temperature and allowed to air dry. They were stained with crystal violet 
staining mixture (0.5% crystal violet in 20% methanol) for 30 minutes to allow 
visualisation of cells. The non-invaded cells on the upper surface of the 
Transwell insert were removed with a cotton swab moistened in media. The 
inserts were washed in purified water and left to air dry for 1 hour. Invaded 
cells were visualised using a standard light microscope at 10x magnification 
(Invitrogen, EVOS XL Core, USA). Images were taken of different planes of 
each insert and the invasion assay was conducted in triplicate unless 
otherwise stated.  
5.2.7 Detection of AR and downstream targets in STEAP2 
knockout LNCaP and C4-2B cells 
LNCaPWT, LNCaPKO, C4-2BWT and C4-2BKO cells were cultured to ~70% 
confluency. RNA was extracted, cDNA synthesised, and qRT-PCR performed 
as described in Chapter 2, Section 2.3. Cells were probed for the detection 
of AR and its downstream targets; PSA, FKBP5, TMPRSS2 and GPRC6A, 
with GAPDH as the housekeeping control, using the primers detailed in 
Chapter 2, Section 2.3.3, Table 2.8. The results were subsequently analysed 
as described in Chapter 2, Section 2.3.4. 
5.2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 8 for iOS. 
The one-way ANOVA post-hoc Dunnett test and an unpaired t-test were used, 
as detailed in each figure. Data was considered statistically significant when a 
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p-value of < 0.05 (*), p-value < 0.01 (**) or a p-value of < 0.001 (***) or p-value 




The initial focus of this Chapter was to optimise and develop CRISPR/Cas9 
technology for the successful targeted STEAP2 knockout in LNCaP and C4-
2B prostate cancer cells in vitro. Following this, the work within the current 
Chapter was aimed at evaluating the impact of CRISPR/Cas9 knockout of 
STEAP2 on the aggressive traits of LNCaP and C4-2B prostate cancer cells. 
This aim was addressed by evaluating the following properties of LNCaPKO 
and C4-2BKO cells in comparison to their wild-type counterparts: cell viability, 
proliferation, migration and invasion. Finally, this chapter also aimed to 
determine whether targeted STEAP2 knockout influenced the expression 
levels of AR and the androgen-associated genes PSA, FKBP5, TMPRSS2 and 
GPRC6A. This was achieved through qRT-PCR analysis of these genes in 
LNCaPKO and C4-2BKO cells in comparison to their wild-type counterparts.  
5.3.1 STEAP2 gene and protein expression is upregulated in 
androgen-sensitive prostate cancer cell lines 
As demonstrated in Chapter 3, Section 3.3.1, of the four STEAP family 
members, STEAP2 gene expression was highest in androgen-sensitive 
human prostate cancer cell lines. Additionally, western blotting was carried out 
to determine if the STEAP2 protein expression levels in C4-2B and LNCaP 
prostate cancer cell lines, were increased in the same manner as the STEAP2 
gene expression levels. The normal prostate epithelial cell line PNT2 was used 
for comparison. 
 
In Chapter 3, Section 3.3.1, STEAP2 was found to have the highest increase 
in expression in all 4 of the cell lines screened, as determined by a >2-fold 
increase in fold expression. Moreover, the highest and most significant 
overexpression levels of STEAP2 were observed in the androgen-sensitive 
cell lines LNCaP and C4-2B, which exhibited 264.7-fold and 53.5-fold 
increases in expression respectively (p £ 0.001; Figure 5.4A). The data is 
presented again in this Chapter for comparison purposes with STEAP2 protein 
expression. STEAP2 protein levels in LNCaP and C4-2B cells were also 
evaluated to determine whether the STEAP2 overexpression was translated 
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at a protein level, as determined by Western blot analysis (Figure 5.4B). On 
the basis of these results, the cell lines LNCaP and C4-2B were carried 




Figure 5.4. STEAP2 is highly expressed in androgen-sensitive prostate 
cancer cell lines. (A) Fold changes in STEAP2 gene expression in a panel of 
human prostate cancer cell lines as compared to the normal prostate epithelial 
cell line PNT2. An ANOVA post-hoc Dunnett test was performed for statistical 
analysis. Error bars denote S.E.M. p-value < 0.01 (**), p-value < 0.001 (***), 
p-value < 0.0001 (****) (N = 3). (B) Western blot analysis of STEAP2 protein 
expression in LNCaP and C4-2B prostate cancer cell lines (Loading control = 




5.3.2 Development of CRISPR/Cas9 technology for STEAP2 
knockout in androgen-sensitive prostate cancer cells in vitro 
 
5.3.2.1 CRISPR/Cas9 engineering successfully knocks out STEAP2 from 
LNCaP and C4-2B cell colonies 
Two STEAP2 knockout plasmids were designed using the WGE database and 
BLAST analysis to encode for the full length STEAP2 protein (plasmid #1) and 
a STEAP2 transcript variant (plasmid #2). Plasmids were expanded, purified 
and quantified prior to lentiviral transfection into LNCaPWT and C4-2BWT cells. 
Single colonies of LNCaPKO and C4-2BKO cells were then expanded, and 
protein lysates collected. In order to confirm whether STEAP2 had 
successfully been knocked out of the expanded colonies of LNCaPKO and C4-
2BKO cells following CRISPR/Cas9 engineering, Western blotting was 
performed. LNCaPWT and C4-2BWT cells were used as positive controls 
exhibiting high levels of STEAP2 protein expression. Protein lysates from 
three individual colonies per cell line, per STEAP2 plasmid were assessed, 
with GAPDH used as a loading control. 
 
Upon analysis of STEAP2 protein expression, all expanded colonies of 
LNCaPKO cells exhibited a complete ablation of STEAP2 expression in 
comparison to their wild-type counterparts (Figure 5.5A). In C4-2BKO cells, 
CRISPR/Cas9 knockout of STEAP2 was also successful in all expanded 
colonies, with the exception of P1_C3_C, which displayed some, albeit 
reduced, STEAP2 protein expression in comparison with their wild-type 
counterparts (Figure 5.5B). The protein expression of GAPDH loading control 
was consistent across all colonies, demonstrating that similar quantities of 
protein lysates were present across all samples (Figure 5.5). Based on these 
results, all six colonies from both cell lines were carried forward for cell viability 
assessment. STEAP2 protein expression was periodically assessed to ensure 
stable knockout of STEAP2 was achieved in order to confidently determine 
that any subsequent results were the result of STEAP2 knockout (see 




Figure 5.5. STEAP2 protein expression analysis by Western blotting. 
Protein lysates were taken from LNCaPWT and LNCaPKO cells (A) and C4-
2BWT and C4-2BKO cells (B). LNCaPWT cells (A) and C4-2BWT cells (B) 
represent high STEAP2 levels. Three individual colonies per STEAP2 plasmid 
of LNCaPKO and C4-2BKO cells to determine STEAP2 knockout efficiency. 
STEAP2: approx. 56 kDa; GAPDH: approx. 37 kDa. (Loading control = 











5.3.2.2 Optimisation of viable STEAP2 knockout prostate cancer cell 
colonies 
To determine the optimal expanded cell colony from each cell line to carry 
forward for further analysis, the viability of all colonies was assessed by the 
alamarBlue viability assay. Cell viability was measured every 24 h after 
seeding, with the aim of selecting a colony with consistent viability over time. 
Colonies were maintained until cell viability dropped below half that of their 
wild-type counterparts. Cell viability was measured as a percentage of viable 
cells present in the population.  
 
In LNCaPKO cells, the percentage of viable cells varied across colonies. 
Colony P1_C1_L was the only one to display a significant increase in the 
percentage of viable cells (+11%, p < 0.05; Figure 5.6A). Whilst the 
percentage of viable cells did increase in colony P1_C1_L, it was of concern 
that this could be the result of an unstable STEAP2 knockdown. Only 
LNCaPKO colony P2_C1_L showed a significant decrease in the percentage 
of viable cells by day 3 (-35%, p < 0.01; Figure 5.6A). LNCaPKO colony 
P1_C3_L exhibited the least changes in the percentage of viable cells in 
comparison to LNCaPWT cells, as shown by a percentage of viable cells of 
49% in comparison to 51% displayed by LNCaPWT cells on day 3. In P1_C2_L, 
although a decrease in the percentage of viable cells in comparison to 
LNCaPWT cells was observed, this remained the most consistent over the 3-
day period (Figure 5.6A). However, in C4-2BKO cells, a significant reduction 
in the percentage of viable cells was observed at every time point from as early 
as 24 h (Figures 5.6B). By Day 5, the C4-2BKO colony P2_C3_C exhibited the 
largest significant decrease in the percentage of viable cells (-33%, p < 0.0001; 
Figure 5.6B). C4-2BKO colony P1_C2_C exhibited the lowest decreases in the 
percentage of viable cells across all 5 days, as shown by a percentage of 63% 
in comparison to 80% displayed by C4-2BWT cells on day 3. Based on these 
results, LNCaP and C4-2B knockout colonies were chosen as P1_C2_L and 
P1_C2_C respectively, as depicted by the red circles shown in Figure 5.6 and 
expanded for use throughout this chapter; they are herein referred to 
generically as LNCaPKO and C4-2BKO respectively. These colonies were 
chosen as it was important to select colonies from the same knockout plasmid 
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in order for comparisons to be made throughout this Chapter. Plasmid #1 
encoded for the full length STEAP2 protein and was therefore the preferred 
method for complete STEAP2 knockout.
 
 
Figure 5.6. STEAP2 knockout decreases cell viability. Quantification by the 
alamarBlue assay of the percentage of viable cells in individual LNCaPKO (A) 
and C4-2BKO (B) cell colonies. Red circles indicate colonies carried forward. 
An ANOVA post-hoc Dunnett test was performed for statistical analysis. Error 
bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 0.001 
(***), p-value < 0.0001 (****) (N = 3).
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5.3.3 Analysis of aggressive prostate cancer traits in response 
to STEAP2 knockout in androgen-sensitive prostate cancer 
cells 
 
5.3.3.1 STEAP2 knockout reduces cell proliferation and migration 
In order to evaluate the impact of CRISPR/Cas9 knockout of STEAP2 from 
LNCaP and C4-2B cells on cell proliferation, the alamarBlue cell proliferation 
assay was performed. Based on the percentage of viable cells of each cell line 
over time as shown in Section 5.3.2.2, the assay was carried out every 24 h 
after seeding for a total of either 3 days (LNCaP) or 5 days (C4-2B), as after 
this time cell growth began to significantly slow for each cell line. The 
percentage of proliferating cells was normalised to cells on day 1 to determine 
the difference in proliferation rate over time.   
 
In LNCaPKO cells, the percentage of proliferating cells was significantly 
reduced on day 3 (-48%, p < 0.05; Figure 5.7B,). The percentage of 
proliferating C4-2BKO cells  was also consistently and significantly reduced 
across all 5 days and was lowest on day 5 (-53%, p < 0.0001; Figure 5.7B). 
Based on these data, it can be suggested that STEAP2 knockout significantly 
reduces the proliferative capacity of androgen-sensitive prostate cancer cell 
lines.  
 
To further evaluate the potential of CRISPR/Cas9 knockout of STEAP2 on 
reducing aggressive characteristics of LNCaP and C4-2B cells, the cell 
migration assay was carried out. To do so, cells were cultured in separate 
chambers of a silicone tissue culture plate insert. The insert was removed once 
cells had reached ~80% confluency (24 h after seeding of C4-2B cells or 48 h 
after seeding of LNCaP cells), and cells were imaged every 24 h for 5 days.  
 
In LNCaP cells, whilst the wound gap was not completely closed in wild-type 
cells by day 5 (Figure 5.8A), STEAP2 knockout had completely inhibited 
migration of LNCaPKO cells (Figure 5.8B). In C4-2B cells, the wound gap had 
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entirely closed between days 3 and 5 in C4-2BWT cells (Figure 5.8C), 
suggesting that they migrate at a faster rate than LNCaPWT cells. In contrast, 
in C4-2BKO cells, inhibition in cell migration was still observed on day 5 as the 
wound gap remained fully open (Figure 5.8D). These data indicate that 
STEAP2 knockout leads to a complete inhibition of the migratory capacity of 
both LNCaPKO and C4-2BKO cells (Figure 5.8, where representative images 
are shown; additional images from the second replicate can be found in 
Appendix 3, Figure A3.4). 
 
Figure 5.7. STEAP2 knockout significantly reduces cell proliferation. 
Quantification by alamarBlue assay of the percentage of proliferating cells in 
LNCaPKO (A) and C4-2BKO (B) cells in comparison to their wild-type 
counterparts. An ANOVA post-hoc Dunnett test was performed for statistical 
analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-
value < 0.001 (***), p-value < 0.0001 (****) (N = 3). 
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Figure 5.8. STEAP2 knockout decreases the migratory potential of 
LNCaP and C4-2B cells. Each panel represents A) LNCaPWT, B) LNCaPKO 
cells and C) C4-2BWT, D) C4-2BKO cells. Time points at which the images were 
taken: 0 days, 3 days and 6 days. Wild-type LNCaP and C4-2B cells were 
used as positive controls. Images were acquired using an inverted light 
microscope with a 10x objective (Invitrogen, EVOS XL Core, USA). Scale bar 
= 100 µm. (Illustrated are representative images; the experiment was however 







5.3.3.2 STEAP2 knockout reduces cell invasion in LNCaP and C4-2B cells 
The cell invasion assay was performed to evaluate whether targeted knockout 
of STEAP2 using CRISPR/Cas9 engineering had an effect on inhibiting cancer 
cell invasion. To do so, the bottom of a culture plate-insert was coated with 
Matrigel (as per manufacturer’s instructions) and to stimulate the ability of 
cancer cells to invade through this ECM, FBS served as a chemoattractant. 
Cells were grown in the top layer of the insert, and as such only those with 
invasive potential were capable of crossing the Matrigel barrier.  
 
The results illustrated in Figure 5.9 demonstrate that the invasive potential of 
LNCaP and C4-2B cells is significantly inhibited with STEAP2 knockout with 
only 3.0% and 4.1% of LNCaPKO and C4-2BKO cells respectively, invading 
through the ECM as compared to the equivalent wild-type cells (p < 0.001; 
Figure 5.9E). These data, along with the results presented in Sections 5.3.3.1 
& 5.3.3.2, suggest that STEAP2 knockout substantially reduces aggressive 
cancer traits in LNCaP and C4-2B cells (Figure 5.9, where representative 
images are shown; additional images from the second replicate can be found 













Figure 5.9. STEAP2 knockout reduces the invasive potential of LNCaP and C4-2B cells. Images of stained cells were taken to give a 
visual representation of invasion. Each panel represents A) LNCaPWT, B) LNCaPKO cells and C) C4-2BWT, D) C4-2BKO cells. LNCaPWT and 
C4-2BWT cells show invasive potential. STEAP2 knockout in LNCaPKO and C4-2BKO cells reduces invasive capacity. Invaded cells were 
stained with crystal violet. Images were taken 48 h (C4-2B) and 72 h (LNCaP) after seeding. E) The number of stained cells that had 
invaded through the Transwell insert were counted and calculated as a percentage of the wild-type control. An unpaired t-test was 
performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 0.001 (***), p-value < 0.0001 
(****). Images were taken with an inverted light microscope at a 10x objective (Invitrogen, EVOS XL Core, USA). Scale bar = 100 µm. 
Illustrated are representative images; the experiment was however conducted in triplicate with biological replicates, N = 3).
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5.3.4 The impact of CRISPR/Cas9 knockout of STEAP2 on the 
expression of AR and androgen-regulated genes in androgen-
sensitive prostate cancer cells 
 
5.3.4.1 STEAP2 knockout increases the expression of AR and androgen-
regulated genes 
LNCaP and C4-2B are both androgen-sensitive prostate cancer cell lines. 
Following the results of Chapter 4, Section 4.3.3 which found that AR gene 
expression increased in response to STEAP2 polyclonal antibody treatment, 
this chapter explores AR expression in response to STEAP2 knockout by qRT-
PCR.  
 
No significant change in AR expression was observed in LNCaPKO cells (+0.1-
fold; Table 5.5). However, in contrast, AR was found to be highly and 
significantly overexpressed in C4-2BKO cells, which exhibited a 38.9-fold 
increase in expression (p £ 0.0001; Table 5.5). On the basis of these results, 
the impact of STEAP2 knockout on the expression of three genes regulated 
by AR; PSA, FKBP5 and TMPRSS2 in LNCaPKO and C4-2BKO cells was 
assessed.  
 
Chapter 4, Section 4.3.4 found that the expression of three out of four genes 
known to influence AR expression – PSA, FKBP5 and TMPRSS2 – increased 
in response to STEAP2 polyclonal antibody treatment in both LNCaP and C4-
2B cells, whilst GPRC6A expression was undetectable. Following these 
results, the gene expression of the same four AR downstream genes were 
quantified in response to STEAP2 knockout by qRT-PCR in LNCaP and C4-
2B cells. Wild-type cells were used for comparison. 
 
Upon analysis of gene expression of the four AR downstream genes, 
TMPRSS2 was found to be significantly overexpressed in both LNCaPKO and 
C4-2BKO cells, which exhibited 274.9-fold and 92953.2-fold increases in 
expression respectively (Table 5.5). PSA and FKBP5 all showed an increase 
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in expression in LNCaPKO cells when compared to LNCaPWT cells, displaying 
49.7-fold and 582.3-fold increases in expression respectively (Table 5.5). PSA 
and FKBP5 expression in C4-2BKO cells (Table 5.5), and GPRC6A expression 
in either LNCaPKO or C4-2BKO cells was undetermined (Table 5.5). qRT-PCR 
analysis of PSA, FKBP5, TMPRSS2 and GPRC6A expression therefore 
demonstrated that TMPRSS2 is highly expressed in STEAP2 knockout 
androgen-sensitive prostate cancer cell lines and thus, could warrant further 
investigations into its role in AR expression and aggressive cancer traits.  
 
Table 5.5. STEAP2 knockout increases the expression of AR and 
androgen-regulated genes. Fold changes in the gene expression of PSA, 
FKBP5, TMPRSS2 and GPRC6A in LNCaP and C4-2B STEAP2 knockout cell 
lines as compared to their wild-type counterparts. An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. GAPDH was used as the 
housekeeping gene. “Undetectable” indicates that no gene expression of this 
gene was recorded. p-value < 0.01 (**), p-value < 0.001 (***), p-value < 0.0001 
















This chapter aimed to design, optimise and successfully employ 
CRISPR/Cas9 engineering for targeted STEAP2 knockout. The aim of this 
chapter was also to determine whether targeted STEAP2 knockout could 
reduce aggressive cancer traits in androgen-sensitive prostate cancer cells, 
by assessing cell viability, proliferation, migration and invasion in response to 
targeted STEAP2 knockout. The results demonstrated that CRISPR/Cas9 
engineering had resulted in successful STEAP2 knockout, and such targeted 
STEAP2 knockout resulted in significant reductions in cell proliferation and 
viability. Cell migration and invasion was also inhibited by STEAP2 knockout. 
5.4.1 Optimisation and development of CRISPR/Cas9 
technology for STEAP2 knockout in androgen-sensitive 
prostate cancer cells in vitro 
CRISPR/Cas9 technology has the ability to induce complete gene knockout, 
as opposed to the transient gene knockdown offered by siRNA silencing 
(Boutros & Ahringer, 2008; Tuladhar et al., 2019). siRNA silencing has 
previously been used to target STEAP2 in vitro, however only a 50% reduction 
in protein expression was reported, highlighting the need for a more efficient 
genome engineering tool (Burnell et al., 2018). The expression of STEAP2 
and other family members has previously been evaluated in a panel of prostate 
cancer cells (see Chapter 3, Section 3.3.1). Based on the gene expression 
profiles, LNCaP and C4-2B cells were selected for STEAP2 knockout, as their 
high STEAP2 gene expression levels were mirrored when evaluating STEAP2 
protein levels, which for LNCaP, correlates with observations reported in the 
scientific literature (Figure 5.4B; Whiteland et al., 2014).  
 
CRISPR/Cas9 knockout efficiency is primarily determined by protein 
expression, as opposed to gene expression, as clones may display a strong 
attenuation of mRNA expression due to nonsense-mediated decay, but not 
complete ablation of protein expression (Ramlee et al., 2015; Tuladhar et al., 
2019). In this study, STEAP2 was successfully knocked out of all expanded 
colonies in both cell lines (Figure 5.5), and therefore all six knockout colonies 
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from each cell line were carried forward for subsequent cell viability assays. 
Successful targeted knockdown of STEAP2 by lentiviral particles created in 
HEK293T cells was achieved as once viral particles with specific tropism were 
created, they were able to infect the target cells in the same way as a native 
viral particle would, allowing for the persistent presence of CRISPR/Cas9 
components and ultimately a long-term knockout of STEAP2 (Lino et al., 
2018). One of the main challenges of CRISPR/Cas9 technology is the 
generation of stable knockout clones (Lino et al., 2018).  
 
In order to ensure that the results of any subsequent assays were due to 
STEAP2 knockout and not reduced cell viability, it was essential that knockout 
colonies with no significant changes in viability when compared to wild-type 
cells were selected. Based on the alamarBlue viability assay results (Figure 
5.6) and the morphology of parental cells (see Appendix 3, Figures A3.2 & 
3), STEAP2 knockout plasmid #1 was found to be successful in generating 
STEAP2 knockout positive cells which displayed similar behaviour patterns 
and morphological profiles to their wild-type counterparts. STEAP2 knockout 
plasmid #1 encoded for the complete STEAP2 protein, whereas plasmid #2 
encoded for a STEAP2 transcript variant (see Section 5.2.3.1). Plasmid #1 is 
part of a collection of full-length cDNA clones generated by the Mammalian 
Gene Collection project, whereas plasmid #2 encodes the longest STEAP2 
isoform (RefSeq, 2008). Therefore plasmid #1 was chosen for targeted 
knockout of the complete, full length STEAP2 protein. CRISPR/Cas9 targeted 
STEAP2 knockout significantly reduced cell viability in half of the LNCaPKO cell 
colonies (Figure 5.6A), and all of the C4-2BKO cell colonies. Generating stable 
knockout colonies remains to be a challenge in CRISPR/Cas9 engineering, 
and as such the increases observed in the viability of LNCaPKO colonies 
P1_C1_L, P1_C3_L and P2_C2_L to similar levels to LNCaPWT may suggest 
these colonies have not sustained their STEAP2 knockout, and as such 
STEAP2 expression may have returned to basal levels (Giuliano et al., 2019; 
Lino et al., 2018). Previous studies show that STEAP2 knockdown via targeted 
siRNA increases the number of apoptotic events in prostate cancer cells, 
which may account for the decreases in viability observed here (Wang et al., 
2010). In LNCaP cells in which STEAP2 expression had been knocked down, 
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Wang et al., found that the CDKI p21 was upregulated, which was also found 
to be the case when cells were grown as xenografts, suggesting STEAP2 
plays a role in the negative regulation of the cell cycle during G1 and S phase 
(Bertoli et al., 2013; Wang et al., 2010). As the pathways by which STEAP2 
influence cell viability remain unclear, future work would be required to explore 
this in more detail.  
5.4.2 The impact of CRISPR/Cas9 knockout of STEAP2 on 
aggressive prostate cancer traits 
STEAP2 has previously been found to be involved in cellular proliferation in 
prostate cancer cells (Gomes et al., 2012; Wang et al., 2010). Here, 
CRISPR/Cas9 targeted STEAP2 knockout significantly reduced proliferation 
of LNCaPKO and C4-2BKO, which was sustained over a 3- and 5- day period, 
respectively (Figure 5.7). The role of STEAP2 in cell proliferation has 
previously been explored by Wang et al., who found that when STEAP2 was 
overexpressed in COS-7 normal monkey kidney fibroblast cells, an increase 
in cell proliferation rate occurred (Wang et al., 2010). In the same study, 
STEAP2 was ectopically expressed in DU145 prostate cancer cells, which 
resulted in ERK activation in response to EGF, the expression of which was 
increased in response to STEAP2 (Wang et al., 2010). Once ERK becomes 
phosphorylated, a variety of transcription factors become activated upon the 
translocation of ERK into the nucleus, including AP-1, which has canonical 
sequences with MMPs -1, -3, -7, -9, -11 and -13 (Dhillon et al., 2007; Gong et 
al., 2014). The role of STEAP2 in cellular proliferation has previously been 
found to be co-ordinated through the activation of the ERK pathway, which 
when activated by STEAP2 induces this partial cell cycle arrest in the G0-G1 
phase of the cell cycle in cancer cells, and in turn increases cell proliferation 
and tumour progression (Gomes et al., 2012; Wang et al., 2010).  
 
When the expression of STEAP2 has been knocked down by the presence of 
STEAP2 siRNA, the proliferation of LNCaP cells was found to significantly 
decrease, yet no changes in cellular morphology were observed (Wang et al., 
2010). Studies into the changes in the distribution of the cell cycle of LNCaP 
cells transfected with STEAP2 siRNA found that there was a significant 
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increase in the percentage of cells in G1 phase, which corroborated with a 
decrease in cells in the S phase, suggesting that loss of STEAP2 results in a 
partial cell cycle arrest in G0-G1 (Wang et al., 2010). When monitoring the 
proliferation of cells transfected with STEAP2 siRNA using the proliferative 
marker Ki67, Wang et al., found that Ki67 was significantly downregulated by 
day 4 in LNCaP cells transfected with STEAP2 siRNA, further confirming the 
proliferative influence of STEAP2 expression. Therefore, in this Chapter, an 
absence of STEAP2 expression may have led to a decrease in cell 
proliferation as the ERK pathway would not become activated by STEAP2, 
and in turn the partial arrest at G0-G1 observed in previous studies may have 
occurred (Wang et al., 2010). The results in this Chapter further confirm that 
STEAP2 inhibition significantly reduces cell proliferation, as demonstrated by 
previous studies (Burnell et al., 2018; Wang et al., 2010). This reduction in 
proliferation may be the result of an inability to progress through G0-G1 phase 
of the cell cycle (Wang et al., 2010). However, as the exact mechanisms by 
which STEAP2 knockout reduces proliferation were not assessed, future work 
should involve the use of flow cytometry to further understand the impact this 
has on the distribution of the cell cycle in comparison to wild-type cells.   
 
An essential mechanism in the progression of prostate cancer is the ability of 
cells to migrate to distant sites to form metastases (Rycaj & Tang, 2017). 
STEAP2 has previously been hypothesised to be involved in promoting cancer 
cell migration, thus enhancing prostate cancer progression (Burnell et al., 
2018; Whiteland et al., 2014). In this Chapter the hypothesises posed was that 
complete gene knockout of STEAP2 from prostate cancer cells using 
CRISPR/Cas9 technology will significantly inhibit cancer cell migration. 
Indeed, the data generated through use of the proliferation assay 
demonstrated that STEAP2 knockout significantly reduced proliferation in both 
cell lines (Figure 5.7). Furthermore, it was found that migration of STEAP2 
knockout cells was impaired in comparison to their wild-type counterparts 
(Figure 5.8). These results confirm those of previous studies which indicate 
that STEAP2 plays a role in the migration of prostate cancer cells (Burnell et 
al., 2018; Whiteland et al., 2014).  
 215 
In the first study to demonstrate the potential influence of STEAP2 in non-
cancerous cells, the normal prostate cancer epithelial cell line PNT2 was 
transfected to overexpress STEAP2, which induced cell migration at a faster 
rate than wild-type cells (Whiteland et al., 2014). siRNA technology has 
previously been utilised to knock-down STEAP2 in the prostate cancer cell line 
PC3, which significantly decreased the cell migratory potential (Burnell et al., 
2018). As the primary function of STEAP2 is to act as a receptor for iron and 
copper uptake, when absent a lack of iron and copper metabolism may occur, 
resulting in the suppression of intracellular pathways such as ERK/MAPK 
(Gomes et al., 2012; Grunewald et al., 2012; Knutson, 2007). As previously 
suggested, the lack of activation of the ERK pathway due to STEAP2 knockout 
may also inhibit the migratory potential of LNCaPKO and C4-2BKO cells as 
observed in the present study (Burnell et al., 2018; Wang et al., 2010). 
 
One of the principal ways of reducing cancer progression is to inhibit cell 
motility, and subsequently reduce cell migration and invasion (Palmer et al., 
2011). When downregulated, another member of the STEAP family, STEAP4, 
has been found to significantly increase ROS via iron reductase activity (Jin et 
al., 2015; Scarl et al., 2017). Whilst ROS increases are often associated with 
an increase in mutations and disease progression, the induction of excessive 
ROS activity in prostate cancer cells has been found to reduce tumour cell 
motility and metastasis through the inhibition of epithelial-mesenchymal 
transitions (Das et al., 2014; Lim et al., 2005). Apoptosis was also found to 
increase in response to elevated ROS, as a result of caspase-3 and -9 
activation and cytochrome-c release (Das et al., 2014). Similar to STEAP4, 
STEAP2 also contains a N-terminal oxidoreductase domain with a 
nicotinamide adenine di-nucleotide phosphate (NADPH) binding motif, which 
can serve as an electron donor for transmembrane electron transport of iron 
and copper (Grunewald et al., 2012; Knutson, 2007; Scarl et al., 2017). An 
increase in iron uptake has been found to increase ROS and promote 
carcinogenesis, suggesting targeting iron metabolism may be a potential 
therapeutic approach in the treatment of some cancers (Bystrom et al., 2014; 
Jung et al., 2019). Therefore, it could be suggested that the decrease in 
migration observed in this chapter could be the result of STEAP2 knockout 
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inducing an increase in ROS activity through impaired iron reductase activity. 
However, as this connection between ROS and STEAP2 remains unclear, 
further studies would be warranted to explore this theory further which may 
include the use of fluorescent microscopy to determine the intercellular 
localisation of ROS in STEAP2-knockout cells compared to their wild-type 
counterparts (Das et al., 2014). It would also be of interest to assess mRNA 
iron levels using markers such as Tfr1 in STEAP2-knockout and wild-type cells 
alongside monitoring ROS to suggest a mechanism underlying any changes 
in ROS activity (Jung et al., 2019).  
 
Similar to migratory capacity, the invasion potential of PC3 cells has been 
found to substantially decrease following the gene knock-down of STEAP2 
using siRNA technology (Burnell et al., 2018). In addition, when the normal 
prostate epithelial cell lines PNT2 has previously been transfected with a 
STEAP2 plasmid in order to overexpress the gene, cells gained the ability to 
invade through the extracellular matrix (Whiteland et al., 2014). Furthermore, 
work within the group has demonstrated that STEAP2 is involved in promoting 
prostate cancer invasion through treatment with mono- and polyclonal anti-
STEAP2 antibodies (Nguyen-Chi et al., 2020). The data presented in this 
chapter indicates that STEAP2 may play a substantial role in the invasive 
potential of LNCaP and C4-2B cells, which was significantly reduced in both 
cell lines by 97.0% and 95.9% respectively (Figures 5.9E). 
 
An important step in the progression of prostate cancer is the ability to degrade 
the ECM, for which MMPs are often required (Gialeli et al., 2011). Whilst the 
exact mechanism of how STEAP2 is involved in promoting cancer cell invasion 
is not yet fully understood, previous studies have found that siRNA gene 
knockdown of STEAP2 significantly reduces the expression of MMPs needed 
to degrade the ECM (Burnell et al., 2018). In particular, MMPs-3, - 7, -10 and 
-13 have been identified as downstream targets of STEAP2 associated with 
driving invasion (Burnell et al., 2018). Increases in MMP expression in prostate 
cancer have been suggested to promote cancer progression by the NFkB 
signalling pathway (Chen et al., 2013; Nguyen et al., 2014). The NFkB 
 217 
signalling pathway has been found to contribute to an overexpression of the 
receptor activator of nuclear factor kappa- β (RANK) ligand (RANKL) (Xing & 
Boyce, 2005). RANKL is associated with prostate cancer invasion and 
progression to form bone metastases (Wright et al., 2009). It would therefore 
be interesting to culture the STEAP2 knockout cells generated in this chapter 
as 3D spheroid models, as developed in Chapter 3, to assess the role of 
STEAP2 on prostate cancer-bone stromal cell interactions.  
 
The reduction in invasive potential of STEAP2 knockout cells observed in this 
study could be the result of a decrease in MMP expression by the NFkB 
signalling pathway, however further work would be required to determine how 
STEAP2 knockout alters this pathway. Together, the data presented in this 
chapter provides evidence that STEAP2 plays an important role in the 
progression of androgen-sensitive prostate cancer cells as the ability of both 
LNCaP and C4-2B to proliferate, migrate and invade was significantly 
decreased when STEAP2 expression was knocked out. Whilst the key 
mechanism behind how STEAP2 knockout inhibits cell migration remains 
unknown, the data presented here implies that STEAP2 could provide a novel 
therapeutic target for inhibiting prostate cancer migration and metastasis.  
5.4.3 The impact of CRISPR/Cas9 knockout of STEAP2 on the 
expression of AR and androgen-regulated genes in androgen-
sensitive prostate cancer cells 
Androgen plays a vital role in the regulation of normal development of the 
prostate gland (Heinlein & Chang, 2004; Davey & Grossman, 2016; Rokhlin et 
al., 2005). AR has been widely studied in association with aggressive prostate 
cancer traits, particularly in LNCaP cells and their derivatives, which are 
androgen-sensitive prostate cancer cell lines (Gonen-Korkmaz et al., 2014). 
To date, previous studies have determined that STEAP2 expression may be 
regulated by AR, yet the mechanisms behind this remain unclear (Gomes et 
al., 2012). Following the results of Chapter 4, Section 4.3.3 which found that 
AR gene expression increased in response to STEAP2 polyclonal antibody 
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treatment, this chapter found that the expression of AR was significantly 
increased in C4-2BKO cells, but not LNCaPKO cells (Table 5.5).  
 
As suggested in Section 5.4.2.1, the decrease in proliferation observed in 
LNCaPKO and C4-2BKO cells may be the result of a lack of EGF-induced ERK 
pathway activation (Wang et al., 2010). The transcriptional activity of AR has 
also been known to be activated by EGF, through increasing the expression 
of AR co-activators in prostate cancer cells (Gregory et al., 2004; Kaarbo et 
al., 2007).  Although changes in AR levels in LNCaPKO cells did not reach 
significance, for a lack of EGF activation by STEAP2 to influence AR activity, 
AR expression levels would be expected to decrease in response to STEAP2 
knockout. Therefore, to further explore the role of STEAP2 in the activation of 
the ERK pathway, it would be suggested to assess EGF expression levels in 
STEAP2 knockout cells.   
 
AR expression may be elevated in C4-2BKO cells as a result of p21 
upregulation, as p21 has been found to form a complex with cyclin D3, CDK4 
and caspase-2 (Migita et al., 2012). As previously noted, p21 has been 
reported to increase in response to STEAP2 knock down (Wang et al., 2010). 
Caspase-2, a pro-apoptotic protease, is localised to the Golgi apparatus, 
mitochondria, cytoplasm and nucleus, and is a direct target of AR in androgen-
sensitive prostate cancer cells (Migita et al., 2012; Rokhlin et al., 2005). 
Despite the significant increase in AR expression exhibited by C4-2BKO cells, 
cell proliferation, migration and invasion were substantially reduced, indicating 
that this increase in AR expression does not induce a more invasive phenotype 
in C4-2BKO cells. An increase in caspase-2 in STEAP2 knockout cells could 
provide a mechanism for both the observed decrease in cell viability yet 
concurrent increase in AR expression, and warrants further studies to 
determine caspase-2 and p21 expression (Migita et al., 2012; Wang et al., 
2010).  
 
To further explore the increase in AR expression exhibited by C4-2BKO cells, 
additional work was carried out to assess the levels of four key genes known 
to influence AR expression; PSA, FKBP5, TMPRSS2 and GPRC6A (Velasco 
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et al., 2004; Wright et al., 2003; Zarif & Miranti, 2016). Following the results of 
Chapter 4, Section 4.3.4 which found that the gene expression of all four 
genes increased in response to STEAP2 polyclonal antibody treatment, this 
chapter found that the expression of PSA and FKBP5 was significantly 
increased in LNCaPKO cells, but not C4-2BKO cells (Table 5.5), yet TMPRSS2 
expression was significantly increased in both cell lines (Table 5.5). GPRC6A 
expression was undetected in both STEAP2 knockout cell lines (Table 5.5). 
 
PSA is known to be regulated by AR at a transcriptional level, and previous 
studies have found PSA to become localised to the nucleus in response to 
androgen stimulation (Kaarbo et al., 2007; Migita et al., 2012; Saxena et al., 
2012). Like STEAP2, PSA is also localised to the Golgi apparatus (Saxena et 
al., 2012). In this study, PSA was found to be significantly expressed in 
LNCaPKO cells, yet no expression was determined in C4-2BKO cells, despite 
the latter displaying a significant increase in AR expression (Table 5.5). In 
androgen-sensitive cells, inhibition of mTOR has also been noted to increase 
transcriptional activation of AR and subsequently increase the expression of 
AR target genes such as PSA, whilst inhibiting total AR levels through the 
PI3K/Akt pathway (Cinar et al., 2005; Kaarbo et al., 2007). PSA has also been 
found to be overexpressed through the induction of IL-6 via activation of the 
EGF signalling pathway, which may account for the increase in PSA 
expression observed in LNCaPKO cells (Zhu & Kyprianou, 2008). Activation of 
the EGF signalling pathway may also increase ERK activation, which under 
androgen-independent conditions has been found to contribute to an increase 
in PSA levels (Franco et al., 2003). MAPK and AR signalling crosstalk has 
been implicated in IL-6 induced transcriptional activity of AR in LNCaP cells, 
as previous studies have found PSA expression to decrease when MAPK 
inhibition repressed the IL-6 stimulated expression of PSA (Lin et al., 2001).  
 
FKBP5 functions as a steroid receptor and is involved in the modulation of AR 
function and signalling, through the formation of a complex with the heat shock 
proteins Hsp90/Hsp70 (Li et al., 2011; Ni et al., 2010). Previous studies have 
found FKBP5 expression to be induced through the activation of AR, and the 
protein has been found to physically interact with AR in LNCaP cells 
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(Ratajczak et al., 2003; Febbo et al., 2005; Velasco et al., 2004). In this 
chapter, FKBP5 was found to be significantly expressed in LNCaPKO cells, yet 
AR expression was unchanged (Table 5.5). FKBP5 has been found to be 
constitutively overexpressed in LNCaP cells which also have increased levels 
of endogenous PSA (Febbo et al., 2005). Unlike PSA, the FKBP5 locus is 
more complex and lacks a consensus AR binding site in its proximal locator, 
and AR binding has been localised to an enhancer in the fifth intron of the 
FKBP5 gene (Kang et al., 2004; Magee et al., 2006). The transcriptional 
cofactor cAMP response element-binding protein (CBP) has been found to 
interact with AR when inducing PSA upregulation yet promotes FKBP5 
overexpression through the regulation of histone acetylation, which remains 
unaffected by androgens (Magee et al., 2006). Therefore, the increase in 
FKBP5 expression observed in LNCaPKO cells could be a result of an indirect 
communication between CBP and the proximal FKBP5 promoter region, 
independent to AR expression (Magee et al., 2006). Further studies should 
explore whether an increase in the FKBP5 intron-5 enhancer is observed in 
STEAP2 knockout cells.  
 
TMPRSS2 has previously been characterised as an androgen-regulated gene 
(Wright et al., 2003; Yu et al., 2010). In this chapter, TMPRSS2 expression 
was found to increase in both LNCaPKO and C4-2BKO cells, with an 
exceptionally high increase observed in C4-2BKO cells (Table 5.5). Gene 
fusions commonly occur in prostate cancers, with TMPRSS2-ERG one of the 
most widely studied (Navaei et al., 2017). Overexpression of TMPRSS2 has 
been known to increase gene fusion with ERG, resulting in prostate cancer 
development, consistent with the development of an invasive prostate cancer 
phenotype (Tomlins et al., 2008). Previous studies have found that 
overexpression of AR can initiate TMPRSS2-ERG gene fusion by inducing the 
proximity of TMPRSS2 and ERG genomic loci, and in turn promoting a more 
invasive prostate cancer phenotype (Hermans et al., 2006; Zong et al., 2009). 
In prostate cancer cells where FKBP5 is also overexpressed, as observed 
here in LNCaPKO cells, TMPRSS2-ERG gene fusion is also present (Tomlins 
et al., 2005; Yu et al., 2010). However, data here suggests that STEAP2 
knockout reduces the invasive potential of both LNCaP and C4-2B cells, 
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despite a notable increase in TMPRSS2 expression. As TMPRSS2 is 
commonly known to undergo fusion to ERG, future work may involve further 
characterisation of this gene fusion in STEAP2 knockout cells in order to 
provide a potential mechanism for STEAP2 in the progression of prostate 
cancer.   
 
GPRC6A is a nutrient sensing receptor that has been found to regulate 
prostate cancer growth and progression (Liu et al., 2016; Pi & Quarles, 2012). 
GPRC6A has been found to indirectly mediate the effects of AR in prostate 
cancer progression (Zarif & Miranti, 2016). Here, GPRC6A expression was not 
detected by qRT-PCR in either LNCaPKO or C4-2BKO cells, despite previously 
being upregulated in both cell lines in response to STEAP2 polyclonal antibody 
treatment (see Chapter 4; Section 4.3.4). In previous studies, overexpression 
of GPRC6A has been found to increase cell proliferation, whilst its knockdown 
has been reported to inhibit migration and invasion of prostate cancer cells 
(Liu et al., 2016; Pi & Quarles, 2012; Ye et al., 2017). Therefore, the lack of 
GPRC6A expression noted here may provide a mechanism for the observed 
reduction in aggressive prostate cancer traits, as GPRC6A knockdown has 
also been found to inhibit activation of ERK signalling, which, could provide a 
mechanism for the reduction in cell proliferation in response to STEAP2 
knockout (Wang et al., 2010; Ye et al., 2017). As GPRC6A is the only currently 
known receptor for osteocalcin, in future it would be interesting to monitor the 
expression levels of GPRC6A in STEAP2 knockout cells grown as 3D co-
cultured models, as generated in Chapter 3, to determine whether GPRC6A 
is involved in suppressing prostate cancer-bone stromal cell interactions (Suva 
et al., 2011; Pi et al., 2016; Ye et al., 2017). 
 
MMPs -3, -7 and -10 have been reported to increase when STEAP2 is 
overexpressed (Burnell et al., 2018). Whilst these increases in MMP 
expression in prostate cancer have been suggested to promote cancer 
progression by the NFkB signalling pathway, inhibition of the NFkB pathway 
is also known to suppress AR transcription, indicating crosstalk mechanisms 
between AR, MMPs and NFkB (Chen et al., 2013; Harada et al., 2001; Nguyen 
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et al., 2014). This crosstalk between AR and NFkB signalling is thought to be 
the result of TNF-a binding to its cell surface receptor (TNFR), which results 
in the translocation of NFkB to the nucleus (Chopra et al., 2004; Rokhlin et al., 
2005). In LNCaP cells, long-term exposure to TNF-a resulted in androgen 
hypersensitivity, yet no overall change in levels of total AR, as observed here 
in LNCaPKO cells (Harada et al., 2001). STEAP2 levels have been found to 
significantly increase by TNF-a induction in response to NFkB silencing, 
suggesting NFkB may provide a targeted pathway in the inhibition of prostate 
cancer progression via STEAP2 knockout (Gonen-Korkmaz et al., 2014). 
 
Upregulation of PSA, FKBP5 and TMPRSS2 in LNCaPKO cells despite no 
significant increase in AR levels may suggest a potential AR bypass pathway 
and pro-survival mechanism for STEAP2 knockout cells. It has previously 
been found that certain growth factors are able to crosstalk with the AR 
signalling pathway, resulting in an increase in the expression of AR target 
genes in the absence of androgens (Marques et al., 2010; Zhu et al., 2008). 
One of these is the aforementioned IL-6, which has also been found to 
promote androgen synthesis in prostate cancer cells through enhancing the 
transcription of aldo-keto reductase family-1 member-C3 (AKR1C3) which is 
involved in androgen biosynthesis (Chun et al., 2009). IL-6 has been found to 
play a vital role in the transition of hormone-dependent prostate cancers to 
castrate resistance, notably through the activation of AR (Nguyen et al., 2013). 
IL-6 is not naturally secreted by hormone-sensitive prostate cancer cell lines, 
such as LNCaP and C4-2B, and when exogenously expressed was found to 
inhibit growth in these cell lines, as observed in this Chapter (Nguyen et al., 
2013; Okamoto et al., 1997). IL-6 therefore poses a potential mechanism for 
the overexpression of androgen regulated genes as observed in LNCaPKO 
cells where levels of androgen itself remains unchanged, and therefore 
warrants further studies in the future. 
 
Future studies should focus on exploring the mechanism underlying the role 
of STEAP2 knockout in the increase in PSA, FKBP5 and TMPRSS2 
expression yet unchanged AR expression, that were observed in LNCaPKO 
 223 
cells. In prostate cancer cells with low levels of AR expression, cells have been 
found to carry the T877A AR mutation, which allows for a bypass of the AR 
signalling pathway, yet cells may continue to overexpress AR-regulated 
genes, which may account for the increase in PSA, FKBP5 and TMPRSS2 
levels exhibited by LNCaPKO cells (Marques et al., 2010). It may also be of 
interest to explore the effects of inhibitors of androgen and its target genes on 
STEAP2 knockout cell survival, to determine whether STEAP2 has the 
























The data generated in this chapter provides strong evidence that STEAP2 
could potentially be a viable therapeutic target in the treatment of prostate 
cancer for future clinical translation. CRISPR/Cas9 targeted STEAP2 
knockout resulted in a promising decrease in several aggressive prostate 
cancer traits, suppressing cell proliferation, migration and invasion. Gene 
expression analysis of AR and its regulated genes found that STEAP2 
knockout initiates an increase in expression of key genes in the progression 
of prostate cancer, despite STEAP2 knockout inhibiting cell proliferation, 
migration and invasion; however, the mechanisms behind this remain unclear. 
Therefore, targeting STEAP2 in androgen-sensitive prostate cancer cells may 
warrant further investigations into combination therapy along with pre-existing 
androgen therapy approaches. The involvement of androgens in STEAP2 
expression also warrants further studies, such as how STEAP2 levels are 
affected when androgen is depleted. Overall, the data presented in this 
chapter provides further evidence that STEAP2 presents a novel therapeutic 






















The impact of androgen depletion on aggressive 
prostate cancer traits and androgen-regulated genes 
 
6.1 Introduction 
Prostate cancer is largely an androgen regulated disease, and therefore many 
studies have explored how expression of AR is linked to disease progression 
(see Chapter 1, Section 1.8; Gonen-Korkmaz et al., 2014; Myung et al., 2013; 
Tanner et al., 2011). Prostate cancer cell lines are often characterised as being 
androgen-sensitive, which applies to LNCaP and C4-2B cells, or androgen-
independent, including PC3 and DU145 cells (Chlenski et al., 2001; Guo et al., 
2006; Traish et al., 2009).  
Androgen ablation remains the most common primary therapy in men with 
both locally advanced and metastatic prostate cancer (Fong et al., 2014; 
Harris et al., 2009). However, approximately 20% of men display treatment 
resistance due to the development of androgen-independent clones which 
promptly become fatal due to an increased invasive potential and more rapid 
disease progression (Crawford et al., 2017; Nyquist et al., 2013). Clinically, 
once tumours become resistant to ADT, CRPC develops, the drivers of which 
are currently undetermined (Crawford et al., 2017; Qin et al., 2014). One of 
the major challenges in these resistant prostate cancers is understanding the 
molecular pathways that are androgen-regulated, and determining specific 
biomarkers linked to castrate resistance (Pfeil et al., 2004; Karantanos et al., 
2015).  
AR, a member of the steroid hormone receptor family, binds to specific DNA 
sequences and in doing so mediates the physiological effects of androgens, 
producing AREs (Davey & Grossman, 2016; Heinlein & Chang, 2004). AREs 
are involved in regulating the transcription of androgen-responsive genes 
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(Heinlein & Chang, 2004). Prostate growth and function are modulated by 
androgens through the metabolism of testosterone into 5-alpha-
dihydrotestosterone (5α-DHT) by the enzyme 5α reductase (Heinlein & 
Chang, 2004; Traish et al., 2009). Interactions between AREs and the AR 
hormone complex result in molecular activation and transformation of the 
ligand-bound AR complex (see Chapter 1, Section 1.8, Figure 1.6; Davey & 
Grossman, 2016; Heinlein & Chang, 2004; Traish et al., 2009). 
AR is also known to affect the expression of a variety of genes also linked to 
the progression of prostate cancer, including but not limited to PSA, FKBP5, 
TMPRSS2, and GPRC6A (Velasco et al., 2004; Wright et al., 2003; Zarif & 
Miranti, 2016). Knowledge of a link between STEAP2 and androgen 
dependence is currently limited, and as such this present chapter will explore 
the effect of androgen depletion on STEAP2 expression, and the expression 
of the androgen-regulated genes PSA, FKBP5, GPRC6A and TMPRSS2 
(Gomes et al., 2012). 
Standard culture conditions of prostate cancer cell lines use culture medium 
that is supplemented with FBS, which contains testosterone and provides the 
cells with androgens (Cao et al., 2009; Fiandalo et al., 2018; Sikora et al., 
2016). To deprive cells of androgens, media supplemented with androgen-free 
serum, such as that which has been stripped of androgens using charcoal to 
create charcoal-stripped serum (CSS), is often used (Fiandalo et al., 2018; 
Sedelaar et al., 2009). One of the drawbacks of using CSS is that composition 
can vary batch-to-batch, which can subsequently impact upon the 
reproducibility of experiments (Sikora et al., 2016). SFM may therefore provide 
an alternative to CSS supplemented media, yet studies have shown no 
variation between the viability and responsiveness of cells grown in SFM 
compared to cells grown in CSS (Fiandalo et al., 2018). Charcoal-stripped 
dextran-treated (CDT) FBS has also been used to deprive cells of androgens, 
however, has been reported to significantly alter the behaviour, particularly the 
adherence, of prostate cancer cells and subsequently produce erroneous 
results (Song & Khera et al., 2014). CDT is best used in experiments involving 
the study of AR ligands, whereas CSS provides the optimal conditions for 
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assessing cell behavioural patterns in response to androgen depletion 
(Fiandalo et al., 2018; Song & Khera et al., 2014). Androgen inhibition can also 
be targeted with drugs, the most commonly used being the hormone 
therapeutic agent enzalutamide which blocks translocation of AR to the 
nucleus by competitively binding with the testosterone / DHT receptor on AR 
(Scher et al., 2012). In this chapter, androgen depletion was achieved through 
cell culture in CSS-supplemented phenol-red free medium to allow gene 
expression and functional cellular changes to be assessed.  
 
Given that a link between STEAP2 and AR-dependent growth has not 
previously been explored, the aims of this Chapter were to identify if androgen 
depletion by growth in CSS could reduce aggressive prostate cancer traits, 
and in turn effect the expression of genes known to impact upon prostate 
cancer progression. To achieve this aim, the Chapter was therefore divided 
into the following objectives: 
1. To evaluate the impact of androgen depletion on cell viability, 
proliferation, migration and invasion in androgen-sensitive and 
androgen-independent prostate cancer cells 
2. To evaluate the impact of androgen depletion on the expression of 
STEAP2 and the androgen regulated genes PSA, FKBP5, TMPRSS2 
and GPRC6A in androgen-sensitive and androgen-independent 
prostate cancer cells. 
3. To evaluate the impact of androgen depletion on cell viability and 









6.2 Materials and methods 
6.2.1 Cell culture 
The prostate cancer cell lines PC3, LNCaP and C4-2B used in this chapter 
are described in Chapter 2, Section 2.2.1, 2.2.2 & 2.7.4 and were routinely 
cultured and maintained as described in Chapter 2, Section 2.2.7.1. STEAP2-
knockout LNCaP and C4-2B cells were generated as described in Chapter 5, 
Section 5.2.3. LNCaPKO and C4-2BKO cells were maintained in puromycin-
supplemented RPMI and DMEM media respectively, as described in Chapter 
5, Section 5.2.4.8. 
6.2.2 Androgen depleted conditions  
To strip cells of androgens and other growth hormones present in normal cell 
culture media, CSS (Sigma Aldrich, US, Cat. F6765) was used, as described 
in Chapter 2, Section 2.2.6. Phenol-red free RPMI-1640 (Life Technologies, 
UK, Cat. 31870025) was supplemented with 10% CSS, 1% L-glutamine and 
1% P/S for the growth of LNCaP cells. Phenol-red free DMEM (Life 
Technologies UK, Cat. 21063029) was supplemented with 10% CSS and 1% 
P/S for the growth of C4-2B cells. To achieve androgen depletion, cells were 
first thawed following cryopreservation (see Chapter 2, Section 2.2.1.5) and 
centrifuged at 270 g for 5 minutes using a bench-top centrifuge (VWR, Himac 
CT6E, UK). Cryopreservation media was discarded, and the cell pellet 
resuspended in cell line appropriate media supplemented with CSS. Cells 
were sub-cultured as normal following the supplier’s recommendations as 
detailed in Section 2.1.5 for a minimum of three passages before being used 




6.2.3 Assays to study the effect of androgen depletion on 
aggressive cancer traits 
 
6.2.3.1 Cell viability quantification  
Cell suspensions of desired cell numbers were prepared as described in 
Chapter 2, Section 2.2.7.2 and seeded in 100 µl culture media in 96-well 
tissue culture plates. Cells were cultured in either 10% FBS-supplemented 
media or 10% CSS-supplemented media as described in Section 6.2.2. Every 
24 h for 5 days, cell viability was assessed by the MTT assay as described in 
Chapter 2, Section 2.4.1. The alamarBlue assay was also used to assess cell 
viability as described in Chapter 2, Section 2.4.2 in the STEAP2-knockout 
cells generated in Chapter 5. The cell viability assay was performed in 
triplicate unless otherwise stated. 
 
6.2.3.2 Cell proliferation  
Cell suspensions of desired cell numbers were prepared as described in 
Chapter 2, Section 2.2.7.2 and seeded in 100 µl culture media in 96-well 
tissue culture plates. Cells were cultured in either 10% FBS-supplemented 
media or 10% CSS-supplemented media as described in Section 6.2.2. Every 
24 h, proliferation was assessed by the alamarBlue assay as described in 
Chapter 2, Section 2.5.1. Proliferation of cells grown in androgen-depleted 
media were compared to that of cells grown in androgen-positive conditions. 
The cell proliferation assay was conducted in triplicate unless otherwise 
stated. 
 
6.2.3.3 Cell migration assay 
Migration assays were carried out as described in Chapter 2, Section 2.9. 
After PC3, C4-2B and LNCaP cells had reached ~80% confluency, medium 
was replaced for 24 h with serum-free, phenol-red free RPMI-1640 (PC3 and 
LNCaP) or serum-free, phenol-red free DMEM (C4-2B) medium. Cells were 
trypsinised, resuspended and adjusted to a desired cell concentration, as 
described in Chapter 2, Section 2.2.7.2. One cell culture insert (IBIDI, 
Germany, Cat. 80209) was placed in the centre of a well of a 12-well plate, 
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and 70 µl cell suspension was added per chamber. Cells were left to adhere 
for 24 h in standard tissue culture conditions. Media and inserts were removed, 
and cells were washed with PBS to remove cell debris, before fresh media 
was applied, supplemented with either 10% FBS to represent AR-positive 
(+ve) or androgen replete conditions, or 10% CSS to represent AR-negative 
(-ve) conditions or androgen deplete conditions. The time taken to close the 
gap created was monitored using an inverted light microscope (AxioCam 
ERC55, Zeiss, Germany) every 24 h for 5 days. Media was replaced every 3 
days. The migration assay was conducted in triplicate unless otherwise stated.  
 
6.2.3.4 Invasion assay 
Invasion assays were carried out as described in Chapter 2, Section 2.10. To 
investigate the role androgen depletion plays in mediating invasive cell 
behaviour, prior to the addition of cells to the Matrigel coated Transwell insert, 
600 µl of media containing either 10% FBS (AR +ve) or 10% CSS (AR -ve) 
was added to the lower chamber. Cells were incubated for 48 h in standard 
cell culture conditions to allow for cell invasion to occur. Cell invasion was 
quantified through staining with crystal violet, as described in Chapter 2, 
Section 2.10. Invaded cells were visualised using a standard light microscope 
at 10x magnification (AxioCam ERC55, Zeiss, Germany Images were taken of 
different planes of each insert and the invasion assay was conducted in 
triplicate unless otherwise stated.  
 
6.2.4 Detection of STEAP2 gene and protein expression in 
androgen-depleted cells 
 
6.2.4.1 Detection of STEAP2 gene expression in androgen-depleted cells 
PC3, LNCaP and C4-2B cells were cultured to ~70% confluency in media 
supplemented with either 10% FBS (AR +ve conditions) or 10% CSS (AR -ve 
conditions). RNA was extracted, cDNA synthesised, and qRT-PCR performed 
as described in Chapter 2, Section 2.3. Cells were probed for the detection 
of STEAP2, with GAPDH as the housekeeping control, using the primers 
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detailed in Chapter 2, Section 2.3.3, Table 2.8. The results were 
subsequently analysed as described in Chapter 2, Section 2.3.4. 
 
6.2.4.2 Detection of STEAP2 protein expression in androgen-depleted 
cells 
 
6.2.4.2.1 Protein extraction and quantification 
Protein was extracted from PC3, LNCaP and C4-2B cells as described in 
Chapter 2, Section 2.8.1, following culture in media supplemented with either 
10% FBS (AR +ve conditions) or 10% CSS (AR -ve conditions). Protein 
quantification was carried out using a Bradford assay for protein quantification 
as described in Chapter 2, Section 2.8.2. 
 
6.2.4.2.2 Blocking and antibody incubations 
Western blotting for STEAP2 detection was conducted as described in 
Chapter 2, Section 2.8 and Chapter 5, Section 5.2.5.  
 
6.2.4.2.3 Protein detection analysis 
Images were acquired and analysed as described in Chapter 2, Section 
2.8.7.  
6.2.5 Detection of androgen-regulated genes in androgen-
depleted cells 
PC3, LNCaP and C4-2B cells were cultured to ~70% confluency in media 
supplemented with either 10% FBS (AR +ve conditions) or 10% CSS (AR -ve 
conditions). RNA was extracted, cDNA synthesised, and qRT-PCR performed 
as described in Chapter 2, Section 2.3. Cells were probed for the detection 
of the androgen-regulated genes; PSA, FKBP5, TMPRSS2 and GPRC6A, with 
GAPDH as the housekeeping control, using the primers detailed in Chapter 
2, Section 2.3.3, Table 2.8. The results were subsequently analysed as 
described in Chapter 2, Section 2.3.4. 
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6.2.6 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 8 for iOS. 
The one-way ANOVA post-hoc Dunnett test and an unpaired t-test were used, 
as detailed in each figure. Data was considered statistically significant when a 
p-value of < 0.05 (*), p-value < 0.01 (**) or a p-value of < 0.001 (***) or p-value 








The focus of this Chapter was to determine the effects of androgen-depletion 
on aggressive prostate cancer traits. This aim was addressed by evaluating 
the following properties of androgen-depleted PC3, LNCaP and C4-2B cells, 
in comparison to their androgen-replete counterparts; cell viability, 
proliferation, migration and invasion.  Following this, the next objective within 
this Chapter was to determine whether androgen-depletion influenced 
STEAP2 gene and protein expression in androgen-depleted PC3, LNCaP and 
C4-2B cells, in comparison to their androgen-replete counterparts, which was 
assessed through qRT-PCR and Western blots. Additionally, to determine 
whether androgen-depletion influenced the expression of the androgen-
associated genes PSA, FKBP5, TMPRSS2 and GPRC6A, their transcriptional 
levels were assessed by qRT-PCR analysis in PC3, LNCaP and C4-2B cells. 
Finally, cell viability and proliferation assays were used to determine whether 
androgen-depletion impacted STEAP2-knockout LNCaP and C4-2B cells.  
6.3.1 Androgen depletion reduces the viability of LNCaP and 
C4-2B cells over time 
To evaluate the effect of androgen depletion on cell viability over time, the 
MTT cell viability assay was used. MTT response was used to assess the 
metabolic activity of the cells, with MTT absorbance values proportionate to 
the number of viable cells present.  To determine the difference in the number 
of cells capable of metabolising MTT over time, MTT absorbance values were 
compared to those of cells on day 1 for each cell line and growth condition.  
 
The MTT assay revealed that the absorbance of androgen-sensitive prostate 
cancer cell lines LNCaP and C4-2B remained consistent over time when 
grown in CSS supplemented media (AR-), whilst that of their counterparts 
grown in FBS-supplemented media (AR+) significantly increased. On day 5, 
AR+ LNCaP cells showed a significant increase in MTT absorbance (+0.67 
nm, p < 0.0001; Figure 6.1B), whilst there was no significant difference in the 
MTT absorbance of AR- LNCaP cells (+0.247 nm; Figure 6.1B). AR+ C4-2B 
cells showed a significant increase in MTT absorbance (+0.728 nm, p < 
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0.0001; Figure 6.1C) on day 5, whilst the AR- C4-2B cells showed no 
significant change at this time point (-0.011 nm; Figure 6.1C). AR+ PC3 cells 
and AR- PC3 cells showed similar changes in viability over time as shown by 
an increase in MTT absorbance of +0.292 nm and +0.204 nm on day 5 
respectively (p < 0.001; Figure 6.1A). Based on these data, it can be 
suggested that growth under androgen depleted conditions reduces the 
capability of androgen-sensitive prostate cancer cell lines to metabolise MTT 
in comparison to growth under normal conditions. The MTT response of 
androgen-sensitive prostate cancer cell lines LNCaP and C4-2B was much 
more pronounced than that of the androgen-independent cell line PC3, 
suggesting that the availability of androgens in the growth medium significantly 
impacts upon the viability of cells sensitive to androgen.  
6.3.2 Androgen depletion reduces the proliferation of PC3, 
LNCaP and C4-2B cells over time 
To evaluate the effect of androgen depletion on the percentage of proliferating 
cells over time, the alamarBlue cell proliferation assay was used. To determine 
the difference in the percentage of proliferating cells over time, cells were 
normalised to cells on day 1 for each cell line and growth conditions. 
 
The alamarBlue cell proliferation assay revealed a significant increase in the 
percentage of proliferating cells all three cell lines; PC3, LNCaP and C4-2B 
over time when grown in FBS-supplemented media (AR+) and CSS-
supplemented media (AR-). On day 5, AR+ PC3 cells showed an increase in 
the percentage of proliferating cells (+64.8%, p < 0.0001; Figure 6.2A), whilst 
AR- PC3 cells showed a higher increase in the percentage of proliferating cells 
than their AR+ counterparts (+98.8%, p < 0.05; Figure 6.2A). Similarly, on day 
5, AR+ C4-2B cells showed an increase in the percentage of proliferating cells 
(+58.7%, p < 0.0001; Figure 6.2C), whilst their AR- counterparts showed a 
higher increase in the percentage of proliferating cells (+125.4%, p < 0.05; 
Figure 6.2C). In AR- LNCaP cells, the percentage of proliferating cells was 
also increased by day 5 (+101.3%, p < 0.0001; Figure 6.2B) yet was lower 
than their AR+ counterparts (+207.9%, p < 0.05; Figure 6.2B). Based on these 
data, it can be suggested that androgen depletion has little effect on the 
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proliferative capacity of prostate cancer cell lines over time when compared to 




Figure 6.1. Effect of growth in charcoal stripped FBS on MTT 
absorbance. PC3 (A), LNCaP (B) and C4-2B (C) prostate cancer cells were 
grown in either FBS-supplemented media (AR+) or CSS-supplemented media 
(AR-). Every 24 h, cell viability was assessed by MTT assay. An ANOVA post-
hoc Dunnett test was performed for statistical analysis comparing MTT 
absorbance on each day after seeding to cells on day 1. Error bars denote 
S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 0.001 (***), p-value < 





Figure 6.2. Effect of growth in charcoal stripped FBS on cell proliferation. 
PC3 (A), LNCaP (B) and C4-2B (C) prostate cancer cells were grown in either 
FBS-supplemented media (AR+) or CSS-supplemented media (AR-). Every 
24 h, cell proliferation was assessed by alamarBlue assay. An ANOVA post-
hoc Dunnett test was performed for statistical analysis comparing the 
proliferation rate of cells each day after seeding with that of cells on day 1. 
Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 
0.001 (***), p-value < 0.0001 (****) (N = 3).
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6.3.3 Androgen depletion inhibits cell migration in PC3, LNCaP 
and C4-2B prostate cancer cells 
To further evaluate the potential of androgen depletion on reducing aggressive 
characteristics of PC3, LNCaP and C4-2B cells, the cell migration assay was 
carried out. To do so, cells were cultured in separate chambers of a silicone 
tissue culture plate insert. The insert was removed after 24 h and cells were 
imaged every 24 h for 5 days.  
 
In all three cell lines, the wound gap was completely closed in cells grown in 
FBS-supplemented media (AR+) by day 5 (Figure 6.3A, 6.3C & 6.3E). 
Androgen-depletion through growth in CSS-supplemented media (AR-) had 
completely inhibited migration of LNCaP and C4-2B cells as the wound gap 
remained fully open by day 5 (Figure 6.3D & 6.3F). Cell migration was 
somewhat inhibited in PC3 cells as shown by the partial closing of the wound 
gap by day 5 (Figure 6.3B). These data suggest that androgen-depletion 
leads to a complete inhibition of the migratory capacity of the androgen-
sensitive prostate cancer cell lines LNCaP and C4-2B, and partially inhibits 
the migratory capacity of androgen-independent PC3 cells (Figure 6.3; where 
representative images are shown; additional images from the second replicate 













Figure 6.3. Androgen depletion by charcoal stripped FBS decreases the 
migratory potential of PC3, LNCaP and C4-2B cells. Time points at which 
the images were taken: 0 days, 3 days and 5 days. PC3 (A), LNCaP (C) and 
C4-2B (E) cells cultured in FBS-supplemented media (AR+). Androgen 
depleted PC3 (B), LNCaP (D) and C4-2B (F) cells were cultured in CSS-
supplemented media (AR-). Images were acquired using an inverted light 
microscope with a 10x objective (AxioCam ERC55, Zeiss, Germany). Scale 
bar = 50 µm. (Illustrated are representative images; the experiment was 
however conducted in triplicate with biological replicates, N = 3).  
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6.3.4 Androgen depletion reduces cell invasion in PC3, LNCaP 
and C4-2B prostate cancer cells 
The cell invasion assay was performed to evaluate whether androgen 
depletion by growth of cells in CSS had an effect on inhibiting prostate cancer 
cell invasion. To do so, the bottom of a culture plate-insert was coated with 
Matrigel (as per manufacturer’s instructions), and to stimulate the ability of 
cancer cells to invade through this ECM, FBS and CSS served as 
chemoattractants. Cells were grown in the top layer of the insert, and as such 
only those with invasive potential were capable of crossing the Matrigel barrier.  
 
The results illustrated in Figure 6.4 (where representative images are shown; 
additional images from the second replicate can be found in Appendix 4, 
Figure A4.2). demonstrate that the invasive potential of LNCaP and C4-2B 
cells is significantly inhibited when cultured in androgen depleted conditions. 
When compared to cells grown in FBS-supplemented media, 35.4% of 
androgen depleted PC3 cells invaded through the ECM (p < 0.01; Figure 
6.4G). In androgen-sensitive cells, invasion was lower with 18.9% of LNCaP 
cells and 7.4% of C4-2B cells invading through the ECM (p < 0.001; Figure 
6.4G). These data, along with the results presented in Sections 6.3.1 & 6.3.3, 
suggest that androgen depletion substantially reduces aggressive cancer 










Figure 6.4. Androgen depletion reduces the invasive potential of PC3, 
LNCaP and C4-2B cells. Images of stained cells were taken to give a visual 
representation of invasion. PC3 (A), LNCaP (C) and C4-2B (E) cells cultured 
in FBS-supplemented media (AR+). Androgen depleted PC3 (B), LNCaP (D) 
and C4-2B (F) cells were cultured in CSS-supplemented media (AR-). Each 
panel represents A) PC3 AR+, B) PC3 AR- C) LNCaP AR+ D) LNCaP AR-, E) 
C4-2B AR+ and F) C4-2B AR-. AR+ cells show invasive potential. Invaded 
cells were stained with crystal violet and images were taken 48 h after seeding. 
G) The number of stained cells that had invaded through the Transwell insert 
were counted and calculated as a percentage of the AR+ control for each cell 
line. An unpaired t-test was performed for statistical analysis. Error bars 
denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 0.001 (***), p-
value < 0.0001 (****). Images were taken with an inverted light microscope at 
a 10x objective (AxioCam ERC55, Zeiss, Germany). Scale bar = 50 µm. 
(Illustrated are representative images; the experiment was however conducted 
in triplicate with biological replicates, N = 3).   
 
 241 
6.3.5 The impact of androgen depletion on the expression of 
STEAP2 in PC3, LNCaP and C4-2B prostate cancer cells 
 
6.3.5.1 Androgen depletion increases STEAP2 expression in androgen-
sensitive prostate cancer cells 
LNCaP and C4-2B are both androgen-sensitive prostate cancer cell lines. 
Following the results of Chapter 4, Section 4.3.3 which found that AR gene 
expression increased in response to STEAP2 polyclonal antibody treatment, 
this chapter explores AR expression in response to STEAP2 knockout by qRT-
PCR.  
 
No significant change in STEAP2 expression was observed in androgen-
depleted PC3 cells (0.96-fold; Figure 6.5A). However, in contrast, STEAP2 
was found to be highly and significantly overexpressed in both LNCaP and C4-
2B androgen-depleted cells, which exhibited 98.0- and 13.2-fold increases in 
expression respectively (p £ 0.01; Figure 6.5A). When STEAP2 protein 
expression was observed by Western blot analysis, STEAP2 was found to be 
elevated in both C4-2B and LNCaP androgen-depleted cells yet remained 
















Figure 6.5. Growth of cells in charcoal stripped FBS alters STEAP2 gene 
and protein expression in androgen sensitive cells. Changes in STEAP2 
gene expression (A) and protein expression (B) in prostate cancer cell lines 
grown in castrate-resistant conditions as compared to normal conditions, 
analysed by RT-PCR and Western blot respectively. An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. Error bars denote S.E.M. 
p-value < 0.01 (**), p-value < 0.001 (***), p-value < 0.0001 (****) (N = 3). 
Western blot image shows STEAP2 expression in protein lysates from AR-
replete and AR-deprived cells. STEAP2: approx. 56 kDa; GAPDH: approx. 37 
kDa. (Loading control = GAPDH, Black lines represent where the western blot 





6.3.6 Androgen depletion increases the expression of genes involved in 
prostate cancer progression  
Section 5.3.4.1 demonstrated that AR is significantly overexpressed in C4-2B 
cells but not in LNCaP cells, following STEAP2 knockout. Chapter 4, Section 
4.3.4 found that the expression of three out of four genes known to influence 
AR expression – PSA, FKBP5 and TMPRSS2 – increased in response to 
STEAP2 polyclonal antibody treatment in both LNCaP and C4-2B cells, whilst 
GPRC6A expression was undetected. Following these results, the gene 
expression of the same four AR-regulated genes were quantified in response 
to androgen depletion by qRT-PCR in PC3, LNCaP and C4-2B cells. Cells 
grown under standard conditions were used for comparison. 
 
Upon analysis of gene expression of the four AR regulated genes, all four 
genes were found to be significantly overexpressed in all three androgen-
depleted prostate cancer cell lines. The highest increase was observed in 
TMPRSS2 expression, which was found to be overexpressed by 43.9-, 12.2- 
and 9946.8-fold in androgen-depleted PC3, LNCaP and C4-2B cells 
respectively, (p £ 0.01; Figures 6.6A, 6.6B & 6.6C). The highest expression 
of the three other genes was observed in androgen-depleted C4-2B cells, 
which exhibited increases of 112.1-, 96.3- and 83.2-fold in PSA, FKBP5 and 
GPRC6A expression respectively (p £ 0.01; Figure 6.6C). qRT-PCR analysis 
therefore demonstrated that androgen regulated genes are highly expressed 
in androgen depleted prostate cancer cell lines and thus, could warrant further 
investigations into the mechanisms of androgen-regulated prostate cancer 







Figure 6.6. Androgen depletion increases the expression of genes 
regulated by AR. Fold changes in the gene expression of PSA, FKBP5, 
TMPRSS2 and GPRC6A in PC3 (A), LNCaP (B) and C4-2B (C) cells grown in 
CSS (AR-), as compared to cells grown in FBS (AR+). An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. GAPDH was used as the 
housekeeping gene. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 
0.01 (**), p-value < 0.001 (***), p-value < 0.0001 (****) (N = 3). 
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6.3.7 Androgen depletion decreases the viability and proliferation of 
STEAP2-knockout prostate cancer cells 
To assess the impact of androgen depletion on the percentage of viable and 
proliferating STEAP2 knockout C4-2B and LNCaP cells generated in Chapter 
5, the alamarBlue assay was used. alamarBlue has the ability to be used as 
both a marker of cell viability and proliferation as it measures a cell’s ability to 
metabolise resazurin to resorufin yet relies upon different manipulations of the 
molar extinction coefficients (E) for alamarBlue (see Chapter 2, Sections 
2.4.2 & 2.5.1). Both the percentages of viable and proliferating cells were 
normalised to cells on day 1 to determine the difference over time.   
 
The percentage of viable cells was significantly reduced in both STEAP2-
knockout cell lines when grown in media supplemented with CSS. The 
percentage of viable LNCaPKO cells was consistently and significantly reduced 
across all 3 days and was lowest on day 3 (-85%, p < 0.05; Figure 6.7A). In 
C4-2BKO cells, the percentage of viable cellswas also significantly reduced on 
all 3 days (-44%, -46% and -62% respectively, p £ 0.01; Figure 6.7B).  
 
The percentage of proliferating cells was significantly reduced in both 
STEAP2-knockout cell lines when grown in media supplemented with CSS. 
Proliferative capacity was significantly reduced in LNCaPKO cells on all 3 days 
(-88%, -87% and -89% respectively, p < 0.0001; Figure 6.8A). In C4-2BKO 
cells, the percentage of proliferating cells was also significantly reduced on all 
3 days (-40%, -50% and -59% respectively, p < 0.0001; Figure 6.8B). Based 
on these data combined with results displayed in Section 6.3.7, it can be 
suggested that androgen depletion significantly reduces the viability and 
proliferative capacity of STEAP2-knockout androgen-sensitive prostate 






Figure 6.7. Androgen depletion significantly reduces STEAP2-knockout 
cell viability. Quantification by alamarBlue assay of the percentage of viable 
LNCaPKO (A) and C4-2BKO (B) cells grown in media supplemented with CSS. 
An ANOVA post-hoc Dunnett test was performed for statistical analysis. Error 
bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 (**), p-value < 0.001 










Figure 6.8. Androgen depletion significantly reduces STEAP2-knockout 
cell proliferation. Quantification by alamarBlue assay of the percentage of 
proliferating LNCaPKO (A) and C4-2BKO (B) cells grown in media 
supplemented with CSS. An ANOVA post-hoc Dunnett test was performed for 
statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 







The aim of this chapter was to determine the effect of androgen depletion 
through growth in CSS on aggressive prostate cancer traits. This chapter also 
aimed to determine whether androgen depletion effected STEAP2 expression, 
and the expression of androgen-regulated genes. Finally, the effects of 
androgen depletion on the viability and proliferation of the STEAP2-knockout 
androgen-sensitive cells generated in Chapter 5, Section 5.3.2 was also 
assessed. The results demonstrated that androgen depletion successfully 
reduced prostate cancer cell viability, migration and invasion. Androgen 
depletion also significantly increased the expression of STEAP2 and all four 
androgen-regulated genes. Furthermore, cell viability and proliferation were 
also inhibited in STEAP2-knockout cells under androgen-depletion conditions.  
 
To date, links between STEAP2 and AR in prostate cancer have not been well 
established (Gomes et al., 2012). Whilst Chapter 5, Section 5.3.4 
demonstrated that STEAP2-knockout significantly increased AR expression in 
C4-2BKO cells, studies into the effects of androgen depletion on STEAP2 
expression were warranted. Growth in CSS removes lipophilic materials 
generally present in standard FBS, including hormones, growth factors and 
cytokines, yet leaves salts, amino acids and glucose levels unchanged, 
allowing for any changes observed to be the result of hormone depletion 
(Sedelaar et al., 2009). Phenol-red free media was also used alongside CSS 
supplementation to further limit the involvement of steroids present in the 
media (Fiandalo et al., 2018; Sedelaar et al., 2009). The use of CSS is 
warranted in this chapter to remove androgens present in standard FBS to 
observe any changes occurring as a result of androgen signalling (Fiandalo et 
al., 2018; Sedelaar et al., 2009). To further explore the downstream effects of 
inhibiting androgen signalling, the expression of four androgen-regulated 
genes was assessed. The expression of these four genes – FKBP5, PSA, 
GPRC6A and TMPRSS2 – was found to increase in response to STEAP2-
knockout (see Chapter 5, Section 5.3.4), therefore suggesting interplay 
between AR and STEAP2. 
 249 
6.4.1 The impact of androgen depletion on aggressive prostate 
cancer traits 
The results of the cell viability assay showed that the ability of androgen-
depleted PC3 prostate cancer cells, an androgen-independent cell line, to 
metabolise MTT followed the same trend as PC3 cells grown under standard 
(androgen-replete) conditions (Figure 6.1A). However, in androgen-sensitive 
cell lines LNCaP and C4-2B, the MTT response remained consistent over the 
5-day period and no significant difference was observed over time, whilst the 
same cell lines grown under standard conditions exhibited a significant 
increase in MTT absorbance over time (Figure 6.1B & 6.1C). MTT can only 
be cleaved by active mitochondria present in metabolically active cells and is 
therefore a relevant survival assay for distinguishing living cells from dead 
ones (van Meerloo et al., 2011). As such, the results from the MTT assay were 
used herein as a method of assessing the number of viable cells present. 
 
When proliferative capacity was assessed, all three androgen-depleted cell 
lines followed similar proliferation trends as those grown under standard 
conditions, with all three androgen-depleted cell lines proliferating at a higher 
rate on day 5 than those under standard conditions (Figure 6.2). Under 
androgen-depleted conditions, studies have demonstrated that cells can 
become resistant to androgen-depletion, through the elevated expression of 
several peptide growth factors including EGF, TGF-α, IL-6 and IGF1 (Bartlett 
et al., 2005; Di Lorenzo et al., 2002; Krueckl et al., 2004; Tam et al., 2007; 
Traish et al., 2009). This overexpression can subsequently induce androgen-
independent activation of AR transcriptional activity, or sensitise AR to low 
androgen levels, allowing for cells to continue to proliferate (Gregory et al., 
2004).  Growth of prostate cancer cells in androgen-depleted medium has 
been found to be significantly increased by EGF, a process which requires 
steroid receptor coactivator (Src) tyrosine kinase (Dasgupta et al., 2015; Guo 
et al., 2006). This Src promoted growth is dependent on the phosphorylation 
of AR-Y534, which has been found to be inhibited through Src siRNA, 
suggesting that Src kinase is required for the growth of hormone-refractory 
prostate cancer cells (Guo et al., 2006; Leung & Sadar, 2017). Y534 was 
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identified by Guo et al., 2006 by mass spectrometry as a major site of Src-
induced tyrosine phosphorylation, which was increased in hormone-refractory 
tumour xenografts in comparison to their hormone-sensitive counterparts. 
 
The expression of neutral endopeptidase 24.11 (NEP), a cell-surface enzyme, 
is regulated by androgens and is upregulated in androgen-sensitive cell lines 
such as LNCaP, yet is downregulated in cell lines lacking AR such as PC3 
(Usmani et al., 2000). NEP loss has been reported to contribute to disease 
progression under androgen-depleted conditions through the activation of Akt, 
which may subsequently accelerate tumour progression (Osman et al., 2006). 
Hypermethylation of the NEP promotor has been reported in CRPC following 
reactivation of NEP by the demethylation agent 5-aza-2’-deoxycytidine, 
suggesting NEP loss may be characteristic of a switch to CRPC (Bastian et 
al., 2008; Osman et al., 2006; Usmani et al., 2000). Loss of NEP activity may 
therefore provide a mechanism for the sustained proliferation rates observed 
in all androgen-depleted cell lines (Figure 3.2; Osman et al., 2006).  
 
Increased cellular proliferation may also be the result of EGFR activation 
through autophosphorylation of EGF and EGFR binding, leading to a 
downstream signalling cascade resulting in activation of PI3K (Migliaccio et 
al., 2006). PI3K activation leads to Akt and signal transduce and activator of 
transcription (STAT) activation, the downstream effects of which modulate 
cellular proliferation and survival (Bonnaccorsi et al., 2004; Migliaccio et al., 
2006). In terms of AR activation, these pathways are involved in 
phosphorylation in the absence of the androgen ligand, subsequently 
promoting enhanced cell growth and proliferation without androgen stimulation 
(Traish et al., 2009). This signalling pathway of EGFR crosstalk with the AR 
pathway is of significance when regulating cell growth under androgen-
depleted conditions (Bonnaccorsi et al., 2004; Migliaccio et al., 2006; Traish 
et al., 2009).  
 
Under androgen-depleted conditions, it has been debated that growth factor 
induced androgen-independent activation of AR transcriptional activity alone 
may only induce relatively small (few-fold) increases in AR transcriptional 
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activity (Guo et al., 2006). In comparison with the optimal induction of AR 
transcriptional activity under normal conditions and in the presence of 
androgens, such an increase has been deemed negligible as it is in the same 
range as that induced by growth factors (Guo et al., 2006). In vitro, studies 
monitoring a dose-dependent response of LNCaP cells to androgens found 
that low levels of androgens (0.01-0.1 nM) promoted cellular proliferation, 
whilst higher levels (1-100 nM) inhibited cellular proliferation (Guo et al., 2006; 
Song & Khera, 2014). It has been suggested that this few-fold increase in AR 
transcriptional activity may be enough to regulate a subset of AR-regulated 
genes involved in the survival and proliferation of prostate cancer cells (Guo 
et al., 2006). Under androgen-depleted conditions, paracrine loops have been 
found to produce localised high levels of growth factors sufficient to maintain 
AR transcriptional activity and promote cell growth and survival (Guo et al., 
2006; Song & Khera, 2014). Therefore, with respect to the data generated in 
this chapter, future work could involve monitoring androgen levels over time in 
order to determine androgen concentration in relation to proliferative capacity. 
It would also be of interest to conduct future work that assesses concentrations 
of growth factors under androgen-depleted conditions to determine a 
mechanism behind the observed cell survival and proliferation.  
 
Following androgen ablation therapy, androgen-independent prostate cancers 
have been known to exhibit increased tumorigenicity, characterised by a more 
invasive phenotype (Karantanos et al., 2015). During prostate cancer 
progression, interactions between extracellular matrix proteins and prostate 
cancer cells change significantly (Stewart et al., 2004). In this present chapter, 
androgen-independent PC3 cells grown in CSS migrated in a similar, albeit 
slower, manner to PC3 cells grown in standard conditions, as shown by the 
partial wound closure by day 5 in Figure 6.3A. A possible mechanism for this 
is α6β4 integrin expression, which was found to decrease in PC3 cells 
transfected with AR cDNA to match naturally occurring levels of AR in LNCaP 
cells, resulting in a less invasive phenotype and migratory potential 
(Bonaccorsi et al., 2000 & 2004). α6β4, a laminin receptor, has been found to 
play a vital role in the migration and invasion of cancer cells through promoting 
the migration of laminin through association with the actin cytoskeleton (Davis 
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et al., 2001). A study by Bonaccorsi et al., 2004 implied that in androgen-
independent prostate cancers, androgen withdrawal may have significant 
clinical implications due to the upregulation of α6β4 and subsequent increased 
invasion. Despite displaying similar rates of migration, androgen-depleted PC3 
cells invaded through the extracellular matrix at a significantly lower rate than 
their androgen-replete counterparts (Figures 6.4A, 6.4B & 6.4G). It would 
therefore be warranted to conduct gene expression analysis of α6β4 integrin 
expression and other markers of migration and invasion to suggest a 
mechanism behind this observed effect.  
 
Conversely, in androgen-sensitive LNCaP and C4-2B cells, migratory potential 
was inhibited by growth in CSS, as displayed by the wound gap remaining 
open by day 5 in Figures 6.3B & 6.3C. Studies have found that invasive and 
migratory capability of LNCaP cells has been suppressed by microRNA-185 
(miR-185), coupled with cell cycle arrest at G0/G1 phase (Qu et al., 2013). In 
prostate cancer xenograft models, tumorigenicity was also inhibited by miR-
185, thought to be the result of CDC6 upregulation (Mallik et al., 2008; Qu et 
al., 2013). The expression of CDC6, another AR target gene, has been found 
to be regulated through AR-binding in LNCaP cells, and is downregulated as 
a result of AR inhibition by miR-185 overexpression (Bai et al., 2005; Mallik et 
al., 2008; Qu et al., 2013). This downregulation of CDC6 in LNCaP cells has 
been found to reduce cell migration and invasion through cell cycle blockade 
at G1 to S phase (Bai et al., 2005).   
 
In this chapter, cell proliferation of androgen-depleted cells in comparison to 
androgen-replete cells was relatively unchanged (Figure 6.2), yet cell 
migration and invasion was significantly reduced (Figures 6.3 & 6.4). Protein-
kinase-C-related kinase (PRK1) has been found to modulate cell migration 
through kinase activity, whilst not affecting cell proliferation in androgen-
independent cell lines PC3 and DU145 in vitro and murine models in vivo (Jilg 
et al., 2014; Metzger et al., 2003). This inhibition of migration is thought to be 
the result of changes in the ETS domain following PRK1 depletion (Jilg et al., 
2014; Patki et al., 2013). In androgen-dependent LNCaP cells, PRK1 was 
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found to not only inhibit cell migration and invasion, but also proliferation, 
suggesting crosstalk between PRK1 and AR (Metzger et al., 2008).  
The growth of androgen-sensitive prostate cancer cells under androgen-
depleted conditions has been found to be inhibited as a result of a mutation in 
the major tyrosine phosphorylation site in AR (Guo et al., 2006). In the absence 
of androgens, phosphorylation may also control the transition of AR from 
inactive to active conformation, and in turn dissociate from negative regulatory 
proteins, for example HSP90 (Guo et al., 2006). This dissociation upon 
tyrosine phosphorylation may allow androgen to become dimerised with the 
nuclear import machinery complex in the absence of androgens, promoting 
AR nuclear translocation (Guo et al., 2006).  
The migration and invasion of prostate cancer cells has been found to be 
inhibited both in in vitro cell lines and tumour in vivo following AR-knockdown 
(Cinar et al., 2001). In androgen-independent PC3 cells, studies have found 
AR-knockdown to reduce EGFR phosphorylation and PI3K activation, implying 
that androgens are involved in the modulation of EGFR expression and 
function (Bonaccorsi et al., 2004 & 2007). Under normal growth conditions, 
EGFR expression and phosphorylation are found at high levels in androgen-
independent PC3 and DU145 cells, but lower in androgen-sensitive LNCaP 
cells (Bonaccorsi et al., 2004 & 2007; Traish et al., 2009). The reduction in 
EGFR expression in PC3 cells following AR-knockdown was suggested to 
lead to a less invasive phenotype through AR-EGFR crosstalk, and therefore 
may provide a mechanism for the reduction in cell migration and invasion 
observed in this Chapter (Figures 6.3 & 6.4; Traish et al., 2009).  
 
Future studies into cell viability, proliferation, migration and invasion in 
response to long-term culture would provide insight into whether the results 
observed in this chapter are sustained over time. These studies would be 
warranted as it has been previously noted that prostate cancer cell 
proliferation may occur in a biphasic manner, with increased proliferation being 
promoted initially at low levels of androgens (Song & Khera, 2014). Coupled 
with AR expression over the course of a longer culture period in CSS, such 
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data could provide information on determining whether a switch to CRPC has 
occurred.  
6.4.2 The impact of androgen depletion on the expression of 
STEAP2 and androgen-regulated genes in prostate cancer 
cells 
STEAP2 is highly expressed in the androgen-sensitive prostate cancer cell 
line LNCaP and C4-2B, but not the androgen-independent cell lines PC3 and 
DU145 (see Chapter 5, Figure 5.4; Korkmaz et al., 2002; Porkka et al., 2002). 
In this chapter, STEAP2 was found to be significantly overexpressed in 
androgen-sensitive LNCaP and C4-2B cells under androgen-depleted 
conditions, when compared to their androgen-replete counterparts (Figure 
6.5A). This observed increase in STEAP2 gene expression was also mirrored 
in STEAP2 protein expression (Figure 5.5B). It has previously been found that 
STEAP2 expression requires an intact AR, suggesting that AR activation may 
have been achieved in these cells (Korkmaz et al., 2002). High transcript levels 
of STEAP2 have also been found in CRPC samples, further suggesting AR 
activation may have occurred (Ylitalo et al., 2017). 
 
Following growth in androgen-depleted medium, the gene expression of the 
androgen-regulated genes PSA, FKBP5, TMPRSS2 and GPRC6A was found 
to increase significantly in both androgen-independent PC3 cells (Figure 
6.6A), and androgen-sensitive LNCaP and C4-2B cells (Figures 6.6B & 
6.6C). This increase in gene expression of androgen-regulated genes could 
be the result of a switch to castrate-resistant disease following the AR 
transcriptional activity becoming reinstated (Cai et al., 2009). The transcription 
of these androgen-regulated genes is stimulated once nuclear AR, which has 
been translocated from the cytoplasm to the nucleus, interacts with AREs in 
the promoter regions of these target genes (Dehm & Tindall, 2005).  
 
Studies have found this to be the case in LNCaP cells cultured in androgen-
depleted medium, which exhibited an increase in PSA expression due to 
enhanced receptor protein tyrosine kinase ErbB2 signalling (Cai et al., 2009). 
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Cai et al., 2009 also showed that EGF and heregulin-β1, a ligand for ErbB2, 
stimulated the expression of PSA, suggesting that AR transcriptional activity 
can be enhanced by ErbB2 stimulation even in the absence of androgens or 
at low androgen levels (Cai et al., 2009; Liu et al., 2005; Mellinghoff et al., 
2004). Activation of EGFR or ErbB2 signalling could provide a mechanism for 
the maintenance of AR protein expression in CRPC, resulting in an increased 
AR protein stability (Cai et al., 2009). In human samples matched from pre- 
and post-androgen therapy, EGFR was found to influence progression to 
androgen-independent hormone relapse and subsequent disease 
progression, for which elevated PSA expression was used to confirm 
biochemical relapse (Bartlett et al., 2005). Further studies into the levels of AR 
expression over time by qRT-PCR in cells cultured in CSS would be warranted 
to confirm this hypothesis.  
 
In androgen depleted tumours, a loss of androgen regulation coupled with 
increased PI3K and MAPK signalling may not only account for the sustained 
proliferative potential of androgen-depleted prostate cancer cells, but also the 
increase in FKBP5 expression (Figures 6.2 & 6.6; Traish et al., 2009). FKBP5 
expression is modulated through PI3K signalling, which can become 
stimulated following AR activation in the absence of ligand binding, triggering 
AR signalling, cellular proliferation and survival (Traish et al., 2009). This may 
also suggest a mechanism behind the sustained cell viability observed in all 
androgen-depleted cell lines (Figure 6.1). PI3K signalling may also become 
active in androgen-depleted cells as a result of nuclear receptor coactivator 2 
(NCoA2) induction, which may also contribute to the development of CRPC 
(Qin et al., 2014). NCoA2, also known as Src-2, is a coregulator of transcription 
and modulates transcription once recruited to the enhancer or promoter 
regions of target genes (Dasgupta et al., 2015; Qin et al., 2014). NCoA2 may 
be involved in supporting growth and survival of androgen-depleted prostate 
cancer cells through glutamine metabolism (Dasgupta et al., 2015; Qin et al., 
2014). In murine models, NCoA2 has been found to stimulate hyperactivation 
of PI3K/Akt signalling, promoting cell survival and proliferation (Qin et al., 
2014). Similarly, the depletion of NCoA2 prevented the development of CPRC, 
indicating NCoA2 may provide a potential therapeutic target alongside 
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androgen ablation (Qin et al., 2014). This may provide a mechanism for the 
sustained viability of androgen-depleted prostate cancer cells in this chapter 
(Figure 3.1), however further studies to monitor NCoA2 expression would be 
required to confirm this hypothesis.  
 
Transcription factor cyclin AMP-responsive element-binding protein 5 
(CREB5) has been identified as a modulator of conferring resistance to 
androgen depletion in androgen-dependent prostate cancer cell lines and 
enhances proliferation rates under androgen-depleted conditions (Hwang et 
al., 2019). When androgen ablation therapy was delivered in vitro, the ability 
of low residual levels of nuclear AR to bind to AR target sequences was 
enhanced by CREB5 and AR transcription was subsequently promoted 
(Hwang et al., 2019). As a result, Hwang et al., 2019 reported that the gene 
expression of 16 out of 43 AR target genes was upregulated more than 2-fold 
in cells also overexpressing CREB5 when treated with CSS, whilst AR 
expression and localisation was not directly altered. These upregulated target 
genes included PSA and FKBP5, both of which were overexpressed in 
response to CSS in this chapter (Figure 6.6; Hwang et al., 2019). These 
results suggest that the expression of AR-regulated genes may be enhanced 
in parallel to CREB5 expression under androgen-depleted conditions (Hwang 
et al., 2019). To confirm this hypothesis, it would be interesting to conduct 
further qRT-PCR analysis to determine CREB5 expression in androgen-
depleted cells in comparison to their androgen-replete counterparts to suggest 
a mechanism driving the overexpression of the AR-regulated genes observed 
in this chapter.  
 
When treated with a peroxisome proliferator-activated receptor alpha (PPARα) 
androgen agonist, fenofibrate, G1 phase cell cycle arrest and inhibition of Akt 
phosphorylation was induced in LNCaP cells (Zhao et al., 2013). PSA and 
TMPRSS2 expression were also reduced in a dose dependent manner, whilst 
intracellular ROS signalling was increased (Zhao et al., 2013). In androgen-
independent PC3 cells, fenofibrate only induced apoptosis at higher 
concentrations than in LNCaP cells, suggesting that G1 phase cell cycle arrest 
may be mediated by downregulation of AR (Zhao et al., 2013). In CRPC, 
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TMPRSS2 expression and subsequent fusion with the ERG gene is often 
increased following a gain of function mutation in AR sufficient to drive 
expression of AR-regulated genes (Montgomery et al., 2008; Tomlins et al., 
2005). TMPRSS2 was found to be significantly overexpressed in all three 
androgen-depleted cell lines (Figure 6.6), suggesting a switch to CRPC has 
occurred. TMPRSS2 expression has also been found to increase alongside 
PSA, also observed in this Chapter, in CRPC following a gain in function 
mutation in DHT synthesis (Figure 6.6; Chang et al., 2013).  
 
As GPRC6A has been found to indirectly mediate the effects of AR in prostate 
cancer progression, its overexpression observed in this chapter in conjunction 
with increased proliferation could further suggest a switch to CRPC (Figure 
6.6; Pi & Quarles, 2012; Zarif & Miranti, 2016). GPRC6A also regulates the 
non-genomic, rapid signalling responses to testosterone which activate the 
PI3K/Akt pathways responsible for AR-independent progression, onset of 
CRPC and subsequent resistance to ADT (Pi et al., 2015; Zarif & Miranti, 
2016). Overexpression of GPRC6A may also trigger stimulation of interleukin-
6 (IL-6), which may in turn promote androgen synthesis in the absence of 
androgens through enhancing AKR1C3 transcription (Chun et al., 2009; Thulin 
et al., 2016).  
 
Whilst growth in CSS strips cells of androgens present in the serum, complete 
androgen-free conditions cannot exist entirely as low levels of residual 
androgens remain, as observed in the serum of patients undergoing androgen 
ablation therapy (Chang et al., 2013). Transcripts encoding androgen 
synthesising steroidogenic enzymes such as hydroxy-delta-5-steroid 
dehydrogenase beta-1 (HSD3β1), cytochrome P450 17A1 (CYP17A1), and 
AKR1C3 have been found to be expressed in biopsies from metastatic 
prostate cancer tumours (Chang et al., 2013; Montgomery et al., 2008). These 
enzymes have been found to be capable of maintaining intratumoural 
androgen levels at high enough concentrations to activate AR target genes 
and maintain tumour cell survival in the absence of androgens (Chang et al., 
2013; Montgomery et al., 2008). In particular, HSD3β1 has been found to limit 
DHT synthesis under androgen-depleted conditions (Chang et al., 2013). In 
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LNCaP cells grown in androgen-depleted media, a castrate level of 
testosterone remains, which cells then metabolise to produce a level of 
intracellular DHT similar to physiological conditions (approximately 10 nM), 
allowing for the stimulation of androgen-depleted LNCaP cells in vitro 
(Sedelaar et al., 2009). This maintenance of androgen levels may account for 
the activation of AR-regulated genes observed in androgen-depleted cells 
(Figure 6.6; Chang et al., 2013; Montgomery et al., 2008). To further relate 
the findings in this Chapter to the literature with regards to AR-regulated gene 
expression, it would be of interest to assess gene expression across a range 
of androgen levels, along with DHT expression (Chang et al., 2013; 
Montgomery et al., 2008).  
6.4.3 The impact of androgen depletion on the viability and 
proliferation of STEAP2-knockout androgen-sensitive 
prostate cancer cells 
STEAP2-knockout was previously found to significantly reduce the cellular 
proliferation rate of LNCaP and C4-2B cells in comparison to their wild-type 
counterparts (see Chapter 5, Figure 5.7). As STEAP2 was found to become 
upregulated in response to androgen depletion in androgen-sensitive LNCaP 
and C4-2B cells (Figure 6.5A), it was of interest to explore the impact of 
CRISPR/Cas9 targeted STEAP2-knockout in conjunction with androgen 
depletion. Here, cell viability and proliferation of STEAP2-knockout LNCaP 
and C4-2B cells was significantly decreased under androgen-depleted 
conditions, when compared to androgen-replete LNCaPKO and C4-2BKO cells 
(Figures 6.7 & 6.8).  
 
Both AR and STEAP2 expression have been found to be involved in cellular 
proliferation and survival of prostate cancer cells, yet a link between the two 
has not yet been fully established (Gomes et al., 2012; Wang et al., 2010). 
Under androgen-depleted conditions, LNCaP and C4-2B cell viability was 
consistent over time (Figures 6.1B & 6.1C), yet significantly decreased in 
androgen-depleted LNCaPKO and C4-2BKO cells (Figure 6.7). STEAP2 
knockdown with siRNA has previously been found to increase the number of 
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apoptotic events in prostate cancer cells through upregulation of p21, which 
regulates the cell cycle during G1 and S phase (Bertoli et al., 2013; Wang et 
al., 2010). p21 expression has also been found to increase over time in parallel 
with increased apoptosis of prostate cancer cells in response to androgen 
ablation (Martinez et al., 2002). To confirm the involvement of p21 in cell death 
of androgen-depleted cells, flow cytometry would be warranted to determine 
the phase of cell cycle arrest in response to androgen-depletion in STEAP2-
knockout cells, whilst p21 expression could be explored to suggest a 
mechanism of cell death.  
 
Under androgen-depleted conditions, the proliferative capacity of LNCaP and 
C4-2B cells increased over time (Figures 6.2B & 6.2C), which could be the 
result of EGF overexpression (Dasgupta et al., 2015; Guo et al., 2006; Traish 
et al., 2009). EGF has been found to become overexpressed when STEAP2 
is ectopically expressed in prostate cancer cells, resulting in ERK pathway 
activation and increased proliferation due to partial cell cycle arrest in the G0-
G1 phase (Gomes et al., 2012; Wang et al., 2010). As proliferation decreased 
in response to STEAP2-knockout, it could be suggested that the ERK 
signalling pathway driving cellular proliferation may not become activated by 
STEAP2 (Figure 6.8; Dasgupta et al., 2015; Guo et al., 2006; Traish et al., 
2009; Wang et al., 2010). However more studies to explore the signalling 
pathways involved would be warranted to confirm this hypothesis. It would also 
be of interest to explore changes in MMPs -1, -3, -7, -9, -11 and -13, which 
become activated upon ERK translocation (Dhillon et al., 2007; Gong et al., 
2014). 
 
These data suggest that not only does STEAP2 provide potential as a novel 
therapeutic target in the treatment of prostate cancer, but this could be 
targeted in conjunction with androgen ablation therapy. Further studies into 
the effects of androgen depletion on the migratory and invasive potential of 
STEAP2-knockout cells are warranted, as STEAP2 overexpression has 
previously been thought to enhance prostate cancer cell migration and 
progression (Burnell et al., 2018; Whiteland et al., 2014). Had time allowed, it 
would have been interesting to conduct qRT-PCR gene profiling of androgen-
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depleted STEAP2-knockout cells to assess PSA, FKBP5, TMPRSS2 and 
GPRC6A expression in order to suggest a mechanism behind the reduction in 
cell proliferation and viability. This would also be of importance to determine 
whether these genetic drivers of prostate cancer progression respond to 






The data generated in this chapter provides strong evidence that targeted 
STEAP2 therapy could potentially be a viable therapeutic target alongside 
conventional androgen-depletion therapy in the treatment of prostate cancer 
for future clinical translation. Androgen-depletion through growth in CSS 
resulted in a promising inhibition of cell migration and invasion. Gene 
expression analysis of STEAP2 and androgen-regulated genes found that 
androgen depletion initiates an increase in expression of key genes in the 
progression of prostate cancer, despite androgen-depletion inhibiting cell 
migration and invasion; however, the mechanisms behind this remain unclear. 
When STEAP2 was knocked out by CRISPR/Cas9 engineering, cell viability 
and proliferation decreased, further suggesting AR and STEAP2 crosstalk. 
Further studies into the mechanisms driving the increase of STEAP2 and 
androgen-regulated genes when androgen is depleted are warranted, such as 
RNAseq profiling. Overall, the data presented in this chapter provides further 
evidence that crosstalk between AR and STEAP2 could be involved in the 











Prostate cancer is the most common cancer in men, with approximately 10% 
progressing to advanced or metastatic disease, which has a poor 5-year 
survival rate of approximately 30% (CRUK, 2019). For many men with 
metastatic disease, treatment options are limited to either palliative care or 
radical chemo- or radiotherapy which come with severe adverse effects (e.g., 
extreme fatigue, nausea and erectile dysfunction), hindering a patients’ quality 
of life (CRUK, 2019). Prostate cancer is a highly androgen regulated disease, 
and as such ADT is often offered as the first-line treatment, however many 
men develop resistance to these drugs and go on to develop a more 
aggressive form of the disease; CRPC (Kirby et al., 2011; Scher et al., 2004). 
In order to improve the clinical management of men with advanced prostate 
cancer, the development of more targeted therapeutic drugs is needed. Over 
recent years, advances in the development of mAbs have allowed for 
progression to more personalised treatment strategies in the clinical 
management of patients with cancers such as malignant melanoma and non-
Hodgkin lymphoma (Satta et al., 2018; Tsumoto et al., 2019). mAbs are highly 
specific and can therefore target cancer-specific proteins and trigger cell death 
and / or disrupt downstream pathways involved in cancer progression (Wang 
et al., 2018). Immunotherapy has become a widely studied area of research 
recently, with various drugs being developed to treat metastatic CRPC 
including ipilumumab and Sipuleucel-T (Anassi & Ndefo, 2011; Beer et al., 
2017; Redman et al., 2017). These immunotherapeutics may offer clinical 
benefit over the standard ADT regimen currently offered, however the number 
of patients who may benefit from these drugs is limited (Beer et al., 2017; 
Hossain et al., 2018; Massard & Fizazi, 2011). To further enhance the efficacy 
of mAbs, ADC technology has been utilised which relies on the specificity of 
mAbs along with biochemical linkers to trigger a cytotoxic payload release to 
induce cell death (Chen et al., 2020). Due to their increased specificity, ADCs 
have the added benefit of reduced off-target effects. However, to date, a 
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specific mAb or mAb-ADC for the clinical management of prostate cancer 
patients is lacking. Another development in cancer therapeutic approaches is 
the use of genome editing, particularly through CRISPR/Cas9 technology to 
knockout genes of interest from cancer cells in order to inhibit their effects on 
disease progression (Yi & Li, 2016). However, to date this approach has not 
been applied as a treatment strategy for prostate cancer.  STEAP2, a cell 
surface protein that functions as a metalloreductase, is highly expressed in 
prostate cancer cells when compared to normal tissue and is known to 
contribute to disease progression by modulating aggressive prostate cancer 
traits such as cell migration and invasion in vitro (Gomes et al., 2012). Given 
these features, STEAP2 therefore offers the potential to be a future 
therapeutic target for prostate cancer treatment in combination with mAbs and 
CRISPR/Cas9 technologies.  
 
Thus, the aim of this thesis was to evaluate whether STEAP2 is a viable drug 
target for the potential clinical management of prostate cancer, with a focus 
on the application of therapeutic anti-STEAP2 mono- and poly-clonal 
antibodies, and CRISPR/Cas9 gene knockout technology. This thesis also 
aimed to determine whether STEAP2 is involved in the expression of AR or 
androgen-regulated genes. The data generated in this thesis demonstrated: 
1. Androgen-independent cell lines PC3 and DU145 form more viable 3D 
spheroid structures over time than androgen-sensitive LNCaP and C4-
2B cells (Chapter 3); 
2. Anti-STEAP2 pAb and mAb treatment reduced cell viability in 2D but 
not 3D models, with anti-STEAP2 mAb2 identified as a lead candidate.  
a. Anti-STEAP2 mAb2 triggered receptor internalisation in both a 
dose- and time-dependent manner (Chapter 4);  
3. The expression of AR and androgen-regulated genes significantly 
increased in response to anti-STEAP2 pAb treatment and STEAP2 
knockout (Chapter 4 & 5);  
4. CRISPR/Cas9 technology successfully generated stable STEAP2-
knockout LNCaP and C4-2B cells with reduced cell proliferation, 
migration and invasion capacities in vitro (Chapter 5); 
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5. Androgen deprivation significantly increased STEAP2 expression in 
androgen-sensitive cell lines, whilst reducing cell migration and 
invasion (Chapter 6). 
 
In Chapter 3, gene expression profiling of a panel of prostate cancer cell lines 
found STEAP2 to have the highest expression of the four STEAP family 
members. These findings were consistent with previous studies reporting 
STEAP2 to be highly expressed in prostate cancer tissue, but not the normal 
healthy prostate, and correlates with poor prognosis and advanced disease 
(Burnell et al., 2018; Porkka et al., 2002). These results, along with previous 
work highlighting the role of STEAP2 in disease progression, confirm that 
STEAP2 poses an attractive therapeutic target for the treatment of prostate 
cancer, hence it being the focus for further investigations throughout this thesis 
(Burnell et al., 2018). Due to its high specificity to prostate cancer tissue and 
low expression in normal cells, targeting STEAP2 with therapeutic agents may 
allow for targeting induced cell death of prostate cancer cells, whilst preserving 
normal, healthy cells from the adverse effects associated with many 
conventional treatments (Sikkeland et al., 2016). Indeed, throughout this 
thesis, inhibition of STEAP2 by either anti-STEAP2 antibody treatments or 
CRISPR/Cas9 gene knockout triggered a reduction in cell viability.  
 
One of the key properties gained by cancer cells is the ability to migrate to 
distant sites from their primary tumours and form metastases (Hanahan & 
Weinberg, 2011; Rycaj & Tang, 2017). Disease progression can also be 
increased by the ability of cancer cells to invade out from their original sites 
(Gialeli et al., 2011). The main site for metastases in prostate cancer patients 
is the bone, yet the development of a physiologically relevant platform to 
assess the interactions between prostate cancer cells and bone stromal cells 
is lacking (Taichman et al., 2007; Sun et al., 2007). Thus, Chapter 3 also 
worked to fully develop, optimise and characterise a robust method for the 
generation of viable 3D prostate cancer spheroids for future use throughout 
this thesis. 3D spheroid models are more physiologically relevant 
representatives of the in vivo microenvironments and bridge the gap between 
in vitro and in vivo studies (Donglai et al., 2017; Hirschhaeuser et al., 2010; 
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Lovitt et al., 2014). Previous studies have reported that STEAP2 
overexpression correlated with an increased aggressive cancer phenotype, 
with STEAP2 driving migration and invasion (Burnell et al., 2018; Gomes et 
al., 2012; Wang et al., 2010; Whiteland et al., 2014). The results of Chapter 3 
demonstrated that not only did LNCaP and C4-2B cells display the highest 
levels of STEAP2 expression, but they also formed the most uniformly 
distributed 3D co-culture models with bone stromal cells. This correlation 
between STEAP2 expression and stromal cell integration, along with previous 
studies highlighting the role of STEAP2 in migration and invasion, further 
indicate STEAP2 as a potential target for treating metastatic disease.    
 
STEAP2 consists of six transmembrane helices, giving rise to three ECLs 
which have the potential to be targeted with specific drugs (Grunewald et al., 
2012). The anti-STEAP2 antibodies applied in Chapter 4 all targeted the ECL3 
of STEAP2, following previous work within the wider research group which 
identified a peptide located on ECL3 as the most immunogenic for therapeutic 
targeting (Nguyen-Chi, 2020). When exposed to 2D monolayers in Chapter 4, 
the anti-STEAP2 pAb significantly reduced cell viability in all cell lines, and of 
the three anti-STEAP2 mAbs evaluated, mAb2 was identified as the preferred 
lead candidate due to its ability to significantly reduce cell viability at lower 
doses across all four prostate cancer cell lines. This reduction in cell viability 
was not mirrored when the antibodies were applied to the 3D PC3 and LNCaP 
cell spheroid models generated in Chapter 3. The spheroid models generated 
in Chapter 3 showed variation in their viability over time, with PC3 cells 
generating more viable spheroids than LNCaP cells. Therefore, although the 
viability of LNCaP spheroids was significantly reduced at all doses of anti-
STEAP2 mAb between 62.5 – 1,000 µg/ml, this may be more likely due to the 
time-dependent limitations in model viability. In contrast, PC3 cells did form 
spheroids with sustained viability over time, high cell numbers were initially 
seeded and dense spheroids were formed. PC3 spheroid viability was only 
significantly impacted at the highest dose of anti-STEAP2 mAb2 (1,000 µg/ml). 
However, given the dense tissue structure, the minimal induction of cell death 
induced by the anti-STEAP2 mAb2 is most likely to due to poor penetration 
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through the spheroids (Grimes et al., 2014; Hirschhaeuser et al., 2010; Lazzari 
et al., 2018; Riffle et al., 2017). 
 
Cell death is initiated upon triggering the apoptotic cascade, yet it remains 
unclear whether it is the extrinsic or intrinsic apoptotic pathway that STEAP2 
exerts an effect on (Wang et al., 2010). During the extrinsic pathway, cell death 
is the result of the formation of the DISC, the stability of which may be reduced 
by STEAP2 (Dickens et al., 2012; Wang et al., 2010). STEAP2 may also play 
a role in the intrinsic pathway as its knockdown has been found to trigger 
apoptosis through transcription factors, independent of the extrinsic pathway 
(Sayers, 2011; Wang et al., 2010). LNCaP and C4-2B cells were deemed more 
susceptible to targeted STEAP2 treatment due to their naturally high 
expression levels determined in Chapter 3, and as such significant reductions 
in their viability were observed following both anti-STEAP2 pAb and mAb 
treatment in Chapter 4, and CRISPR/Cas9 STEAP2-knockout in Chapter 5. 
TRAIL-induced apoptosis may also contribute to cell death in LNCaP cells, 
which was found to be the case in response to STEAP2-knockdown (Wang et 
al., 2010). TRAIL-induced apoptosis could also contribute to DISC formation 
through the extrinsic apoptosis pathway via caspase-8 mediated cell death 
(Dickens et al., 2012). The heme-binding domain of STEAP2, also known as 
the ACRATA, has previously been suggested to inhibit cell growth and 
metabolism via electron transport across the membranes of STEAP proteins 
(Oosterheert et al., 2020; Sanches-Polido et al., 2004; Yamada et al., 2004).  
 
Following previous work within the wider research group, it was of interest to 
assess the suitability of the lead mAb candidate, mAb2, for potential future use 
in ADC technology (Nguyen-Chi, 2020). One of the key properties of a 
successful ADC relies on the ability of its mAb to trigger receptor internalisation 
(Kamath & Iyer, 2015; Tarcsa et al., 2020). In Chapter 4, PC3, LNCaP and 
C4-2B cells were exposed to a range of anti-STEAP2 mAb2 doses for various 
lengths of time and were visually assessed under confocal microscopy to 
determine receptor internalisation. In LNCaP and C4-2B cells, lower doses of 
anti-STEAP2 mAb2 of 25 µg/ml and 50 µg/ml respectively were deemed 
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sufficient at triggering receptor internalisation, as higher doses appeared to 
saturate cells (Rhoden et al., 2012). A higher dose range of 100 – 500 µg/ml 
anti-STEAP2 mAb2 was required to trigger receptor internalisation in PC3 
cells. Data from Chapter 3 showed significantly high STEAP2 expression in 
LNCaP and C4-2B cells, but not PC3 cells, which may also account for 
receptor internalisation at lower anti-STEAP2 mAb2 doses. Therefore, the 
data presented in Chapters 3 and 4 suggest that the use of anti-STEAP2 mAb2 
along with ADC technology should be reserved for prostate cancers with high 
STEAP2 levels to allow for lower doses of antibody to be administered.  
 
Previous studies have applied siRNA to knockdown STEAP2 expression, yet 
as siRNA achieves a transient gene knockdown, it was of importance to 
explore other technologies that would provide a complete and sustainable 
STEAP2 knockout for further consideration as a future therapeutic option 
(Burnell et al., 2018). The ability of anti-STEAP2 antibodies to reduce cell 
viability led to the optimisation and development of CRISPR/Cas9 genome 
engineering to achieve a stable STEAP2 knockout. CRISPR/Cas9 has gained 
interest as a potential tool in the development of more personalised 
therapeutics, as it allows for a wide variety of genomic sequences to be 
targeted (Li et al., 2020; Yi & Li, 2016). Two oligonucleotides were designed 
to target either the full STEAP2 protein, or a STEAP2 transcript variant. One 
of the major concerns regarding the use of CRISPR/Cas9 engineering is the 
ability to produce clones with a stable gene knockout (Lino et al., 2018). 
Following the results of Chapter 3 which demonstrated STEAP2 expression 
was highest in LNCaP and C4-2B cells, which was translated into protein 
expression as seen in Chapter 5, results demonstrated that a stable STEAP2 
knockout was successfully achieved and sustained in both of these cell lines.  
Transient knockdown of STEAP2 using siRNA has also been reported to 
decrease cell migration and invasion (Burnell et al., 2018). Chapter 5 therefore 
aimed to assess the impact of CRISPR/Cas9 targeted STEAP2 knockout on 
these aggressive prostate cancer traits. Both of these traits were significantly 
reduced in LNCaPKO and C4-2BKO cells when compared to their wild-type 
counterparts. Cell migration and invasion were also reduced when cells were 
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grown in androgen-depleted conditions in Chapter 6. Previous studies have 
hypothesised that this inhibition of migration and invasion may be due to a 
reduction in EGFR signalling, and subsequent lack of PI3K/Akt activation 
(Bonaccorsi et al., 2004 & 2007). AR-knockdown has also been found to 
induce a less invasive phenotype through AR-EGFR interactions (Traish et al., 
2009).  Data in Chapter 5 shows that STEAP2-knockout significantly inhibits 
prostate cancer cell migration and invasion in vitro, which was also found in 
previous studies within the group in response to anti-STEAP2 pAb and siRNA 
knockdown (Burnell et al., 2018; Nguyen-Chi, 2020). These combined results 
suggest that STEAP2 has potential to be targeted specifically in the treatment 
of advanced prostate cancer as its sustained inhibition using various 
approaches resulted in a less aggressive prostate cancer cell phenotype.  
 
Uncontrolled proliferation is one of the key properties gained by cancer cells 
in order to grow exponentially (Hanahan & Weinberg, 2011). STEAP2 exerts 
an effect on cellular proliferation through activation of the ERK pathway, 
suggesting inhibition of this pathway following STEAP2-knockout (Gomes et 
al., 2012; Wang et al., 2010). Throughout this thesis, proliferation was 
assessed in response to culture conditions and STEAP2 inhibition. STEAP2 
was found to play a role in over-proliferation in Chapter 3, as its high 
expression levels correlated with increased proliferation of both 2D and 3D 
LNCaP and C4-2B cells. The 3D spheroids generated in Chapter 3 also 
recapitulated in vitro some of the key characteristics of in vivo tumours, such 
as the presence of a necrotic core and viable, proliferating peripheral zone 
(Grimes et al., 2014; Hirschhaeuser et al., 2010; Riffle et al., 2017). When 
STEAP2 was knocked out of these cells using CRISPR/Cas9 engineering, 
proliferation significantly decreased (Chapter 5), which was also the case 
when cells were stripped of androgens (Chapter 6). The cyclin-dependent 
kinase inhibitor p21, which when upregulated is known to increase the number 
of apoptotic events in prostate cancer cells, has been reported to be 
overexpressed both in response to STEAP2-knockdown with siRNA, and in 
androgen-depleted cells (Bertoli et al., 2013; Martinez et al., 2002; Wang et 
al., 2010). As cell cycle progression through G1 and S phase is regulated by 
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p21, its expression could provide a mechanism of cell death in androgen-
depleted STEAP2-knockout cells (Bertoli et al., 2013; Wang et al., 2010). 
 
Data presented in Chapter 3 showing the high expression of STEAP2 in 
androgen-sensitive cell lines formed the basis of further investigations into the 
role of androgens throughout this thesis. Androgens play a vital role in normal 
prostate development and homeostasis (Davey & Grossman, 2016). Prostate 
cancer is a largely androgen-regulated disease, with AR linked to aggressive 
prostate cancer traits (Eder et al., 2000; Gonen-Korkmaz et al., 2014). Studies 
into the relationship between AR and STEAP2 have been inconclusive at 
establishing the mechanisms between the two, yet it has been proposed that 
STEAP2 expression may be influenced by AR (Gomes et al., 2012; Korkmaz 
et al., 2002). Data presented in Chapter 4 showed AR expression significantly 
increases following anti-STEAP2 pAb treatment in androgen-sensitive cell 
lines. This was further explored in Chapter 5 following CRISPR/Cas9 targeted 
STEAP2 knockout, which similarly showed an increase in AR expression in 
LNCaPKO and C4-2BKO cells when compared to their wild-type counterparts. 
This increase in AR expression in response to STEAP2 inhibition using two 
different approaches could be a cause for concern as it may induce a more 
invasive phenotype in patients (Hu et al., 2015; Whiteland et al., 2014). MMPs 
are often required for the progression of prostate cancer, and aid in the 
degradation of the extracellular matrix and subsequent invasion of cells from 
their primary site (Gialeli et al., 2011). Prostate cancer progression is regulated 
through MMPs -2, -7, -9, -13 and -14, of which MMP-9 is known to increase in 
response to AR overexpression, whilst MMPs -3, -7, -10 and -13 have been 
found to decrease in response to STEAP2 inhibition (Brehmer et al., 2003; 
Burnell et al., 2018; Daja et al., 2003; Hu et al., 2015; Morgia et al., 2005). 
MMPs are downstream effectors of ERK signalling, which increases in 
response to STEAP2 overexpression, leading to a more invasive phenotype 
(Wang et al., 2010; Whiteland et al., 2014). Increases in AR expression are 
often the result of mutations in AR, the most common of which is ARv7, which 
can lead to resistance to ADT (Guo et al., 2009; Hu et al., 2009; Nelson & 
Shah, 2019; Qu et al., 2015).  
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Whilst AR expression had been evaluated following STEAP2 inhibition in 
Chapters 4 and 5, it was then of interest to determine whether STEAP2 
expression was altered in response to androgen depletion, which formed the 
basis of Chapter 6. In this Chapter, CSS-supplemented media was used to 
remove androgens from the growth conditions of cells (Fiandalo et al., 2018; 
Sedelaar et al., 2009). Crosstalk between STEAP2 and AR was further 
evidenced in Chapter 6, as STEAP2 expression significantly increased in cells 
grown in CSS when compared to their androgen-replete counterparts. As 
STEAP2 is involved in driving prostate cancer progression, clinically this 
increase would be concerning for the patient as ADT is commonly given as a 
first-line treatment approach (Burnell et al., 2018). These findings suggest that 
AR expression may have been restored, as STEAP2 requires an intact AR 
(Korkmaz et al., 2002). Biochemical resurgence of androgen levels is 
indicative of a switch to CRPC, a more aggressive form of the disease in which 
high STEAP2 levels have been reported (Ylitalo et al., 2017).  
 
Along with the expression of AR, androgen-regulated genes including PSA, 
FKBP5, TMPRSS2 and GPRC6A have also been implicated in the 
development and progression of prostate cancer (Velasco et al., 2004; Yu et 
al., 2010; Zarif & Miranti, 2016). Throughout this thesis, the expression of 
these genes was assessed in response to anti-STEAP2 pAb treatment, 
CRISPR/Cas9 targeted STEAP2 knockout and following growth in CSS-
supplemented media in Chapters 4, 5 and 6 respectively. Following anti-
STEAP2 pAb treatment, the expression of all four genes increased in C4-2B 
cells, whilst PSA, FKBP5 and GPRC6A expression increased in a dose-
dependent manner in LNCaP cells. In LNCaPKO cells the expression of PSA 
and FKBP5 increased significantly, whilst TMPRSS2 was overexpressed in 
both LNCaPKO and C4-2BKO cells. Of these, PSA expression is of particular 
interest in prostate cancer research as it serves as both a diagnostic indicator 
of prostate cancer and is used to determine disease relapse following 
conventional therapy (Cornford et al., 2020; Lipianskaya et al., 2014; Scher et 
al., 2004). The observed increases in PSA expression following STEAP2 
inhibition could be the result of NFκB activity, which has also been found to 
correlate with STEAP2 expression in LNCaP cells (Gonen-Korkmaz et al., 
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2014; Kikuchi et al., 2003; Murillo et al., 2001). Previous studies have 
hypothesised that interleukin-6 activation through the EGF signalling pathway 
may also induce PSA overexpression, whilst increased FKBP5 expression 
could be the result of histone acetylation through cAMP (Lin et al., 2001; 
Magee et al., 2006; Zhu & Kyprianou, 2008). TMPRSS2 overexpression often 
correlates with the fusion of TMPRSS2 with ERG, as AR overexpression can 
increase the proximity of the two genes (Hermans et al., 2006; Zong et al., 
2009). GPRC6A is currently the only identified receptor of osteocalcin which 
is involved in the formation of bone metastases from primary prostate tumours 
and is thought to be overexpressed (Suva et al., 2011; Pi et al., 2016; Ye et 
al., 2017).  
 
A major challenge still faced in cancer research is the identification of novel 
biomarkers which can be used in the development of treatment strategies in 
the clinical management of patients with advanced disease. In prostate 
cancer, such biomarkers could also aid in providing a more specific diagnosis, 
risk stratification and prognosis for patients, whilst also defining those who are 
more likely to benefit from certain therapies. Advances in immunotherapies 
such as the development of immune checkpoint inhibitors and drugs such as 
ipilumumab and Sipuleucel-T have allowed for more tailored clinical 
management strategies, with trials into the optimal treatment combinations 
and sequences still underway. However, appropriate targeted and specific 
therapies are still lacking for men with advanced prostate cancer. The findings 
of this thesis provide proof-of-concept that targeting STEAP2 with anti-
STEAP2 antibodies or complete gene knockout may be a viable treatment 
approach. However, given the prevalence of men who develop CRPC, the 
androgen responses observed following anti-STEAP2 antibody treatment are 






7.1 Future Perspectives 
Whilst the data presented in this thesis highlights the potential of STEAP2 as 
a target in the treatment of prostate cancer, further work is needed to confirm 
the hypotheses suggested. Various approaches were used to achieve 
STEAP2 inhibition throughout this thesis, all of which triggered a reduction in 
prostate cancer cell viability, yet the mechanism behind this remains unclear 
(Table 7.1). Future studies should focus on assessing interactions between 
anti-STEAP2 antibodies and the DISC, TRAIL and the ACRATA to determine 
the exact mechanism through which anti-STEAP2 antibodies induce cell 
death. The expression of AR and androgen-regulated genes was highly 
upregulated in response to STEAP2 inhibition in Chapters 4 and 5, and as 
such future studies should focus upon determining whether these increases 
are the result of interactions between signalling pathways involved in both 
STEAP2 and AR expression. The observed increases in the four androgen-
regulated genes following various methods of STEAP2 inhibition warrant 
further investigations due to the potential negative impact this may pose for 
the patient, particularly with regards to disease progression and the 
development of CRPC. This would allow for the identification of novel 
therapeutic strategies which may be delivered alongside anti-STEAP2 
antibody treatment, without the associated negative impact of increased AR 
expression. The data presented in this thesis would need to be confirmed by 
in vivo studies in future to further confirm STEAP2 as a viable drug target for 
the clinical management of men with advanced prostate cancer. 
 
The anti-STEAP2 monoclonal antibody lead candidate highlighted in this 
thesis, along with the successful knockout of CRISPR/Cas9 STEAP2 in vitro, 
provides three possible avenues of continued research to expand upon in the 
future: 
1. Investigation of CRISPR/Cas9 STEAP2 knockout as therapeutic agent 




2. Development of ADC technology based on anti-STEAP2 monoclonal 
antibodies in combination with various linkers and payloads to increase 
the efficacy of reducing aggressive prostate cancer traits in vitro and in 
vivo. 
3. Explore the effects mAb2 has on STEAP2 metalloreductase activity to 






Table 7.1. Summary of the in vitro findings that resulted from the knock-out of STEAP2 and androgens in androgen-sensitive 
LNCaP and C4-2B prostate cancer cell lines. In this study, STEAP2 was shown to be directly involved with influencing the viability, 
proliferation, migration and invasion of prostate cancer cells. STEAP2 knock-out played a major role in the expression of AR and androgen-
regulated genes. Androgen depletion decreased aggressive prostate cancer traits whilst increasing the expression of STEAP2 and 
androgen-regulated genes. Dashed line indicates experiments that were not conducted.  
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7.2 Conclusion 
STEAP2 shows promise as a potential novel therapeutic target due to its 
overexpression being specific to prostate cancer tissues, and low expression 
profile in other tissues. Within this thesis a fully optimised protocol for 
producing viable 3D prostate cancer cell spheroids was developed. This 
platform was carefully characterised and can be implemented in future studies 
to assess the efficacy of therapeutic targets in a model that is more 
physiologically representative. Mono- and polyclonal antibodies have shown 
potential in the treatment of various cancers, yet their use in prostate cancer 
is limited. The anti-STEAP2 mono- and polyclonal antibodies applied within 
this thesis which target the ECL3 of STEAP2 showed promise in reducing 
prostate cancer cell viability and proliferation in vitro. The anti-STEAP2 
monoclonal antibody lead (mAb2) showed promise for further development 
with ADC technology due to its capability for triggering STEAP2 receptor 
internalisation in a panel of prostate cancer cell lines. These findings highlight 
the therapeutic value of antibody-based therapeutics targeting the ECL3 of 
STEAP2 based on the ability of both the anti-STEAP2 pAb and mAbs to induce 
cell death in prostate cancer cells. CRISPR/Cas9 technology was successfully 
optimised and developed to generate stable STEAP2-knockout LNCaP and 
C4-2B cells in vitro. This knockout further implicates STEAP2 as a potential 
therapeutic target as LNCaPKO and C4-2BKO exhibited reduced proliferation, 
migration and invasive potential compared to their wild-type counterparts. 
However, STEAP2 inhibition both via anti-STEAP2 antibody treatment and 
CRISPR/Cas9 knockout triggered an overexpression of AR and androgen-
regulated genes, which warrants further investigations as clinically this finding 
could result in the onset of a more aggressive form of the disease; castrate 
resistant prostate cancer. Crosstalk between androgens and STEAP2 was 
further suggested as STEAP2 overexpression was observed in androgen-
sensitive LNCaP and C4-2B cells, and AR expression increased following 
STEAP2-knockout. The in vitro findings of this thesis support STEAP2 as a 
viable therapeutic target for reducing aggressive prostate cancer traits. The 
data presented in this thesis provides rationale for future investigations into 
the pathways involved in regulating androgen responses to STEAP2 therapy. 
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Overall, STEAP2 could potentially provide a target for the development of 
more tailored and personalised therapeutic agents to improve the clinical 
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Additional supporting data for Chapter 3 
 
 
Figure A1.1. Growth curve showing the effects of different initial seeding 
densities on the size of 3D monoculture HS5 bone stromal cell spheroids 
over time. Bone stromal cell line HS5 were cultured at various initial seeding 
densities on agarose coated 96-well flat-bottomed plates to generate cultures 
of reproducibly sized, single spheroids in each well. The diameter of each 
spheroid was measured (µm) every day for 5 days. Measurements were taken 
from images acquired from 3 separate spheroids per cell line, per seeding 
density using a standard light microscope (AxioCam ERC55, Zeiss, Germany) 
using a 5x objective. An ANOVA post-hoc Dunnett test was performed for 
statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), p-value < 0.01 









Figure A1.2. Representative light microscopy images of prostate cancer 
and stromal cell monoculture spheroids over time. (A) PC3, (B) DU145, 
(C) LNCaP and (D) C4-2B prostate cancer cells and (E) bone stromal cells 
were cultured as 3D spheroids with a range of initial seeding densities. Images 
were taken 1, 3 and days after seeding and were acquired using a standard 
light microscope (AxioCam ERC55, Zeiss, Germany) using a 5x objective. 




Figure A1.3. Viability of 3D HS5 cell spheroids over time. HS5 bone 
stromal cells were cultured at a density of 10,000 cells per well as 3D 
spheroids. An MTT viability assay was carried out each day for 5 days, with 
viability calculated as a percentage of day 1. An ANOVA post-hoc Dunnett test 
was performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 












Figure A1.4. Representative light microscopy images of prostate cancer 
co-culture spheroids over time. (A) PC3, (B) DU145, (C) LNCaP and (D) 
C4-2B prostate cancer cells were cultured with different ratios of HS5 stromal 
cells as 3D spheroids. Images were taken every 5 days and were acquired 
using a standard light microscope (AxioCam ERC55, Zeiss, Germany) using 
a 5x objective. Scale bar = 100 µm. 
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Figure A1.5. Proliferation rate of 3D HS5 cell spheroids over time. HS5 
bone stromal cells were cultured at a density of 10,000 cells per well as 3D 
spheroids. An alamarBlue proliferation assay was carried out each day for 5 
days, with viability calculated as a percentage of day 1. An ANOVA post-hoc 
Dunnett test was performed for statistical analysis. Error bars denote S.E.M. 




Figure A1.6. Z-stack showing PI staining of 3D PC3 co-culture spheroids by fluorescence microscopy. PI / Hoechst co-staining of 
3D mono- (A & B) and co-culture (C & D) spheroids at 10x magnification showing an increase in PI uptake in both mono- and co-culture 
spheroids, indicative of cell death. Scale bar = 100 µm. Blue: nuclei; red: cell death. Images were taken on days 3 (A & C) and 5 (B & D) 




Figure A1.7. Z-stack showing PI staining of 3D DU145 co-culture spheroids by fluorescence microscopy. PI / Hoechst co-staining 
of 3D mono- (A & B) and co-culture (C & D) spheroids at 10x magnification showing an increase in PI uptake in both mono- and co-culture 
spheroids, indicative of cell death. Scale bar = 100 µM. Blue: nuclei; red: cell death. Images were taken on days 3 (A & C) and 5 (B & D) 




Figure A1.8. Z-stack showing PI staining of 3D LNCaP co-culture spheroids by fluorescence microscopy. PI / Hoechst co-staining 
of 3D mono- (A & B) and co-culture (C & D) spheroids at 10x magnification showing an increase in PI uptake in both mono- and co-culture 
spheroids, indicative of cell death. Scale bar = 100 µM. Blue: nuclei; red: cell death. Images were taken on days 3 (A & C) and 5 (B & D) 




Figure A1.9. Z-stack showing PI staining of 3D C4-2B co-culture spheroids by fluorescence microscopy. PI / Hoechst co-staining 
of 3D mono- (A & B) and co-culture (C & D) spheroids at 10x magnification showing an increase in PI uptake in both mono- and co-culture 
spheroids, indicative of cell death. Scale bar = 100 µM. Blue: nuclei; red: cell death. Images were taken on days 3 (A & C) and 5 (B & D) 




Figure A1.10. Z-stack showing integration of bone stromal (HS5) cells when co-cultured as 3D spheroids with prostate cancer 
cells. (A) PC3, (B) DU145, (C) LNCaP and (D) C4-2B prostate cancer cells were cultured with HS5 stromal cells as 3D spheroids. Confocal 
microscopy revealed HS5 cells were better integrated into androgen-sensitive prostate cancer cell spheroids (C & D). Scale bar = 100 µM. 
Blue: nuclei; green: STRO-1 stromal-specific antibody expression. Images were taken 3 days after seeding and were acquired with the 








Figure A2.1. Anti-STEAP2 mAb2 exposure triggers STEAP2 receptor 
internalisation in PC3 cells. PC3 cells were exposed to anti-STEAP2 mAb2 
for 0, 3, 12 and 24h at doses of 0, 100, 200 and 500 μg/ml. 0h: cell surface 
STEAP2 was visualised before receptor internalisation. 3h & 12h: STEAP2 
receptor internalisation was initiated. 24h: fully internalised STEAP2 was 
evident. Blue: nuclei; green: STEAP2. Images were acquired with a Confocal 






Figure A2.2. Anti-STEAP2 mAb2 exposure triggers STEAP2 receptor 
internalisation in LNCaP cells. PC3 cells were exposed to anti-STEAP2 
mAb2 for 0, 3, 12 and 24h at doses of 0, 100, 200 and 500 μg/ml. 0h: cell 
surface STEAP2 was visualised before receptor internalisation. 3h & 12h: 
STEAP2 receptor internalisation was initiated. 24h: fully internalised STEAP2 
was evident. Blue: nuclei; green: STEAP2. Images were acquired with a 
Confocal LSM 710 with a 63x zoom objective (ZEISS, Germany). Scale bar = 








Figure A2.3. Anti-STEAP2 mAb2 exposure triggers STEAP2 receptor 
internalisation in C4-2B cells. PC3 cells were exposed to anti-STEAP2 
mAb2 for 0, 3, 12 and 24h at doses of 0, 100, 200 and 500 μg/ml. 0h: cell 
surface STEAP2 was visualised before receptor internalisation. 3h & 12h: 
STEAP2 receptor internalisation was initiated. 24h: fully internalised STEAP2 
was evident. Blue: nuclei; green: STEAP2. Images were acquired with a 
Confocal LSM 710 with a 63x zoom objective (ZEISS, Germany). Scale bar = 











Additional supporting data for Chapter 5 
 
 
Figure A3.1. Analysis of STEAP2 knockout by Western blotting. Protein 
llysates were periodically obtained from passaged LNCaPWT,LNCaPKO, C4-
2BWT and C4-2BKO cells and passaged LNCaPKO and C4-2BKO cells to 
LNCaPWT and C4-2BWT cells represent high STEAP2 levels. Western blot 
image shows STEAP2 expression in wild-type and knock-out cells 10 
passages after colony expansion. STEAP2: approx. 56 kDa; GAPDH: approx. 
37 kDa. (Loading control = GAPDH, Black lines represent where the western 









Figure A3.2. LNCaP wild-type and STEAP2-knockout cells over time. 
Morphology of LNCaP prostate cancer cells shown as wild-type cells and with 
CRISPR/Cas9 targeted STEAP2 knockout via plasmid #1 and plasmid #2 prior 
to the isolation of single colonies. Images were taken every 24 h and were 
acquired using a standard light microscope (Invitrogen, EVOS XL Core, USA) 










Figure A3.3. C4-2B wild-type and STEAP2-knockout cells over time. 
Morphology of C4-2B prostate cancer cells shown as wild-type cells and with 
CRISPR/Cas9 targeted STEAP2 knockout via plasmid #1 and plasmid #2 prior 
to the isolation of single colonies. Images were taken every 24 h and were 
acquired using a standard light microscope (Invitrogen, EVOS XL Core, USA) 














Figure A3.4. STEAP2 knockout decreases the migratory potential of 
LNCaP and C4-2B cells. Each panel represents A) LNCaPWT, B) LNCaPKO 
cells and C) C4-2BWT, D) C4-2BKO cells. Time points at which the images were 
taken: 0 days, 3 days and 6 days. Wild-type LNCaP and C4-2B cells were 
used as positive controls. Images were acquired using an inverted light 
microscope with a 10x objective (Invitrogen, EVOS XL Core, USA). Scale bar 
= 100 µm. (Illustrated are representative images; the experiment was however 







Figure A3.5. STEAP2 knockout reduces the invasive potential of LNCaP 
and C4-2B cells. Images of stained cells were taken to give a visual 
representation of invasion. Each panel represents A) LNCaPWT, B) LNCaPKO 
cells and C) C4-2BWT, D) C4-2BKO cells. LNCaPWT and C4-2BWT cells show 
invasive potential. STEAP2 knockout of LNCaPKO and C4-2BKO reduces 
invasive capacity. Invaded cells were stained with crystal violet. Images were 
taken 48 h (C4-2B) and 72 h (LNCaP) after seeding. E) The number of stained 
cells that had invaded through the Transwell insert were counted and 
calculated as a percentage of the wild-type control. An unpaired t-test was 
performed for statistical analysis. Error bars denote S.E.M. p-value < 0.05 (*), 
p-value < 0.01 (**), p-value < 0.001 (***), p-value < 0.0001 (****). Images were 
taken with an inverted light microscope at a 10x objective (Invitrogen, EVOS 








Figure A4.1. Androgen depletion by charcoal stripped FBS decreases the 
migratory potential of PC3, LNCaP and C4-2B cells. Time points at which 
the images were taken: 0 days, 3 days and 5 days. PC3 (A), LNCaP (C) and 
C4-2B (E) cells cultured in FBS-supplemented media (AR+). Androgen 
depleted PC3 (B), LNCaP (D) and C4-2B (F) cells were cultured in CSS-
supplemented media (AR-). Images were acquired using an inverted light 
microscope with a 10x objective (AxioCam ERC55, Zeiss, Germany). Scale 
bar = 50 µm. (N = 2).  
 358 
 
Figure A4.2. Androgen depletion reduces the invasive potential of PC3, 
LNCaP and C4-2B cells. Images of stained cells were taken to give a visual 
representation of invasion. PC3 (A), LNCaP (C) and C4-2B (E) cells cultured 
in FBS-supplemented media (AR+). Androgen depleted PC3 (B), LNCaP (D) 
and C4-2B (F) cells were cultured in CSS-supplemented media (AR-). Each 
panel represents A) PC3 AR+, B) PC3 AR- C) LNCaP AR+ D) LNCaP AR-, E) 
C4-2B AR+ and F) C4-2B AR-. AR+ cells show invasive potential. Invaded 
cells were stained with crystal violet and images were taken 48 h after seeding. 
Images were acquired using an inverted light microscope with a 10x objective 
(AxioCam ERC55, Zeiss, Germany). Scale bar = 50 µm. (N = 2).
 
